	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S71-PMC2290997	PMC2290997	4/2008	S71-PMC2290997	['other health LINKS\nVARIOUS STUDIES have LINKED low 25(Oh)D levels to diseases other than cancer, raising the POSSIBILITY that Vitamin D insufficiency is CONTRIBUTING to many major illnesses.']	[('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 40), ('INCOMPLETE_EVIDENCE', 109), ('SUPERFICIAL_RELATIONSHIP', 153)]	5	[('CHEBI_71657', 'versiconol acetate', 51, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 57, 'D'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S74-PMC2290997	PMC2290997	4/2008	S74-PMC2290997	['STILL to be resolved, HOWEVER, is the QUESTION of WHAT levels of Vitamin D are OPTIMAL for preventing the disease—and WHETHER the statistical ASSOCIATIONS REFLECT DIFFERENT Gene pools RATHER than DIFFERENT levels of 25(Oh)D. (INTERESTINGLY, holick REPORTED in the august 1988 issue of the journal of clinical endocrinology & Metabolism that no previtamin d3formed when Human skin was exposed to sunlight on cloudless days in boston, at 42.2°n, from november through february or in edmonton, at 52°n, from october through march.)']	[('IMPORTANT_CONSIDERATION', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('EXPLICIT_QUESTION', 38), ('EXPLICIT_QUESTION', 50), ('IMPORTANT_CONSIDERATION', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('EXPLICIT_QUESTION', 118), ('SUPERFICIAL_RELATIONSHIP', 142), ('SUPERFICIAL_RELATIONSHIP', 155), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 163), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 196), ('ANOMALY_CURIOUS_FINDING', 226), ('INCOMPLETE_EVIDENCE', 248)]	14	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('SO_0000704', 'gene', 173, 'gene'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('GO_0008152', 'metabolic process', 325, 'Metabolism'), ('NCBITaxon_9606', 'Homo sapiens', 369, 'human')]
S95-PMC2290997	PMC2290997	4/2008	S95-PMC2290997	['in addition, 25(Oh)D levels are inversely ASSOCIATED with the clinical status of ra patients, and greater intake of Vitamin D HAS BEEN LINKED with lower ra RISK, AS REPORTED in january 2004 in arthritis & rheumatism .']	[('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 126), ('SUPERFICIAL_RELATIONSHIP', 135), ('IMPORTANT_CONSIDERATION', 156), ('PROBABLE_UNDERSTANDING', 162), ('INCOMPLETE_EVIDENCE', 165)]	6	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
S108-PMC2290997	PMC2290997	4/2008	S108-PMC2290997	['THESE days, MOST EXPERTS DEFINE Vitamin D deficiency AS a Serum 25(Oh)D level of less than 20 ng/ml.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 12), ('PROBABLE_UNDERSTANDING', 17), ('PROBABLE_UNDERSTANDING', 25), ('PROBABLE_UNDERSTANDING', 25), ('PROBABLE_UNDERSTANDING', 53)]	6	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 64, '25 ... OH ... D')]
S115-PMC2290997	PMC2290997	4/2008	S115-PMC2290997	['so when you ESTIMATE the number of deaths LIKELY to be attributable to uv light or Vitamin D, it does is not APPEAR TO BE the BEST policy to ADVISE People to simply keep out of the sun just to prevent skin cancer.”\nto maximize protection against cancer, grant RECOMMENDS raising 25(Oh)D levels to between 40 and 60 ng/ml.']	[('INCOMPLETE_EVIDENCE', 12), ('PROBABLE_UNDERSTANDING', 42), ('ANOMALY_CURIOUS_FINDING', 109), ('IMPORTANT_CONSIDERATION', 126), ('FUTURE_WORK', 141), ('FUTURE_WORK', 260)]	6	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 148, 'people'), ('CHEBI_71657', 'versiconol acetate', 279, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 279, '25(OH ... D')]
S23-PMC2798111	PMC2798111	12/2010	S23-PMC2798111	['as part of an ongoing Vitamin D supplementation trial of fully Lactating women and their infants, we SOUGHT TO DETERMINE WHETHER a dosing regimen that utilizes an oil emulsion of one drop per day to Deliver 400\u2009iu/day is effective in raising infant 25(Oh)D levels from baseline.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('QUESTION_ANSWERED_BY_THIS_WORK', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 63, 'lactating'), ('GO_0007567', 'parturition', 199, 'deliver'), ('CHEBI_71657', 'versiconol acetate', 249, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 249, '25(OH)D')]
S105-PMC2798111	PMC2798111	12/2010	S105-PMC2798111	['WHILE prescription of a Vitamin or medication and changes in Blood levels of that vitamin or medication, in this case, Vitamin D does NOT prove direct causality, the change in circulating 25(Oh)D status was INDEPENDENT of season.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 134), ('SUPERFICIAL_RELATIONSHIP', 207)]	3	[('CHEBI_33229', 'vitamin (role)', 24, 'vitamin'), ('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 188, '25(OH ... D')]
S5-PMC2821652	PMC2821652	2/2010	S5-PMC2821652	"[""one measurement of adherence was obtained via pill counts remaining COMPARED to a NOVEL definition for adherence using Serum 25-Hydroxy-Vitamin D (25-Oh-d) levels (absolute change in 25(Oh)D over the study period and the subject's steady-state variation in their 25(Oh)d levels).""]"	[('ANOMALY_CURIOUS_FINDING', 68), ('FULL_UNKNOWN', 82)]	2	[('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_70487', '(-)-sanguinolignan C', 125, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_75393', 'Y-27632', 147, '25-OH-'), ('CHEBI_71657', 'versiconol acetate', 183, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 263, '25(OH')]
S19-PMC2821652	PMC2821652	2/2010	S19-PMC2821652	['at the time of Birth, Cord Blood AS a direct reflection of fetal Vitamin D status will contain APPROXIMATELY 50–60% of the maternal circulating levels of 25(Oh)D. this RELATIONSHIP APPEARS TO BE linear EVEN at Pharmacological intakes of Vitamin D [12].']	[('PROBABLE_UNDERSTANDING', 33), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 168), ('ANOMALY_CURIOUS_FINDING', 181), ('ANOMALY_CURIOUS_FINDING', 202)]	5	[('GO_0007567', 'parturition', 15, 'birth'), ('UBERON_0009472', 'axilla', 22, 'cord blood'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 154, '25(OH)D'), ('CHEBI_52217', 'pharmaceutical', 210, 'pharmacological'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]
S23-PMC2821652	PMC2821652	2/2010	S23-PMC2821652	['THUS, in the Human fetus, Vitamin D Metabolism in all LIKELIHOOD begins with 25(Oh)D. as a result, the nutritional Vitamin D status of the Human fetus/neonate is totally DEPENDENT on the Vitamin D stores of the mother [11]; THUS, IF the mother is hypovitaminotic D, her fetus will experience depleted Vitamin D exposure throughout Gestation [14].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 54), ('SUPERFICIAL_RELATIONSHIP', 170), ('PROBABLE_UNDERSTANDING', 224), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 230)]	5	[('NCBITaxon_9606', 'Homo sapiens', 13, 'human'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 26, 'vitamin D metabolism'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 139, 'human'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 331, 'gestation')]
S25-PMC2821652	PMC2821652	2/2010	S25-PMC2821652	['the main determinants of Calcium Homeostasis during Pregnancy are Parathyroid hormone, calcitonin, and the active form of Vitamin D—1,25(Oh)2D (whose synthesis is preferentially maintained EVEN during times of Vitamin D deficiency by upregulation of enzymes for improved utilization of whatever 25(Oh)D is available).']	[('ANOMALY_CURIOUS_FINDING', 189)]	1	"[('GO_0055073', 'cadmium ion homeostasis', 25, 'calcium homeostasis'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('UBERON_0001132', 'parathyroid gland', 66, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 134, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 295, '25(OH)D')]"
S57-PMC2821652	PMC2821652	2/2010	S57-PMC2821652	['at each study visit, AS a MARKER of Vitamin D status, circulating levels of 25(Oh)D and Vitamin D3Were measured in patient Serum.']	[('PROBABLE_UNDERSTANDING', 21), ('SUPERFICIAL_RELATIONSHIP', 26)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('CHEBI_73706', 'bromosuccinate', 88, 'vitamin D3were'), ('UBERON_0001977', 'blood serum', 123, 'serum')]
S74-PMC2821652	PMC2821652	2/2010	S74-PMC2821652	['WHILE there is a MODEL in existence which calculates the predicted change in Serum 25(Oh)D for different doses of Vitamin D supplement, this model was developed using data from men [64], and its applicability to a population of Pregnant females is debatable.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 17)]	2	[('UBERON_0001977', 'blood serum', 77, 'serum'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 83, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 228, 'pregnant')]
S75-PMC2821652	PMC2821652	2/2010	S75-PMC2821652	['THEREFORE, we were faced with the CHALLENGE of establishing novel criteria for Vitamin D supplement adherence by Serum 25(Oh)D levels; HOW we arrived at this definition is described below.']	[('PROBABLE_UNDERSTANDING', 0), ('DIFFICULT_TASK', 34), ('EXPLICIT_QUESTION', 135)]	3	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 121, '(OH ... D')]
S77-PMC2821652	PMC2821652	2/2010	S77-PMC2821652	"[""in developing a definition of adherence by Serum 25(Oh)D levels, SEVERAL ASSUMPTIONS were made a priori about WHAT types of PATTERNS of 25(Oh)D levels would be exhibited by adherent and nonadherent patients BASED ON CURRENT KNOWLEDGE about the Metabolism Of Vitamin D.\nassumption 1\nBASED ON KNOWN pharmacokinetics of Vitamin D [64], adherent patients' 25(Oh)D levels would be expected to rise over time, eventually reaching a steady state after 2 months of therapy; nonadherent patients' 25(Oh)D levels would be expected to be erratic and to exhibit variable PATTERNS that would differ significantly from adherent patients' 25(Oh)D levels over the same dosing interval.""]"	[('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('EXPLICIT_QUESTION', 110), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 207), ('PROBABLE_UNDERSTANDING', 207), ('SUPERFICIAL_RELATIONSHIP', 207), ('INCOMPLETE_EVIDENCE', 216), ('PROBABLE_UNDERSTANDING', 282), ('SUPERFICIAL_RELATIONSHIP', 282), ('INCOMPLETE_EVIDENCE', 291), ('SUPERFICIAL_RELATIONSHIP', 559)]	12	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 136, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 244, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 317, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 325, 'D'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 358, 'D'), ('CHEBI_71657', 'versiconol acetate', 488, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 488, '25'), ('PR_000011614', 'opioid growth factor receptor', 491, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 494, 'D'), ('CHEBI_71657', 'versiconol acetate', 624, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 624, '25(OH ... D')]
S78-PMC2821652	PMC2821652	2/2010	S78-PMC2821652	"[""THEREFORE, the average of each subject's steady-state 25(Oh)D levels (i.e., levels obtained at least 2 months after initiation of Vitamin D therapy) was calculated, and the subject's baseline 25(Oh)D level was subtracted from that value to obtain a value for the change in 25(Oh)D level during the study (change 25Ohd).""]"	[('PROBABLE_UNDERSTANDING', 0)]	1	"[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 192, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 273, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 279, 'D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 312, '25OHD')]"
S41-PMC2913107	PMC2913107	8/2010	S41-PMC2913107	['a comment to the authors (20) DETAILED the EVIDENCE that Antiepileptic Drugs are one of the few classes of Drugs that CONSISTENTLY and SIGNIFICANTLY INTERFERE with Vitamin D Metabolism, lowering 25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 118), ('IMPORTANT_CONSIDERATION', 135), ('SUPERFICIAL_RELATIONSHIP', 149)]	5	[('CHEBI_35218', 'anthocyanin cation', 57, 'antiepileptic'), ('CHEBI_23888', 'drug', 71, 'drugs'), ('CHEBI_23888', 'drug', 107, 'drugs'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0008152', 'metabolic process', 174, 'metabolism'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D')]
S49-PMC2913107	PMC2913107	8/2010	S49-PMC2913107	['seventeen Vitamin D EXPERTS RECENTLY STATED, ‘IN OUR OPINION, children with chronic illnesses such as autism, diabetes and/or frequent infections SHOULD BE supplemented with higher doses of sunshine or Vitamin D3, doses ADEQUATE to maintain their 25(Oh)D levels in the mid-normal of the reference range [65 ng/ml (162 nmol/l)] – and SHOULD BE so supplemented year round.’ (22)\nfinally, IF TRUE, a DARKER SIDE of the THEORY EMERGES.']	[('PROBABLE_UNDERSTANDING', 20), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 46), ('IMPORTANT_CONSIDERATION', 146), ('IMPORTANT_CONSIDERATION', 220), ('IMPORTANT_CONSIDERATION', 333), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 386), ('PROBABLE_UNDERSTANDING', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 397), ('INCOMPLETE_EVIDENCE', 416), ('INCOMPLETE_EVIDENCE', 423)]	12	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 202, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 202, 'vitamin D3'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D')]
S1-PMC2963768	PMC2963768	10/2010	S1-PMC2963768	['POOR Vitamin D status, INDICATED by low Serum concentrations of 25-Hydroxyvitamin D [25(Oh)D], HAS BEEN observed in south asian populations.']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 95)]	3	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('UBERON_0001977', 'blood serum', 40, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 64, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D')]
S3-PMC2963768	PMC2963768	10/2010	S3-PMC2963768	['THEREFORE, to gain PRELIMINARY INSIGHTS into the Vitamin D status of infants in rural bangladesh, 25(Oh)D was ASSESSED in a group of community-sampled control participants in a pneumonia case-control study in rural sylhet, bangladesh (25°n) during the winter dry season (january-february).']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 31), ('QUESTION_ANSWERED_BY_THIS_WORK', 110)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D')]
S7-PMC2963768	PMC2963768	10/2010	S7-PMC2963768	['within a larger group of 74 infants and toddlers aged 1-17 months (cases and controls recruited for the pneumonia study), young age was the ONLY significant RISK FACTOR for Vitamin D deficiency [25(Oh)D <25 nmol/l].']	[('ANOMALY_CURIOUS_FINDING', 140), ('SUPERFICIAL_RELATIONSHIP', 157)]	2	[('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D')]
S13-PMC2963768	PMC2963768	10/2010	S13-PMC2963768	['HOWEVER, SINCE Vitamin D status has become READILY estimable BASED on Serum/Plasma 25-Hydroxyvitamin D concentration [25(Oh)D] (2), epidemiologic RESEARCH aimed at identifying PREVIOUSLY-UNCHARACTERIZED AT-risk populations and characterizing NOVEL disease ASSOCIATIONS with Vitamin D status HAS BEEN greatly facilitated.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 9), ('PROBABLE_UNDERSTANDING', 43), ('QUESTION_ANSWERED_BY_THIS_WORK', 61), ('FUTURE_WORK', 146), ('INCOMPLETE_EVIDENCE', 176), ('INCOMPLETE_EVIDENCE', 187), ('IMPORTANT_CONSIDERATION', 203), ('FULL_UNKNOWN', 242), ('SUPERFICIAL_RELATIONSHIP', 256), ('INCOMPLETE_EVIDENCE', 291)]	11	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0001977', 'blood serum', 70, 'serum'), ('UBERON_0001969', 'blood plasma', 76, 'plasma'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 83, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
S15-PMC2963768	PMC2963768	10/2010	S15-PMC2963768	['low 25(Oh)D is SURPRISINGLY common in south asia, where systemic Vitamin D deficits would be expected to be PREVENTED by cutaneous Vitamin D Synthesis stimulated by exposure to sun at relatively low latitudes (3).']	[('ANOMALY_CURIOUS_FINDING', 15), ('PROBABLE_UNDERSTANDING', 15), ('SUPERFICIAL_RELATIONSHIP', 108)]	3	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('GO_0031151', 'histone methyltransferase activity (H3-K79 specific)', 139, 'D synthesis')]
S19-PMC2963768	PMC2963768	10/2010	S19-PMC2963768	"[""summary of studies of Vitamin D status of infants and children aged 1 month to <5 years in bangladesh, pakistan, and indiastudyparticipantslocationlatitudeseasonno.mean 25(Oh)d (nmol/l)categorical descriptions of Vitamin D statuscombs et al ., 2008 (9)aged 1-5 years; no clinical signs of ricketschakaria subdistrict, cox's bazar, bangladesh21°nunknown15868.3\n25(Oh)D <25 nmol/l in 6% (10/158)\n25(Oh)D <37.5 nmol/l in 21% (33/158)fischer et al ., 1999 (10)cases in case-control study of rickets; aged 10-120 monthschakaria subdistrict, bangladesh21°nunknown1450\nrange 17.5-162.5 nmol/l\n25(Oh)D <35 nmol/l in 2/14 (14%).controlschakaria subdistrict, bangladesh21°nunknown1362.5\nrange 55-87.5 nmol/l\nnone with 25(Oh)D <35 nmol/latiq et al ., 1998 (11)aged 6 weeks-11 months; immunization clinickarachi, pakistan25°nnovember-march2324.5\n25(Oh)D <25 nmol/l in 52% (throughout the year)april-october4840.7agarwal et al ., 2002 (12)aged 9-24 months; high-pollution areamorigate, delhi, india28°nmarch-april2631\n25(oh)d <30 nmol/l in 35%aged 9-24 months; low-pollution areagurgaon, delhi, india28°nmarch-april3168\n25(Oh)D <30 nmol/l in 0%bhalala et al ., 2007 (13)healthy breastfed infants aged 3 monthsmumbai, india18°nthroughout the year3545.5\n25(Oh)D <62.5 nmol/l in 80%tiwari and puliyel, 2004 (14)aged 9-30 months living in impoverished neighbourhoodssundernagari, delhi, india28°njanuary4796.3\n25(Oh)D <35 nmol/l in 2%rajiv colony, delhi, india28°nfebruary4923.8\n25(Oh)D <35nmol/l in 82.9%rajiv colony, delhi, india28°naugust4817.8\n25(Oh)D <35 nmol/l in 84.0%gurgaon, delhi, india28°naugust5219.2\n25(Oh)D <35 nmol/l in 82.0%wayse et al ., 2004 (15)healthy controls in case-control study; aged <5 yearsindapur, india17°nmay-june7038.4\n25(Oh)D <22.5 nmol/l in 31%\n25(Oh)D <50 nmol/l in 61%\nknowledge of the Vitamin D status of young children and infants IS NEEDED to DESIGN STUDIES targeting the aetiologic mechanisms and POTENTIAL health IMPLICATIONS of deficiency.""]"	[('FUTURE_WORK', 1851), ('FUTURE_WORK', 1864), ('INCOMPLETE_EVIDENCE', 1919), ('IMPORTANT_CONSIDERATION', 1936)]	4	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_37972', 'phosphorus-32 atom', 169, '25'), ('CHEBI_17792', 'organohalogen compound', 172, 'OH'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 360, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 394, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 588, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 708, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 711, 'OH ... D'), ('CHEBI_71657', 'versiconol acetate', 834, '25(OH)D'), ('PR_000006880', 'extracellular matrix protein 2', 834, '25 ... OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1110, 'OH)D'), ('CHEBI_71657', 'versiconol acetate', 1239, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1393, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1399, 'D'), ('CHEBI_71657', 'versiconol acetate', 1462, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1531, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1596, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1733, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1761, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1804, 'vitamin D')]
S21-PMC2963768	PMC2963768	10/2010	S21-PMC2963768	['HERE, we AIMED to describe the Vitamin D status of the source population and briefly review the POTENTIAL DETERMINANTS of low infant 25(Oh)D in this setting.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 106)]	4	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 133, '25 ... OH ... D')]
S45-PMC2963768	PMC2963768	10/2010	S45-PMC2963768	['as a secondary exploratory analysis, observations relating to infant, maternal or household FACTORS that POTENTIALLY INFLUENCED Vitamin D status were drawn from the complete sample of 74 participants (cases and controls) in whom 25(Oh)D was measured.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('INCOMPLETE_EVIDENCE', 105), ('SUPERFICIAL_RELATIONSHIP', 117)]	3	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 229, '25(OH)D')]
S72-PMC2963768	PMC2963768	10/2010	S72-PMC2963768	['in this group, age was the ONLY FACTOR that was significantly ASSOCIATED with Vitamin D deficiency DEFINED by 25(Oh)D <25 nmol/l (table 3).']	[('ANOMALY_CURIOUS_FINDING', 27), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 62), ('PROBABLE_UNDERSTANDING', 99)]	4	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 110, '25(OH ... D')]
S74-PMC2963768	PMC2963768	10/2010	S74-PMC2963768	['ALTHOUGH there were no significant associations between maternal dietary intake and infant/toddlers’ 25(Oh)D (data not shown) or Vitamin D deficiency (table 3), a higher proportion of the mothers of infants with 25(Oh)D ≥25 nmol/l consumed Milk, meat, and eggs on at least one occasion during the week preceding the interview (fig.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 101, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('UBERON_0001913', 'milk', 240, 'milk')]
S84-PMC2963768	PMC2963768	10/2010	S84-PMC2963768	['applying a very CONSERVATIVE definition of Vitamin D deficiency [25(Oh)D <25 nmol/l], we ESTIMATED that ABOUT one-third of infants aged 1-6 months MAY BE Vitamin D-deficient.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('INCOMPLETE_EVIDENCE', 89), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 147)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 65, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 71, 'D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
S96-PMC2963768	PMC2963768	10/2010	S96-PMC2963768	['so, it is WORTHWHILE NOTING that, among formula-Fed or Vitamin D-supplemented infants (mean Vitamin D intake of ∼370 iu per day) aged 1-6 months (n=37) enrolled in a hospital-based study during the winter in alberta, canada (53°n) (20), the mean 25(Oh)D was 78 nmol/l (roth d et al .']	[('ANOMALY_CURIOUS_FINDING', 10)]	1	[('GO_0007631', 'feeding behavior', 48, 'fed'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D')]
S108-PMC2963768	PMC2963768	10/2010	S108-PMC2963768	['young infants DEPEND ALMOST ENTIRELY on the transplacental transfer of Vitamin D and 25(Oh)D, which EXPLAINS the CONSISTENT ASSOCIATION between maternal and Cord-blood 25(Oh)D (25) and the observation that maternal Antenatal Vitamin D supplementation augments both maternal and Cord-Blood 25(Oh)D (26).']	[('SUPERFICIAL_RELATIONSHIP', 14), ('PROBABLE_UNDERSTANDING', 21), ('PROBABLE_UNDERSTANDING', 100), ('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 124)]	5	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 157, 'cord'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 168, '25(OH ... D'), ('GO_0007567', 'parturition', 215, 'antenatal'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 278, 'cord'), ('UBERON_0000178', 'blood', 283, 'blood'), ('CHEBI_71657', 'versiconol acetate', 289, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 289, '25 ... OH ... D')]
S109-PMC2963768	PMC2963768	10/2010	S109-PMC2963768	['THEREFORE, the MAJOR REASON that bangladeshi infants start Life with POOR Vitamin D stores is low maternal Antenatal 25(Oh)D, which HAS BEEN DOCUMENTED in urban and rural bangladeshi women of Reproductive age (27).']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 15), ('PROBABLE_UNDERSTANDING', 21), ('IMPORTANT_CONSIDERATION', 69), ('INCOMPLETE_EVIDENCE', 132), ('INCOMPLETE_EVIDENCE', 141)]	6	[('UBERON_0000104', 'life cycle', 59, 'life'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007567', 'parturition', 107, 'antenatal'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 123, 'D'), ('GO_0000003', 'reproduction', 192, 'reproductive')]
S111-PMC2963768	PMC2963768	10/2010	S111-PMC2963768	['RECENTLY STUDIED female workers in a garment factory in dhaka and SPECULATED that their long day-time hours in indoors, brief exposure to low-intensity sunlight in the early morning, outdoor air pollution, and widespread sunscreen use, in combination with darkly-Pigmented skin, MAY CONTRIBUTE to their POOR Vitamin D status (mean 25(Oh)D of 37 nmol/l, and 15% of the participants had 25(Oh)D <25 nmol/l) (28).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 283), ('IMPORTANT_CONSIDERATION', 303)]	5	[('CHEBI_26130', 'biological pigment', 263, 'pigmented'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 331, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 385, '25(OH)D')]
S116-PMC2963768	PMC2963768	10/2010	S116-PMC2963768	['the amount of Vitamin D in the local diet is UNKNOWN but low calcium intake (or reduced absorption of Calcium due to high Phytate intake), typical of low-income diets in bangladesh (30,31), MAY accelerate 25(Oh)D use, leading to relatively-increased Vitamin D demands (32).']	[('FULL_UNKNOWN', 45), ('INCOMPLETE_EVIDENCE', 190)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 102, 'calcium'), ('CHEBI_15361', 'pyruvate', 122, 'phytate'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D')]
S117-PMC2963768	PMC2963768	10/2010	S117-PMC2963768	['SINCE the concentration of Vitamin D Metabolites in Breastmilk is determined by maternal Vitamin D status, maternal Vitamin D deficiency during Lactation MAY cause ongoing deficits in Postnatal infants’ Vitamin D intake (42); YET, maternal FACTORS CANNOT ENTIRELY ACCOUNT for the persistence of low 25(Oh)D among toddlers (table 1) who experience direct exposure to sun and should BE unaffected by the conservative clothing practices of their mothers.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBLEM_COMPLICATION', 0), ('INCOMPLETE_EVIDENCE', 154), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 226), ('ANOMALY_CURIOUS_FINDING', 226), ('SUPERFICIAL_RELATIONSHIP', 240), ('INCOMPLETE_EVIDENCE', 248), ('IMPORTANT_CONSIDERATION', 264), ('ANOMALY_CURIOUS_FINDING', 381)]	9	[('CHEBI_26871', 'terpene alkaloid', 27, 'vitamin D metabolites'), ('UBERON_0001348', 'brown adipose tissue', 52, 'breastmilk'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007595', 'lactation', 144, 'lactation'), ('GO_0007567', 'parturition', 184, 'postnatal'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 299, '25(OH)D')]
S118-PMC2963768	PMC2963768	10/2010	S118-PMC2963768	['THEREFORE, much remains to be learnt about the DETERMINANTS of Vitamin D status throughout infancy and childhood, PARTICULARLY where 25(Oh)D APPEARS DISCREPANT from that which would be expected BASED ON latitude.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 47), ('IMPORTANT_CONSIDERATION', 114), ('ANOMALY_CURIOUS_FINDING', 141), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 149), ('SUPERFICIAL_RELATIONSHIP', 194)]	6	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D')]
S125-PMC2963768	PMC2963768	10/2010	S125-PMC2963768	['Vitamin D Receptor, 24-hydroxylase\nDESPITE the current enthusiasm for Vitamin D supplementation in the usa (22), the EFFECTS of Vitamin D deficits during early infancy are STILL NOT FULLY UNDERSTOOD, and meaningful inflection points in 25(Oh)D-outcome RELATIONSHIPS have NOT BEEN ESTABLISHED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('ANOMALY_CURIOUS_FINDING', 35), ('SUPERFICIAL_RELATIONSHIP', 117), ('FULL_UNKNOWN', 172), ('IMPORTANT_CONSIDERATION', 172), ('INCOMPLETE_EVIDENCE', 178), ('SUPERFICIAL_RELATIONSHIP', 252), ('FULL_UNKNOWN', 271), ('ANOMALY_CURIOUS_FINDING', 275)]	9	[('CHEBI_27300', 'vitamin D', 0, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 0, 'vitamin D receptor'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 236, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 236, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 239, 'OH ... D')]
S129-PMC2963768	PMC2963768	10/2010	S129-PMC2963768	['ALTHOUGH 25(Oh)D <25 nmol/l is typical of clinically-apparent rickets, early stages of the disease MAY occur at higher 25(Oh)D (∼40 nmol/l) (47), with declines in 25(Oh)D occurring as the disease progresses and Vitamin D stores are depleted.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 99)]	2	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 122, 'OH)D'), ('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S137-PMC2963768	PMC2963768	10/2010	S137-PMC2963768	"[""a PLAUSIBLE HYPOTHESIS is that Vitamin D deficiency ACTS SYNERGISTICALLY with OTHER causes of INADEQUATE bone mineralization and that an Individual's 25(Oh)D concentration below which clinical signs emerge DEPENDS ON the severity and multiplicity of OTHER Genetic and environmental FACTORS.""]"	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 52), ('SUPERFICIAL_RELATIONSHIP', 57), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('IMPORTANT_CONSIDERATION', 94), ('SUPERFICIAL_RELATIONSHIP', 206), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 250), ('SUPERFICIAL_RELATIONSHIP', 282)]	9	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('NCBITaxon_1', 'root', 137, 'individual'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 150, '25 ... OH ... D'), ('SO_0000704', 'gene', 256, 'genetic')]
S87-PMC3004407	PMC3004407	12/2010	S87-PMC3004407	['the mean Vitamin D status of the cohort, AS measured by total circulating 25(Oh)D, was 21.7 ± 9.7\u2009ng/ml (range 3.8 to 73.8; unavailable for 7 participants).']	[('PROBABLE_UNDERSTANDING', 41)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 74, '25(OH)D')]
S95-PMC3004407	PMC3004407	12/2010	S95-PMC3004407	['the odds of Vitamin D deficiency (AS measured by 25(Oh)D concentration) did NOT APPEAR TO change as a function of Gestational age; women in their later stages of Pregnancy had a SIMILAR odds of Vitamin D deficiency and insufficiency for a given race/ethnicity than women who had their 25(Oh)D concentrations measured earlier in Pregnancy ( p = .43).']	[('PROBABLE_UNDERSTANDING', 34), ('ANOMALY_CURIOUS_FINDING', 76), ('ANOMALY_CURIOUS_FINDING', 80), ('SUPERFICIAL_RELATIONSHIP', 178)]	4	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 285, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 291, 'D'), ('GO_0007565', 'female pregnancy', 328, 'pregnancy')]
S131-PMC3004407	PMC3004407	12/2010	S131-PMC3004407	['WHILE there was a significant variation in 25(Oh)D concentrations between racial/ethnic categories, the deficiency did not APPEAR to change as a function of Gestational age; women in their later stages of Pregnancy had a SIMILAR risk of Vitamin D deficiency and insufficiency for a given race/ethnicity compared with women who had their 25(Oh)D concentrations measured earlier in Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 123), ('SUPERFICIAL_RELATIONSHIP', 221)]	3	[('CHEBI_71657', 'versiconol acetate', 43, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 43, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 49, 'D'), ('GO_0007565', 'female pregnancy', 157, 'gestational'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 337, '25(OH)D'), ('GO_0007565', 'female pregnancy', 380, 'pregnancy')]
S143-PMC3004407	PMC3004407	12/2010	S143-PMC3004407	['after accounting for the EFFECT of Gestational age through multivariable regression, 25(Oh)D status retained a significant negative ASSOCIATION with pth, CONFIRMING that EVEN during Pregnancy, pth is a PREDICTOR of Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('SUPERFICIAL_RELATIONSHIP', 132), ('PROBABLE_UNDERSTANDING', 154), ('ANOMALY_CURIOUS_FINDING', 170), ('SUPERFICIAL_RELATIONSHIP', 202)]	5	[('GO_0007565', 'female pregnancy', 35, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 87, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D')]
S146-PMC3004407	PMC3004407	12/2010	S146-PMC3004407	['using both circulating 25(Oh)D and pth as MARKERS of Vitamin D deficiency, THESE FINDINGS UNDERSCORE RECENT REPORTS of widespread Vitamin D deficiency among Pregnant women, EVEN in areas of the world with ample sunlight.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 90), ('INCOMPLETE_EVIDENCE', 101), ('INCOMPLETE_EVIDENCE', 108), ('ANOMALY_CURIOUS_FINDING', 173)]	6	[('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnant')]
S4-PMC3257641	PMC3257641	3/2010	S4-PMC3257641	['the EVIDENCE to date SUPPORTS that women SHOULD BE monitored and treated for Vitamin D deficiency during Pregnancy BUT OPTIMAL and upper limit Serum 25(Oh)D levels during Pregnancy are NOT KNOWN.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('FUTURE_WORK', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('IMPORTANT_CONSIDERATION', 119), ('FULL_UNKNOWN', 185)]	6	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'pregnancy'), ('UBERON_0001977', 'blood serum', 143, 'serum'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 149, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy')]
S7-PMC3257641	PMC3257641	3/2010	S7-PMC3257641	['with regard to terminology, we use Vitamin D when referring to Cholecalciferol or Ergocalciferol (BUT ‘Vitamin D3’ or ‘Vitamin D2’ where reference is made specifically to only a single form of Calciferol); 25(Oh)D to refer to 25 Hydroxycalciferol (including both 25(Oh)D2And 25(Oh)d3), and 1,25(Oh)2D, the active form of the hormone, to include both 1,25(Oh)2D2And 1,25(Oh)2D3.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 98)]	1	"[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 63, 'cholecalciferol'), ('CHEBI_4910', 'etomidate', 82, 'ergocalciferol'), ('CHEBI_33279', 'vitamin D5', 103, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 103, 'vitamin D3'), ('CHEBI_28934', 'vitamin D2', 119, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 119, 'vitamin D2'), ('CHEBI_28623', 'campesterol', 193, 'calciferol'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('CHEBI_65819', 'eckol', 226, '25 hydroxycalciferol'), ('CHEBI_76948', 'ent-manool', 263, '25(OH)D2and'), ('CHEBI_63056', 'zinc cation', 275, '25(OH'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 292, '25(OH)2D'), ('CHEBI_76948', 'ent-manool', 352, '25(OH)2D2and'), ('CHEBI_73394', 'Ala-Ser', 367, '25(OH)2D3')]"
S43-PMC3257641	PMC3257641	3/2010	S43-PMC3257641	['furthermore, SINCE 25(Oh)D is stored in Adipose Tissue, there is SOME EVIDENCE that obesity is a FURTHER RISK FACTOR for Vitamin D insufficiency.nutrients-02-00389-t001_table 1\n\ncaption (table-wrap): table 1\n\nrisk factors for Vitamin D deficiency.low ambient uvr level high latitude locationwinter season inadequate sun exposure built or indoor environmentextensive clothing cover (e.g., veiled)excess sun avoidance – (shade, sunscreen) host factors dark skin pigmentationold ageobesitymalabsorptive syndromes (e.g., inflammatory Bowel disease)\nMANY STUDIES HAVE REPORTED on the Vitamin D status of Pregnant women, in a range of environments (summarized intable 2, including studies from 1997–2006).']	[('PROBLEM_COMPLICATION', 13), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 97), ('SUPERFICIAL_RELATIONSHIP', 105), ('INCOMPLETE_EVIDENCE', 545), ('INCOMPLETE_EVIDENCE', 558)]	6	[('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('UBERON_0001013', 'adipose tissue', 40, 'adipose tissue'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('UBERON_0000160', 'intestine', 530, 'bowel'), ('CHEBI_27300', 'vitamin D', 579, 'vitamin D'), ('GO_0007565', 'female pregnancy', 599, 'pregnant')]
S48-PMC3257641	PMC3257641	3/2010	S48-PMC3257641	['a NUMBER OF STUDIES within non-Pregnant Adult populations have examined 25(Oh)D levels in RELATION to DIFFERENT dosages, preparations or dosing intervals of oral Vitamin D (reviewed in[33]).']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 102)]	3	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('UBERON_0007023', 'adult organism', 40, 'adult'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
S49-PMC3257641	PMC3257641	3/2010	S49-PMC3257641	['recent RECOMMENDATIONS SUGGEST that the lower level of Vitamin D adequacy SHOULD BE a Serum 25(Oh)D level of 75–80 nmol/l.']	[('FUTURE_WORK', 7), ('INCOMPLETE_EVIDENCE', 23), ('FUTURE_WORK', 74)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 92, '25(OH ... D')]
S51-PMC3257641	PMC3257641	3/2010	S51-PMC3257641	['FEW STUDIES to date have examined Vitamin D supplementation during Pregnancy, and optimal 25(Oh)D levels have not yet been defined [35,36].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D')]
S56-PMC3257641	PMC3257641	3/2010	S56-PMC3257641	['a RECENT meta-analysis of Vitamin D supplementation in RELATION to bone health in Adults, SHOWED that for every 1 iu increase in oral Vitamin D3, the 25(Oh)D level COULD BE expected to increase by 0.016 nmol/l, with a relatively linear RELATIONSHIP AT LEAST up to 2000 iu/day [45].']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 90), ('INCOMPLETE_EVIDENCE', 164), ('SUPERFICIAL_RELATIONSHIP', 236), ('PROBABLE_UNDERSTANDING', 249)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0007023', 'adult organism', 82, 'adults'), ('CHEBI_33279', 'vitamin D5', 134, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 134, 'vitamin D3'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D')]
S81-PMC3257641	PMC3257641	3/2010	S81-PMC3257641	['there was a positive CORRELATION between the maternal 25(Oh)D level and the Fetal Metaphyseal cross-sectional area, with the latter 5% and 14% greater in fetuses of mothers who were Vitamin D insufficient (Serum 25(Oh)D 25-50 nmol/l) and Vitamin D deficient (Serum 25(Oh)D < 25 nmol/l) compared to Vitamin D sufficient mothers (Serum 25(Oh)D > 50 nmol/l) [56].']	[('SUPERFICIAL_RELATIONSHIP', 21)]	1	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('UBERON_0000922', 'embryo', 76, 'fetal'), ('UBERON_0001438', 'metaphysis', 82, 'metaphyseal'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 218, 'D'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D'), ('UBERON_0001977', 'blood serum', 259, 'serum'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 265, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('UBERON_0001977', 'blood serum', 328, 'serum'), ('CHEBI_71657', 'versiconol acetate', 334, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 334, '25(OH)D')]
S90-PMC3257641	PMC3257641	3/2010	S90-PMC3257641	['in a cross sectional study, caesarean section was almost four-times MORE COMMON in women with Vitamin D insufficiency (Serum 25(Oh)D < 37.5 nmol/l) compared to Vitamin D-sufficient women (Serum 25(Oh)D ≥ 37.5 nmol/l), after adjustment for race, age, education level, insurance status, and Alcohol use (adjusted or 3.84; 95% ci 1.71–8.62) [59].']	[('PROBABLE_UNDERSTANDING', 68)]	1	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_71657', 'versiconol acetate', 125, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 125, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0001977', 'blood serum', 188, 'serum'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 194, '25(OH)D'), ('CHEBI_30879', 'alcohol', 289, 'alcohol')]
S106-PMC3257641	PMC3257641	3/2010	S106-PMC3257641	['NEVERTHELESS, in two studies in Pigs, Vitamin D administration to two sows at doses that achieved Serum 25(Oh)D levels, APPROXIMATING RECOMMENDED Human levels, was ASSOCIATED with Coronary lesions in offspring at six weeks [74,75].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 120), ('FUTURE_WORK', 134), ('SUPERFICIAL_RELATIONSHIP', 164)]	4	[('NCBITaxon_10088', 'Mus <genus>', 32, 'pigs'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 104, '25(OH ... D'), ('NCBITaxon_9606', 'Homo sapiens', 146, 'human'), ('UBERON_0005985', 'coronary vessel', 180, 'coronary')]
S6-PMC3271033	PMC3271033	1/2012	S6-PMC3271033	['daily Vitamin D intake of 400 iu during the first months of Life APPEARS adequate to increase Serum 25(Oh)D and SUPPORT bmc increases DESPITE low initial 25(Oh)D levels in some infants.']	[('ANOMALY_CURIOUS_FINDING', 65), ('SUPERFICIAL_RELATIONSHIP', 112), ('ANOMALY_CURIOUS_FINDING', 134)]	3	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('UBERON_0000104', 'life cycle', 60, 'life'), ('UBERON_0001977', 'blood serum', 94, 'serum'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 102, '(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 154, '25(OH)D')]
S14-PMC3271033	PMC3271033	1/2012	S14-PMC3271033	['Serum 25-Hydroxyvitamin D (25(Oh)D) is ACCEPTED as the BEST MARKER of Vitamin D status ALTHOUGH it MAY serve PRIMARILY as a MARKER of exposure RATHER than clinical outcomes [2].there are FEW DATA that CORRELATE Serum 25(Oh)D levels with functional outcomes in newborns and small infants.']	[('INCOMPLETE_EVIDENCE', 39), ('IMPORTANT_CONSIDERATION', 55), ('SUPERFICIAL_RELATIONSHIP', 60), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 87), ('INCOMPLETE_EVIDENCE', 99), ('PROBABLE_UNDERSTANDING', 109), ('SUPERFICIAL_RELATIONSHIP', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 143), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 201)]	10	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 6, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0001977', 'blood serum', 211, 'serum'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D')]
S15-PMC3271033	PMC3271033	1/2012	S15-PMC3271033	['neonatal Serum 25(Oh)D levels REFLECT a range of in utero FACTORS, most significant of these being the maternal Vitamin D status [6].']	[('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 58)]	2	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 15, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
S109-PMC3271033	PMC3271033	1/2012	S109-PMC3271033	['supplementation with 400 iu/day of Vitamin D to these infants LED TO a relatively greater increase in those who were Born with the lowest Vitamin D status and there was no suggestion of any bone Mineral outcome deficits at one week or three months of age in infants with low Cord 25(Oh)D levels.']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007567', 'parturition', 117, 'born'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_46662', 'mineral', 195, 'mineral'), ('UBERON_0002240', 'spinal cord', 275, 'cord'), ('CHEBI_71657', 'versiconol acetate', 280, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 280, '25(OH)D')]
S134-PMC3271033	PMC3271033	1/2012	S134-PMC3271033	['greer et al [16] FOUND an increase in 25(Oh)D from 24 to 39 ng/ml at three months of age with the provision of 400 iu/day of Vitamin D to Breast-Fed infants.']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 38, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007567', 'parturition', 138, 'breast'), ('UBERON_0000310', 'breast', 138, 'breast'), ('GO_0007631', 'feeding behavior', 145, 'fed')]
S138-PMC3271033	PMC3271033	1/2012	S138-PMC3271033	['high doses of Vitamin D in early Life) with or without monitoring of 25(Oh)D levels or WHETHER the 400 iu/day dose is adequate.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 87)]	1	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0000104', 'life cycle', 33, 'life'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 75, 'D')]
S156-PMC3271033	PMC3271033	1/2012	S156-PMC3271033	['THUS, IT IS CLEAR that a southern us location is not protective against seasonal deficiency of Vitamin D or low Cord 25(Oh)D levels.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 6)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 112, 'cord'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 123, 'D')]
S3-PMC3277098	PMC3277098	12/2011	S3-PMC3277098	['there is a GROWING BODY of LITERATURE LINKING Vitamin D (Serum 25(Oh)D, Oral Intake and SURROGATE indicators such as latitude) to various immune-RELATED conditions, including allergy, ALTHOUGH the nature of this RELATIONSHIP is STILL UNCLEAR.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 88), ('SUPERFICIAL_RELATIONSHIP', 145), ('ANOMALY_CURIOUS_FINDING', 184), ('SUPERFICIAL_RELATIONSHIP', 212), ('FULL_UNKNOWN', 228)]	8	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('UBERON_0001977', 'blood serum', 57, 'serum'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 63, '25 ... OH ... D'), ('UBERON_0000165', 'mouth', 72, 'oral'), ('GO_0007631', 'feeding behavior', 77, 'intake')]
S8-PMC3277098	PMC3277098	12/2011	S8-PMC3277098	['we now KNOW that all Tissues in the body posses receptors for the active form of Vitamin D, 1,25-Dihydroxyvitamin D (1α,25(Oh)2D3) and it HAS RECENTLY BEEN DISCOVERED that there are Extrarenal Tissues capable of converting 25(Oh)D to the active Metabolite, including certain Immune Cells [1,2].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 138), ('INCOMPLETE_EVIDENCE', 156)]	3	[('UBERON_0000479', 'tissue', 21, 'tissues'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 92, '1,25-dihydroxyvitamin D'), ('CHEBI_34898', 'OM-174', 123, 'OH)2D3'), ('UBERON_0005292', 'extraembryonic tissue', 182, 'extrarenal tissues'), ('CHEBI_71657', 'versiconol acetate', 223, '25(OH)D'), ('CHEBI_39382', 'flufenoxuron', 245, 'metabolite'), ('CL_0000738', 'leukocyte', 275, 'immune cells'), ('UBERON_0002405', 'immune system', 275, 'immune')]
S31-PMC3277098	PMC3277098	12/2011	S31-PMC3277098	['this ASSOCIATION persists after adjusting for physical activity and dietary intake SUGGESTING obesity is an INDEPENDENT risk factor for reduced Serum 25(Oh)D and SUPPORTS the notion that Vitamin D deficiency MAY follow from modern lifestyle change.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 83), ('SUPERFICIAL_RELATIONSHIP', 108), ('INCOMPLETE_EVIDENCE', 162), ('INCOMPLETE_EVIDENCE', 208)]	5	[('UBERON_0001977', 'blood serum', 144, 'serum'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 150, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S33-PMC3277098	PMC3277098	12/2011	S33-PMC3277098	['the developing foetus depends entirely on its mother for supply of 25(Oh)D and poor maternal Vitamin D status is REFLECTED in the infant at Birth [23].']	[('SUPERFICIAL_RELATIONSHIP', 113)]	1	[('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('GO_0007567', 'parturition', 140, 'birth')]
S34-PMC3277098	PMC3277098	12/2011	S34-PMC3277098	['in non-supplemented infants serum 25(Oh)D status TENDS to decrease over the first few months of Life until sun exposure is increased and Vitamin D-containing Foods introduced into the diet.']	[('SUPERFICIAL_RELATIONSHIP', 49)]	1	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('UBERON_0000104', 'life cycle', 96, 'life'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('CHEBI_33290', 'food', 158, 'foods')]
S60-PMC3277098	PMC3277098	12/2011	S60-PMC3277098	['this line of argument HIGHLIGHTS that the potency and pharmacokinetics of endogenous and exogenous Vitamin D MAY BE DIFFERENT and that Serum 25(Oh)D, sun exposure and oral Intake SHOULD BE CONSIDERED INDEPENDENTLY of one another.']	[('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 109), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('FUTURE_WORK', 179), ('FUTURE_WORK', 189), ('SUPERFICIAL_RELATIONSHIP', 200)]	6	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('UBERON_0001977', 'blood serum', 135, 'serum'), ('CHEBI_71657', 'versiconol acetate', 141, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 141, '25(OH ... D'), ('GO_0007631', 'feeding behavior', 172, 'intake')]
S68-PMC3277098	PMC3277098	12/2011	S68-PMC3277098	['the latter study FOUND a high prevalence of Vitamin D deficiency in patients, with 88.9% of having Serum 25(Oh)D <50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('UBERON_0001977', 'blood serum', 99, 'serum'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 105, '25(OH)D')]
S132-PMC3277098	PMC3277098	12/2011	S132-PMC3277098	['RECORDED Serum 25(Oh)D in addition to dietary and supplemental Vitamin D intake and ESTIMATED uv exposure in 466 Pregnant women in the uk [55].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 84)]	2	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S181-PMC3277098	PMC3277098	12/2011	S181-PMC3277098	['[64] FOUND that lower Serum 25(Oh)D (of ≤37.5 nmol/l) was ASSOCIATED with both Peanut (or 2.39; 95% ci 1.29–4.45, p = 0.005) and shrimp (or 3.08; 95% ci 1.16–8.19, p = 0.02) sensitization, HOWEVER, OTHER studies of Food allergy are LARGELY LIMITED TO epidemiological data without serological measures of Vitamin D [69,70,71,72].']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 58), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 189), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 198), ('INCOMPLETE_EVIDENCE', 232), ('INCOMPLETE_EVIDENCE', 240)]	6	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 28, '25(OH)D'), ('NCBITaxon_10088', 'Mus <genus>', 79, 'peanut'), ('CHEBI_33290', 'food', 215, 'food'), ('CHEBI_27300', 'vitamin D', 304, 'vitamin D')]
S184-PMC3277098	PMC3277098	12/2011	S184-PMC3277098	['this data has the advantage of focussing on the Early Life Period and MAY THEREFORE provide INSIGHT into the aetiological ROLE of Vitamin D. DESPITE the OBSERVED PROTECTIVE ASSOCIATION of Serum 25(Oh)D and allergy, it has been NOTED that the widespread practice of supplementation COINCIDED with the rise in allergic disease [35].']	[('INCOMPLETE_EVIDENCE', 70), ('PROBABLE_UNDERSTANDING', 74), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('ANOMALY_CURIOUS_FINDING', 141), ('INCOMPLETE_EVIDENCE', 153), ('SUPERFICIAL_RELATIONSHIP', 162), ('SUPERFICIAL_RELATIONSHIP', 173), ('ANOMALY_CURIOUS_FINDING', 227), ('SUPERFICIAL_RELATIONSHIP', 281)]	11	[('UBERON_0019248', 'early embryo', 48, 'early life period'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('UBERON_0001977', 'blood serum', 188, 'serum'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 194, '25(OH)D')]
S199-PMC3277098	PMC3277098	12/2011	S199-PMC3277098	['most of these OBSERVATIONAL studies DID NOT have direct serological measures of 25(Oh)D levels to ACCURATELY CONFIRM Vitamin D status and cross sectional study designs involving older children and Adults fail TO provide EVIDENCE on aetiological FACTORS.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 98), ('INCOMPLETE_EVIDENCE', 109), ('QUESTION_ANSWERED_BY_THIS_WORK', 209), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 245)]	7	[('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('UBERON_0007023', 'adult organism', 197, 'adults')]
S0-PMC3296991	PMC3296991	2/2012	S0-PMC3296991	['EVIDENCE of ASSOCIATIONS between feto-maternal Vitamin D status, Cord Parathyroid Hormone and bone-specific alkaline phosphatase, and newborn Whole body bone Mineral content\n\nabstract\nin SPITE of a high prevalence of Vitamin D inadequacy in Pregnant women and neonates, RELATIONSHIPS among Vitamin D status (25(Oh)D), Parathyroid hormone (pth), bone specific alkaline phosphatase (balp), and Whole body bone Mineral content (wbbmc) in the newborn are POORLY characterized.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 12), ('ANOMALY_CURIOUS_FINDING', 187), ('SUPERFICIAL_RELATIONSHIP', 270), ('PROBLEM_COMPLICATION', 451)]	5	[('CHEBI_28384', 'vitamin K', 47, 'Vitamin D'), ('UBERON_0000948', 'heart', 65, 'Cord'), ('UBERON_0001132', 'parathyroid gland', 70, 'Parathyroid'), ('CHEBI_5762', 'hordatine A', 82, 'Hormone'), ('UBERON_0004043', 'semicircular canal ampulla', 142, 'Whole'), ('CHEBI_46662', 'mineral', 158, 'Mineral'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0007565', 'female pregnancy', 241, 'pregnant'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 308, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 318, 'parathyroid'), ('UBERON_0007688', 'anlage', 392, 'whole'), ('CHEBI_46662', 'mineral', 408, 'mineral')]
S67-PMC3296991	PMC3296991	2/2012	S67-PMC3296991	['Cord Serum 25(Oh)D was significantly higher, and maternal Serum 25(Oh)D marginally higher, in women whose total daily Vitamin D intake was ESTIMATED to be >600 iu/day ( n = 50, p = 0.0015 and p = 0.06 for Cord and maternal values, respectively).']	[('INCOMPLETE_EVIDENCE', 139)]	1	[('UBERON_0000948', 'heart', 0, 'Cord'), ('UBERON_0001977', 'blood serum', 5, 'serum'), ('CHEBI_71657', 'versiconol acetate', 11, '25(OH)D'), ('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 205, 'cord')]
S85-PMC3296991	PMC3296991	2/2012	S85-PMC3296991	['in the PRESENT STUDY, total maternal daily Vitamin D intake >600 iu/day was ASSOCIATED with significantly higher Cord, and a TREND towards higher maternal, Serum 25(Oh)D at Delivery.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 125)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 113, 'cord'), ('UBERON_0001977', 'blood serum', 156, 'serum'), ('CHEBI_71657', 'versiconol acetate', 162, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 162, '25(OH ... D'), ('GO_0007567', 'parturition', 173, 'delivery')]
S12-PMC3347007	PMC3347007	4/2012	S12-PMC3347007	['during Pregnancy, Vitamin D is transported from mother to fetus through the Placenta in the form of 25(Oh)D which is also the established MARKER of Vitamin D status [1,3,4].']	[('SUPERFICIAL_RELATIONSHIP', 138)]	1	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('UBERON_0001987', 'placenta', 76, 'placenta'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S175-PMC3347007	PMC3347007	4/2012	S175-PMC3347007	['also, VALIDATION of a similar database from the norwegian Birth cohort moba SHOWED good agreement between supplementary Vitamin D measured by ffq and 25(Oh)D levels [24].']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 76)]	2	[('GO_0007567', 'parturition', 58, 'birth'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 150, '25(OH ... D')]
S40-PMC3347028	PMC3347028	3/2012	S40-PMC3347028	['WHILE there APPEARS TO BE a DIFFERENTIAL conversion rate of the two forms of Vitamin D to 25(Oh)D [8], the conversion of either form is DEPENDENT on a functional Liver and the activity of 25-hydroxylase.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('SUPERFICIAL_RELATIONSHIP', 136)]	4	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('UBERON_0002107', 'liver', 162, 'liver')]
S41-PMC3347028	PMC3347028	3/2012	S41-PMC3347028	['THUS, those with impaired Liver function will have diminished conversion of Vitamin D to 25(Oh)D. following its synthesis, 25(Oh) then enters the circulation where it is tightly bound to Vdbp.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('UBERON_0002107', 'liver', 26, 'liver'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 123, '25(OH)'), ('PR_000017279', 'testis-specific basic protein Y 1', 187, 'VDBP')]
S43-PMC3347028	PMC3347028	3/2012	S43-PMC3347028	['the half-life of 25(Oh)D is 2–3 weeks, making it a much better INDICATOR of the body’s Vitamin D status than Vitamin D. OF NOTE, 25(Oh)D can be expressed as ng/ml or nmol/l.']	[('SUPERFICIAL_RELATIONSHIP', 63), ('ANOMALY_CURIOUS_FINDING', 120)]	2	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D')]
S46-PMC3347028	PMC3347028	3/2012	S46-PMC3347028	['BEST KNOWN is the processing of 25(Oh)D by the Kidney where 25(Oh)D Complexed with Vdbp and Megalin is taken up by the Epithelial Cells of the Proximal Tubules and converted to the active hormonal form of Vitamin D—Di-Hydroxy-Vitamin D (1,25(Oh)2d or Calcitriol)—by the action of the Mitochondrial enzyme 1-α-hydroxylase.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('UBERON_0002113', 'kidney', 47, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('GO_0032991', 'protein-containing complex', 68, 'complexed'), ('PR_000017279', 'testis-specific basic protein Y 1', 83, 'VDBP'), ('PR_000010409', 'midnolin', 92, 'megalin'), ('CL_0000066', 'epithelial cell', 119, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 119, 'epithelial'), ('UBERON_0004134', 'proximal tubule', 143, 'proximal tubules'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D'), ('CHEBI_67723', 'Anhydrofurospongin-1', 215, 'di-hydroxy-'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('CHEBI_87140', '3-oxochola-4,22-dien-24-oyl-CoA', 237, '1,25(OH)'), ('CHEBI_17823', 'calcitriol', 251, 'calcitriol'), ('GO_0005739', 'mitochondrion', 284, 'mitochondrial')]
S49-PMC3347028	PMC3347028	3/2012	S49-PMC3347028	['adequate Vitamin D MUST BE on hand to provide enough substrate to form 25(Oh)D, which in turn, is converted to 1,25(Oh)2D, whose half-life is 8 hours.']	[('IMPORTANT_CONSIDERATION', 19)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 116, 'OH)2D')]
S83-PMC3347028	PMC3347028	3/2012	S83-PMC3347028	['THUS, pth levels are RELATED to Vitamin D status as well: pth upregulates 1-α-hydroxylase, the enzyme responsible for 1-α-hydroxylation of 25(Oh)D, converting 25(Oh)D to 1,25(Oh)2D.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 21)]	2	"[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 139, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 159, '25(OH)D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 172, '25(OH)2D')]"
S97-PMC3347028	PMC3347028	3/2012	S97-PMC3347028	['WHILE okonofua, et al, SUGGEST that normalization of maternal calcium and pth would be useful endpoints in determining the success of Vitamin D supplementation during Pregnancy, more RECENT STUDIES SUGGEST that BECAUSE pth threshold ESTIMATES cannot be precisely defined, total circulating 25(Oh)D ALONE is a BETTER measure of maternal Vitamin D status [60,64,65].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 198), ('PROBLEM_COMPLICATION', 211), ('INCOMPLETE_EVIDENCE', 233), ('ANOMALY_CURIOUS_FINDING', 298), ('INCOMPLETE_EVIDENCE', 298), ('INCOMPLETE_EVIDENCE', 309)]	9	[('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S110-PMC3347028	PMC3347028	3/2012	S110-PMC3347028	['in addition, BASED on rickets and osteoporosis data, it APPEARS that bone health, which is LINKED with Renal production of 1,25(Oh)2D and Calcium Metabolism is maintained at significantly lower levels of circulating Vitamin D concentrations COMPARED to OTHER health factors such as Immune function, which is dependent on delivery of 25(Oh)D to cells of the target Tissue.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('ANOMALY_CURIOUS_FINDING', 56), ('SUPERFICIAL_RELATIONSHIP', 91), ('ANOMALY_CURIOUS_FINDING', 241), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 253)]	5	"[('UBERON_0002113', 'kidney', 103, 'renal'), ('CHEBI_37958', 'dye', 123, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 125, '25(OH)2D'), ('CHEBI_22313', 'alkaline earth metal atom', 138, 'calcium'), ('GO_0018884', 'carbazole metabolic process', 138, 'calcium metabolism'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('UBERON_0002405', 'immune system', 282, 'immune'), ('CHEBI_71657', 'versiconol acetate', 333, '25(OH)D'), ('UBERON_0000479', 'tissue', 364, 'tissue')]"
S115-PMC3347028	PMC3347028	3/2012	S115-PMC3347028	['using the RECENTLY revised institute of medicine’s (iom) 2010 criterion for Vitamin D deficiency of total circulating 25(Oh)D < 20 ng/ml (50 nmol/l) [72], approximately 70% of the african american COMPARED TO 35% of caucasian women in the rhode island study had evidence of Vitamin D deficiency during winter, with slight improvement during summer months compared to winter months in both groups.']	[('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197)]	2	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 118, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
S144-PMC3347028	PMC3347028	3/2012	S144-PMC3347028	['there is a strong RELATIONSHIP between maternal and fetal (Cord Blood) circulating 25(Oh)D levels [92,93,94,95] such that maternal Vitamin D deficiency is MIRRORED by neonatal Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('SUPERFICIAL_RELATIONSHIP', 155)]	2	[('UBERON_0002240', 'spinal cord', 59, 'cord'), ('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 83, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D')]
S153-PMC3347028	PMC3347028	3/2012	S153-PMC3347028	['FOUND significantly wider posterior Fontanelle diameter in neonates of mothers with Vitamin D deficiency (AS defined by a 25(Oh)D level <34.9 nmol/l or ~14 ng/ml) compared to neonates whose mothers were not deficient [102].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 106)]	2	[('UBERON_0002221', 'fontanelle', 36, 'fontanelle'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D')]
S184-PMC3347028	PMC3347028	3/2012	S184-PMC3347028	['AS PREDICTED by Vitamin D pharmacokinetics, supplements of 1000 iu/day of Vitamin D to Pregnant women result in a 12.5 to 15.0 nmol/l increase in circulating 25(Oh)D concentrations in both maternal and Cord Serum compared with nonsupplemented controls [75,76,77].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 3)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 158, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 158, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 202, 'cord'), ('UBERON_0001977', 'blood serum', 207, 'serum')]
S215-PMC3347028	PMC3347028	3/2012	S215-PMC3347028	['the SIGNIFICANCE of these trials is that Vitamin D status is improved with 4000 iu vitamin D3Taken daily to achieve: (1) optimization of 1,25(Oh)2D production, and (2) improved Cord Blood 25(Oh)D concentration.']	[('IMPORTANT_CONSIDERATION', 4)]	1	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_51469', 'butyllithium', 91, 'D3taken'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 142, 'OH)2D'), ('UBERON_0009472', 'axilla', 177, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 188, '25(OH ... D')]
S216-PMC3347028	PMC3347028	3/2012	S216-PMC3347028	['having a higher 25(Oh)D concentration was ASSOCIATED with improved health outcomes in both studies, BUT WHETHER improved Vitamin D status is a MARKER of some OTHER parameter or a direct EFFECT of Vitamin D supplementation REMAINS UNCLEAR at this time.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 104), ('SUPERFICIAL_RELATIONSHIP', 143), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('SUPERFICIAL_RELATIONSHIP', 186), ('FULL_UNKNOWN', 222)]	7	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S220-PMC3347028	PMC3347028	3/2012	S220-PMC3347028	['unanswered questions and direction of FUTURE RESEARCH endeavors\nthere are many UNANSWERED QUESTIONS about Vitamin D’s “true” ROLE during Pregnancy: at no other time during the Lifecycle is 25(Oh)D so closely LINKED with 1,25(Oh)2D [6].']	[('FUTURE_WORK', 38), ('ANOMALY_CURIOUS_FINDING', 79), ('EXPLICIT_QUESTION', 90), ('SUPERFICIAL_RELATIONSHIP', 125), ('SUPERFICIAL_RELATIONSHIP', 208)]	5	"[('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0000104', 'life cycle', 176, 'lifecycle'), ('CHEBI_71657', 'versiconol acetate', 189, '25(OH)D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 222, '25(OH)2D')]"
S226-PMC3347028	PMC3347028	3/2012	S226-PMC3347028	['the health effects data from Vitamin D supplementation trials THUS FAR, WHILE TANTALIZING, are NOT CONCLUSIVE in SHOWING definitive “proof” for Vitamin D AS a POTENTIAL CANDIDATE in the reduction of comorbidities of Pregnancy, YET one CANNOT DISMISS the strong CORRELATION between reduced RISK with increased Serum 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 72), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 113), ('PROBABLE_UNDERSTANDING', 154), ('INCOMPLETE_EVIDENCE', 159), ('INCOMPLETE_EVIDENCE', 169), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('ANOMALY_CURIOUS_FINDING', 227), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('SUPERFICIAL_RELATIONSHIP', 261), ('IMPORTANT_CONSIDERATION', 289)]	13	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0001977', 'blood serum', 309, 'serum'), ('CHEBI_71657', 'versiconol acetate', 315, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 315, '25(OH)D')]
S242-PMC3347028	PMC3347028	3/2012	S242-PMC3347028	['a RECENT randomized controlled TRIAL with 350 women of diverse racial and ethnic backgrounds SHOWED that 4000 iu Vitamin D/day is MOST EFFECTIVE in improving the Vitamin D status of Pregnant women, attaining circulating levels of at least 40 ng/ml (100 nmol/l) for 25(Oh)D, and was NECESSARY to achieve OPTIMAL 1,25(Oh)2D production.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 93), ('PROBABLE_UNDERSTANDING', 130), ('SUPERFICIAL_RELATIONSHIP', 135), ('IMPORTANT_CONSIDERATION', 282), ('IMPORTANT_CONSIDERATION', 303)]	6	"[('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 267, '(OH ... D'), ('CHEBI_37983', 'sulfur-35 atom', 311, '1'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 313, '25(OH)2D')]"
S26-PMC3356951	PMC3356951	4/2012	S26-PMC3356951	['Vitamin D that comes from the skin or diet is biologically inert and REQUIRES its first hydroxylation in the Liver by the Vitamin D-25-hydroxylase (25-ohase) to 25(Oh)D.[311] HOWEVER, 25(Oh)D requires a further hydroxylation in the Kidneys by the 25(Oh)D-1-Ohase (Cyp27B1) to form the biologically active form of Vitamin D 1,25(Oh)2D.']	[('IMPORTANT_CONSIDERATION', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 175), ('ANOMALY_CURIOUS_FINDING', 175)]	3	"[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('UBERON_0002107', 'liver', 109, 'liver'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 161, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('UBERON_0002113', 'kidney', 232, 'kidneys'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 250, 'OH)D'), ('CHEBI_32906', 'gibberellin A24', 257, 'OHase'), ('PR_000006101', 'cytochrome P450 1A1', 264, 'CYP27B1'), ('CHEBI_27300', 'vitamin D', 313, 'vitamin D'), ('CHEBI_17996', 'chloride', 324, ','), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 325, '25(OH)2D')]"
S32-PMC3356951	PMC3356951	4/2012	S32-PMC3356951	['[614–16] the local Production Of 1,25(Oh)2D MAY BE responsible for Regulating up to 200 Genes[17] that MAY facilitate MANY of the pleiotropic health benefits that HAVE BEEN REPORTED for Vitamin D.[38914]\n\nVitamin D deficiency: prevalence\nvdd HAS BEEN historically defined and RECENTLY RECOMMENDED by the institute of medicine (iom) AS a 25(Oh)D of less than 0.8 iu.']	[('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 242), ('INCOMPLETE_EVIDENCE', 276), ('FUTURE_WORK', 285), ('PROBABLE_UNDERSTANDING', 332)]	8	"[('GO_0008283', 'cell proliferation', 19, 'production of ... )2D'), ('CHEBI_37958', 'dye', 33, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 35, '25(OH)2D'), ('GO_0065007', 'biological regulation', 67, 'regulating'), ('SO_0000704', 'gene', 88, 'genes'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 205, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 337, '25(OH)D')]"
S43-PMC3356951	PMC3356951	4/2012	S43-PMC3356951	['[39]\npatients with one of the fat malabsorption syndromes and bariatric patients are OFTEN UNABLE TO absorb the fat-soluble Vitamin D, and patients with nephritic syndrome lose 25(Oh)D bound to the Vitamin D-binding protein in the Urine.']	[('PROBABLE_UNDERSTANDING', 85), ('DIFFICULT_TASK', 91)]	2	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 177, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('UBERON_0001088', 'urine', 231, 'urine')]
S70-PMC3356951	PMC3356951	4/2012	S70-PMC3356951	['obese People MAY NEED larger than usual intakes of Vitamin D to achieve 25(Oh)D levels COMPARABLE to those of normal weight.']	[('INCOMPLETE_EVIDENCE', 13), ('IMPORTANT_CONSIDERATION', 17), ('INCOMPLETE_EVIDENCE', 87)]	3	[('NCBITaxon_10088', 'Mus <genus>', 6, 'people'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D')]
S112-PMC3356951	PMC3356951	4/2012	S112-PMC3356951	['levels of 25(Oh)D are inversely ASSOCIATED with bmi, waist circumference, and body fat BUT are positively ASSOCIATED with age, lean body mass, and Vitamin D intake.']	[('SUPERFICIAL_RELATIONSHIP', 32), ('ANOMALY_CURIOUS_FINDING', 87), ('SUPERFICIAL_RELATIONSHIP', 106)]	3	[('CHEBI_71657', 'versiconol acetate', 10, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 10, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]
S143-PMC3356951	PMC3356951	4/2012	S143-PMC3356951	['[102] among women younger than 75 years, there is a lower RISK for early amd with higher Vitamin D levels, with a threshold EFFECT at 15.22 ng/l Serum 25 (Oh)D.\n\nrecommendation guidelines: endocrine society of clinical practice\n\ndiagnostic procedure\nescp RECOMMEND screening for vdd in Individuals at risk for deficiency and not for patients who are not AT RISK.']	[('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 124), ('FUTURE_WORK', 255), ('IMPORTANT_CONSIDERATION', 354)]	4	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0001977', 'blood serum', 145, 'serum'), ('CHEBI_71657', 'versiconol acetate', 151, '25 (OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 151, '25 (OH)D'), ('NCBITaxon_1', 'root', 286, 'individuals')]
S144-PMC3356951	PMC3356951	4/2012	S144-PMC3356951	['Serum circulating 25-Hydroxyvitamin D [25(Oh) D] level SHOULD BE measured to evaluate Vitamin D status in patients who are AT RISK for vdd.']	[('FUTURE_WORK', 55), ('IMPORTANT_CONSIDERATION', 55), ('IMPORTANT_CONSIDERATION', 123)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 18, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 39, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 46, 'D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D')]
S150-PMC3356951	PMC3356951	4/2012	S150-PMC3356951	['in patients with Extrarenal Production of 1,25(Oh)2D, serial monitoring of 25(Oh)D levels and Serum calcium levels during treatment with Vitamin D to prevent hypercalcemia is SUGGESTED [table 2].']	[('INCOMPLETE_EVIDENCE', 175)]	1	[('UBERON_0001691', 'external ear', 17, 'extrarenal'), ('GO_0007128', 'meiotic prophase I', 28, 'production'), ('CHEBI_82784', 'PVP38-Ag NP', 42, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('UBERON_0001977', 'blood serum', 94, 'serum'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S82-PMC3407995	PMC3407995	7/2012	S82-PMC3407995	['the MAJORITY of circulating Vitamin D, known as Serum 25-Hydroxyvitamin D [25(Oh)D] that is NECESSARY to maintain health and function of the Immune, Reproductive, Muscular, Skeletal and Integumentary System, originates from Vitamin D3 (Cholecalciferol) and REFLECTS endogenous synthesis from exposure to sunlight as well as Intake from the diet [46].']	[('PROBABLE_UNDERSTANDING', 4), ('IMPORTANT_CONSIDERATION', 92), ('SUPERFICIAL_RELATIONSHIP', 257)]	3	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('UBERON_0001977', 'blood serum', 48, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 54, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('UBERON_0002405', 'immune system', 141, 'immune ...'), ('GO_0000003', 'reproduction', 149, 'reproductive'), ('UBERON_0022230', 'retrohippocampal region', 149, 'reproductive ...'), ('UBERON_0004469', 'musculature of back', 163, 'muscular ...'), ('UBERON_0004288', 'skeleton', 173, 'skeletal'), ('UBERON_0002416', 'integumental system', 186, 'integumentary system'), ('CHEBI_33279', 'vitamin D5', 224, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 224, 'vitamin D3'), ('CHEBI_52550', 'theopalauamide', 236, 'cholecalciferol'), ('GO_0007631', 'feeding behavior', 324, 'intake')]
S85-PMC3407995	PMC3407995	7/2012	S85-PMC3407995	['HOWEVER, a recent global review of Vitamin D status HAS SHOWN that its Intake is OFTEN TOO low TO sustain healthy circulating 25(Oh)D in countries without mandatory staple Food fortification and is EVEN too low in countries that do fortify due to low Milk Consumption, vegetarianism, non-supplement use and low fish Intake [46].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 52), ('PROBABLE_UNDERSTANDING', 81), ('DIFFICULT_TASK', 87), ('ANOMALY_CURIOUS_FINDING', 198)]	5	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007631', 'feeding behavior', 71, 'intake'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 126, '25(OH ... D'), ('CHEBI_33290', 'food', 172, 'food'), ('UBERON_0001913', 'milk', 251, 'milk'), ('GO_0007631', 'feeding behavior', 256, 'consumption'), ('GO_0007631', 'feeding behavior', 316, 'intake')]
S249-PMC3407995	PMC3407995	7/2012	S249-PMC3407995	['evidence of the POTENTIAL benefits of maternal Vitamin D supplementation for foetal/infant Brain health\npublished placebo-controlled intervention trials studying the IMPACT of Vitamin D supplementation in mothers with low Serum 25(Oh)D are RARE [45] because such trials are deemed UNACCEPTABLE by ethics committees.']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 166), ('INCOMPLETE_EVIDENCE', 240), ('IMPORTANT_CONSIDERATION', 281)]	4	[('CHEBI_28384', 'vitamin K', 47, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 47, 'Vitamin D'), ('UBERON_0000955', 'brain', 91, 'Brain'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 228, '25(OH)D')]
S253-PMC3407995	PMC3407995	7/2012	S253-PMC3407995	['a STUDY in black and white Pregnant women residing in the northern united states FOUND that approximately 29% of black Pregnant women and 5% of white Pregnant women had Vitamin D deficiency (Serum 25(Oh)D less than 37.5 nmol/l); WHEREAS 54% of black women and 47% of white women had Vitamin D insufficiency (defined as Serum 25(Oh)D levels 37.5 to 80 nmol/l) [122].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 229)]	3	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('GO_0007565', 'female pregnancy', 119, 'pregnant'), ('GO_0007565', 'female pregnancy', 150, 'pregnant'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('UBERON_0001977', 'blood serum', 191, 'serum'), ('CHEBI_71657', 'versiconol acetate', 197, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 197, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D'), ('UBERON_0001977', 'blood serum', 319, 'serum'), ('CHEBI_71657', 'versiconol acetate', 325, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 325, '25 ... OH ... D')]
S449-PMC3407995	PMC3407995	7/2012	S449-PMC3407995	['the authors CONCLUDED that Vitamin D supplementation of 4000 iu/day for Pregnant women is SAFE and MOST EFFECTIVE in achieving sufficiency in all women and their neonates regardless of race, WHEREAS the current ESTIMATED average REQUIREMENT is comparatively ineffective at achieving adequate circulating 25(Oh)D concentrations, especially in african americans [179].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 90), ('PROBABLE_UNDERSTANDING', 99), ('SUPERFICIAL_RELATIONSHIP', 104), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('INCOMPLETE_EVIDENCE', 211), ('IMPORTANT_CONSIDERATION', 229)]	7	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 304, '25(OH)D')]
S19-PMC3427192	PMC3427192	4/2012	S19-PMC3427192	['Biosynthesis Of Vitamin D.\n\nVitamin D THRESHOLDS\nSerum concentrations of 25(Oh)D are CONSIDERED to be a BIOMARKER and INDICATOR of Vitamin D status.44,45ALTHOUGH Vitamin D insufficiency HAS TRADITIONALLY BEEN defined as a Serum 25(Oh)D concentration of 20 to 29 ng/ml,46a panel of experts from the institute of medicine RECENTLY SUGGESTED that Vitamin D INSUFFICIENCY be redefined AS a Serum 25(Oh)D concentration less than 20 ng/ml.47this RECOMMENDATION was based ON INCONCLUSIVE evidence for the threshold of 29 ng/ml and EVIDENCE for adverse Skeletal EFFECTS at thresholds less than 20 ng/ml.47HOWEVER, this revised definition of Vitamin D insufficiency has generated significant CONTROVERSY48,49AND THUS there is presently NO universally ACCEPTED definition for “optimal” 25(Oh)d concentrations INDEPENDENT of Musculoskeletal health.']	[('PROBABLE_UNDERSTANDING', 38), ('INCOMPLETE_EVIDENCE', 85), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 118), ('ANOMALY_CURIOUS_FINDING', 151), ('IMPORTANT_CONSIDERATION', 186), ('INCOMPLETE_EVIDENCE', 190), ('PROBABLE_UNDERSTANDING', 190), ('INCOMPLETE_EVIDENCE', 320), ('INCOMPLETE_EVIDENCE', 329), ('IMPORTANT_CONSIDERATION', 354), ('PROBABLE_UNDERSTANDING', 381), ('FUTURE_WORK', 440), ('ANOMALY_CURIOUS_FINDING', 465), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 468), ('INCOMPLETE_EVIDENCE', 524), ('SUPERFICIAL_RELATIONSHIP', 554), ('ANOMALY_CURIOUS_FINDING', 595), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 683), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 697), ('PROBABLE_UNDERSTANDING', 703), ('INCOMPLETE_EVIDENCE', 727), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 742), ('INCOMPLETE_EVIDENCE', 742), ('SUPERFICIAL_RELATIONSHIP', 799)]	25	[('GO_0033593', 'BRCA2-MAGE-D1 complex', 0, 'Biosynthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 49, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 73, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 228, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 344, 'vitamin D'), ('UBERON_0001977', 'blood serum', 386, 'serum'), ('CHEBI_71657', 'versiconol acetate', 392, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 392, '25(OH)D'), ('UBERON_0004288', 'skeleton', 545, 'skeletal'), ('CHEBI_27300', 'vitamin D', 633, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 776, '25(OH)'), ('UBERON_0002204', 'musculoskeletal system', 814, 'musculoskeletal')]
S28-PMC3427192	PMC3427192	4/2012	S28-PMC3427192	['studies of Vitamin D exposure in early Life and Respiratory outcomesauthoryearcountrystudy designsample sizeage of children at assessmentdetermination of Vitamin D statusassociation between Vitamin D and Respiratory outcomesbelderbos572011netherlandsprospective cohort156 neonatesbirth to 1 ymaternal Food-frequency questionnaire and Cord Blood 25(Oh)Dlower 25(Oh)D concentrations ASSOCIATED with an increased risk of Respiratory syncytial Virus infectioncamargo582007united statesprospective cohort1194 mother-child dyads3 ymaternal Food-frequency questionnairehighest quartile of Vitamin D intake during Pregnancy ASSOCIATED with a lower risk of recurrent wheezingcamargo592011new zealandprospective cohort922 newbornsbirth to 5 ycord Blood 25(Oh)Dhigher 25(Oh)D ASSOCIATED with a decreased risk of Respiratory infection and wheezing BUT NO associations with childhood asthma NOTEDCARROLL602011CANADACROSS-sectional340 mother-infant dyads5–29 weeksmaternal whole Blood 25(Oh)Dincreasing maternal 25(Oh)D ASSOCIATED with decreased odds of asthma in mothers BUT no associations with infantile wheezing noteddevereux612007scotlandprospective cohort2000 Pregnant women, 1212 children5 ymaternal Food-frequency questionnairehighest and lowest maternal Vitamin D intakes ASSOCIATED with lower risk of wheezingerkkola622009finlandprospective cohort1669 mother-child dyads5 ymaternal Food-frequency questionnairehigher maternal Vitamin D intake ASSOCIATED with lower risk of asthma and allergic rhinitisgale632008ukprospective cohort466 mothers and 178 children9 mo and 9 ymaternal Serum 25(Oh)Dmaternal Vitamin D levels > 75 nmol/l ASSOCIATED with increased risk of atopic dermatitis and asthmamiyake642010japanprospective cohort763 mother-child dyads16–24 momaternal Food-frequency questionnairehigher maternal Vitamin D intake ASSOCIATED with a decreased risk of wheeze and atopic dermatitismorales652012spainprospective cohort1724 children12 mo, 4–6 ymaternal plasma 25(Oh)Dincreased maternal 25(Oh)D ASSOCIATED with a decreased risk of lower Respiratory infections BUT NOT wheezing or asthmarothers662011united statesprospective cohort219 childrenbirth to 5 ycord Blood 25(Oh)Dboth low and high Cord Blood 25(Oh)D ASSOCIATED with increased Aeroallergen sensitization BUT NOT with allergic rhinitis or asthma\nin other Birth cohort studies where 25(Oh)D concentrations were measured in the Plasma and whole Blood of Pregnant women, median 25(Oh)D concentrations ranged from APPROXIMATELY 20 to 29.5 ng/ml.60,63,65a 50% decrease in the odds of maternal asthma was FURTHER OBSERVED with every 35 nmol/l increase in 25(Oh)D levels, SUGGESTING a POSSIBLE LINK between Vitamin D status and asthma during Pregnancy.60HOWEVER, similar to the studies of maternal Vitamin D intake, NO CONSISTENT RELATIONSHIPS between 25(Oh)D concentrations and Respiratory symptoms during childhood HAVE BEEN observed.']	[('SUPERFICIAL_RELATIONSHIP', 381), ('SUPERFICIAL_RELATIONSHIP', 616), ('SUPERFICIAL_RELATIONSHIP', 765), ('ANOMALY_CURIOUS_FINDING', 836), ('ANOMALY_CURIOUS_FINDING', 878), ('SUPERFICIAL_RELATIONSHIP', 1006), ('ANOMALY_CURIOUS_FINDING', 1058), ('SUPERFICIAL_RELATIONSHIP', 1267), ('SUPERFICIAL_RELATIONSHIP', 1439), ('SUPERFICIAL_RELATIONSHIP', 1627), ('SUPERFICIAL_RELATIONSHIP', 1824), ('SUPERFICIAL_RELATIONSHIP', 1999), ('ANOMALY_CURIOUS_FINDING', 2064), ('SUPERFICIAL_RELATIONSHIP', 2213), ('ANOMALY_CURIOUS_FINDING', 2266), ('INCOMPLETE_EVIDENCE', 2471), ('INCOMPLETE_EVIDENCE', 2560), ('INCOMPLETE_EVIDENCE', 2568), ('INCOMPLETE_EVIDENCE', 2626), ('INCOMPLETE_EVIDENCE', 2639), ('SUPERFICIAL_RELATIONSHIP', 2648), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2706), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2770), ('SUPERFICIAL_RELATIONSHIP', 2784), ('INCOMPLETE_EVIDENCE', 2871)]	25	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0000104', 'life cycle', 39, 'life'), ('UBERON_0001004', 'respiratory system', 48, 'respiratory'), ('CHEBI_28384', 'vitamin K', 154, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 204, 'respiratory'), ('CHEBI_33290', 'food', 301, 'food'), ('UBERON_0002240', 'spinal cord', 334, 'cord'), ('UBERON_0000178', 'blood', 339, 'blood'), ('CHEBI_78858', '(R)-2-methylpyrrolidine', 345, '25(OH)DLower'), ('CHEBI_71657', 'versiconol acetate', 358, '25(OH)D'), ('UBERON_0001004', 'respiratory system', 418, 'respiratory'), ('NCBITaxon_1', 'root', 440, 'virus'), ('CHEBI_33290', 'food', 534, 'food'), ('CHEBI_27300', 'vitamin D', 582, 'vitamin D'), ('GO_0007565', 'female pregnancy', 606, 'pregnancy'), ('UBERON_0000178', 'blood', 737, 'blood'), ('CHEBI_72842', '9-oxo-ODE', 743, '25(OH)DHigher'), ('CHEBI_71657', 'versiconol acetate', 757, '25(OH)D'), ('UBERON_0001004', 'respiratory system', 801, 'respiratory'), ('UBERON_0000178', 'blood', 965, 'blood'), ('CHEBI_74350', 'N-diazoacetylnorleucine methyl ester', 971, '25(OH)DIncreasing'), ('PR_000011614', 'opioid growth factor receptor', 974, 'OH'), ('PR_000006449', 'diacylglycerol kinase kappa', 977, 'DIncreasing'), ('CHEBI_71657', 'versiconol acetate', 998, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 998, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 1152, 'pregnant'), ('CHEBI_33290', 'food', 1193, 'food'), ('CHEBI_27300', 'vitamin D', 1249, 'vitamin D'), ('CHEBI_33290', 'food', 1378, 'food'), ('CHEBI_27300', 'vitamin D', 1422, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1576, 'serum'), ('CHEBI_51469', 'butyllithium', 1582, '25(OH)DMaternal'), ('CHEBI_27300', 'vitamin D', 1598, 'vitamin D'), ('CHEBI_33290', 'food', 1763, 'food'), ('CHEBI_27300', 'vitamin D', 1807, 'vitamin D'), ('CHEBI_86378', '(25R)-3beta-hydroxycholest-5-en-26-oic acid', 1965, '25(OH)DIncreased'), ('PR_000011040', 'nuclear receptor coactivator 1', 1967, '(OH'), ('CHEBI_71657', 'versiconol acetate', 1991, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1991, '25(OH ... D'), ('UBERON_0001004', 'respiratory system', 2041, 'respiratory'), ('UBERON_0000178', 'blood', 2163, 'blood'), ('CHEBI_73803', 'Ala-Asp', 2169, '25(OH)DBoth'), ('UBERON_0002240', 'spinal cord', 2194, 'cord'), ('UBERON_0000178', 'blood', 2199, 'blood'), ('CHEBI_71657', 'versiconol acetate', 2205, '25(OH)D'), ('CHEBI_2500', 'Aescin', 2239, 'aeroallergen'), ('GO_0007567', 'parturition', 2316, 'birth'), ('CHEBI_71657', 'versiconol acetate', 2343, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 2387, 'plasma'), ('UBERON_0000178', 'blood', 2404, 'blood'), ('GO_0007565', 'female pregnancy', 2413, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 2436, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 2610, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 2616, 'D'), ('CHEBI_27300', 'vitamin D', 2661, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2696, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2752, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 2806, '25(OH)D'), ('UBERON_0001004', 'respiratory system', 2833, 'respiratory')]
S32-PMC3427192	PMC3427192	4/2012	S32-PMC3427192	['HOWEVER, in THESE STUDIES, there were no associations between Cord-Blood 25(Oh)D concentrations and subsequent asthma at 5 y of age.59,66\ncollectively, these studies SUGGEST that the benefits of Vitamin D during early Life MAY BE LIMITED to its EFFECTS on Respiratory infections and Viral-induced wheezing and not asthma per se.17HOWEVER, ALTHOUGH Vitamin D MAY have IMPORTANT ROLES in Immune Regulation during early Life, excessive Vitamin D exposure MAY also be ASSOCIATED with adverse health outcomes.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 166), ('INCOMPLETE_EVIDENCE', 223), ('INCOMPLETE_EVIDENCE', 230), ('SUPERFICIAL_RELATIONSHIP', 245), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 328), ('ANOMALY_CURIOUS_FINDING', 339), ('INCOMPLETE_EVIDENCE', 358), ('IMPORTANT_CONSIDERATION', 367), ('SUPERFICIAL_RELATIONSHIP', 377), ('INCOMPLETE_EVIDENCE', 452), ('SUPERFICIAL_RELATIONSHIP', 464)]	13	[('UBERON_0002240', 'spinal cord', 62, 'cord'), ('UBERON_0000178', 'blood', 67, 'blood'), ('CHEBI_71657', 'versiconol acetate', 73, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 73, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('UBERON_0000104', 'life cycle', 218, 'life'), ('UBERON_0001004', 'respiratory system', 256, 'respiratory'), ('NCBITaxon_1', 'root', 283, 'viral'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin D'), ('GO_0002521', 'leukocyte differentiation', 386, 'immune regulation'), ('UBERON_0002405', 'immune system', 386, 'immune'), ('UBERON_0000104', 'life cycle', 417, 'life'), ('CHEBI_27300', 'vitamin D', 433, 'vitamin D')]
S34-PMC3427192	PMC3427192	4/2012	S34-PMC3427192	['this finding is SIMILAR TO OTHER STUDIES where an INCREASED risk of allergic sensitization was NOTED in infants who received Vitamin D supplementation.67,68likewise, gale et al.63NOTED that maternal 25(Oh)D concentrations greater than 75\u2009nmol/l (30 ng/ml) were ASSOCIATED with 5-fold increased odds of asthma at 9 y of age in the exposed children.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 27), ('IMPORTANT_CONSIDERATION', 50), ('ANOMALY_CURIOUS_FINDING', 95), ('INCOMPLETE_EVIDENCE', 177), ('SUPERFICIAL_RELATIONSHIP', 261)]	6	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 199, '25(OH)D')]
S35-PMC3427192	PMC3427192	4/2012	S35-PMC3427192	['HOWEVER, it is IMPORTANT TO NOTE that a large percentage of children were lost to follow-up, and THUS the resulting sample of mothers had higher concentrations of 25(Oh)D and were older, less LIKELY to smoke during Pregnancy, and more educated.63therefore WHILE there MAY BE therapeutic window for vitamin D supplementation in early Life, FURTHER STUDIES ARE NEEDED to more clearly understand the RISKS of high Vitamin D intake and bioavailability during the early childhood years.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 15), ('PROBABLE_UNDERSTANDING', 97), ('PROBABLE_UNDERSTANDING', 192), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 256), ('INCOMPLETE_EVIDENCE', 268), ('FUTURE_WORK', 339), ('FUTURE_WORK', 347), ('IMPORTANT_CONSIDERATION', 397)]	9	[('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 306, 'D'), ('UBERON_0000104', 'life cycle', 333, 'life'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D')]
S40-PMC3427192	PMC3427192	4/2012	S40-PMC3427192	['HOWEVER, 25(Oh)D concentrations in the non-asthmatic group were significantly higher than PREVIOUSLY-REPORTED average values in african american children.21the childhood asthma management program study, which consisted of a racially diverse population, also FOUND that 24% of Vitamin D deficient subjects were african american, compared with only 7% in the Vitamin D sufficient group.69the FACTORS responsible for the racial DISPARITY in Vitamin D status are UNCLEAR and WARRANT FURTHER STUDY.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 90), ('INCOMPLETE_EVIDENCE', 101), ('INCOMPLETE_EVIDENCE', 258), ('SUPERFICIAL_RELATIONSHIP', 390), ('IMPORTANT_CONSIDERATION', 425), ('FULL_UNKNOWN', 459), ('FUTURE_WORK', 471), ('FUTURE_WORK', 479)]	10	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 357, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 438, 'vitamin D')]
S42-PMC3427192	PMC3427192	4/2012	S42-PMC3427192	['studies of Vitamin D status in school-age children with asthmaauthoryearn(% male)age (years)study designsampleoutcome measuresfindingsbrehm412009616 (60)8.7cross-sectionalmild-to-severe persistent asthmaasthma exacerbationsincreased 25(Oh)D ASSOCIATED with reduced hospitalization, reduced Anti-Inflammatory Medication use and reduced Airway hyperresponsivenessbrehm6920101024 (60)8.9prospective cohortmild-to-moderate persistent asthmahospitalization or emergency Department visitbaseline 25(Oh)D levels < 30 ng/ml ASSOCIATED with higher odds of hospitalization or emergency department over 4 ychinellato70201175 (60)9.6cross-sectionalwell-controlled and POORLY controlled asthmaspirometry, asthma controlpositive CORRELATIONS NOTED between 25(Oh)d and asthma controlchinellato71201145 (60)10cross-sectionalintermittent asthmalung function and Airway hyperresponsivenesslower Serum 25(Oh)D ASSOCIATED with decreased Lung function and increased Airway hyperresponsiveness with exercisefreishtat72201092 (63)11.1cross-sectionalafrican americans with and without asthmaphysician-diagnosed asthmadecreased 25(Oh)D in asthmatics vs. controlsmajak73201148 (67)11.5randomized, double-blind, parallel arm clinical trialnewly diagnosed asthmaasthma exacerbationsfewer exacerbations in children with Vitamin D3Supplementation added to inhaled Budesonidesearing742010100 (64)7cross-sectionalmoderate to severe persistent asthmacorticosteroid use and Airflow limitationdecreased 25(Oh)D ASSOCIATED with lower Lung function and higher Corticosteroid requirementsurashima752010217 (57)10.0randomized, double-blind clinical trialschoolchildren (allcomers), subgroup with physician-diagnosed asthmaasthma exacerbationsreduced risk of asthma exacerbations in the subgroup with asthma after Vitamin D3Supplementation\nother cross-sectional studies of Vitamin D status have also examined the ASSOCIATIONS between 25(Oh)D concentrations and asthma Control in school-age children.']	[('SUPERFICIAL_RELATIONSHIP', 241), ('SUPERFICIAL_RELATIONSHIP', 516), ('PROBLEM_COMPLICATION', 656), ('SUPERFICIAL_RELATIONSHIP', 715), ('ANOMALY_CURIOUS_FINDING', 728), ('SUPERFICIAL_RELATIONSHIP', 891), ('SUPERFICIAL_RELATIONSHIP', 1476), ('SUPERFICIAL_RELATIONSHIP', 1873)]	8	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH)D'), ('CHEBI_60426', 'dioleoyl phosphatidylglycerol', 290, 'anti-inflammatory medication'), ('UBERON_0001005', 'respiratory airway', 335, 'airway'), ('UBERON_0008247', 'tube foot', 465, 'department'), ('CHEBI_71657', 'versiconol acetate', 490, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 490, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 742, '25(OH'), ('UBERON_0001005', 'respiratory airway', 845, 'airway'), ('UBERON_0001977', 'blood serum', 877, 'serum'), ('CHEBI_71657', 'versiconol acetate', 883, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 885, '(OH ... D'), ('UBERON_0002048', 'lung', 917, 'lung'), ('UBERON_0001005', 'respiratory airway', 945, 'airway'), ('CHEBI_71657', 'versiconol acetate', 1103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1103, '25(OH)D'), ('CHEBI_52915', 'phosphatediyl group', 1291, 'vitamin D3supplementation'), ('CHEBI_72362', 'phosphatidylethanolamine 44:1-OH', 1334, 'budesonideSearing742010100'), ('UBERON_0001005', 'respiratory airway', 1440, 'airflow'), ('CHEBI_71657', 'versiconol acetate', 1468, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1468, '25(OH)D'), ('UBERON_0002048', 'lung', 1498, 'lung'), ('CHEBI_36916', 'cation', 1523, 'corticosteroid'), ('CHEBI_52915', 'phosphatediyl group', 1774, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 1833, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1894, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1900, 'D'), ('GO_0065007', 'biological regulation', 1928, 'control')]
S45-PMC3427192	PMC3427192	4/2012	S45-PMC3427192	['WHILE these studies SHOW INTRIGUING ASSOCIATIONS between Vitamin D insufficiency (or deficiency) and asthma Control, the cross-sectional nature of the 25(Oh)D measurement and outcome assessment prevents causal INTERPRETATION.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 20), ('ANOMALY_CURIOUS_FINDING', 25), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 210)]	5	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0065007', 'biological regulation', 108, 'control'), ('CHEBI_71657', 'versiconol acetate', 151, '25(OH)D')]
S55-PMC3427192	PMC3427192	4/2012	S55-PMC3427192	['furthermore, in those subjects with current asthma, lower 25(Oh)D concentrations were ASSOCIATED with increased odds of asthma exacerbations and healthcare utilization in the preceding year.81OTHER STUDIES have also NOTED ASSOCIATIONS between decreased Serum 25(Oh)D concentrations and decreased Lung function, increased Airway hyperresponsiveness to Methacholine, and blunted Glucocorticoid responsiveness.80,82,84HOWEVER, in a RECENT case-control STUDY of obese subjects with and without asthma, no associations between Vitamin D status and asthma prevalence were NOTED.83the cross-sectional nature of these studies SHOULD again BE EMPHASIZED SINCE causation CANNOT BE determined DUE TO potential CONFOUNDING of the study results.']	[('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 190), ('ANOMALY_CURIOUS_FINDING', 216), ('SUPERFICIAL_RELATIONSHIP', 222), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 413), ('INCOMPLETE_EVIDENCE', 429), ('ANOMALY_CURIOUS_FINDING', 566), ('FUTURE_WORK', 618), ('ANOMALY_CURIOUS_FINDING', 631), ('IMPORTANT_CONSIDERATION', 634), ('PROBLEM_COMPLICATION', 645), ('DIFFICULT_TASK', 661), ('PROBLEM_COMPLICATION', 682), ('PROBLEM_COMPLICATION', 699)]	14	[('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('UBERON_0001977', 'blood serum', 253, 'serum'), ('CHEBI_71657', 'versiconol acetate', 259, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 259, '25 ... OH ... D'), ('UBERON_0002048', 'lung', 296, 'lung'), ('UBERON_0001005', 'respiratory airway', 321, 'airway'), ('CHEBI_6805', 'methacycline', 351, 'methacholine'), ('CHEBI_24261', 'glucocorticoid', 377, 'glucocorticoid'), ('CHEBI_27300', 'vitamin D', 522, 'vitamin D')]
S60-PMC3427192	PMC3427192	4/2012	S60-PMC3427192	['studies of Vitamin D status in Adults with asthmaauthoryearn(% male)age (years)study designsampleoutcome measuresfindingsblack80200514,091 (55)> 20 ycross-sectionalgeneral us populationlung functionhigher Serum 25(Oh)D ASSOCIATED with increased Lung functionkeet8120116857 (49)23.6cross-sectionalgeneral us populationwheeze, history of asthma, and asthma exacerbationhigher serum 25(Oh)D ASSOCIATED with decreased odds of current wheezing and asthma as well as emergency visits for asthma and asthma exacerbationsli822011435 (38)48.57cross-sectionalnewly diagnosed asthmaticslung function, total Serum igehigher 25(Oh)D ASSOCIATED with greater Lung function with no associations NOTED for igeoren832008290 (26)43cross-sectionalobese patientsasthma and allergic rhinitis25(Oh)D deficiency (< 25 ng/ml) ASSOCIATED with increased odds of atopic dermatitis BUT no associations with asthmasutherland84201054 (43)38.3cross-sectionalpersistent asthmalung function, Airway hyper-responsiveness, Glucocorticoid responsivenessdecreased 25(Oh)D ASSOCIATED with decreased Lung function, increased Airway hyperresponsiveness, and reduced Glucocorticoid responses\n\ngenetics of Vitamin D and asthma\nSOME STUDIES have FOCUSED on Genetic ASSOCIATIONS between Vitamin D and asthma in larger populations.']	[('SUPERFICIAL_RELATIONSHIP', 219), ('SUPERFICIAL_RELATIONSHIP', 388), ('SUPERFICIAL_RELATIONSHIP', 620), ('ANOMALY_CURIOUS_FINDING', 679), ('SUPERFICIAL_RELATIONSHIP', 801), ('ANOMALY_CURIOUS_FINDING', 853), ('SUPERFICIAL_RELATIONSHIP', 1034), ('INCOMPLETE_EVIDENCE', 1184), ('QUESTION_ANSWERED_BY_THIS_WORK', 1202), ('SUPERFICIAL_RELATIONSHIP', 1221)]	10	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0007023', 'adult organism', 31, 'adults'), ('UBERON_0001977', 'blood serum', 205, 'serum'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 211, '25(OH)D'), ('UBERON_0002048', 'lung', 245, 'lung'), ('CHEBI_71657', 'versiconol acetate', 380, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 380, '25(OH)D'), ('UBERON_0001977', 'blood serum', 596, 'serum'), ('CHEBI_71657', 'versiconol acetate', 612, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 612, '25(OH)D'), ('UBERON_0002048', 'lung', 644, 'lung'), ('CHEBI_33010', 'chromide(1-)', 771, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 775, 'D'), ('UBERON_0001005', 'respiratory airway', 958, 'airway'), ('CHEBI_24261', 'glucocorticoid', 987, 'glucocorticoid'), ('CHEBI_71657', 'versiconol acetate', 1026, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 1029, 'OH ... D'), ('UBERON_0002048', 'lung', 1060, 'lung'), ('UBERON_0001005', 'respiratory airway', 1085, 'airway'), ('CHEBI_24261', 'glucocorticoid', 1125, 'glucocorticoid'), ('CHEBI_28384', 'vitamin K', 1163, 'Vitamin D'), ('SO_0000704', 'gene', 1213, 'genetic'), ('CHEBI_27300', 'vitamin D', 1242, 'vitamin D')]
S69-PMC3427192	PMC3427192	4/2012	S69-PMC3427192	['these studies also DIFFER significantly in terms of the populations studied, the timing of the Vitamin D intake assessments and the 25(Oh)D sampling, the 25(Oh)D THRESHOLDS used for determining insufficiency, and the Respiratory outcomes of interest.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 19), ('PROBABLE_UNDERSTANDING', 162)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 154, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 154, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 157, 'OH ... D'), ('UBERON_0001004', 'respiratory system', 217, 'respiratory')]
S117-PMC3427250	PMC3427250	8/2012	S117-PMC3427250	['SOME studies SUGGEST that the dietary requirement during Pregnancy and Lactation MAY BE as high as 6000 iu/d[59]and recognize that AT LEAST 1500–2000 iu/d of Vitamin D MAY BE NEEDED in order to maintain a Blood level of 25(Oh)D above 30 ng/ml[24].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 81), ('PROBABLE_UNDERSTANDING', 131), ('INCOMPLETE_EVIDENCE', 168), ('FUTURE_WORK', 175)]	6	[('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('GO_0007595', 'lactation', 71, 'lactation'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('UBERON_0000178', 'blood', 205, 'blood'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25(OH)D')]
S118-PMC3427250	PMC3427250	8/2012	S118-PMC3427250	['as those authors recognize that the EVIDENCE to propose such Intakes IS SCARCE and as long as the health benefits of having Serum 25(Oh)D levels higher than 30 ng/ml are NOT clearly ESTABLISHED particularly in Pregnant women, the belgian superior health council STILL RECOMMENDS a Vitamin D supplement of 20 µg/day or 800 iu during Pregnancy[58].']	[('INCOMPLETE_EVIDENCE', 36), ('FULL_UNKNOWN', 170), ('IMPORTANT_CONSIDERATION', 262), ('FUTURE_WORK', 268)]	4	[('GO_0007631', 'feeding behavior', 61, 'intakes'), ('UBERON_0001977', 'blood serum', 124, 'serum'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 132, '(OH ... D'), ('GO_0007565', 'female pregnancy', 210, 'pregnant'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D'), ('GO_0007565', 'female pregnancy', 332, 'pregnancy')]
S26-PMC3552819	PMC3552819	12/2012	S26-PMC3552819	['HOWEVER, to enhance the assessment of 25(Oh)D response and SAFETY during the first week of follow-up, an additional cohort of participants who continued to receive weekly Vitamin D doses beginning on day 7 (“weekly-dose group”) contributed biochemical data to the present analysis for the first 7 days after the 70,000 iu dose (i.e., up to the time preceding their 2nd dose).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 59)]	2	[('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 38, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
S113-PMC3552819	PMC3552819	12/2012	S113-PMC3552819	['the Stillbirth and newborn deaths were explained by medical problems, and there was NO EVIDENCE that either was RELATED to the Vitamin D supplementation, given their timing (i.e., did not occur at peak [25(Oh)D]) and the absence of biochemical EVIDENCE of Vitamin D toxicity in the mother (table\u20093).']	[('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 112), ('INCOMPLETE_EVIDENCE', 244)]	3	[('GO_0001966', 'thigmotaxis', 4, 'stillbirth'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 203, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]
S189-PMC3552819	PMC3552819	12/2012	S189-PMC3552819	['MANY participants DEMONSTRATED a rapid rise in [25(Oh)D] during the first week, which is SIMILAR TO the response to an acute dose of ultraviolet radiation exposure [25]; BUT distinct from the more gradual EFFECTS of OTHER forms of exogenous Vitamin D Intake (e.g., oral D2 Ingestion [10]).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('SUPERFICIAL_RELATIONSHIP', 205), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 216)]	6	[('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 48, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('GO_0007631', 'feeding behavior', 251, 'intake'), ('CHEBI_37987', 'Cy3 dye', 270, 'D2'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 270, 'D2'), ('GO_0007631', 'feeding behavior', 273, 'ingestion')]
S201-PMC3552819	PMC3552819	12/2012	S201-PMC3552819	['we SPECULATE that the massive dose administered in that study (600,000 iu) saturated the Hepatic 25-hydroxylase system, resulting in the engagement of subsidiary Vitamin D Catabolic pathways which reduced the 25(Oh)D yield.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('UBERON_0002107', 'liver', 89, 'hepatic'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('GO_0006281', 'DNA repair', 170, 'D catabolic'), ('CHEBI_71657', 'versiconol acetate', 209, '25(OH)D')]
S218-PMC3552819	PMC3552819	12/2012	S218-PMC3552819	['these erratic PATTERNS COULD NOT EASILY BE EXPLAINED on THE BASIS OF KNOWN Vitamin D pharmacokinetics, but were MOST LIKELY ATTRIBUTABLE TO small-sample ARTIFACTS, biological variability in the absorption and Metabolism Of Vitamin D, and inherent imprecision in the laboratory assessment of [25(Oh)D].']	[('SUPERFICIAL_RELATIONSHIP', 14), ('DIFFICULT_TASK', 23), ('INCOMPLETE_EVIDENCE', 29), ('PROBABLE_UNDERSTANDING', 43), ('INCOMPLETE_EVIDENCE', 56), ('INCOMPLETE_EVIDENCE', 69), ('PROBABLE_UNDERSTANDING', 112), ('PROBABLE_UNDERSTANDING', 124), ('QUESTION_ANSWERED_BY_THIS_WORK', 137), ('PROBLEM_COMPLICATION', 153)]	10	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 209, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 292, '25(OH)D')]
S222-PMC3552819	PMC3552819	12/2012	S222-PMC3552819	['HOWEVER, the unpredictability of the 25(Oh)D response at the individual level, PREVIOUS REPORTS of adverse EFFECTS of large single doses [23], and the THEORETICAL DISADVANTAGES of excessive fluctuations in Vitamin D status [29] SUGGEST that the use of large single or infrequent intermittent doses of Vitamin D3 MAY BE physiologically DISADVANTAGEOUS DESPITE its practical APPEAL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 107), ('INCOMPLETE_EVIDENCE', 151), ('IMPORTANT_CONSIDERATION', 163), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 312), ('IMPORTANT_CONSIDERATION', 335), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 351), ('ANOMALY_CURIOUS_FINDING', 351), ('IMPORTANT_CONSIDERATION', 373)]	12	[('CHEBI_71657', 'versiconol acetate', 37, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 301, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 301, 'vitamin D3')]
S56-PMC3613945	PMC3613945	2/2013	S56-PMC3613945	['OF more immediate clinical INTEREST, PERHAPS, was our OBSERVATION that this Allele was also CORRELATED with the response of Serum 25(Oh)D levels to long-term Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 27), ('INCOMPLETE_EVIDENCE', 37), ('ANOMALY_CURIOUS_FINDING', 54), ('SUPERFICIAL_RELATIONSHIP', 92)]	5	[('SO_0001023', 'allele', 76, 'allele'), ('UBERON_0001977', 'blood serum', 124, 'serum'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 130, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S5-PMC3641012	PMC3641012	4/2013	S5-PMC3641012	['results\nmean maternal 25(Oh)D concentration was SIMILAR in the Vitamin D and placebo groups at baseline (45 vs. 44\xa0nmol/l; p\u2009=\u20090.66), but was significantly higher in the Vitamin D group vs. placebo group among mothers at Delivery (134 vs. 38\xa0nmol/l; p\u2009<\u20090.001) and newborns (Cord Blood: 103 vs. 39; p\u2009<\u20090.001).']	[('SUPERFICIAL_RELATIONSHIP', 48)]	1	[('CHEBI_71657', 'versiconol acetate', 22, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 24, '(OH ... D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('GO_0007567', 'parturition', 221, 'delivery'), ('UBERON_0002240', 'spinal cord', 275, 'cord'), ('UBERON_0000178', 'blood', 280, 'blood')]
S12-PMC3641012	PMC3641012	4/2013	S12-PMC3641012	['the MAJOR circulating vitamin d metabolite, 25-Hydroxyvitamin D (25(Oh)D), crosses the Placenta from the maternal to the fetal circulation, thereby establishing fetal-neonatal Vitamin D stores [5].']	[('IMPORTANT_CONSIDERATION', 4)]	1	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 44, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('UBERON_0001987', 'placenta', 87, 'placenta'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D')]
S20-PMC3641012	PMC3641012	4/2013	S20-PMC3641012	['SIMILARLY, the 25(Oh)D THRESHOLD to define Vitamin D sufficiency is DEBATED; the iom set 50\xa0nmol/l as a lower limit of sufficiency [7], YET OTHER expert bodies such as the american academy of pediatrics have SUGGESTED that Pregnant women attain Serum 25(Oh)D >80\xa0nmol/l [14].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 136), ('ANOMALY_CURIOUS_FINDING', 136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 140), ('INCOMPLETE_EVIDENCE', 208)]	7	[('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 223, 'pregnant'), ('UBERON_0001977', 'blood serum', 245, 'serum'), ('CHEBI_71657', 'versiconol acetate', 251, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 251, '25(OH)D')]
S21-PMC3641012	PMC3641012	4/2013	S21-PMC3641012	['determination of the Vitamin D intake level (and corresponding Serum 25(Oh)D concentration) that SAFELY optimizes Vitamin D-responsive maternal-infant health outcomes would have GLOBAL IMPLICATIONS, but MAY be particularly RELEVANT to resource-poor communities in south asia, where a relatively low Prenatal Vitamin D status OVERLAPS with a HIGH BURDEN of morbidity and mortality ASSOCIATED with adverse Birth and early infant health outcomes [15].']	[('IMPORTANT_CONSIDERATION', 97), ('IMPORTANT_CONSIDERATION', 178), ('IMPORTANT_CONSIDERATION', 185), ('INCOMPLETE_EVIDENCE', 203), ('SUPERFICIAL_RELATIONSHIP', 223), ('SUPERFICIAL_RELATIONSHIP', 325), ('IMPORTANT_CONSIDERATION', 341), ('SUPERFICIAL_RELATIONSHIP', 380)]	8	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 69, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 299, 'prenatal'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D'), ('GO_0007567', 'parturition', 404, 'birth')]
S55-PMC3641012	PMC3641012	4/2013	S55-PMC3641012	['Serum aliquots were frozen at −20°c and shipped at ambient temperature from bangladesh to toronto for measurement of Serum 25(Oh)D concentration, a WELL-ESTABLISHED BIOMARKER of systemic Vitamin D status [17].']	[('PROBABLE_UNDERSTANDING', 148), ('SUPERFICIAL_RELATIONSHIP', 165)]	2	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S94-PMC3641012	PMC3641012	4/2013	S94-PMC3641012	['this approach enabled the estimation of the average difference in 25(Oh)D between the two groups at a PRESUMED ‘steady-state’ (i.e., where group-averaged 25(Oh)D did not continue to appreciably rise DESPITE ongoing Vitamin D supplementation).']	[('PROBABLE_UNDERSTANDING', 102), ('ANOMALY_CURIOUS_FINDING', 199)]	2	[('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 154, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D')]
S110-PMC3641012	PMC3641012	4/2013	S110-PMC3641012	['maternal characteristics and 25(Oh)D at baseline were SIMILAR in the placebo and Vitamin D groups (tables\xa01and2).']	[('SUPERFICIAL_RELATIONSHIP', 54)]	1	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S126-PMC3641012	PMC3641012	4/2013	S126-PMC3641012	['most participants in both groups were Vitamin D insufficient by the iom THRESHOLD (25(Oh)D\u2009<50\xa0nmol/l) at baseline (table\xa02).']	[('PROBABLE_UNDERSTANDING', 72)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 89, 'D')]
S128-PMC3641012	PMC3641012	4/2013	S128-PMC3641012	['Vitamin D supplementation had a substantial, statistically significant EFFECT on maternal and neonatal Vitamin D status at the time of Delivery, as reflected in the overall 25(Oh)D distributions (figure\xa02; table\xa04) as well as the proportion of participants considered to have low 25(Oh)D using cut-offs (table\xa02).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007567', 'parturition', 135, 'delivery'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 176, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 179, 'D'), ('CHEBI_71657', 'versiconol acetate', 280, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 280, '25(OH)D')]
S132-PMC3641012	PMC3641012	4/2013	S132-PMC3641012	['AS EVIDENCE that this plateau was not an artifact of diminishing supplement adherence over time, a sensitivity analysis in which 25(Oh)D was MODELED as a function of cumulative Vitamin D dose REVEALED the same PATTERN (figure\xa03), and fit the data well (table\xa05).']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 141), ('INCOMPLETE_EVIDENCE', 192), ('SUPERFICIAL_RELATIONSHIP', 210)]	6	[('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D')]
S161-PMC3641012	PMC3641012	4/2013	S161-PMC3641012	['given the substantial inter-Individual VARIABILITY in the response to Vitamin D supplementation (figure\xa03), we EXPLORED the ROLE of the following POTENTIAL MODIFIERS of the magnitude of the change in 25(Oh)D (δ25(Oh)D) from baseline to Delivery (selected a priori ): maternal weight at baseline, maternal age, Gestational age, maternal body mass index at baseline (bmi), gravidity, parity, baseline Pth status, season and baseline Vitamin D status.']	[('DIFFICULT_TASK', 39), ('QUESTION_ANSWERED_BY_THIS_WORK', 111), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 156)]	5	[('NCBITaxon_1', 'root', 28, 'individual'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 206, 'D'), ('CHEBI_33010', 'chromide(1-)', 212, '(OH)D'), ('GO_0007567', 'parturition', 236, 'delivery'), ('GO_0007565', 'female pregnancy', 310, 'gestational'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 399, 'PTH'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D')]
S163-PMC3641012	PMC3641012	4/2013	S163-PMC3641012	['ALTHOUGH δ25(Oh)D was inversely ASSOCIATED with baseline Vitamin D status, and ABOUT 24% of the variance in δ25(Oh)D in the Vitamin D group was EXPLAINED by baseline 25(Oh)D, this ASSOCIATION APPEARED TO BE due to regression to the mean, SINCE similar TRENDS were observed in both the Vitamin D and placebo groups.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 79), ('PROBABLE_UNDERSTANDING', 144), ('SUPERFICIAL_RELATIONSHIP', 180), ('ANOMALY_CURIOUS_FINDING', 192), ('PROBABLE_UNDERSTANDING', 238), ('SUPERFICIAL_RELATIONSHIP', 252)]	8	[('CHEBI_33010', 'chromide(1-)', 12, '(OH)D'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 111, '(OH)D'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 166, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 166, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 285, 'vitamin D')]
S165-PMC3641012	PMC3641012	4/2013	S165-PMC3641012	['NOTABLY, variation in Cord 25(Oh)D within the Vitamin D group was not associated with duration of supplementation (p\u2009=\u20090.86) or cumulative Vitamin D supplement dose administered (p\u2009=\u20090.93), INDICATING that the maternal-fetal Vitamin D equilibrium was achieved rapidly.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 190)]	2	[('UBERON_0002240', 'spinal cord', 22, 'cord'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 27, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D')]
S222-PMC3641012	PMC3641012	4/2013	S222-PMC3641012	['this is CONSISTENT with the HYPOTHESIZED constraint in Hepatic Vitamin D–To–25(Oh)D Conversion that occurs at a 25(Oh)D concentration of ABOUT 80–90\xa0nmol/l [28].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 137)]	3	[('UBERON_0002107', 'liver', 55, 'hepatic'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0019073', 'viral DNA genome packaging', 63, 'vitamin D–to ... OH)D conversion'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D')]
S226-PMC3641012	PMC3641012	4/2013	S226-PMC3641012	['in comparison to the lc-ms/ms method used HERE, the immunoassay used in the pilot study (diasorin liaison total) MAY have UNDER-estimated 25(Oh)D because of raised dbp concentrations in Pregnancy [29] OR relative imprecision at the higher 25(Oh)D range attained in the Vitamin D group [30,31].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 42), ('INCOMPLETE_EVIDENCE', 113), ('IMPORTANT_CONSIDERATION', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 201)]	4	[('CHEBI_71657', 'versiconol acetate', 138, '25(OH)D'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 239, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
S242-PMC3641012	PMC3641012	4/2013	S242-PMC3641012	['this SUGGESTED a Homeostatic Adjustment to the altered Vitamin D status, with no further increase in Serum calcium after a steady-state 25(Oh)D was reached.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('GO_0044809', 'chemokine (C-C motif) ligand 17 production', 17, 'homeostatic adjustment'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0001977', 'blood serum', 101, 'serum'), ('CHEBI_71657', 'versiconol acetate', 136, '25(OH)D')]
S243-PMC3641012	PMC3641012	4/2013	S243-PMC3641012	['third, a positive ASSOCIATION between adj-ca and 25(Oh)D was apparent in the range of 25(Oh)D below 100\xa0nmol/l BUT not above 100\xa0nmol/l; evidence of POSSIBLE harm would be more CONSISTENT with the OPPOSITE FINDING of a Serum calcium that was tightly Controlled (i.e., unassociated with 25(Oh)D) within the lower range of 25(Oh)D, but deflected upward at higher 25(Oh)D. all maternal uncorrected and adj-ca values were below the threshold for hypercalcemia used by the iom in the 1997 Vitamin D dris (2.75\xa0mmol/l) [10] and the 2010 revision (2.63\xa0mmol/l) [7].']	[('SUPERFICIAL_RELATIONSHIP', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('INCOMPLETE_EVIDENCE', 149), ('INCOMPLETE_EVIDENCE', 177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197), ('INCOMPLETE_EVIDENCE', 206)]	6	[('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('UBERON_0001977', 'blood serum', 219, 'serum'), ('GO_0065007', 'biological regulation', 250, 'controlled'), ('CHEBI_71657', 'versiconol acetate', 286, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 321, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 364, 'OH)D'), ('CHEBI_27300', 'vitamin D', 484, 'vitamin D')]
S88-PMC3659910	PMC3659910	1/2013	S88-PMC3659910	['REPORTED that as hypoparathyroid patients have completed many Pregnancies while receiving Ergocalciferol,[21] it is UNLIKELY that material Vitamin D, 25(Oh) D, or 24,25(Oh) 2D per se are Teratogens.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 116)]	2	"[('GO_0007565', 'female pregnancy', 62, 'pregnancies'), ('CHEBI_4910', 'etomidate', 90, 'ergocalciferol'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH) D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 166, '25(OH) 2D'), ('CHEBI_50114', 'estrogen', 187, 'teratogens')]"
S92-PMC3659910	PMC3659910	1/2013	S92-PMC3659910	['[1819] to attain circulating 25(Oh) D concentrations that exceed 250 nmol/l (100 ng/ml), a daily Vitamin D intake well in excess of 10,000 iu/d (250 μg/d) for several months WOULD BE REQUIRED.']	[('FUTURE_PREDICTION', 174), ('IMPORTANT_CONSIDERATION', 183)]	2	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH) D'), ('PR_000008838', 'serine protease HTRA1', 29, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
S158-PMC3659910	PMC3659910	1/2013	S158-PMC3659910	['the BASIS for these RECOMMENDATIONS was made BEFORE IT WAS POSSIBLE to measure the circulating concentration of 25-Hydroxyvitamin D [25(Oh) D], the INDICATOR of nutritional Vitamin D status.']	[('PROBABLE_UNDERSTANDING', 4), ('FUTURE_WORK', 20), ('DIFFICULT_TASK', 45), ('SUPERFICIAL_RELATIONSHIP', 148)]	4	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 112, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH) D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]
S185-PMC3659910	PMC3659910	1/2013	S185-PMC3659910	['HOWEVER, getting 25(Oh) D levels consistently above 75 nmol/l (30 ng/ml) MAY REQUIRE AT LEAST 1500-2000 iu/day of Vitamin D. if a mother is Vitamin D deficient, Breast Milk is not a good source of Vitamin D, so infants need to be given Vitamin D supplementation until they are weaned.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 73), ('FUTURE_WORK', 77), ('PROBABLE_UNDERSTANDING', 85)]	4	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 24, 'D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('UBERON_0000310', 'breast', 161, 'breast'), ('UBERON_0001913', 'milk', 168, 'milk'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
S187-PMC3659910	PMC3659910	1/2013	S187-PMC3659910	['it was RECENTLY SHOWN that a maternal supplementation of 2100 iu Vitamin D/day was NEEDED, when administered during the period of Lactation, in order to observe an increase in Serum levels of 25(Oh) D in the Breast-Fed infants comparable to that observed in children given 400 iu/day.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 83)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007595', 'lactation', 130, 'lactation'), ('UBERON_0001977', 'blood serum', 176, 'serum'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH) D'), ('PR_000010220', 'mannose-binding protein C', 194, '('), ('PR_000006444', 'diacylglycerol kinase delta', 199, 'D'), ('GO_0007567', 'parturition', 208, 'breast'), ('UBERON_0000310', 'breast', 208, 'breast'), ('GO_0007631', 'feeding behavior', 215, 'fed')]
S11-PMC3668200	PMC3668200	5/2013	S11-PMC3668200	['in exclusively breastfed infants, 25(Oh)D Serum levels were low during the winter DESPITE supplementation3), whereas Serum levels of 1,25-Oh2-D and Vitamin D-Binding Protein were higher in the winter than in the summer4).']	[('ANOMALY_CURIOUS_FINDING', 82)]	1	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 34, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 40, 'D'), ('UBERON_0001977', 'blood serum', 42, 'serum'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_17996', 'chloride', 134, ','), ('CHEBI_34309', '21-Fluoroprogesterone', 135, '25-OH2'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 148, 'vitamin D-binding protein')]
S33-PMC3668200	PMC3668200	5/2013	S33-PMC3668200	['RECENTLY, aap RECOMMENDATION of 400 iu/day for Vitamin D supplementation was DOCUMENTED to maintain a 25(Oh)D Serum concentration higher than 50 nmol/l in exclusively Breast-Fed infants15).']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 14), ('INCOMPLETE_EVIDENCE', 77)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 102, '25(OH)D'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('GO_0007567', 'parturition', 167, 'breast'), ('UBERON_0000310', 'breast', 167, 'breast'), ('GO_0007631', 'feeding behavior', 174, 'fed')]
S15-PMC3691177	PMC3691177	6/2013	S15-PMC3691177	['THESE STUDIES DID NOT REPORT outcomes in RELATION to maternal Serum 25-Hydroxyvitamin D (25(Oh)D) concentration, which takes account of skin synthesis, our primary source of Vitamin D, and is the gold STANDARD measure of Vitamin D status[5],[6].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 41), ('INCOMPLETE_EVIDENCE', 201)]	4	[('UBERON_0001977', 'blood serum', 62, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 68, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D')]
S74-PMC3691177	PMC3691177	6/2013	S74-PMC3691177	['as PREVIOUSLY reported[19], median Cord 25(Oh)D levels at Delivery were significantly higher in supplemented children COMPARED TO the control group [control 17 nmol/l (interquartile range (iqr) 14–22); daily dose 26 nmol/l (iqr 17–45); p<0.001; bolus dose 25 nmol/l (iqr 18–34); p<0.001)].10.1371/journal.pone.0066627.g001\n\ncaption (fig): figure 1\nrecruitment and follow up of study participants.10.1371/journal.pone.0066627.t001\n\ncaption (table-wrap): table 1\ncharacteristics of study participants followed up at age three years.controldaily Vitamin dbolus vitamin dcombined Vitamin D(n\u200a=\u200a50)(n\u200a=\u200a56)(n\u200a=\u200a52)(n\u200a=\u200a108)baseline maternal 25(Oh)D <25 nmol/l, n/n (%)24/50 (48)25/56 (45)22/52 (42)47/108 (44)male sex, n/n (%)27/50 (54)32/56 (57)26/52 (50)58/108 (55)Birth weight (g), mean (sd)3268 (585)3321 (525)3290 (467)3307 (497)ethnicity, n (%)asian12 (24)15 (27)13 (25)28 (26)middle eastern13 (26)14 (25)14 (26)28 (26)black12 (24)14 (25)13 (25)27 (25)white13 (26)13 (23)12 (24)25 (23)ga at Delivery (weeks), mean (sd)40 (1)39 (2)40 (1)39 (2)nulliparous mother, n/n (%)23/50 (46)20/56 (36)21/52 (40)41/108 (38)Vaginal Delivery, n/n (%)29/50 (58)35/56 (63)28/52 (54)63/108 (58)maternal smoking during Pregnancy, n/n (%)2/48 (4)3/55 (5)0/46 (0)3/101 (3)presence of household smokers, n/n (%)16/48 (33)15/55 (27)17/46 (37)32/101 (32)number of children in household, mean (sd)2 (1)2 (1)2 (1)2 (1)age mother left full time education, mean (sd)20 (3)20 (4)21 (4)21 (4)child in nursery, n/n (%)27/48 (56)36/55 (65)20/45 (44)57/101 (56)Cat or Dog in household, n/n (%)4/48 (8)5/54 (9)4/46 (9)9/100 (9)maternal fitzpatrick skin score grade 3–6, n/n (%)28/44 (64)33/49 (67)28/43 (65)61/92 (66)maternal regular vitamin intake at three years, n/n (%)9/46 (20)16/53 (30)16/45 (36)32/98 (33)at least one parent with allergic disease, n/n (%)23/45 (51)35/53 (66)21/45 (47)56/98 (57)exclusively Breast-Fed for 4 months, n/n (%)22/48 (46)20/54 (37)23/44 (52)43/98 (44)any child vitamin supplementation, n/n (%)30/48 (63)34/55 (62)30/46 (65)64/101 (63)completed immunizations to date, n/n (%)48/49 (98)54/55 (98)43/47 (91)97/102 (95)age at time of assessment (months), median (iqr)37.9 (36.9, 39.9)37.1 (36.5, 38.8)37.4 (36.5, 39.5)37.3 (36.5, 39.0)child fitzpatrick skin score grade 3–6, n (%)29/42 (69)34/48 (71)29/43 (67)63/91 (69)child bmi z score age 3, mean (sd)0.51 (1.48)0.35 (1.15)0.62 (1.15)0.47 (1.15)child outdoors >1 hour/day, n/n (%)32/48 (67)34/53 (64)33/45 (73)67/98 (68)child tv/computer >2 hours/day, n/n (%)24/48 (50)18/53 (34)17/45 (38)35/98 (36)child 25(Oh)D (nmol/l) age 3, median (iqr)42 (27, 68)35 (21, 66)42 (30, 93)41 (26, 72)\ndata shown are for all participants analysed.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118)]	2	[('UBERON_0002240', 'spinal cord', 35, 'cord'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 40, '25(OH ... D'), ('GO_0007567', 'parturition', 58, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 543, 'vitamin'), ('CHEBI_27300', 'vitamin D', 576, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 636, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 636, '25(OH ... D'), ('GO_0007567', 'parturition', 762, 'Birth'), ('GO_0007567', 'parturition', 992, 'delivery'), ('GO_0007567', 'parturition', 1111, 'Vaginal'), ('UBERON_0000970', 'eye', 1111, 'Vaginal'), ('GO_0007567', 'parturition', 1119, 'delivery'), ('GO_0007565', 'female pregnancy', 1201, 'pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 1529, 'Cat'), ('NCBITaxon_33208', 'Metazoa', 1536, 'dog'), ('GO_0007567', 'parturition', 1880, 'breast'), ('UBERON_0000310', 'breast', 1880, 'breast'), ('GO_0007631', 'feeding behavior', 1887, 'fed'), ('CHEBI_71657', 'versiconol acetate', 2555, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 2558, 'OH)D')]
S126-PMC3691177	PMC3691177	6/2013	S126-PMC3691177	['ALTHOUGH the Vitamin D doses used in this trial were greater than the current RECOMMENDED intake for Pregnant women of 400 iu/day during Pregnancy in the united kingdom[14],[17], and 600 iu in the united states[25], ONLY a small percentage of offspring had Cord 25(Oh)D levels in the sufficient range (13% daily group, 3% bolus group).']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 78), ('INCOMPLETE_EVIDENCE', 216)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnant'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 257, 'cord'), ('CHEBI_71657', 'versiconol acetate', 262, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 262, '25(OH)D')]
S129-PMC3691177	PMC3691177	6/2013	S129-PMC3691177	['two RECENT OBSERVATIONAL STUDIES that DOCUMENTED Prenatal Vitamin D status by measuring Cord Blood 25(Oh)D concentration, FOUND RELATIONSHIPS with allergic sensitisation and/or wheezing in early childhood[8],[31].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 38), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 128)]	5	[('GO_0007565', 'female pregnancy', 49, 'prenatal'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 88, 'cord'), ('UBERON_0000178', 'blood', 93, 'blood'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 99, '25(OH ... D')]
S134-PMC3691177	PMC3691177	6/2013	S134-PMC3691177	['the FINDINGS of OUR STUDY are specific to a population of Vitamin D deficient women (half had baseline 25(Oh)D levels below 25 nmol/l) and two specific forms of Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 161, 'prenatal'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S9-PMC3702245	PMC3702245	6/2013	S9-PMC3702245	['SEVERAL REPORTS in the literature HAVE SHOWN that INADEQUATE or lack of sunlight exposure without appropriate corrective Vitamin D intake or supplements accounts FOR the high prevalence of Vitamin D deficiency in women.11–18\nafter synthesis in the skin, Vitamin D attaches to Vitamin D-binding protein and is transported to the Liver, where it undergoes a process of hydroxylation to form 25-Hydroxyvitamin D [25(Oh)D].9the Serum concentration of 25(Oh)D is the MOST reliable MARKER of Vitamin D nutritional status.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 34), ('IMPORTANT_CONSIDERATION', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 162), ('PROBABLE_UNDERSTANDING', 462), ('SUPERFICIAL_RELATIONSHIP', 476)]	7	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 254, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 284, 'D'), ('UBERON_0002107', 'liver', 328, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 389, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 410, '25(OH)D'), ('UBERON_0001977', 'blood serum', 424, 'serum'), ('CHEBI_71657', 'versiconol acetate', 447, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 486, 'vitamin D')]
S10-PMC3702245	PMC3702245	6/2013	S10-PMC3702245	['a second hydroxylation takes place in the Kidney, which converts 25(Oh)D to the most biologically active Metabolite, 1,25-Dihydroxyvitamin D, the major classical physiologic function of which is to increase calcium and Phosphorus absorption from the Gut in order to maintain Calcium Homeostasis and promote mineralization of Osteoid bone.9\nalthough the Renal 1-alpha hydroxylase (Cytochrome P450 [Cyp]27B1) enzyme is a MAJOR DETERMINANT of Synthesis of 1,25-Dihydroxyvitamin D, IT IS KNOWN that Cyp27B1 is Expressed in Nonrenal Tissues to produce 1,25 Dihydroxyvitamin D.6,19in addition, Vitamin D receptors are also Expressed in a variety of Organs, Tissues, and cells (seefigure 1).20the 1,25-Dihydroxyvitamin D locally produced in Extrarenal Tissues, such as immune cells, Pancreatic Beta Cells, the Intestine, Prostate, Breast, and other Organs, Controls multiple Vitamin D-responsive Genes, and THUS plays an important physiologic ROLE in Cardiovascular health,21,22the Adaptive and Innate Immune Responses,23,24insulin secretion,25,26regulation of Cell Proliferation, Differentiation, and Apoptosis, and inhibition of Angiogenesis.27\n\nVitamin D Homeostasis and functions during Pregnancy\nthe classical function of Vitamin D is to maintain calcium Homeostasis.']	[('IMPORTANT_CONSIDERATION', 419), ('SUPERFICIAL_RELATIONSHIP', 425), ('INCOMPLETE_EVIDENCE', 478), ('PROBABLE_UNDERSTANDING', 900), ('SUPERFICIAL_RELATIONSHIP', 936)]	5	[('UBERON_0002113', 'kidney', 42, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('CHEBI_39382', 'flufenoxuron', 105, 'metabolite'), ('CHEBI_67472', '15-epi-lupulin B', 117, '1,25-dihydroxyvitamin D'), ('CHEBI_35885', 'secondary phosphine', 219, 'phosphorus'), ('UBERON_0001555', 'digestive tract', 250, 'gut'), ('GO_0055073', 'cadmium ion homeostasis', 275, 'calcium homeostasis'), ('UBERON_0008883', 'osteoid', 325, 'osteoid'), ('UBERON_0002113', 'kidney', 353, 'renal'), ('CHEBI_4056', 'cytochrome', 380, 'cytochrome'), ('PR_000006100', 'aromatase', 380, 'cytochrome P450'), ('PR_000006138', 'cytochrome P450 4F11', 397, 'CYP ... 27B1'), ('GO_0009057', 'macromolecule catabolic process', 440, 'synthesis'), ('CHEBI_67472', '15-epi-lupulin B', 453, '1,25-dihydroxyvitamin D'), ('PR_000006101', 'cytochrome P450 1A1', 495, 'CYP27B1'), ('GO_0010467', 'gene expression', 506, 'expressed'), ('UBERON_0002481', 'bone tissue', 519, 'nonrenal tissues'), ('CHEBI_67469', '15-hydroxyajubractin C', 547, '1,25 dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 588, 'vitamin D'), ('GO_0010467', 'gene expression', 617, 'expressed'), ('UBERON_0000062', 'organ', 643, 'organs'), ('UBERON_0000479', 'tissue', 651, 'tissues'), ('CHEBI_67472', '15-epi-lupulin B', 690, '1,25-dihydroxyvitamin D'), ('UBERON_0005292', 'extraembryonic tissue', 734, 'extrarenal tissues'), ('CL_0000169', 'type B pancreatic cell', 776, 'pancreatic beta cells'), ('UBERON_0001264', 'pancreas', 776, 'pancreatic'), ('UBERON_0000160', 'intestine', 803, 'intestine'), ('UBERON_0002367', 'prostate gland', 814, 'prostate'), ('UBERON_0000310', 'breast', 824, 'breast'), ('UBERON_0000062', 'organ', 842, 'organs'), ('GO_0065007', 'biological regulation', 850, 'controls'), ('CHEBI_27300', 'vitamin D', 868, 'vitamin D'), ('SO_0000704', 'gene', 889, 'genes'), ('UBERON_0004535', 'cardiovascular system', 944, 'cardiovascular'), ('GO_0051886', 'negative regulation of timing of anagen', 975, 'adaptive ...'), ('GO_0044419', 'biological process involved in interspecies interaction between organisms', 988, 'innate immune responses'), ('UBERON_0002405', 'immune system', 995, 'immune'), ('GO_0030154', 'cell differentiation', 1054, 'cell proliferation ... differentiation'), ('GO_0006915', 'apoptotic process', 1095, 'apoptosis'), ('GO_0001525', 'angiogenesis', 1124, 'angiogenesis'), ('CHEBI_28384', 'vitamin K', 1141, 'Vitamin D'), ('GO_0042592', 'homeostatic process', 1151, 'homeostasis'), ('GO_0007565', 'female pregnancy', 1184, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1220, 'vitamin D'), ('GO_0042592', 'homeostatic process', 1253, 'homeostasis')]
S13-PMC3702245	PMC3702245	6/2013	S13-PMC3702245	['HOWEVER, sustained Vitamin D deficiency results in rickets in children and osteomalacia in Adults.28the COMMONLY evaluated BIOMARKERS of Vitamin D nutrition include Serum 25(Oh)D concentrations, the inverse RELATIONSHIP between 25(Oh)D and Parathyroid hormone, Intestinal calcium absorption, and assessment of Skeletal integrity.29WHILE there is an inverse RELATIONSHIP between Serum Parathyroid hormone and 25(Oh)D in nonpregnant states, this RELATIONSHIP HAS BEEN SHOWN in RECENT STUDIES to be weak during Pregnancy,6,18,30,31INDICATING that Serum Parathyroid hormone MAY BE a LESS RELIABLE BIOMARKER of maternal Vitamin D status during Pregnancy than Serum 25(Oh)d.32the maternal 25(Oh)D level does not vary significantly during Pregnancy unless there is a change in Vitamin D intake or Endogenous Synthesis.2,33,34HOWEVER, Serum 1,25(Oh)2D levels increase by 100%–200% starting in the first trimester in both the mother and the fetus.35–37the increase in maternal 1,25(Oh)2D, which originates mostly from the Kidneys, accounts for increased Intestinal calcium absorption during Pregnancy.38,39the increase in fetal 1,25(Oh)2D level SEEMS to BE RELATED to synthesis in Placental and Fetal Tissues.39,40\nan IMPORTANT aspect of Vitamin D nutrition in Pregnancy is that the Vitamin D status of the infant at Birth and in early infancy DEPENDS ON the vitamin d status of the mother during Pregnancy.41vitamin D stores in the infant start with transplacental Transfer of 25(Oh)D in early Pregnancy from mother to fetus.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 104), ('SUPERFICIAL_RELATIONSHIP', 123), ('SUPERFICIAL_RELATIONSHIP', 207), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('SUPERFICIAL_RELATIONSHIP', 357), ('SUPERFICIAL_RELATIONSHIP', 444), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 475), ('INCOMPLETE_EVIDENCE', 526), ('INCOMPLETE_EVIDENCE', 570), ('INCOMPLETE_EVIDENCE', 579), ('IMPORTANT_CONSIDERATION', 584), ('SUPERFICIAL_RELATIONSHIP', 593), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 816), ('ANOMALY_CURIOUS_FINDING', 1136), ('ANOMALY_CURIOUS_FINDING', 1145), ('SUPERFICIAL_RELATIONSHIP', 1148), ('IMPORTANT_CONSIDERATION', 1209), ('SUPERFICIAL_RELATIONSHIP', 1335)]	20	"[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('UBERON_0007023', 'adult organism', 91, 'adults'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('UBERON_0001977', 'blood serum', 165, 'serum'), ('CHEBI_30778', 'gallic acid', 171, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 177, 'D'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 240, 'parathyroid'), ('UBERON_0000160', 'intestine', 261, 'intestinal'), ('UBERON_0004288', 'skeleton', 310, 'skeletal'), ('UBERON_0001977', 'blood serum', 378, 'serum'), ('UBERON_0001132', 'parathyroid gland', 384, 'parathyroid'), ('CHEBI_71657', 'versiconol acetate', 408, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 411, 'OH ... D'), ('GO_0007565', 'female pregnancy', 508, 'pregnancy'), ('UBERON_0001977', 'blood serum', 544, 'serum'), ('UBERON_0001132', 'parathyroid gland', 550, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 615, 'vitamin D'), ('GO_0007565', 'female pregnancy', 639, 'pregnancy'), ('UBERON_0001977', 'blood serum', 654, 'serum'), ('CHEBI_30778', 'gallic acid', 660, '25(OH)'), ('CHEBI_71657', 'versiconol acetate', 683, '25(OH)D'), ('GO_0007565', 'female pregnancy', 732, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 770, 'vitamin D'), ('GO_0042400', 'ectoine catabolic process', 790, 'endogenous synthesis'), ('UBERON_0001977', 'blood serum', 827, 'serum'), ('CHEBI_37958', 'dye', 833, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 835, '25(OH)2D'), ('CHEBI_37958', 'dye', 968, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 970, '25(OH)2D'), ('UBERON_0002113', 'kidney', 1013, 'kidneys'), ('UBERON_0000160', 'intestine', 1045, 'intestinal'), ('GO_0007565', 'female pregnancy', 1082, 'pregnancy'), ('CHEBI_37958', 'dye', 1119, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 1121, '25(OH)2D'), ('UBERON_0001987', 'placenta', 1172, 'placental'), ('UBERON_0005291', 'embryonic tissue', 1186, 'fetal tissues'), ('CHEBI_27300', 'vitamin D', 1229, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1252, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1274, 'vitamin D'), ('GO_0007567', 'parturition', 1308, 'birth'), ('GO_0007565', 'female pregnancy', 1388, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1408, 'D'), ('GO_0006412', 'translation', 1457, 'transfer'), ('CHEBI_71657', 'versiconol acetate', 1469, '25(OH)D'), ('GO_0007565', 'female pregnancy', 1486, 'pregnancy')]"
S14-PMC3702245	PMC3702245	6/2013	S14-PMC3702245	['physiologically active 1,25(Oh)2D does not readily cross the Placenta.41MANY STUDIES HAVE SHOWN that the Vitamin D status of infants at Birth as measured by Cord Blood 25(Oh)D CORRELATES positively with maternal Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 70), ('INCOMPLETE_EVIDENCE', 85), ('SUPERFICIAL_RELATIONSHIP', 176)]	3	[('CHEBI_82784', 'PVP38-Ag NP', 23, '1,25(OH)2D'), ('UBERON_0001987', 'placenta', 61, 'placenta'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007567', 'parturition', 136, 'birth'), ('UBERON_0002240', 'spinal cord', 157, 'cord'), ('UBERON_0000178', 'blood', 162, 'blood'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 171, 'OH ... D'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D')]
S15-PMC3702245	PMC3702245	6/2013	S15-PMC3702245	['IN GENERAL, Cord Blood 25(Oh)D concentrations are APPROXIMATELY 60%–89% of the maternal value.11,17,35,41–47THEREFORE, maintaining optimum Vitamin D nutrition during Pregnancy is ESSENTIAL for PREVENTION of hypovitaminosis D in the fetus and Vitamin D deficiency at Birth and in early infancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 106), ('IMPORTANT_CONSIDERATION', 179), ('SUPERFICIAL_RELATIONSHIP', 193)]	5	[('UBERON_0002240', 'spinal cord', 12, 'cord'), ('UBERON_0000178', 'blood', 17, 'blood'), ('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 223, 'D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('GO_0007567', 'parturition', 266, 'birth')]
S17-PMC3702245	PMC3702245	6/2013	S17-PMC3702245	['the institute of medicine in the us in its RECENT report RECOMMENDS that a Serum 25(Oh)D concentration of 50 nmol/l (20 ng/ml) is adequate for calcium absorption and bone health in Adults, including Pregnant women, in the us and canada.7HOWEVER, new clinical guidelines from the endocrine society RECOMMEND maintaining a Serum 25(Oh)D concentration >75 nmol/l (30 ng/ml) in order to maximize calcium absorption and bone health, and for POTENTIAL Extraskeletal benefits noted in observational studies.8many RECENT STUDIES13,15–17,48–57that evaluated Vitamin D nutrition during Pregnancy in different geographic locations REPORTED wide VARIATION in Vitamin D status depending on latitude, season, sunlight exposure behavior, and Vitamin D intake (table 1).']	[('INCOMPLETE_EVIDENCE', 43), ('FUTURE_WORK', 57), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('FUTURE_WORK', 297), ('INCOMPLETE_EVIDENCE', 436), ('INCOMPLETE_EVIDENCE', 506), ('INCOMPLETE_EVIDENCE', 620), ('DIFFICULT_TASK', 634)]	8	[('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 81, '25(OH)D'), ('UBERON_0007023', 'adult organism', 181, 'adults'), ('GO_0007565', 'female pregnancy', 199, 'pregnant'), ('UBERON_0001977', 'blood serum', 321, 'serum'), ('CHEBI_71657', 'versiconol acetate', 327, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 327, '25(OH)D'), ('UBERON_0001431', 'distal carpal bone 2', 446, 'extraskeletal'), ('CHEBI_27300', 'vitamin D', 549, 'vitamin D'), ('GO_0007565', 'female pregnancy', 576, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 647, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 727, 'vitamin D')]
S19-PMC3702245	PMC3702245	6/2013	S19-PMC3702245	['there is a high prevalence of Vitamin D deficiency [Serum 25(Oh) D <50 nmol/l], and as shown intable 1, most women studied (>80%) have Serum 25(Oh)D concentrations <75 nmol/l, which are CONSIDERED “INSUFFICIENT”.8mean Serum 25(Oh)D concentrations are highest and the prevalence of Vitamin D deficiency is lowest in sun-enriched populations,51,57WHILE the lowest mean Serum 25(Oh)d and the highest prevalence of Vitamin D deficiency are REPORTED in sunshine-deprived populations.16,17,50,55,56the high prevalence of low Vitamin D ASSOCIATED with sunshine deprivation and INADEQUATE corrective Vitamin D intake SHOULD RAISE PUBLIC HEALTH CONCERN about the INCREASED RISK of adverse health EFFECTS of low Vitamin D status for the mother and fetus and poor Vitamin D nutrition in the infant at Birth.']	[('INCOMPLETE_EVIDENCE', 186), ('PROBLEM_COMPLICATION', 198), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 343), ('INCOMPLETE_EVIDENCE', 436), ('SUPERFICIAL_RELATIONSHIP', 529), ('IMPORTANT_CONSIDERATION', 570), ('FUTURE_WORK', 609), ('IMPORTANT_CONSIDERATION', 616), ('IMPORTANT_CONSIDERATION', 622), ('IMPORTANT_CONSIDERATION', 654), ('SUPERFICIAL_RELATIONSHIP', 687)]	11	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH) D'), ('UBERON_0001977', 'blood serum', 135, 'serum'), ('CHEBI_71657', 'versiconol acetate', 141, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 141, '25(OH)D'), ('UBERON_0001977', 'blood serum', 218, 'serum'), ('CHEBI_30778', 'gallic acid', 224, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 230, 'D'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D'), ('UBERON_0001977', 'blood serum', 367, 'serum'), ('CHEBI_30778', 'gallic acid', 373, '25(OH)'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 519, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 592, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 702, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 753, 'vitamin D'), ('GO_0007567', 'parturition', 790, 'birth')]
S21-PMC3702245	PMC3702245	6/2013	S21-PMC3702245	['a Serum 25(Oh)D concentration <25 nmol/l (10 ng/ml), which is ASSOCIATED with INCREASED RISK of osteomalacia in Adults,7is common during Pregnancy, AS INDICATED by RECENT REPORTS from many parts of the world.1for example, Serum 25(Oh)D < 25 nmol/l during Pregnancy HAS BEEN REPORTED in 17%–18% of the caucasian population in the uk,48,4961% of a mixed population in new zealand,5432%–42% in the indian population,15,4559%–84% of a nonwestern population in the netherlands,1441% of the kuwaiti population,1680% of the iranian population,17and 75% of the arab population in the united arab emirates.1HOWEVER, there are LIMITED STUDIES on the ASSOCIATION between such low levels of Vitamin D status and Skeletal integrity in Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 62), ('IMPORTANT_CONSIDERATION', 78), ('PROBABLE_UNDERSTANDING', 148), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 164), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 265), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 597), ('INCOMPLETE_EVIDENCE', 617), ('SUPERFICIAL_RELATIONSHIP', 640)]	10	[('UBERON_0001977', 'blood serum', 2, 'serum'), ('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 8, '25(OH)D'), ('UBERON_0007023', 'adult organism', 112, 'adults'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 228, '25(OH)D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 679, 'vitamin D'), ('UBERON_0004288', 'skeleton', 700, 'skeletal'), ('GO_0007565', 'female pregnancy', 722, 'pregnant')]
S24-PMC3702245	PMC3702245	6/2013	S24-PMC3702245	['further, a RECENT STUDY of the RELATIONSHIP between Serum 25(Oh)D and bone turnover in Pregnant women in istanbul, turkey, FOUND a negative CORRELATION between the second and third trimester and Postpartum 25(Oh)D concentrations and Serum cross-linked c-terminal telopeptide of Type 1 Collagen, which is a MARKER of Bone Resorption.58THESE studies SEEM to INDICATE a LINK between very low Vitamin D status and subclinical osteomalacia in the mothers.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 31), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 140), ('SUPERFICIAL_RELATIONSHIP', 306), ('INCOMPLETE_EVIDENCE', 332), ('ANOMALY_CURIOUS_FINDING', 348), ('INCOMPLETE_EVIDENCE', 356), ('SUPERFICIAL_RELATIONSHIP', 367)]	9	[('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 58, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('GO_0007565', 'female pregnancy', 195, 'postpartum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('UBERON_0001977', 'blood serum', 233, 'serum'), ('PR_000002123', 'C-C motif chemokine 3', 278, 'type 1 collagen'), ('GO_0045453', 'bone resorption', 316, 'bone resorption'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin D')]
S30-PMC3702245	PMC3702245	6/2013	S30-PMC3702245	['maternal 25(Oh)D concentrations during Pregnancy was SHOWN in ONE uk STUDY48TO AFFECT childhood bone mass at nine years of age, but this WAS NOT confirmed in a larger more RECENT STUDY from the uk.61in populations where Vitamin D deficiency is very SEVERE, maternal Vitamin D deficiency during Pregnancy HAS BEEN ASSOCIATED with neonatal craniotabes62and congenital rickets.63–65taken TOGETHER, the results from OBSERVATIONAL studies SUGGEST a POSSIBLE EFFECT of low maternal 25(Oh)D during Pregnancy on Fetal Bone Development, BUT the ASSOCIATION with lower childhood bone mass is UNPROVEN.']	[('INCOMPLETE_EVIDENCE', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 62), ('INCOMPLETE_EVIDENCE', 69), ('SUPERFICIAL_RELATIONSHIP', 79), ('INCOMPLETE_EVIDENCE', 137), ('INCOMPLETE_EVIDENCE', 172), ('IMPORTANT_CONSIDERATION', 249), ('INCOMPLETE_EVIDENCE', 304), ('SUPERFICIAL_RELATIONSHIP', 313), ('INCOMPLETE_EVIDENCE', 385), ('INCOMPLETE_EVIDENCE', 412), ('INCOMPLETE_EVIDENCE', 434), ('INCOMPLETE_EVIDENCE', 444), ('SUPERFICIAL_RELATIONSHIP', 453), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 528), ('ANOMALY_CURIOUS_FINDING', 528), ('SUPERFICIAL_RELATIONSHIP', 536), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 582), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 582)]	19	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 9, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('GO_0007565', 'female pregnancy', 294, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 476, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 479, 'OH ... D'), ('GO_0007565', 'female pregnancy', 491, 'pregnancy'), ('GO_0007631', 'feeding behavior', 504, 'fetal'), ('GO_0048539', 'bone marrow development', 510, 'bone development')]
S41-PMC3702245	PMC3702245	6/2013	S41-PMC3702245	['a study from pittsburgh SHOWED an inverse RELATIONSHIP between Vitamin D status and the risk of pre-eclampsia.83the authors FOUND that the risk of pre-eclampsia was more than doubled (odds ratio 2.4; ci 1.1–5.4) for a 50 nmol/l decrease in maternal Serum 25(Oh)D concentration.']	[('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 124)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0001977', 'blood serum', 249, 'serum'), ('CHEBI_71657', 'versiconol acetate', 255, '25(OH)D')]
S44-PMC3702245	PMC3702245	6/2013	S44-PMC3702245	['with INCREASING INTEREST in the ROLE of Vitamin D in Glucose Homeostasis, the ASSOCIATION between maternal Serum 25(Oh)D concentration in early Pregnancy and the risk of Gestational diabetes mellitus was investigated in a study from the national institutes of health, bethesda, md.85the authors FOUND that maternal Vitamin D deficiency [serum 25(Oh)D < 50 nmol/l] was ASSOCIATED with a higher risk of Gestational diabetes mellitus (adjusted odds ratio 2.66; ci 1.01–7.02).']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 78), ('INCOMPLETE_EVIDENCE', 295), ('SUPERFICIAL_RELATIONSHIP', 368)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0042593', 'glucose homeostasis', 53, 'glucose homeostasis'), ('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_71657', 'versiconol acetate', 113, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 113, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 343, '25(OH)D'), ('GO_0007565', 'female pregnancy', 401, 'gestational')]
S45-PMC3702245	PMC3702245	6/2013	S45-PMC3702245	['CONSISTENT with THIS report, a systematic review and meta-analysis of seven observational studies performed between 2008 and 2011 FOUND Serum 25(Oh)D < 50 nmol/l to be ASSOCIATED with Gestational diabetes BUT with an overall lower odds ratio of 1.61 (ci 1.19–2.17).86another meta-analysis of maternal Vitamin D status and Pregnancy outcomes,87which included 24 studies up to 2012, FOUND an overall INCREASED RISK of Preeclampsia (odds ratio 2.09; ci 1.50–2.90) and Gestational diabetes (odds ratio 1.38; ci 1.12–1.70).']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 168), ('ANOMALY_CURIOUS_FINDING', 205), ('INCOMPLETE_EVIDENCE', 381), ('IMPORTANT_CONSIDERATION', 398)]	7	[('UBERON_0001977', 'blood serum', 136, 'serum'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 142, '25(OH)D'), ('GO_0007565', 'female pregnancy', 184, 'gestational'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 322, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 416, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 465, 'gestational')]
S49-PMC3702245	PMC3702245	6/2013	S49-PMC3702245	['in SUPPORT of this premise is the FINDING that Vitamin D deficiency is an INDEPENDENT RISK FACTOR for bacterial vaginosis in Pregnant women.88a study from pittsburgh SHOWED an inverse dose-response RELATIONSHIP between Serum 25(Oh)D concentrations and the prevalence of bacterial vaginosis.88compared with a Serum concentration of 75 nmol/l, the prevalence of bacterial vaginosis increased 1.65-fold (ci 1.01–2.69) and 1.26-fold (ci 1.01–1.57) at Serum concentrations of 20 nmol/l and 50 nmol/l, respectively.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 166), ('SUPERFICIAL_RELATIONSHIP', 198)]	6	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnant'), ('UBERON_0001977', 'blood serum', 219, 'serum'), ('CHEBI_71657', 'versiconol acetate', 225, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 225, '25(OH ... D'), ('UBERON_0001977', 'blood serum', 308, 'serum'), ('UBERON_0001977', 'blood serum', 447, 'serum')]
S50-PMC3702245	PMC3702245	6/2013	S50-PMC3702245	['in another large study from new york in the us,89bacterial vaginosis was ONLY ASSOCIATED with Vitamin D deficiency (Serum 25(Oh)D < 75 nmol/l) in Pregnant women (adjusted odds ratio 2.87; ci 1.13–7.28).']	[('INCOMPLETE_EVIDENCE', 73), ('SUPERFICIAL_RELATIONSHIP', 78)]	2	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 116, 'serum'), ('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 122, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 146, 'pregnant')]
S51-PMC3702245	PMC3702245	6/2013	S51-PMC3702245	['further, there is a SUGGESTION of an ASSOCIATION between Vitamin D and Periodontal disease,90and maternal Serum 25(Oh)D < 75 nmol/l during Early Pregnancy HAS BEEN ASSOCIATED with a two-fold INCREASED risk of Periodontal disease.91in a RECENT randomized controlled TRIAL of Vitamin D supplementation from south carolina, Vitamin D supplementation of 4000 iu/day during Pregnancy was ASSOCIATED with a reduction in the risk of combined morbidities, such as Maternal infection, Preterm labor, and Preterm Birth.92\nIN VIEW of the POSSIBLE ASSOCIATION between maternal Vitamin D status and the pattern of fetal growth, pre-eclampsia, Gestational diabetes mellitus, and maternal infection, and the significant POTENTIAL for Perinatal morbidities ASSOCIATED with these conditions, evaluation of Vitamin D nutrition in early Pregnancy and the EFFECT of appropriate supplementation SEEMS WARRANTED.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 155), ('SUPERFICIAL_RELATIONSHIP', 164), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 236), ('SUPERFICIAL_RELATIONSHIP', 383), ('QUESTION_ANSWERED_BY_THIS_WORK', 512), ('INCOMPLETE_EVIDENCE', 515), ('INCOMPLETE_EVIDENCE', 527), ('SUPERFICIAL_RELATIONSHIP', 536), ('INCOMPLETE_EVIDENCE', 705), ('SUPERFICIAL_RELATIONSHIP', 741), ('SUPERFICIAL_RELATIONSHIP', 836), ('ANOMALY_CURIOUS_FINDING', 874), ('FUTURE_WORK', 874)]	16	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0001758', 'periodontium', 71, 'periodontal'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 112, '25(OH ... D'), ('GO_0051318', 'G1 phase', 139, 'early'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('UBERON_0001758', 'periodontium', 209, 'periodontal'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin D'), ('GO_0007565', 'female pregnancy', 369, 'pregnancy'), ('GO_0007618', 'mating', 456, 'maternal'), ('GO_0007565', 'female pregnancy', 476, 'preterm'), ('GO_0007565', 'female pregnancy', 495, 'preterm'), ('GO_0007567', 'parturition', 503, 'birth'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D'), ('GO_0007565', 'female pregnancy', 630, 'gestational'), ('GO_0036268', 'swimming', 719, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 719, 'perinatal'), ('CHEBI_27300', 'vitamin D', 789, 'vitamin D'), ('GO_0007565', 'female pregnancy', 818, 'pregnancy')]
S54-PMC3702245	PMC3702245	6/2013	S54-PMC3702245	['Monocytes cultured in Vitamin D-deficient Plasma (Serum 25(Oh)D < 30 nmol/l) SHOWED significantly decreased Tolllike Receptor-mediated Expression of Cathelicidin (p < 0.05) compared with those conditioned in Vitamin D-sufficient Plasma (Serum 25(Oh)D > 75 nmol/l).93CONSISTENT with these in vitro FINDINGS, OBSERVATIONAL clinical DATA FOUND an ASSOCIATION between Vitamin D status in Cord Blood and the RISK of Lower Respiratory Tract infection in the first year of Life.94the risk of Respiratory syncytial Virus bronchiolitis in the first year of Life is increased by six-fold (ci 1.6–24.9) in infants with Cord Blood 25(Oh)D < 50 nmol/l compared with infants with 25(Oh)D > 75 nmol/l.']	[('INCOMPLETE_EVIDENCE', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('INCOMPLETE_EVIDENCE', 297), ('INCOMPLETE_EVIDENCE', 307), ('FUTURE_WORK', 330), ('INCOMPLETE_EVIDENCE', 335), ('SUPERFICIAL_RELATIONSHIP', 344), ('IMPORTANT_CONSIDERATION', 403)]	9	[('CL_0000576', 'monocyte', 0, 'Monocytes'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 42, 'plasma'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('PR_000001660', 'prostaglandin F2-alpha receptor', 108, 'tolllike receptor'), ('GO_0010467', 'gene expression', 135, 'expression'), ('PR_000006009', 'alpha-catulin', 149, 'cathelicidin'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 229, 'plasma'), ('UBERON_0001977', 'blood serum', 237, 'serum'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 243, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 364, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 384, 'cord'), ('UBERON_0000178', 'blood', 389, 'blood'), ('UBERON_0004905', 'articulation', 411, 'lower respiratory tract'), ('UBERON_0000104', 'life cycle', 466, 'life'), ('UBERON_0001004', 'respiratory system', 485, 'respiratory'), ('NCBITaxon_1', 'root', 507, 'virus'), ('UBERON_0000104', 'life cycle', 548, 'life'), ('UBERON_0002240', 'spinal cord', 608, 'cord'), ('UBERON_0000178', 'blood', 613, 'blood'), ('CHEBI_71657', 'versiconol acetate', 619, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 619, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 666, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 666, '25(OH)D')]
S56-PMC3702245	PMC3702245	6/2013	S56-PMC3702245	['IN CONTRAST, an OBSERVATIONAL study REPORTED an increased RISK of infantile eczema and pneumonia in ASSOCIATION with maternal Serum 25(Oh)D > 75 nmol/l in the last trimester.76HOWEVER, another RECENT STUDY with a larger sample size from the same institution DID NOT FIND an ASSOCIATION between maternal 25(Oh)d > 75 nmol/l in late Pregnancy and eczema or asthma at 12 months and three and six years of age.97there was no report on the ASSOCIATION between maternal Vitamin D status and Respiratory infections in the latter study.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 36), ('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('INCOMPLETE_EVIDENCE', 193), ('INCOMPLETE_EVIDENCE', 258), ('SUPERFICIAL_RELATIONSHIP', 274), ('SUPERFICIAL_RELATIONSHIP', 435)]	10	[('UBERON_0001977', 'blood serum', 126, 'serum'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 303, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 303, '25(OH'), ('GO_0007565', 'female pregnancy', 331, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 464, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 485, 'respiratory')]
S57-PMC3702245	PMC3702245	6/2013	S57-PMC3702245	['regarding Neurocognitive Development, WHILE ONE STUDY FOUND no association between maternal Vitamin D status during Pregnancy and Neurocognitive function,76a RECENT larger-sized STUDY LINKED maternal Serum 25(Oh)D levels during Pregnancy with Language Development in the offspring.98the results of the above studies SUGGEST that childhood infections, atopy, and Neurocognitive development NEED TO BE included as outcomes of interest following Vitamin D supplementation in Pregnancy, and that clinical trials SHOULD include a RELEVANT group of subjects CONSIDERED to be replete for Vitamin D.\ntaken TOGETHER, the high prevalence of Vitamin D deficiency in Pregnancy and the POSSIBLE multiple POTENTIAL adverse EFFECTS on mother and offspring IDENTIFIED in SEVERAL epidemiologic STUDIES UNDERSCORE the URGENT NEED FOR large randomized controlled TRIALS to identify the amount of Vitamin D supplementation that optimizes Vitamin D status during Pregnancy, and to DETERMINE the EFFECT of supplementation on POTENTIAL adverse conditions ASSOCIATED with Vitamin D deficiency and any POSSIBLE Vitamin D excess.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 158), ('SUPERFICIAL_RELATIONSHIP', 184), ('INCOMPLETE_EVIDENCE', 316), ('FUTURE_WORK', 389), ('FUTURE_WORK', 508), ('IMPORTANT_CONSIDERATION', 525), ('IMPORTANT_CONSIDERATION', 552), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 691), ('SUPERFICIAL_RELATIONSHIP', 709), ('INCOMPLETE_EVIDENCE', 741), ('INCOMPLETE_EVIDENCE', 755), ('IMPORTANT_CONSIDERATION', 785), ('IMPORTANT_CONSIDERATION', 800), ('FUTURE_WORK', 807), ('INCOMPLETE_EVIDENCE', 807), ('FUTURE_WORK', 844), ('QUESTION_ANSWERED_BY_THIS_WORK', 960), ('SUPERFICIAL_RELATIONSHIP', 974), ('INCOMPLETE_EVIDENCE', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1077)]	26	[('GO_0007399', 'nervous system development', 10, 'neurocognitive development'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0050905', 'neuromuscular process', 130, 'neurocognitive'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 206, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('GO_0060132', 'prolactin secreting cell development', 243, 'language development'), ('GO_0050905', 'neuromuscular process', 362, 'neurocognitive'), ('CHEBI_27300', 'vitamin D', 443, 'vitamin D'), ('GO_0007565', 'female pregnancy', 472, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 581, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 631, 'vitamin D'), ('GO_0007565', 'female pregnancy', 655, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 877, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 918, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1048, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1086, 'vitamin D')]
S58-PMC3702245	PMC3702245	6/2013	S58-PMC3702245	['Vitamin D REQUIREMENT during Pregnancy\nin ORDER TO DETERMINE the Vitamin D REQUIREMENT during Pregnancy, one NEEDS to define the target Serum 25(Oh)D concentration considered as “normal” or “optimal”.']	[('IMPORTANT_CONSIDERATION', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 42), ('IMPORTANT_CONSIDERATION', 75), ('FUTURE_WORK', 109), ('IMPORTANT_CONSIDERATION', 109)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 29, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0001977', 'blood serum', 136, 'serum'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 148, 'D')]
S61-PMC3702245	PMC3702245	6/2013	S61-PMC3702245	['a target concentration of 75 nmol/l is CONSISTENT with the Cord Blood 25(Oh)D level REPORTED in SOME STUDIES as being PROTECTIVE against lower respiratory infection, wheezing, and eczema in infants.94–96to achieve a target Serum concentration >75 nmol/l, the society RECOMMENDS a daily Vitamin D Intake of 1500–2000 iu.']	[('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 118), ('FUTURE_WORK', 267)]	5	[('UBERON_0002240', 'spinal cord', 59, 'cord'), ('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 70, '25(OH ... D'), ('UBERON_0001977', 'blood serum', 223, 'serum'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0007631', 'feeding behavior', 296, 'intake')]
S63-PMC3702245	PMC3702245	6/2013	S63-PMC3702245	['a review of the FEW previous randomized controlled TRIALS of Vitamin D supplementation during Pregnancy INDICATES that doses of 400–1600 iu/day were INSUFFICIENT in achieving a mean Serum 25(Oh)D concentration ≥50 nmol/l in most of the studies.41in a RECENT Vitamin D supplementation TRIAL from the uk, a multiethnic group of 180 Pregnant women were randomized at 27 weeks’ Gestation to receive a single Oral dose of 200,000 iu of Vitamin D, daily supplementation of 800 iu, or no treatment.33the median Serum 25(Oh)D concentration in the 800 iu/day group at study entry was 26 nmol/l (interquartile range 22–37), and the median 25(Oh)D concentration at delivery following supplementation was 42 nmol/l (interquartile range 31–76).']	[('INCOMPLETE_EVIDENCE', 16), ('FUTURE_WORK', 51), ('INCOMPLETE_EVIDENCE', 104), ('IMPORTANT_CONSIDERATION', 149), ('PROBLEM_COMPLICATION', 149), ('INCOMPLETE_EVIDENCE', 251), ('INCOMPLETE_EVIDENCE', 284)]	7	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0001977', 'blood serum', 182, 'serum'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 188, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('GO_0007565', 'female pregnancy', 330, 'pregnant'), ('GO_0007565', 'female pregnancy', 374, 'gestation'), ('UBERON_0000165', 'mouth', 404, 'oral'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D'), ('UBERON_0001977', 'blood serum', 504, 'serum'), ('CHEBI_71657', 'versiconol acetate', 510, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 510, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 629, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 629, '25(OH)D')]
S64-PMC3702245	PMC3702245	6/2013	S64-PMC3702245	['ONLY 30% of the women treated with 800 iu/day of Vitamin D achieved a Serum 25(Oh)D concentration >50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 76, '25(OH)D')]
S68-PMC3702245	PMC3702245	6/2013	S68-PMC3702245	['these two studies and older RESEARCH41INDICATE that, in populations with a high prevalence of SEVERE Vitamin D sufficiency, supplementation up to 1600 iu/day MAY BE inadequate to achieve the RECOMMENDED target Serum 25(Oh)D concentration of 50 nmol/l.7in two RECENT STUDIES from india, which used large single-dose supplementation of 120,000 iu at the fifth and seventh month of Gestation15Or at the second and third trimester,69only 25% and 62%, respectively, achieved a Serum 25(Oh)D concentration >50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 94), ('INCOMPLETE_EVIDENCE', 158), ('FUTURE_WORK', 191), ('INCOMPLETE_EVIDENCE', 259)]	5	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 216, '25(OH)D'), ('GO_0007565', 'female pregnancy', 379, 'gestation15or'), ('UBERON_0001977', 'blood serum', 472, 'serum'), ('CHEBI_71657', 'versiconol acetate', 478, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 478, '25(OH)D')]
S69-PMC3702245	PMC3702245	6/2013	S69-PMC3702245	['the RECENT cochrane review of Vitamin D supplementation alone during Pregnancy79Considered five trials that compared the EFFECTS of supplementation with placebo or no supplementation.33,73,77,78,102the review CONCLUDED that Vitamin D supplementation increases Serum 25(Oh)D concentrations during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 121), ('INCOMPLETE_EVIDENCE', 209)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0016441', 'posttranscriptional gene silencing', 69, 'pregnancy79considered'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('UBERON_0001977', 'blood serum', 260, 'serum'), ('CHEBI_71657', 'versiconol acetate', 266, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 266, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 296, 'pregnancy')]
S70-PMC3702245	PMC3702245	6/2013	S70-PMC3702245	['OF NOTE, in two of the five studies, the mean concentration of 25(Oh)D after supplementation was <50 nmol/l,33,78and Serum 25(Oh)D WAS NOT MEASURED in ONE STUDY.73all these STUDIES underscore the uncertainty about the amount of Vitamin D supplementation REQUIRED to optimize Vitamin D status in Pregnancy and which would be generalizable worldwide.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 131), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 173), ('IMPORTANT_CONSIDERATION', 254)]	5	[('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 275, 'vitamin D'), ('GO_0007565', 'female pregnancy', 295, 'pregnancy')]
S72-PMC3702245	PMC3702245	6/2013	S72-PMC3702245	['the institute of MEDICINE7CONSIDERS a Serum 25(Oh)D concentration >50 nmol/l AS acceptable, WHILE the Endocrine society and Vitamin D EXPERTS RECOMMEND >75 nmol/l.8,99a RECENT STUDY among traditional populations in tanzania with type vi (dark) skin color living in a sun-abundant environment RECOMMENDED a mean Serum 25(Oh)D concentration of 115 nmol/l in nonpregnant Adults and 139 nmol/l in Pregnant women.57the question then is: WHAT Serum concentration of 25(Oh)D is “normal” in Adults, including during Pregnancy?']	[('INCOMPLETE_EVIDENCE', 17), ('PROBABLE_UNDERSTANDING', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92), ('PROBABLE_UNDERSTANDING', 134), ('FUTURE_WORK', 142), ('INCOMPLETE_EVIDENCE', 169), ('FUTURE_WORK', 292), ('EXPLICIT_QUESTION', 432), ('EXPLICIT_QUESTION', 517)]	9	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 44, '25(OH)D'), ('UBERON_0005063', 'left ventricular compact myocardium', 102, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('UBERON_0001977', 'blood serum', 311, 'serum'), ('CHEBI_71657', 'versiconol acetate', 317, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 317, '25(OH)D'), ('UBERON_0007023', 'adult organism', 368, 'adults'), ('GO_0007565', 'female pregnancy', 393, 'pregnant'), ('UBERON_0001977', 'blood serum', 437, 'serum'), ('CHEBI_71657', 'versiconol acetate', 460, '25(OH)D'), ('UBERON_0007023', 'adult organism', 483, 'adults'), ('GO_0007565', 'female pregnancy', 508, 'pregnancy')]
S73-PMC3702245	PMC3702245	6/2013	S73-PMC3702245	['WHILE the DEBATE and studies to identify OPTIMAL Serum 25(Oh)D concentration CONTINUE, it is PRUDENT to monitor Vitamin D status and develop STRATEGIES to ensure AT LEAST a minimum Serum 25(Oh)D concentration of 50 nmol/l in Pregnant women, especially in an environment where Vitamin D deficiency is endemic.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('IMPORTANT_CONSIDERATION', 41), ('FUTURE_WORK', 77), ('FUTURE_WORK', 93), ('IMPORTANT_CONSIDERATION', 93), ('FUTURE_WORK', 141), ('PROBABLE_UNDERSTANDING', 162)]	8	[('UBERON_0001977', 'blood serum', 49, 'serum'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('UBERON_0001977', 'blood serum', 181, 'serum'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('GO_0007565', 'female pregnancy', 225, 'pregnant'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D')]
S74-PMC3702245	PMC3702245	6/2013	S74-PMC3702245	['in studies of Adults and nonpregnant women, a Vitamin D intake of up to 10,000 iu/day is ASSOCIATED with achievement of a Serum 25(Oh)D concentration ≥80 nmol/l without Vitamin D toxicity.103,104from a review of PREVIOUS STUDIES, an additional daily intake of 100 iu of Vitamin D increases the Serum 25(Oh)D concentration by 1–2 nmol/l.7,105THEREFORE, knowing the population baseline Serum 25(Oh)D concentration, IT IS POSSIBLE to ESTIMATE the Vitamin D intake REQUIRED to replete body stores and achieve an expected target Serum 25(Oh)d concentration.']	[('SUPERFICIAL_RELATIONSHIP', 89), ('INCOMPLETE_EVIDENCE', 212), ('PROBABLE_UNDERSTANDING', 338), ('INCOMPLETE_EVIDENCE', 413), ('INCOMPLETE_EVIDENCE', 431), ('IMPORTANT_CONSIDERATION', 461)]	6	[('UBERON_0007023', 'adult organism', 14, 'adults'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('UBERON_0001977', 'blood serum', 122, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 131, 'OH)D'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D'), ('UBERON_0001977', 'blood serum', 294, 'serum'), ('CHEBI_71657', 'versiconol acetate', 300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 300, '25(OH)D'), ('UBERON_0001977', 'blood serum', 384, 'serum'), ('CHEBI_33010', 'chromide(1-)', 392, '(OH)D'), ('CHEBI_27300', 'vitamin D', 444, 'vitamin D'), ('UBERON_0001977', 'blood serum', 524, 'serum'), ('CHEBI_30778', 'gallic acid', 530, '25(OH)')]
S75-PMC3702245	PMC3702245	6/2013	S75-PMC3702245	['because of CONTROVERSY surrounding Vitamin D REQUIREMENTS during Pregnancy, investigators from south carolina performed a comprehensive, large, randomized controlled study of Vitamin D supplementation in Pregnancy to achieve optimal Vitamin D status, DEFINED as a Serum 25(Oh)D concentration ≥80 nmol/l at Delivery.18BASED on the pharmacokinetics of Vitamin d, the authors INVESTIGATED the SAFETY and EFFECTIVENESS of high-dose Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 11), ('IMPORTANT_CONSIDERATION', 45), ('PROBABLE_UNDERSTANDING', 251), ('PROBABLE_UNDERSTANDING', 315), ('QUESTION_ANSWERED_BY_THIS_WORK', 373), ('IMPORTANT_CONSIDERATION', 390), ('SUPERFICIAL_RELATIONSHIP', 401)]	7	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('UBERON_0001977', 'blood serum', 264, 'serum'), ('CHEBI_71657', 'versiconol acetate', 270, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 270, '25(OH)D'), ('GO_0007567', 'parturition', 306, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 350, 'vitamin'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]
S76-PMC3702245	PMC3702245	6/2013	S76-PMC3702245	['they HYPOTHESIZED that daily Vitamin D3Supplementation of 4000 iu/day would be more effective than 2000 iu and a standard dosing regimen of 400 iu in achieving a Serum 25(Oh)D concentration of >80 nmol/l without any safety ISSUES referable to Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 223), ('PROBLEM_COMPLICATION', 223)]	3	[('CHEBI_52915', 'phosphatediyl group', 29, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 29, 'vitamin D3supplementation'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 168, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]
S89-PMC3702245	PMC3702245	6/2013	S89-PMC3702245	['IF the institute of medicine’s target of a Serum 25(Oh)D concentration ≥50 nmol/l7was adopted for neonatal Vitamin D status, 79%, 58%, and 40%, respectively, of the infants of mothers on 4000, 2000, and 400 iu per day achieved adequate Vitamin D status ( p = 0.0001).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 49, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
S15-PMC3705320	PMC3705320	3/2013	S15-PMC3705320	['Serum 25-Hydroxyvitamin D concentration ([25(Oh)D]) ≥ 50 nmol/l is ASSOCIATED with Skeletal health benefits [1], BUT SOME data SUGGEST that IMPROVING Vitamin D status to attain Serum [25(Oh)D] ≥ 80 nmol/l MAY enhance a range of Vitamin D-related functions [6,7,8].']	[('SUPERFICIAL_RELATIONSHIP', 67), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 113), ('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 127), ('FUTURE_WORK', 140), ('INCOMPLETE_EVIDENCE', 205)]	6	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 6, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 42, '25(OH)D'), ('UBERON_0004288', 'skeleton', 83, 'skeletal'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('UBERON_0001977', 'blood serum', 177, 'serum'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D')]
S114-PMC3705320	PMC3705320	3/2013	S114-PMC3705320	['there was substantial inter-subject variability in the response to Vitamin D supplementation, with one pl participant demonstrating ONLY a 7 nmol/l final increase in [25(Oh)D] above her baseline.']	[('INCOMPLETE_EVIDENCE', 132)]	1	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 167, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 170, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 173, 'D')]
S157-PMC3705320	PMC3705320	3/2013	S157-PMC3705320	['among bangladeshi women with a mean [25(Oh)D] of 33 nmol/l, 70,000 iu followed by 35,000 iu/week of Vitamin D3 until Delivery yielded an average [25(Oh)D] that was ABOUT 20 nmol/l higher than an Antenatal dose of 14,000 iu/week (the iom Vitamin D upper limit at the time the study was conducted).']	[('INCOMPLETE_EVIDENCE', 164)]	1	[('CHEBI_71657', 'versiconol acetate', 37, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 37, '25(OH ... D'), ('CHEBI_33279', 'vitamin D5', 100, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 100, 'vitamin D3'), ('GO_0007567', 'parturition', 117, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 152, 'D'), ('GO_0007567', 'parturition', 195, 'antenatal'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]
S173-PMC3705320	PMC3705320	3/2013	S173-PMC3705320	['(2008) [24], as well the RECENT iom REPORT (2010) [1], have DEMONSTRATED that the ∆[25(Oh)D] per mcg is a curvilinear inverse FUNCTION of Vitamin D Intake at doses <50 mcg/day, but nearly proportional to Intake at >50 mcg/day [24], which MAY EXPLAIN the greater OBSERVED efficiency of the lower dose.']	[('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 36), ('INCOMPLETE_EVIDENCE', 60), ('SUPERFICIAL_RELATIONSHIP', 126), ('INCOMPLETE_EVIDENCE', 238), ('PROBABLE_UNDERSTANDING', 242), ('INCOMPLETE_EVIDENCE', 262)]	7	[('CHEBI_71657', 'versiconol acetate', 84, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007631', 'feeding behavior', 148, 'intake'), ('GO_0007631', 'feeding behavior', 204, 'intake')]
S13-PMC3773018	PMC3773018	4/2013	S13-PMC3773018	['to date, ONLY three birth cohort studies have examined the EFFECT of Prenatal Vitamin D exposure on allergic phenotypes using Cord Blood 25(Oh)D concentrations, an objective measure of Vitamin D status reflecting both dietary intake and sun exposure.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 59)]	2	[('GO_0007565', 'female pregnancy', 69, 'prenatal'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 126, 'cord'), ('UBERON_0000178', 'blood', 131, 'blood'), ('CHEBI_71657', 'versiconol acetate', 137, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 137, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]
S35-PMC3773018	PMC3773018	4/2013	S35-PMC3773018	['we grouped the children according to longitudinal trajectory of 25(Oh)D based on if a child had: 1) low Vitamin D status at Birth (< 11ng/ml) AS SUGGESTED by the institute of medicine (26) or 2) low Postnatal Vitamin D status (< 30ng/ml) ACCORDING TO the Endocrine society clinical practice guidelines on Vitamin D insufficiency (27,28).']	[('PROBABLE_UNDERSTANDING', 142), ('INCOMPLETE_EVIDENCE', 145), ('INCOMPLETE_EVIDENCE', 238)]	3	[('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 64, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007567', 'parturition', 124, 'birth'), ('GO_0007567', 'parturition', 199, 'postnatal'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 255, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 305, 'Vitamin D')]
S54-PMC3773018	PMC3773018	4/2013	S54-PMC3773018	['SIMILAR ASSOCIATION PATTERNS between persistently low Vitamin D and high risk of fs were SEEN among children with 25(Oh)D measurements within 1 year of age and 1–3 years of age; among children Born in winter and non-winter; among children Born Preterm (< 37 weeks of Gestation) and children born term (>= 37 weeks) (data not shown).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 8), ('SUPERFICIAL_RELATIONSHIP', 20), ('INCOMPLETE_EVIDENCE', 89)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 114, '25(OH ... D'), ('GO_0007567', 'parturition', 193, 'born'), ('GO_0007567', 'parturition', 239, 'born'), ('GO_0007565', 'female pregnancy', 244, 'preterm'), ('GO_0007565', 'female pregnancy', 267, 'gestation')]
S61-PMC3773018	PMC3773018	4/2013	S61-PMC3773018	['discussion\nTHIS is the FIRST STUDY TO EXAMINE the EFFECTS of longitudinal trajectory Vitamin D status, by measurement of Plasma 25(Oh)D concentrations from Birth to early childhood, on the development of fs.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('INCOMPLETE_EVIDENCE', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('QUESTION_ANSWERED_BY_THIS_WORK', 38), ('SUPERFICIAL_RELATIONSHIP', 50)]	6	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 121, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 128, '25(OH ... D'), ('GO_0007567', 'parturition', 156, 'birth')]
S17-PMC3809191	PMC3809191	1/2013	S17-PMC3809191	['Serum 25 (Oh) D levels ≤20 ng/ml are ACCEPTED AS the cutoff level for Vitamin D deficiency SINCE this level was the highest level to maintain the Serum pth levels below 45 pg/ml.']	[('INCOMPLETE_EVIDENCE', 37), ('PROBABLE_UNDERSTANDING', 46), ('PROBABLE_UNDERSTANDING', 91)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 6, '25 (OH) D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0001977', 'blood serum', 146, 'serum')]
S53-PMC3809191	PMC3809191	1/2013	S53-PMC3809191	['THIS EVIDENCE is CONSISTENT with low Vitamin D levels in either Pregnant or non-Pregnant Individuals in our country as in the rest of the world.11,12HOWEVER we did not FIND significant association of low levels of Serum 25 (Oh) D with elevated RISK for gdm EVEN after adjustment for conventional risk FACTORS for diabetes.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 147), ('INCOMPLETE_EVIDENCE', 168), ('IMPORTANT_CONSIDERATION', 244), ('ANOMALY_CURIOUS_FINDING', 257), ('SUPERFICIAL_RELATIONSHIP', 301)]	8	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('NCBITaxon_1', 'root', 89, 'individuals'), ('UBERON_0001977', 'blood serum', 214, 'serum'), ('CHEBI_71657', 'versiconol acetate', 220, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25 (OH) D')]
S55-PMC3809191	PMC3809191	1/2013	S55-PMC3809191	['in ONE cross-sectional STUDY, Serum 25(Oh) D levels during 24-28 weeks of Gestation were lower in gdm women than in nondiabetic Pregnant women.9in ANOTHER STUDY, maternal Serum 25 (Oh) D concentrations measured at the time of gdm screening test were significantly and inversely ASSOCIATED with fasting glucose, ALTHOUGH the ASSOCIATION of Vitamin D with gdm risk was not statistically significant.8our FINDINGS are also CONSISTENT with a study in an indian population, SHOWING no significant ASSOCIATION between 25 (Oh) D concentrations (at 30 weeks of Gestation) and gdm risk.6\ndeficiency of Vitamin D was shown to be ASSOCIATED with fetal and Brain growth deficiency and type 1 diabetes in children.13significantly reduced risk of type 1 Diabetes Mellitus Development was FOUND when high doses of Vitamin D supplementation (up to 2000 iu/d) were given during infancy in a Birth-cohort study.14\nVitamin D deficiency was also ASSOCIATED with INCREASED risk for Pregnancy complications and SERIOUS health PROBLEMS in the offspring.5,15-17higher risks of Preeclampsia and cesarean section ratios were shown in Pregnants with low levels of Vitamin D.16,17moreover supplementation of Vitamin D HAS BEEN DEMONSTRATED to decrease the RISK of Preeclampsia by 27% in a STUDY.18\n\ncaption (fig): fig.1\n\nthe correlation between Serum Vitamin D and pth levels\n\ncaption (fig): fig.2\n\nSerum Vitamin D levels in veiled and nonveiled Pregnant\n\ncaption (fig): fig.3\n\nVitamin D levels and the frequency of muscle cramps (x²=3.57, p=0.05).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 147), ('SUPERFICIAL_RELATIONSHIP', 278), ('ANOMALY_CURIOUS_FINDING', 311), ('SUPERFICIAL_RELATIONSHIP', 324), ('INCOMPLETE_EVIDENCE', 402), ('INCOMPLETE_EVIDENCE', 420), ('INCOMPLETE_EVIDENCE', 469), ('SUPERFICIAL_RELATIONSHIP', 492), ('SUPERFICIAL_RELATIONSHIP', 619), ('INCOMPLETE_EVIDENCE', 774), ('SUPERFICIAL_RELATIONSHIP', 926), ('IMPORTANT_CONSIDERATION', 942), ('IMPORTANT_CONSIDERATION', 989), ('IMPORTANT_CONSIDERATION', 1004), ('INCOMPLETE_EVIDENCE', 1190), ('IMPORTANT_CONSIDERATION', 1228), ('INCOMPLETE_EVIDENCE', 1261)]	19	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_71657', 'versiconol acetate', 36, '25(OH) D'), ('PR_000008838', 'serine protease HTRA1', 36, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('GO_0007565', 'female pregnancy', 128, 'pregnant'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_71657', 'versiconol acetate', 177, '25 (OH) D'), ('PR_000009880', 'Lon protease, mitochondrial', 177, '25 ... OH ... D'), ('CHEBI_28384', 'vitamin K', 339, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 339, 'Vitamin'), ('CHEBI_71657', 'versiconol acetate', 512, '25 (OH) D'), ('GO_0007565', 'female pregnancy', 553, 'gestation'), ('CHEBI_27300', 'vitamin D', 593, 'vitamin D'), ('UBERON_0000955', 'brain', 645, 'brain'), ('GO_1903709', 'uterine gland development', 740, 'diabetes mellitus development'), ('CHEBI_27300', 'vitamin D', 799, 'vitamin D'), ('GO_0007567', 'parturition', 874, 'birth'), ('CHEBI_28384', 'vitamin K', 896, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 961, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 1053, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 1108, 'pregnants'), ('CHEBI_28384', 'vitamin K', 1137, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 1180, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 1236, 'preeclampsia'), ('UBERON_0001977', 'blood serum', 1317, 'serum'), ('CHEBI_28384', 'vitamin K', 1323, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1323, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 1371, 'Serum'), ('CHEBI_28384', 'vitamin K', 1377, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1377, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1418, 'pregnant'), ('CHEBI_28384', 'vitamin K', 1450, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1450, 'Vitamin D')]
S60-PMC3809191	PMC3809191	1/2013	S60-PMC3809191	['first, Serum 25 (Oh) D concentrations determined in late trimester MAY not show the status of maternal Vitamin D during the whole Pregnancy Period and HENCE to IDENTIFY the ASSOCIATION of Gdm Development and Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 67), ('PROBABLE_UNDERSTANDING', 151), ('QUESTION_ANSWERED_BY_THIS_WORK', 160), ('SUPERFICIAL_RELATIONSHIP', 173)]	4	[('UBERON_0001977', 'blood serum', 7, 'serum'), ('CHEBI_71657', 'versiconol acetate', 13, '25 (OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 21, 'D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('UBERON_0018298', 'stylocone', 130, 'pregnancy period'), ('GO_0072147', 'glomerular parietal epithelial cell fate commitment', 188, 'GDM development'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D')]
S16-PMC3814422	PMC3814422	10/2013	S16-PMC3814422	['the gold STANDARD measure of Vitamin D status is the Blood concentration of 25-Hydroxyvitamin D (25(Oh)D)11.']	[('INCOMPLETE_EVIDENCE', 9)]	1	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('UBERON_0000178', 'blood', 53, 'blood'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 76, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D')]
S53-PMC3814422	PMC3814422	10/2013	S53-PMC3814422	['this variable incorporates the seasonal INFLUENCE on 25(Oh)D. to remove this seasonal INFLUENCE in an ATTEMPT to obtain a MARKER of habitual Vitamin D concentrations for each mother, we used the residuals from the sine–cosine regression model.']	[('SUPERFICIAL_RELATIONSHIP', 40), ('SUPERFICIAL_RELATIONSHIP', 86), ('DIFFICULT_TASK', 102), ('SUPERFICIAL_RELATIONSHIP', 122)]	4	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 53, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 149, 'D')]
S63-PMC3814422	PMC3814422	10/2013	S63-PMC3814422	['additional analyses\nTO TEST WHETHER ASSOCIATIONS were driven by a threshold effect of greater risk in those whose mothers had insufficient levels of Vitamin D, we EXAMINED ASSOCIATIONS of categories of 25(Oh)D levels (≥ 50 nmol/l; 27.5–49.99 nmol/l and < 27.5 nmol/l) with outcomes, we also repeated analyses using 75 nmol/l as a higher THRESHOLD for sufficiency as recommended in a more RECENT REVIEW23.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('SUPERFICIAL_RELATIONSHIP', 36), ('QUESTION_ANSWERED_BY_THIS_WORK', 163), ('SUPERFICIAL_RELATIONSHIP', 172), ('PROBABLE_UNDERSTANDING', 337), ('INCOMPLETE_EVIDENCE', 388)]	7	[('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 202, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 208, 'D')]
S123-PMC3814422	PMC3814422	10/2013	S123-PMC3814422	['Serum 25(Oh)D HAS BEEN CRITICIZED as a PROXY for Vitamin D ASSOCIATIONS.']	[('INCOMPLETE_EVIDENCE', 14), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 23), ('SUPERFICIAL_RELATIONSHIP', 39), ('SUPERFICIAL_RELATIONSHIP', 59)]	4	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S124-PMC3814422	PMC3814422	10/2013	S124-PMC3814422	['for instance, it HAS BEEN SUGGESTED that there is a NEED to DISTINGUISH between Serum 25(Oh)D and EFFECTS of Vitamin D supplementation, the former being a prohormone representing a physiological state that is only relevant at extremely high or low levels, and the latter representing the non-physiological action of interest4.']	[('INCOMPLETE_EVIDENCE', 17), ('FUTURE_WORK', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 60), ('SUPERFICIAL_RELATIONSHIP', 98)]	4	[('UBERON_0001977', 'blood serum', 80, 'serum'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 86, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
S130-PMC3814422	PMC3814422	10/2013	S130-PMC3814422	['ALTHOUGH we COULD NOT directly investigate the ASSOCIATION of maternal 25(Oh)D with Early Life Respiratory infections, the LACK OF ASSOCIATION with transient early wheezing phenotype ARGUES AGAINST a PROTECTIVE EFFECT of Prenatal Vitamin D on Respiratory Viral infections in early childhood.']	[('ANOMALY_CURIOUS_FINDING', 0), ('DIFFICULT_TASK', 12), ('ANOMALY_CURIOUS_FINDING', 18), ('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 131), ('INCOMPLETE_EVIDENCE', 183), ('SUPERFICIAL_RELATIONSHIP', 200), ('SUPERFICIAL_RELATIONSHIP', 211)]	9	[('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 71, '25(OH ... D'), ('UBERON_0001847', 'lobule of pinna', 84, 'early life'), ('UBERON_0001004', 'respiratory system', 95, 'respiratory'), ('GO_0007565', 'female pregnancy', 221, 'prenatal'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 243, 'respiratory'), ('NCBITaxon_1', 'root', 255, 'viral')]
S134-PMC3814422	PMC3814422	10/2013	S134-PMC3814422	['by way of analogy, in a study of Vitamin D and Adult Lung function we FOUND that, WHILST there were APPARENT ASSOCIATIONS with dietary Vitamin D intake, there was NO EVIDENCE for an association with Blood 25(Oh)D concentrations29.']	[('INCOMPLETE_EVIDENCE', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82), ('ANOMALY_CURIOUS_FINDING', 82), ('ANOMALY_CURIOUS_FINDING', 100), ('SUPERFICIAL_RELATIONSHIP', 109), ('INCOMPLETE_EVIDENCE', 163)]	6	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0007023', 'adult organism', 47, 'adult'), ('UBERON_0002048', 'lung', 53, 'lung'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('UBERON_0000178', 'blood', 199, 'blood'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 205, '25(OH)D')]
S27-PMC3827489	PMC3827489	10/2013	S27-PMC3827489	['diagnostic criteria of Vitamin D insufficiency or deficiency\nNO CONSENSUS on the definition of Vitamin D deficiency exists; HOWEVER, most clinicians and researchers agree on the following stratifications BASED ON the Serum concentration of 25(Oh)D: deficiency, <50.0 nmol/l or <20.0 ng/ml; insufficiency, 50.0-74.9 nmol/l or 20.0-29.9 ng/ml; and sufficiency, ≥75.0 nmol/l or ≥30.0 ng/ml1,6,16,17).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 61), ('INCOMPLETE_EVIDENCE', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('INCOMPLETE_EVIDENCE', 204), ('PROBABLE_UNDERSTANDING', 204)]	5	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0001977', 'blood serum', 217, 'serum'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 240, '25(OH)D')]
S33-PMC3827489	PMC3827489	10/2013	S33-PMC3827489	['IN LINE WITH THESE data, a study FOCUSING on adolescents aged 12-13 years REPORTED that 98.9% of boys and 100% of girls showed Vitamin D insufficiency or deficiency; 5.3% had 25(Oh)D insufficiency (20.0-29.9 ng/ml), 94.2% had deficient concentrations (<20.0 ng/ml), and ONLY 1 boy (1.1%) had OPTIMAL concentrations of 25(Oh)d6).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('INCOMPLETE_EVIDENCE', 74), ('ANOMALY_CURIOUS_FINDING', 270), ('INCOMPLETE_EVIDENCE', 270), ('IMPORTANT_CONSIDERATION', 292)]	7	[('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 175, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 318, '25(OH')]
S89-PMC3827489	PMC3827489	10/2013	S89-PMC3827489	['EFFECTS of maternal Vitamin D insufficiency/deficiency on infants and children\nstudies have SUGGESTED that Vitamin D concentrations in the fetus and newborn are highly DEPENDENT on and significantly RELATED to maternal Serum 25(Oh)D concentrations61-64).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 168), ('SUPERFICIAL_RELATIONSHIP', 199)]	4	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0001977', 'blood serum', 219, 'serum'), ('CHEBI_71657', 'versiconol acetate', 225, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 225, '25(OH ... D')]
S2-PMC3873449	PMC3873449	12/2013	S2-PMC3873449	['the PURPOSE of THIS STUDY was TO ASSESS the Vitamin D status of Pregnant women residing in beijing in winter AND EVALUATE the IMPACT of maternal factors on Serum 25-hydroxyvitamin d [25(Oh)D] levels.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('QUESTION_ANSWERED_BY_THIS_WORK', 109), ('SUPERFICIAL_RELATIONSHIP', 126)]	5	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('UBERON_0001977', 'blood serum', 156, 'serum'), ('CHEBI_71657', 'versiconol acetate', 183, '25(OH)D')]
S17-PMC3873449	PMC3873449	12/2013	S17-PMC3873449	['adequate 25(Oh)D levels are particularly IMPORTANT for women who Become Pregnant, BECAUSE mothers HAVE to sustain their own Vitamin D stores as well as those of their fetuses [2,3].']	[('IMPORTANT_CONSIDERATION', 41), ('PROBABLE_UNDERSTANDING', 82), ('IMPORTANT_CONSIDERATION', 98)]	3	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007567', 'parturition', 65, 'become'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S62-PMC3873449	PMC3873449	12/2013	S62-PMC3873449	['ALTHOUGH there HAS BEEN DEBATE over WHICH level of Serum 25(Oh)D REFLECTS optimum Vitamin D status, it is GENERALLY ACCEPTED that Serum 25(Oh)d level of < 30ng/ml(75nmol/l) is the cut-off value for insufficiency [15-17], which is ASSOCIATED with maximal suppression of Parathyroid hormone [18].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('EXPLICIT_QUESTION', 36), ('SUPERFICIAL_RELATIONSHIP', 65), ('PROBABLE_UNDERSTANDING', 106), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 230)]	9	[('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001977', 'blood serum', 130, 'serum'), ('CHEBI_63056', 'zinc cation', 136, '25(OH'), ('UBERON_0001132', 'parathyroid gland', 269, 'parathyroid')]
S65-PMC3873449	PMC3873449	12/2013	S65-PMC3873449	['for the analysis, in OUR STUDY we classified women into groups that defined Vitamin D status: severe Vitamin D deficiency: 25(Oh)D < 25 nmol/l; mild Vitamin D deficiency: 25 nmol/l ≤ 25(Oh)D < 50 nmol/l; Vitamin D insufficiency: 50 nmol/l ≤ 25(Oh)D < 75 nmol/l; and sufficiency: 25(Oh)D≥75 nmol/l.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 21)]	1	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 183, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 241, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 279, '25(OH)D')]
S92-PMC3873449	PMC3873449	12/2013	S92-PMC3873449	['the prevalence of Vitamin D deficiency (25(Oh)D < 50 nmol/l ) was 96.8% and no women had Serum 25(Oh)D concentrations ≥ 75 nmol/l which is CONSIDERED AS an OPTIMAL level.10.1371/journal.pone.0085081.t001\n\ncaption (table-wrap): table 1\nprevalence of Vitamin D deficiency and insufficiency in Pregnant women.25(Oh)D levelsnumber%severe deficiency5644.8(< 25 nmol/l )mild deficiency6552.0(25- < 50 nmol/l)insufficiency43.2(50 - < 75 nmol/l)sufficiency00.0(≥75 nmol/l)total125100.0\n\nmaternal characteristics and Vitamin D status\nmaternal characteristics, stratified by Vitamin D status, are shown intable 2.']	[('IMPORTANT_CONSIDERATION', 139), ('PROBABLE_UNDERSTANDING', 150), ('IMPORTANT_CONSIDERATION', 156)]	3	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 40, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 46, 'D'), ('UBERON_0001977', 'blood serum', 89, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 98, 'OH)D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 306, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 508, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D')]
S94-PMC3873449	PMC3873449	12/2013	S94-PMC3873449	['better educated women were less COMMON in the severe Vitamin D deficient group than that in women with 25(Oh)D ≥ 25 nmol/l.']	[('PROBABLE_UNDERSTANDING', 32)]	1	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 105, '('), ('PR_000006444', 'diacylglycerol kinase delta', 109, 'D')]
S184-PMC3873449	PMC3873449	12/2013	S184-PMC3873449	['in 2011, the us endocrine society endorsed the need for at LEAST 600 iu(15 ug)/ day of Vitamin D supplementation for women during Pregnancy and up to 1500–2000 iu/day to maintain 25(Oh)D Blood levels above 30 ng/ml [16].']	[('PROBABLE_UNDERSTANDING', 59)]	1	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 179, '25(OH)D'), ('UBERON_0000178', 'blood', 187, 'blood')]
S192-PMC3873449	PMC3873449	12/2013	S192-PMC3873449	['measures SHOULD BE taken to improve their knowledge about Vitamin D. treatment SHOULD BE paired with health education and advice and basic knowledge of the role of Vitamin D.\nin the study, the 25(Oh) D level was low in all subjects, but was PARTICULARLY low in less educated women.']	[('FUTURE_WORK', 9), ('FUTURE_WORK', 79), ('ANOMALY_CURIOUS_FINDING', 241)]	3	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH) D')]
S199-PMC3873449	PMC3873449	12/2013	S199-PMC3873449	['it HAS BEEN REPORTED that pre-gravid obese women had significantly lower Serum 25(Oh)D concentrations and dose-DEPENDENT RELATIONS between pre-Pregnancy bmi and maternal Vitamin D status [48].']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 111), ('SUPERFICIAL_RELATIONSHIP', 121)]	3	[('UBERON_0001977', 'blood serum', 73, 'serum'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 79, '25(OH)D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S12-PMC3933171	PMC3933171	3/2014	S12-PMC3933171	['introduction\nlow Vitamin D (vitd) status is a risk FACTOR for rickets and HAS BEEN ASSOCIATED with INCREASED prevalence of Respiratory infections and other adverse health outcomes in infants and children.12in response to the CONCERN about widespread childhood vitd deficiency, professional bodies have RECOMMENDED vitd intake of 400\u2005iu/ day for all infants.13the european society for paediatrics gastroenterology, hepatology and nutrition RECOMMENDS 800–1000\u2005iu/day for preterm infants.4based on BIOMARKERS of vitd status MOSTLY in adults, Serum 25-Hydroxyvitamin-D [25(Oh)D] concentration ≥50\u2005nmol/l was also RECOMMENDED.13HOWEVER, the functional benefit of this level is CONTROVERSIAL.']	[('SUPERFICIAL_RELATIONSHIP', 51), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 83), ('IMPORTANT_CONSIDERATION', 99), ('IMPORTANT_CONSIDERATION', 225), ('FUTURE_WORK', 302), ('FUTURE_WORK', 439), ('SUPERFICIAL_RELATIONSHIP', 496), ('PROBABLE_UNDERSTANDING', 522), ('FUTURE_WORK', 610), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 622), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 673)]	12	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 123, 'respiratory'), ('UBERON_0001977', 'blood serum', 540, 'serum'), ('CHEBI_67320', 'majusculamide A', 546, '25-hydroxyvitamin-D'), ('CHEBI_71657', 'versiconol acetate', 567, '25(OH)D')]
S84-PMC4113768	PMC4113768	7/2014	S84-PMC4113768	['background: Serum 25-Hydroxy Vitamin D (25(Oh)D) is the ESTABLISHED BIOMARKER of Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 68)]	2	[('UBERON_0001977', 'blood serum', 12, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 18, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S101-PMC4113768	PMC4113768	7/2014	S101-PMC4113768	['Cyp2R1 and Cyp24A1 are capable of the 25-hydroxylation and 24-Hydroxylation, respectively, of Vitamin D. IT IS REPORTED that different Single Nucleotide Polymorphisms of Cyp2R1 and Cyp24A1 are ASSOCIATED with the 25(Oh)D status (wang, t.j., et al.']	[('PROBABLE_UNDERSTANDING', 105), ('INCOMPLETE_EVIDENCE', 111), ('SUPERFICIAL_RELATIONSHIP', 193)]	3	[('PR_000006110', 'cytochrome P450 27, mitochondrial', 0, 'CYP2R1'), ('PR_000006101', 'cytochrome P450 1A1', 11, 'CYP24A1'), ('GO_0006298', 'mismatch repair', 59, '24-hydroxylation'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('SO_0000694', 'SNP', 135, 'single nucleotide polymorphisms'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 170, 'CYP2R1'), ('PR_000006101', 'cytochrome P450 1A1', 181, 'CYP24A1'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D')]
S118-PMC4113768	PMC4113768	7/2014	S118-PMC4113768	['background: PREVIOUS RESEARCH has FOUND an ASSOCIATION between Vitamin D status (25-Hydroxy Vitamin D, 25(Oh)D) and volumetric bone Mineral density (vbmd) in caucasians (pedone, c., et al.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 43)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 81, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('CHEBI_46662', 'mineral', 132, 'Mineral')]
S174-PMC4113768	PMC4113768	7/2014	S174-PMC4113768	['higher Vitamin D status (per 25 nmol/l increase in Serum/Plasma 25(Oh)D) was ASSOCIATED with IMPROVED Colorectal cancer specific survival (adjusted hr = 0.92 (95% ci: 0.86–0.98, p< 0.001) and overall survival (pooled adjusted hr = 0.87 (95% ci: 0.79–0.95, p< 0.001) in pooled estimates of 5 prospective studies.']	[('SUPERFICIAL_RELATIONSHIP', 77), ('IMPORTANT_CONSIDERATION', 93)]	2	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('UBERON_0001977', 'blood serum', 51, 'serum'), ('UBERON_0001969', 'blood plasma', 57, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 64, '25(OH ... D'), ('UBERON_0012652', 'colorectum', 102, 'colorectal')]
S377-PMC4113768	PMC4113768	7/2014	S377-PMC4113768	['background: INTERACTIONS between dietary Calcium and Vitamin D MAY have IMPLICATIONS for the Regulation of Serum 25-Hydroxy Vitamin D (25(Oh)D) and its Catabolism, and CONSEQUENTLY for the dietary REQUIREMENT for Vitamin D ((iom) institute of medicine.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 63), ('IMPORTANT_CONSIDERATION', 72), ('SUPERFICIAL_RELATIONSHIP', 93), ('PROBABLE_UNDERSTANDING', 168), ('IMPORTANT_CONSIDERATION', 197)]	6	[('CHEBI_22313', 'alkaline earth metal atom', 41, 'calcium'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0065007', 'biological regulation', 93, 'regulation'), ('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 113, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 135, '25(OH)D'), ('GO_0009056', 'catabolic process', 152, 'catabolism'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
S378-PMC4113768	PMC4113768	7/2014	S378-PMC4113768	['the national academies press : washington, dc, usa, 2011).we INVESTIGATED WHETHER DIFFERENT levels of habitual Calcium Intake INFLUENCED Serum 25(Oh)D and indices of Vitamin D activation and Catabolism during winter and in the context of both adequate and inadequate Vitamin D intakes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('EXPLICIT_QUESTION', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82), ('SUPERFICIAL_RELATIONSHIP', 126)]	5	[('CHEBI_22313', 'alkaline earth metal atom', 111, 'calcium'), ('GO_0007631', 'feeding behavior', 119, 'intake'), ('UBERON_0001977', 'blood serum', 137, 'serum'), ('CHEBI_71657', 'versiconol acetate', 143, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 143, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0009056', 'catabolic process', 191, 'catabolism'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D')]
S381-PMC4113768	PMC4113768	7/2014	S381-PMC4113768	['results: repeated measures anova SHOWED that there was no significant ( p = 0.2) time × Vitamin D treatment × Calcium intake grouping interaction effect on mean Serum 25(Oh)D concentration over the 15-week intervention period.']	[('INCOMPLETE_EVIDENCE', 33)]	1	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 110, 'calcium'), ('UBERON_0001977', 'blood serum', 161, 'serum'), ('CHEBI_71657', 'versiconol acetate', 167, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 167, '25(OH)D')]
S631-PMC4113768	PMC4113768	7/2014	S631-PMC4113768	['; kiely, m.\nbackground: obesity is a RISK FACTOR for low circulating 25-Hydroxy Vitamin D (25(Oh)D), which is the BIOMARKER of Vitamin D status, and there are CONSISTENT negative ASSOCIATIONS between 25(Oh)D and measures of adiposity in Adults and children.']	[('SUPERFICIAL_RELATIONSHIP', 37), ('SUPERFICIAL_RELATIONSHIP', 114), ('INCOMPLETE_EVIDENCE', 159), ('SUPERFICIAL_RELATIONSHIP', 179)]	4	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 69, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 206, 'D'), ('UBERON_0007023', 'adult organism', 237, 'adults')]
S747-PMC4113768	PMC4113768	7/2014	S747-PMC4113768	['25(Oh)D assay standardization is, THEREFORE, ESSENTIAL to the development of EVIDENCED-BASED clinical and PUBLIC HEALTH guidelines for Vitamin D.\nmethods: Vitamin D standardization program (vdsp) is an international program designed to promote the standardized laboratory measurement of 25(Oh)D. it was established in 2010 by the us nih office of dietary supplements in collaboration with us national institute of standards and technology (nist), cdc, and ghent university.']	[('PROBABLE_UNDERSTANDING', 34), ('IMPORTANT_CONSIDERATION', 45), ('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 106)]	4	[('CHEBI_71657', 'versiconol acetate', 0, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 6, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 155, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 287, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 287, '25(OH)D')]
S782-PMC4113768	PMC4113768	7/2014	S782-PMC4113768	['RANDOMIZED controlled trials of Vitamin D supplementation MAY BE WARRANTED for infants with low 25(Oh)D during the initial months of Life, BUT careful selection of the regimen with close monitoring of safety for those who reach high 25(Oh)D levels will be NECESSARY.']	[('FUTURE_WORK', 0), ('INCOMPLETE_EVIDENCE', 58), ('FUTURE_WORK', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139), ('IMPORTANT_CONSIDERATION', 256)]	5	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 102, 'D'), ('UBERON_0000104', 'life cycle', 133, 'life'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 233, '25(OH ... D')]
S960-PMC4113768	PMC4113768	7/2014	S960-PMC4113768	['participants completed a questionnaire detailing potential demographic and lifestyle DETERMINANTS of Vitamin D status, and gave a Blood sample for analysis of Serum 25-Hydroxy Vitamin D (25(Oh)D) concentration and dna extraction.']	[('SUPERFICIAL_RELATIONSHIP', 85)]	1	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0000178', 'blood', 130, 'blood'), ('UBERON_0001977', 'blood serum', 159, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 165, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D')]
S963-PMC4113768	PMC4113768	7/2014	S963-PMC4113768	['logistic regression was used TO IDENTIFY environmental and Genetic factors independently ASSOCIATED with risk of Vitamin D deficiency DEFINED as Serum 25(Oh)D concentration <50 nmol/l.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('SUPERFICIAL_RELATIONSHIP', 89), ('PROBABLE_UNDERSTANDING', 134)]	3	[('SO_0000704', 'gene', 59, 'genetic'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('UBERON_0001977', 'blood serum', 145, 'serum'), ('CHEBI_71657', 'versiconol acetate', 151, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 151, '25(OH ... D')]
S986-PMC4113768	PMC4113768	7/2014	S986-PMC4113768	['ASSOCIATIONS between low circulating 25-Hydroxy Vitamin D (25(Oh)D), the BIOMARKER of Vitamin D status, and muscle weakness in older Adults (bischoff-ferrari, h.a., et al .']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 73)]	2	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 37, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 59, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('UBERON_0007023', 'adult organism', 133, 'adults')]
S995-PMC4113768	PMC4113768	7/2014	S995-PMC4113768	['our AIM was to EXPLORE ASSOCIATIONS between maternal and Cord 25(Oh)D concentrations and Vitamin D supplementation during Pregnancy and infancy and Gross Motor Development in infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('SUPERFICIAL_RELATIONSHIP', 23)]	3	[('UBERON_0002240', 'spinal cord', 57, 'cord'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 65, 'OH ... D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('GO_0008406', 'gonad development', 148, 'gross motor development')]
S1132-PMC4113768	PMC4113768	7/2014	S1132-PMC4113768	['overall, 98% of the subjects supplemented with 400,000 iu of Vitamin D had their level of 25(Oh)D above 20 ng/ml at week 8, WHILE 84% and 52% of patients receiving 200,000 iu or 100,000 iu reached that level after 12 weeks of treatment.']	[('ANOMALY_CURIOUS_FINDING', 124)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 90, '25(OH)D')]
S1301-PMC4113768	PMC4113768	7/2014	S1301-PMC4113768	['; wood, a.d.\nbackground: variation in Vitamin D binding protein (Vdbp) MAY EXPLAIN the INCONSISTENCIES between studies of Vitamin D; EITHER ( a ) through a mechanism by which the circulating half-life of 25-Hydroxy Vitamin D [25(Oh)D] MAY BE extended or ( b ) BECAUSE non-Vdbp bound or free Metabolites of Vitamin D MAY BETTER REFLECT biological activity.']	[('INCOMPLETE_EVIDENCE', 71), ('PROBABLE_UNDERSTANDING', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 87), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 133), ('INCOMPLETE_EVIDENCE', 235), ('PROBABLE_UNDERSTANDING', 260), ('INCOMPLETE_EVIDENCE', 316), ('INCOMPLETE_EVIDENCE', 320), ('SUPERFICIAL_RELATIONSHIP', 327)]	9	[('CHEBI_28384', 'vitamin K', 38, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 38, 'Vitamin D'), ('PR_000017279', 'testis-specific basic protein Y 1', 65, 'VDBP'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 204, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 226, '25(OH)D'), ('PR_000017279', 'testis-specific basic protein Y 1', 272, 'VDBP'), ('CHEBI_25212', 'metabolite', 291, 'metabolites'), ('CHEBI_27300', 'vitamin D', 306, 'vitamin D')]
S1321-PMC4113768	PMC4113768	7/2014	S1321-PMC4113768	['IN CONTRAST, both Vitamin D doses caused a rapid increase in 25(Oh)D, reaching a plateau of 65[20] nmol/l for 400 iu, and 76[19] nmol/l for 1000 iu Vitamin D. we REPORTED that 1000 iu Vitamin D3But not 400 iu attenuated bone mineral density loss, WHEREAS the increase in 25(Oh)D for the 1000 iu dose was ONLY 25% above that for the 400 iu dose (2).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 162), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 247), ('ANOMALY_CURIOUS_FINDING', 247), ('ANOMALY_CURIOUS_FINDING', 304), ('INCOMPLETE_EVIDENCE', 304)]	6	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 61, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('CHEBI_82668', 'DH335(1+)', 184, 'vitamin D3but'), ('PR_000017209', 'utrophin', 184, 'vitamin D3but'), ('CHEBI_71657', 'versiconol acetate', 271, '25(OH)D')]
S1328-PMC4113768	PMC4113768	7/2014	S1328-PMC4113768	['the Vitamin D in the 1000 iu dose that was not converted to 25(Oh)D may BE stored or converted to other Metabolites, or Excreted.']	[('ANOMALY_CURIOUS_FINDING', 72)]	1	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('CHEBI_25212', 'metabolite', 104, 'metabolites'), ('GO_0007588', 'excretion', 120, 'excreted')]
S1359-PMC4113768	PMC4113768	7/2014	S1359-PMC4113768	['after administration, the variation of 25(Oh)D concentration was 6.0 (95% confidence interval [ci]: 3.4–8.6) in Vitamin D group and −0.4 (95% ci: −3.7–2.9) in Placebo, showing a significantly increase in Vitamin D group ( p = 0.0029), BUT after follow-up (visit 3), no significant difference was found between the groups with variations of 2.9 (95% ci: −0.3–6.0) in Vitamin D group and 0.7 (95% ci: −3.8–5.2) in placebo ( p = 0.4040).']	[('ANOMALY_CURIOUS_FINDING', 235)]	1	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 159, 'placebo'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 366, 'vitamin D')]
S1522-PMC4113768	PMC4113768	7/2014	S1522-PMC4113768	['the participants were genotyped for 25 Snps in the Vitamin D pathway and two common Single Nucleotide Polymorphisms (Snps) in the Cyp2R1 Gene (rs10741657 and rs10766197) and two common Snps in the gc Gene (rs4588 and rs842999) were FOUND to PREDICT baseline S-25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 232), ('SUPERFICIAL_RELATIONSHIP', 241)]	2	[('SO_0000694', 'SNP', 39, 'SNPs'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007601', 'visual perception', 51, 'vitamin D'), ('SO_0000694', 'SNP', 84, 'single nucleotide polymorphisms'), ('SO_0000694', 'SNP', 117, 'SNPs'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 130, 'CYP2R1'), ('SO_0000704', 'gene', 137, 'gene'), ('SO_0000694', 'SNP', 185, 'SNPs'), ('SO_0000704', 'gene', 200, 'gene'), ('PR_000015800', 'syntaxin-8', 258, 's-25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 260, '25(OH)D')]
S1529-PMC4113768	PMC4113768	7/2014	S1529-PMC4113768	['we FOUND a significant positive linear RELATIONSHIP between carrying 0–2, 3, 4 or 5 risk Alleles, total Vitamin D intake and the increase in s-25(Oh)D concentrations ( p = 0.0012, 0.0001, 0.0118 and 0.0029), respectively.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 39)]	2	[('SO_0001023', 'allele', 89, 'alleles'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 143, '25(OH)D')]
S1534-PMC4113768	PMC4113768	7/2014	S1534-PMC4113768	['carriers of a high grs MAY NEED a higher amount of Vitamin D supplementation to achieve adequate s-25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 27)]	2	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('PR_000000036', 'BMP receptor type-1B', 98, '-25'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 105, 'D')]
S1598-PMC4113768	PMC4113768	7/2014	S1598-PMC4113768	['it is STILL UNCLEAR WHETHER the altered 25(Oh)D levels SEEN AFFECT the active Vitamin D Metabolite 1,25(Oh)2D and health outcomes (such as bone mineralization).']	[('FULL_UNKNOWN', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('INCOMPLETE_EVIDENCE', 55), ('SUPERFICIAL_RELATIONSHIP', 60)]	4	"[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 88, 'metabolite'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 101, '25(OH)2D')]"
S1632-PMC4113768	PMC4113768	7/2014	S1632-PMC4113768	['conclusions: standardization of 25(Oh)D measurements is IMPORTANT for accurate and consistent identification of INADEQUATE and/or deficient Vitamin D levels and RELATED health consequences in Individuals and populations.']	[('IMPORTANT_CONSIDERATION', 56), ('IMPORTANT_CONSIDERATION', 112), ('SUPERFICIAL_RELATIONSHIP', 161)]	3	[('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 32, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('NCBITaxon_1', 'root', 192, 'individuals')]
S1670-PMC4113768	PMC4113768	7/2014	S1670-PMC4113768	['the difference in mean Serum 25(Oh)D concentration at follow-up vs. baseline REMAINED statistically significant after exclusion of 14 participants who were taking supplemental Vitamin D at follow-up and/or who had increased their sun exposure since time of diagnosis ( p = 0.005), and after exclusion of 17 participants whose baseline sample was taken from march to july inclusive ( p = 0.0003).']	[('INCOMPLETE_EVIDENCE', 77)]	1	[('UBERON_0001977', 'blood serum', 23, 'serum'), ('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 29, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D')]
S1673-PMC4113768	PMC4113768	7/2014	S1673-PMC4113768	['differences in mean Serum 25(Oh)D concentration between the two time points were not EXPLAINED by differences in use of Vitamin D supplements, self-reported sun exposure or season of sampling at follow-up vs. baseline.']	[('PROBABLE_UNDERSTANDING', 85)]	1	[('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 26, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S1827-PMC4113768	PMC4113768	7/2014	S1827-PMC4113768	['conclusions: insufficient 25(Oh)D Plasma levels were common among elderly, more significantly among centenarians, which MAY SUGGEST Vitamin D deficiency with age, also among oldest old.']	[('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 124)]	2	[('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 26, '25 ... OH ... D'), ('UBERON_0001969', 'blood plasma', 34, 'plasma'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
S1828-PMC4113768	PMC4113768	7/2014	S1828-PMC4113768	['in SOME of the elderly subjects lower Plasma 25(Oh)D levels coexisting with high alkaline phosphatase activity MAY INDICATE developing osteomalacia.taking INTO ACCOUNT lower Plasma 25(Oh)D, 1,25(Oh)D and calcium levels among the MAJORITY of centenarians, the sufficient Vitamin D and calcium supplementation SHOULD be systematically APPLIED also in the oldest old.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 111), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 155), ('PROBABLE_UNDERSTANDING', 229), ('FUTURE_WORK', 308), ('SUPERFICIAL_RELATIONSHIP', 333)]	7	[('UBERON_0001969', 'blood plasma', 38, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 45, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 174, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 181, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]
S1970-PMC4113768	PMC4113768	7/2014	S1970-PMC4113768	['SINCE Vitamin D is also obtained from dietary sources and Vitamin D supplements; THIS STUDY INVESTIGATED the INFLUENCE of Food and Vitamin D supplements on the Serum 25-Hydroxy Vitamin D (25(Oh)D) concentration in children in the netherlands between october and april.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('QUESTION_ANSWERED_BY_THIS_WORK', 92), ('SUPERFICIAL_RELATIONSHIP', 109)]	4	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_33290', 'food', 122, 'food'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('UBERON_0001977', 'blood serum', 160, 'serum'), ('CHEBI_43176', 'hydroxy group', 169, 'hydroxy'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D')]
S1975-PMC4113768	PMC4113768	7/2014	S1975-PMC4113768	['there was a positive CORRELATION between the total amount of Vitamin D obtained from Food and the Serum 25(Oh)D concentration ( r = 0.218, p = 0.004).']	[('SUPERFICIAL_RELATIONSHIP', 21)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_33290', 'food', 85, 'food'), ('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D')]
S1978-PMC4113768	PMC4113768	7/2014	S1978-PMC4113768	['conclusion: in the absence of Vitamin D Synthesis by sunlight, Vitamin D obtained from Food has a significant INFLUENCE on the Serum 25(Oh)D concentration in children.']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0009057', 'macromolecule catabolic process', 40, 'synthesis'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_33290', 'food', 87, 'food'), ('UBERON_0001977', 'blood serum', 127, 'serum'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D')]
S1984-PMC4113768	PMC4113768	7/2014	S1984-PMC4113768	['the PRESENT STUDY AIMS TO EXAMINE the ASSOCIATIONS of Serum 25-Hydroxy Vitamin D levels [25(Oh)D, a BIOMARKER of Vitamin D in blood] with clrd and outcomes using data from a large-scale prospective cohort study in the u.s.\nmethods: a total of 15,772 (m: 7,414, f: 8,358) subjects aged ≥20 year old who participated in the u.s. third national health and nutrition examination survey, had measures of serum 25(Oh)D at baseline (1988–1994), and had been followed up through december of 2006 were analyzed.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 100)]	5	[('UBERON_0001977', 'blood serum', 54, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 60, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 405, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 405, '25(OH)D')]
S2132-PMC4113768	PMC4113768	7/2014	S2132-PMC4113768	['in multivariate analyses, sunnier season, lower latitude, higher Vitamin D intake index, Vitamin D supplement use, higher physical activity, lower bmi, and marital status were significantly ASSOCIATED with higher Serum 25(Oh)D levels in both sexes.']	[('SUPERFICIAL_RELATIONSHIP', 190)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0001977', 'blood serum', 213, 'serum'), ('CHEBI_71657', 'versiconol acetate', 219, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 219, '25 ... OH ... D')]
S2135-PMC4113768	PMC4113768	7/2014	S2135-PMC4113768	['the IDENTIFIED DETERMINANTS of Serum 25(Oh)D MAY CONTRIBUTE to tailor EVIDENCE-BASED RECOMMENDATIONS for optimizing Vitamin D status to specific target groups.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 15), ('INCOMPLETE_EVIDENCE', 45), ('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 70), ('FUTURE_WORK', 85)]	6	[('UBERON_0001977', 'blood serum', 31, 'serum'), ('CHEBI_71657', 'versiconol acetate', 37, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 37, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
S2358-PMC4113768	PMC4113768	7/2014	S2358-PMC4113768	['in THIS FOLLOW-UP STUDY we DETERMINED seasonal differences in Serum 25(Oh)D Vitamin D levels, as well as parallel changes in Metabolic parameters, in a cohort of Adult overweight and obese saudis.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 27)]	4	[('UBERON_0001977', 'blood serum', 62, 'serum'), ('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0008152', 'metabolic process', 125, 'metabolic'), ('UBERON_0007023', 'adult organism', 162, 'adult')]
S2393-PMC4113768	PMC4113768	7/2014	S2393-PMC4113768	['background: we performed a systematic review TO EXPLORE WHETHER (1) low maternal circulating 25(Oh)-Vitamin D (25(Oh)D) during Pregnancy is ASSOCIATED with impairment of offspring health; and (2) maternal supplementation with Vitamin D in Pregnancy MIGHT ameliorate these EFFECTS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 140), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 272)]	5	[('CHEBI_63056', 'zinc cation', 93, '25(OH'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 111, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy')]
S2398-PMC4113768	PMC4113768	7/2014	S2398-PMC4113768	['eligible studies included Pregnant women and their offspring, and one or more RELEVANT exposures (either assessment of Vitamin D status (dietary intake, sunlight exposure, circulating 25(Oh)D) or supplementation of participants with Vitamin D or Vitamin D containing Food e.g., oily fish) and outcomes (offspring birth weight, Birth length, Head circumference, bone mass, anthropometry and body composition, risk of asthma and atopy, small for Gestational dates, Preterm Birth, type 1 diabetes, low Birth weight, Serum calcium concentration, Blood pressure and rickets).']	[('IMPORTANT_CONSIDERATION', 78)]	1	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 184, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 190, 'D'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_33290', 'food', 267, 'food'), ('GO_0007567', 'parturition', 327, 'birth'), ('UBERON_0000033', 'head', 341, 'head'), ('GO_0007565', 'female pregnancy', 444, 'gestational'), ('GO_0007565', 'female pregnancy', 463, 'preterm birth'), ('GO_0007567', 'parturition', 499, 'birth'), ('UBERON_0001977', 'blood serum', 513, 'serum'), ('UBERON_0000178', 'blood', 542, 'blood')]
S2517-PMC4113768	PMC4113768	7/2014	S2517-PMC4113768	['THESE FINDINGS SUGGEST that; (1) there is no additional BENEFIT to calcium absorption or bone mineralisation from a Blood level for 25(Oh)D above ~75 nmol/l; (2)DESPITE adequate Vitamin D and regular physical activity lower dietary Calcium intake is STILL a PREDICTOR of lower total body bmd and bmc; and (3) in certain population groups with baseline 25(Oh)D > 75 nmol/l, Vitamin D supplementation of 50,000 iu/month does not significantly increase 25(Oh)D concentrations over a 12 month period, but POSSIBLY PREVENTS seasonal decline.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 56), ('ANOMALY_CURIOUS_FINDING', 161), ('IMPORTANT_CONSIDERATION', 250), ('SUPERFICIAL_RELATIONSHIP', 258), ('INCOMPLETE_EVIDENCE', 501), ('SUPERFICIAL_RELATIONSHIP', 510)]	8	[('UBERON_0000178', 'blood', 116, 'blood'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 232, 'calcium'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 352, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 450, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 450, '25(OH)D')]
S2521-PMC4113768	PMC4113768	7/2014	S2521-PMC4113768	['background: understanding of the EFFECT of Vitamin D supplementation on Plasma 25(Oh)D levels is ESSENTIAL to optimizing nutritional status and health.']	[('SUPERFICIAL_RELATIONSHIP', 33), ('IMPORTANT_CONSIDERATION', 97)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 72, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 79, '25 ... OH ... D')]
S2523-PMC4113768	PMC4113768	7/2014	S2523-PMC4113768	['the dose response RELATIONSHIP between Vitamin D supplementation and Plasma 25(Oh)D levels IS THOUGHT TO be biphasic (exponential at low intakes and linear at high), HOWEVER this is NOT WELL DOCUMENTED for supplementation levels that exceed 2000 iu per day for large populations of healthy Individuals.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166), ('INCOMPLETE_EVIDENCE', 182)]	4	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 69, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 76, '25(OH ... D'), ('NCBITaxon_1', 'root', 290, 'individuals')]
S2546-PMC4113768	PMC4113768	7/2014	S2546-PMC4113768	['methods: the examination of the INFLUENCE of Vitamin D supplementation and 25(Oh)D on Serum calcium levels was based on 8906 baseline and follow-up assessments of Vitamin D supplementation, Serum 25(Oh)D and calcium of healthy participants of the pure north wellness program.']	[('SUPERFICIAL_RELATIONSHIP', 32)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('UBERON_0001977', 'blood serum', 190, 'serum'), ('CHEBI_71657', 'versiconol acetate', 196, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 196, '25 ... OH ... D')]
S2547-PMC4113768	PMC4113768	7/2014	S2547-PMC4113768	['we applied gee regression methods to quantify the ASSOCIATIONS of Vitamin D supplementation and 25(Oh)D with Serum Calcium, while considering the CONFOUNDING POTENTIAL of age, gender, and body weight status.']	[('SUPERFICIAL_RELATIONSHIP', 50), ('PROBLEM_COMPLICATION', 146), ('INCOMPLETE_EVIDENCE', 158)]	3	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 102, 'D'), ('UBERON_0001977', 'blood serum', 109, 'serum'), ('CHEBI_22313', 'alkaline earth metal atom', 115, 'calcium')]
S2554-PMC4113768	PMC4113768	7/2014	S2554-PMC4113768	['we RECOMMEND that 25(Oh)D and Serum calcium be monitored when supplementing higher doses of Vitamin D.\n\n2.123.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_71657', 'versiconol acetate', 18, '25(OH)D'), ('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S2563-PMC4113768	PMC4113768	7/2014	S2563-PMC4113768	['we AIMED TO EXAMINE the environmental and Genetic DETERMINANTS of change in 25 Hydroxy Vitamin D (25(Oh)D).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('SUPERFICIAL_RELATIONSHIP', 50)]	3	[('SO_0000704', 'gene', 42, 'genetic'), ('CHEBI_45557', 'sec-butyl group', 76, '25 hydroxy'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D')]
S2574-PMC4113768	PMC4113768	7/2014	S2574-PMC4113768	['conclusion: THIS work SHOWS that Genetic FACTORS are ASSOCIATED with change in 25(Oh)D after Vitamin D supplementation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('INCOMPLETE_EVIDENCE', 22), ('SUPERFICIAL_RELATIONSHIP', 41), ('SUPERFICIAL_RELATIONSHIP', 53)]	4	[('SO_0000704', 'gene', 33, 'genetic'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
S2638-PMC4113768	PMC4113768	7/2014	S2638-PMC4113768	['THERE IS EVIDENCE TO SUPPORT a ROLE for Vitamin D in muscle function, YET LITTLE IS KNOWN about the ROLE of Antenatal 25(Oh)D exposure in programming muscle development.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 31), ('ANOMALY_CURIOUS_FINDING', 70), ('FULL_UNKNOWN', 74), ('SUPERFICIAL_RELATIONSHIP', 100)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007567', 'parturition', 108, 'antenatal'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D')]
S2646-PMC4113768	PMC4113768	7/2014	S2646-PMC4113768	['median maternal 25(Oh)D was 61 nmol/l (iqr 43–88 nmol/l), and ONLY 9.2% of mothers were using Vitamin D supplementation (at LEAST 400 iu/day) in late Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 62), ('PROBABLE_UNDERSTANDING', 124)]	2	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy')]
S2674-PMC4113768	PMC4113768	7/2014	S2674-PMC4113768	['conclusions: long-term monthly Vitamin D supplementation, which increased mean 25(Oh)D concentration above 100 nmol/l for 18 months, had no EFFECT on systolic or diastolic bp in predominantly white, healthy Adults without severe Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 140)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 79, '25(OH ... D'), ('UBERON_0007023', 'adult organism', 207, 'adults'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S2773-PMC4113768	PMC4113768	7/2014	S2773-PMC4113768	['conclusions: the free and bio-available forms of 25(Oh)D MAY BE a more INFORMATIVE measure of Vitamin D status than total 25(Oh)d. adjustment for dbp phenotype MAY improve this FURTHER.']	[('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 71), ('INCOMPLETE_EVIDENCE', 160), ('FUTURE_WORK', 177), ('INCOMPLETE_EVIDENCE', 177)]	5	[('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 122, '25(OH')]
S3047-PMC4113768	PMC4113768	7/2014	S3047-PMC4113768	['the main DETERMINANTS of Cord 25(Oh)D [adjusted mean difference in nmol/l (95% ci)] were summer season of sampling [19.2 (17.4, 20.9), p < 0.0001], maternal 25(Oh)D concentrations at 15 weeks [0.3 (0.26, 0.34), p < 0.0001] and the maternal use of a Vitamin D containing supplement at 15 weeks [2.5 (0.6, 4.42), p = 0.011].']	[('SUPERFICIAL_RELATIONSHIP', 9)]	1	[('UBERON_0002240', 'spinal cord', 25, 'cord'), ('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 30, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 157, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]
S3066-PMC4113768	PMC4113768	7/2014	S3066-PMC4113768	['RISK FACTORS for Cardiovascular disease HAVE also BEEN ASSOCIATED with low Serum (25(Oh)D. we AIMED TO INVESTIGATE WHETHER high-dose Vitamin D supplementation CAN improve Glucose Metabolism in a population with impaired fasting Glucose and/or impaired Glucose tolerance.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 55), ('QUESTION_ANSWERED_BY_THIS_WORK', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('INCOMPLETE_EVIDENCE', 159)]	7	[('UBERON_0004535', 'cardiovascular system', 17, 'cardiovascular'), ('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_17234', 'glucose', 171, 'glucose'), ('GO_0006006', 'glucose metabolic process', 171, 'glucose metabolism'), ('CHEBI_17234', 'glucose', 228, 'glucose'), ('CHEBI_17234', 'glucose', 252, 'glucose')]
S3200-PMC4113768	PMC4113768	7/2014	S3200-PMC4113768	['use of Vitamin D supplements, living in an institution and season of Blood sampling were significant independent predictors of 25(Oh)D concentrations using linear regression models, while non-use of Vitamin D containing supplements, season and low physical activity PREDICTED Vitamin D deficiency using logistic regression models.']	[('SUPERFICIAL_RELATIONSHIP', 266)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('UBERON_0000178', 'blood', 69, 'blood'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D')]
S3274-PMC4113768	PMC4113768	7/2014	S3274-PMC4113768	['a pre-specified sub-group analysis was conducted TO DETERMINE whether effects of the intervention on co-primary outcomes were modified by the presence or absence of Vitamin D deficiency (Serum 25(Oh)D < 50 nmol/l) at baseline.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 49)]	1	[('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('UBERON_0001977', 'blood serum', 187, 'serum'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 193, '25(OH)D')]
S3303-PMC4113768	PMC4113768	7/2014	S3303-PMC4113768	['HOWEVER, rcts in iran, where the mean Serum 25(Oh)D levels TEND to be low, IN PART DUE TO sun avoidance during the hot summers, have FOUND beneficial EFFECTS of Vitamin D supplementation on cvd RISK FACTORS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 59), ('INCOMPLETE_EVIDENCE', 75), ('PROBLEM_COMPLICATION', 83), ('INCOMPLETE_EVIDENCE', 133), ('SUPERFICIAL_RELATIONSHIP', 150), ('SUPERFICIAL_RELATIONSHIP', 194)]	7	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 44, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S3328-PMC4113768	PMC4113768	7/2014	S3328-PMC4113768	['when ADDITIONAL EVIDENCE on EFFECTS RELATED to Vitamin D from OBSERVATIONAL studies with respect to Serum 25(Oh)D level or personal uvb irradiance, the ROLE of skin pigmentation, and laboratory studies of mechanisms, hill’s criteria for causality in a biological system (hill ab.']	[('FUTURE_WORK', 5), ('SUPERFICIAL_RELATIONSHIP', 28), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 152)]	5	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0001977', 'blood serum', 100, 'serum'), ('CHEBI_71657', 'versiconol acetate', 106, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 106, '25(OH)D')]
S3353-PMC4113768	PMC4113768	7/2014	S3353-PMC4113768	['in addition, CONSENSUS has not been reached with regard to the concentration of 25(Oh)D to define Vitamin D deficiency for infants and children.']	[('PROBABLE_UNDERSTANDING', 13)]	1	[('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S11-PMC4169453	PMC4169453	9/2014	S11-PMC4169453	['conclusions\nVitamin D supplementation at a dose of 400 iu/d was not sufficient to maintain 25(Oh)D >20 ng/ml in nursing women, WHILE 1200 iu/d APPEARED more EFFECTIVE, but had no effect on Breastfed offspring Vitamin D status, or changes in the bone mass and the body composition OBSERVED in both during breastfeeding.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('ANOMALY_CURIOUS_FINDING', 127), ('ANOMALY_CURIOUS_FINDING', 143), ('SUPERFICIAL_RELATIONSHIP', 157), ('INCOMPLETE_EVIDENCE', 280)]	5	[('CHEBI_28384', 'vitamin K', 12, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('GO_0007567', 'parturition', 189, 'breastfed'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S19-PMC4169453	PMC4169453	9/2014	S19-PMC4169453	['HOWEVER, the OPTIMAL Vitamin D intake as well as OPTIMAL 25(Oh)D level for Lactating women (BASED ON ESTIMATED maternal NEEDS) STILL REMAINS NOT fully ESTABLISHED, or AT LEAST not accepted worldwide.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 13), ('IMPORTANT_CONSIDERATION', 49), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 92), ('INCOMPLETE_EVIDENCE', 101), ('IMPORTANT_CONSIDERATION', 120), ('IMPORTANT_CONSIDERATION', 127), ('FULL_UNKNOWN', 133), ('PROBABLE_UNDERSTANDING', 167)]	10	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('GO_0007594', 'puparial adhesion', 75, 'lactating')]
S20-PMC4169453	PMC4169453	9/2014	S20-PMC4169453	['the RECOMMENDED Vitamin D intake VARIES from 400 iu/d to 2000 iu/d[7],[12]–[16], BUT supplementation using less than 1000 iu/d MAY BE INADEQUATE for maintaining an “optimal” 25(Oh)D level[17].']	[('FUTURE_WORK', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81), ('INCOMPLETE_EVIDENCE', 127), ('IMPORTANT_CONSIDERATION', 134), ('PROBLEM_COMPLICATION', 134)]	6	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 180, 'D')]
S68-PMC4169453	PMC4169453	9/2014	S68-PMC4169453	['Serum 25(Oh)D <20 ng/ml DEFINED the Vitamin D deficiency state, WHEREAS ≥30 ng/ml REFLECTED Vitamin D sufficiency[7].']	[('PROBABLE_UNDERSTANDING', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 64), ('SUPERFICIAL_RELATIONSHIP', 82)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S88-PMC4169453	PMC4169453	9/2014	S88-PMC4169453	['sample size calculation\nto detect a statistically significant difference in Serum 25(Oh)D level (primary outcome) by 4 ng/ml between the intervention groups after Vitamin D supplementation at least 64 mother-infant pairs per group were REQUIRED at 80% power using a two-sided t-test at α\u200a=\u200a0.05.']	[('IMPORTANT_CONSIDERATION', 236)]	1	[('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S89-PMC4169453	PMC4169453	9/2014	S89-PMC4169453	['it was BASED ON an ASSUMPTION that each 400 iu/d of Vitamin D MAY increase 25(Ohd) level by 2.8–4.8 ng/ml (mean ∼4 ng/ml) and the standard deviation of 25(Oh)D measurements was 8[28],[29].']	[('PROBABLE_UNDERSTANDING', 7), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 19), ('INCOMPLETE_EVIDENCE', 62)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_18009', 'NADP(+)', 75, '25(OHD'), ('CHEBI_71657', 'versiconol acetate', 152, '25(OH)D')]
S124-PMC4169453	PMC4169453	9/2014	S124-PMC4169453	['Vitamin D status\nmaternal 25(Oh)D level was SIMILAR in both groups at baseline and after 3 months of Vitamin D supplementation, HOWEVER, at v6 significantly higher 25(Oh)D levels were NOTED in the 1200 iu/d group (fig.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('ANOMALY_CURIOUS_FINDING', 128), ('ANOMALY_CURIOUS_FINDING', 184)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 170, 'D')]
S126-PMC4169453	PMC4169453	9/2014	S126-PMC4169453	['the EFFECT of group (Vitamin D dose) x time INTERACTION ( p \u200a=\u200a0.0004) and the EFFECT of time (p<0.0001) on maternal Serum 25(Oh)D level were statistically significant, BUT the EFFECT of group (Vitamin D dose) was not ( p \u200a=\u200a0.25).']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169), ('SUPERFICIAL_RELATIONSHIP', 177)]	5	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 123, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
S133-PMC4169453	PMC4169453	9/2014	S133-PMC4169453	['AS EXPECTED, a significant increase in 25(Oh)D occurred in breastfed infants supplemented with 400 iu/d of Vitamin D, and no differences were FOUND between the study groups (fig.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 142)]	2	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
S135-PMC4169453	PMC4169453	9/2014	S135-PMC4169453	['the EFFECT of group (Vitamin D dose) x time INTERACTION ( p \u200a=\u200a0.12) and the EFFECT of group ( p \u200a=\u200a0.45) on infants’ Serum 25(Oh)D levels was not statistically significant, WHILE the EFFECT of time was statistically significant ( p<0.0001) (fig.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('ANOMALY_CURIOUS_FINDING', 174), ('SUPERFICIAL_RELATIONSHIP', 184)]	6	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001977', 'blood serum', 118, 'serum'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 124, '25(OH)D')]
S142-PMC4169453	PMC4169453	9/2014	S142-PMC4169453	['a CORRELATION between maternal and breastfed infants’ 25(Oh)D levels was STILL significant after 3 and 6 months of Vitamin D supplementation BUT APPEARED weaker than the Postpartum CORRELATION: in the 400 iu/d group at v3 r\u200a=\u200a0.35 ( p \u200a=\u200a0.003) and at v6 r\u200a=\u200a0.4 ( p \u200a=\u200a0.0009), and in the 1200 iu/d group at v3 r\u200a=\u200a0.3 ( p \u200a=\u200a0.01) and at v6 r\u200a=\u200a0.39 ( p \u200a=\u200a0.0007), respectively.']	[('SUPERFICIAL_RELATIONSHIP', 2), ('ANOMALY_CURIOUS_FINDING', 73), ('IMPORTANT_CONSIDERATION', 73), ('ANOMALY_CURIOUS_FINDING', 141), ('ANOMALY_CURIOUS_FINDING', 145), ('SUPERFICIAL_RELATIONSHIP', 181)]	6	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 60, 'D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'postpartum')]
S162-PMC4169453	PMC4169453	9/2014	S162-PMC4169453	['HOWEVER, maternal total body fat mass was comparable between groups, significant negative CORRELATIONS were noted between maternal 25(Oh)D level and maternal fat mass (r\u200a=\u200a−0.49, p \u200a=\u200a0.00001), Android fat mass (r\u200a=\u200a−0.53, p \u200a=\u200a0.00001), and gynoid fat mass (r\u200a=\u200a−0.43, p \u200a=\u200a0.00001) after 6 months of Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('CHEBI_71657', 'versiconol acetate', 131, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 131, '25(OH)D'), ('UBERON_0001428', 'intermedium', 194, 'android'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D')]
S174-PMC4169453	PMC4169453	9/2014	S174-PMC4169453	['in OUR STUDY maternal median 25(Oh)D levels (∼15 ng/ml) at the baseline visit, INDICATING Vitamin D deficiency.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 79)]	2	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 29, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S183-PMC4169453	PMC4169453	9/2014	S183-PMC4169453	['in CONSEQUENCE, fundamental QUESTIONS of: a) HOW much Vitamin D is enough to reach and maintain OPTIMAL 25(Oh)D level, and b) what is the OPTIMAL range for 25(Oh)D levels, REMAIN an ISSUE of DEBATE[32],[33].']	[('PROBABLE_UNDERSTANDING', 3), ('EXPLICIT_QUESTION', 28), ('EXPLICIT_QUESTION', 45), ('IMPORTANT_CONSIDERATION', 96), ('IMPORTANT_CONSIDERATION', 138), ('INCOMPLETE_EVIDENCE', 172), ('PROBLEM_COMPLICATION', 182), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191)]	8	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 106, '(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 156, '25(OH)D')]
S184-PMC4169453	PMC4169453	9/2014	S184-PMC4169453	['there is GROWING EVIDENCE SHOWING Serum 25(Oh)D levels higher than 30 ng/ml, or EVEN higher than 40 ng/ml as EFFECTIVE for expression of Extra-Skeletal EFFECTS RELATED to proper Vitamin D status[1],[34],[35].']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 26), ('ANOMALY_CURIOUS_FINDING', 80), ('SUPERFICIAL_RELATIONSHIP', 109), ('SUPERFICIAL_RELATIONSHIP', 152), ('SUPERFICIAL_RELATIONSHIP', 160)]	6	[('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 40, '25(OH)D'), ('UBERON_0001431', 'distal carpal bone 2', 137, 'extra-skeletal'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S190-PMC4169453	PMC4169453	9/2014	S190-PMC4169453	['from a clinical POINT OF VIEW, the IMPACT of 1200 iu/d Vitamin D dose on the maternal 25(Oh)D concentration was very subtle.']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 35)]	2	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D')]
S197-PMC4169453	PMC4169453	9/2014	S197-PMC4169453	['taking into account the maternal REQUIREMENT, 1200 iu/d of Vitamin D MAY PROTECT against Vitamin D deficiency, but SEEMS TOO low TO fully replenish Vitamin D insufficiency (20 ng/ml<25(Oh)D <30 ng/ml).']	[('IMPORTANT_CONSIDERATION', 33), ('INCOMPLETE_EVIDENCE', 69), ('SUPERFICIAL_RELATIONSHIP', 73), ('ANOMALY_CURIOUS_FINDING', 115), ('DIFFICULT_TASK', 121)]	5	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 182, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 182, '25 ... OH ... D')]
S200-PMC4169453	PMC4169453	9/2014	S200-PMC4169453	['though supplementation at a dose of 2000 iu/d was PREVIOUSLY REPORTED to increase maternal 25(Oh)D to 30–39 ng/ml[35],[38],[39], it STILL MIGHT be insufficient for Vitamin D-deficient women[40],[41].']	[('INCOMPLETE_EVIDENCE', 50), ('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 132), ('INCOMPLETE_EVIDENCE', 138)]	4	[('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S206-PMC4169453	PMC4169453	9/2014	S206-PMC4169453	['NEVERTHELESS, we SHOULD KEEP IN MIND that each 400 iu/d of Vitamin D MAY increase Serum 25(Oh)D level by 2.8 ng/ml[17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 24), ('INCOMPLETE_EVIDENCE', 69)]	4	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
S215-PMC4169453	PMC4169453	9/2014	S215-PMC4169453	['during Vitamin D supplementation in our infants, an increasing infants’ 25(Oh)D level COINCIDED with an increase in ipth.']	[('SUPERFICIAL_RELATIONSHIP', 86)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D')]
S221-PMC4169453	PMC4169453	9/2014	S221-PMC4169453	['keeping IN MIND the diminutive DIFFERENCES in 25(Oh)D levels among the study groups, we ASSUMED that the Vitamin D status in nursing women had no IMPACT on bone mass and body composition.']	[('IMPORTANT_CONSIDERATION', 8), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 31), ('PROBABLE_UNDERSTANDING', 88), ('SUPERFICIAL_RELATIONSHIP', 146)]	4	[('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 52, 'D'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
S2-PMC4231606	PMC4231606	10/2013	S2-PMC4231606	['the PURPOSE of THIS STUDY was TO DETERMINE the ASSOCIATION between Vitamin D (25(Oh)D) levels and s-ecc.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('SUPERFICIAL_RELATIONSHIP', 47)]	4	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 78, '25(OH)D')]
S106-PMC4231606	PMC4231606	10/2013	S106-PMC4231606	['multiple regression for 25(Oh)D concentrations REVEALED that levels were significantly and INDEPENDENTLY ASSOCIATED with s-ecc, regular Milk Consumption, and season of assessment BUT NOT household income and or the use of Vitamin D drops (table\xa03).']	[('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 91), ('SUPERFICIAL_RELATIONSHIP', 105), ('ANOMALY_CURIOUS_FINDING', 179)]	4	[('CHEBI_71657', 'versiconol acetate', 24, '25(OH)D'), ('UBERON_0001913', 'milk', 136, 'milk'), ('GO_0007631', 'feeding behavior', 141, 'consumption'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D')]
S107-PMC4231606	PMC4231606	10/2013	S107-PMC4231606	['s-ecc, infrequent milk Intake, and winter season were ASSOCIATED with lower 25(Oh)D levels, BUT NOT household income or Vitamin D drop use.']	[('SUPERFICIAL_RELATIONSHIP', 54), ('ANOMALY_CURIOUS_FINDING', 92)]	2	[('GO_0007631', 'feeding behavior', 23, 'intake'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S22-PMC4251419	PMC4251419	12/2014	S22-PMC4251419	['in case-control studies, participants with one of these Autoimmune diseases TEND to report lower past sun exposure, and/or have lower Vitamin D status (measured as the Blood concentration of the intermediary Metabolite, 25(Oh)D, seefigure 1), than healthy controls (see for example recent reviews [12,13]).']	[('SUPERFICIAL_RELATIONSHIP', 76)]	1	[('UBERON_0001442', 'skeleton of manus', 56, 'autoimmune'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('UBERON_0000178', 'blood', 168, 'blood'), ('CHEBI_39382', 'flufenoxuron', 208, 'metabolite'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25(OH)D')]
S32-PMC4251419	PMC4251419	12/2014	S32-PMC4251419	['this BELIEF is DRIVEN BY recognition of cellular Expression of the Vitamin D receptor (vdr), the FINDING of multiple primary 1,25(Oh)2D target Genes in Immune Cells and the discovery that many Immune Cells (Macrophages, Dendritic Cells, T and B Lymphocytes) CAN convert 25(Oh)D to 1,25(Oh)2D through Cyp27B1 activity and therefore provide significant local levels of 1,25(Oh)2D for functional outcomes (for review [8,19]).']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 97), ('INCOMPLETE_EVIDENCE', 258)]	4	[('GO_0010467', 'gene expression', 49, 'expression'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 125, '1,25(OH)2D'), ('SO_0000704', 'gene', 143, 'genes'), ('CL_0000738', 'leukocyte', 152, 'immune cells'), ('UBERON_0002405', 'immune system', 152, 'immune'), ('CL_0000738', 'leukocyte', 193, 'immune cells'), ('UBERON_0002405', 'immune system', 193, 'immune'), ('CL_0000235', 'macrophage', 207, 'macrophages'), ('CL_0000451', 'dendritic cell', 220, 'dendritic cells'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 237, 'T ...'), ('CL_0000236', 'B cell', 243, 'B lymphocytes'), ('CHEBI_71657', 'versiconol acetate', 270, '25(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 281, '1,25(OH)2D'), ('PR_000006101', 'cytochrome P450 1A1', 300, 'CYP27B1'), ('CHEBI_82784', 'PVP38-Ag NP', 367, '1,25(OH)2D')]
S65-PMC4251419	PMC4251419	12/2014	S65-PMC4251419	['HOWEVER, the level of Vitamin D binding protein, and its affinity to 25(Oh)D, CAN also restrict the availability of 25(Oh)d to Dendritic Cells and POSSIBLY other cells [35].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 78), ('INCOMPLETE_EVIDENCE', 147)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 116, '25(OH)'), ('CL_0000451', 'dendritic cell', 127, 'dendritic cells')]
S86-PMC4251419	PMC4251419	12/2014	S86-PMC4251419	['ALTHOUGH childhood Vitamin D levels and sun exposure APPEAR TO BE IMPORTANT DETERMINANTS of the risk of disease onset, higher 25(Oh)D levels early in the disease course MAY PREDICT the rate of disease progression in multiple sclerosis [53].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 53), ('IMPORTANT_CONSIDERATION', 66), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 169), ('SUPERFICIAL_RELATIONSHIP', 173)]	7	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D')]
S139-PMC4251419	PMC4251419	12/2014	S139-PMC4251419	['Genetic variation in the physiological response to Vitamin D supplementation\na high degree of Individual VARIABILITY in the 25(Oh)D response to Vitamin D supplementation has been DESCRIBED that is the result of demographic, environmental and Genetic FACTORS [79].']	[('DIFFICULT_TASK', 105), ('INCOMPLETE_EVIDENCE', 179), ('SUPERFICIAL_RELATIONSHIP', 250)]	3	[('SO_0000704', 'gene', 0, 'Genetic'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('NCBITaxon_1', 'root', 94, 'individual'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('SO_0000704', 'gene', 242, 'genetic')]
S145-PMC4251419	PMC4251419	12/2014	S145-PMC4251419	['TRADITIONALLY the level of total 25(Oh)D HAS BEEN CONSIDERED the best ESTIMATE of Vitamin D status, BUT RECENT STUDIES have SUGGESTED that the “bioavailable” (albumin-bound and free) 25(Oh)D concentration MAY BE more RELEVANT to health and disease [83].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 41), ('INCOMPLETE_EVIDENCE', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 124), ('INCOMPLETE_EVIDENCE', 205), ('SUPERFICIAL_RELATIONSHIP', 217)]	8	[('CHEBI_71657', 'versiconol acetate', 33, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 39, 'D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 183, '25(OH)D')]
S0-PMC4380518	PMC4380518	9/2014	S0-PMC4380518	['Prenatal Vitamin use and Vitamin D status during Pregnancy, differences by race and overweight status\n\nabstract\n\nobjective\nwe AIMED TO STUDY WHETHER Prenatal Vitamin (pnv) use PROTECTS against low 25(Oh)D levels in all women and PARTICULARLY in obese and black women who are both AT RISK of Vitamin D deficiency and poor pregnancy outcomes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 126), ('QUESTION_ANSWERED_BY_THIS_WORK', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('SUPERFICIAL_RELATIONSHIP', 176), ('IMPORTANT_CONSIDERATION', 229), ('IMPORTANT_CONSIDERATION', 280)]	6	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_33229', 'vitamin (role)', 9, 'Vitamin'), ('CHEBI_28384', 'vitamin K', 25, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 49, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 149, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 158, 'vitamin'), ('CHEBI_71657', 'versiconol acetate', 197, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 203, 'D'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin D')]
S2-PMC4380518	PMC4380518	9/2014	S2-PMC4380518	['we used multivariable logistic regression to ANALYZE ASSOCIATIONS of pnv use and odds of Vitamin D deficiency DEFINED as 25(Oh)D levels < 50 nmol/l.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('SUPERFICIAL_RELATIONSHIP', 53), ('PROBABLE_UNDERSTANDING', 110)]	3	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 121, '25 ... OH ... D')]
S23-PMC4380518	PMC4380518	9/2014	S23-PMC4380518	['we DEFINED Vitamin D deficiency as <50 nmol/l, a COMMON cut-point in the literature.5,22,23\n\nstatistical analyses\nfirst, we analyzed bivariate associations between 25(Oh)D category and pnv use as well as covariates including maternal age, race/ethnicity, smoking, education and bmi.']	[('PROBABLE_UNDERSTANDING', 3), ('PROBABLE_UNDERSTANDING', 49)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 164, '25(OH)D')]
S52-PMC4380518	PMC4380518	9/2014	S52-PMC4380518	['shea et al studied 2500 elderly Adults and FOUND that lack of pnv use was ASSOCIATED with higher odds of Vitamin D insufficiency (<75 nmol/l) in both black (5.2 (95% ci: 3.5, 7.7)) and white participants (or 2.6, 95% ci: 2.0, 3.2), HOWEVER these subjects were much older and not Pregnant.26a SMALL turkish STUDY of 79 Pregnant women SHOWED significantly higher 25(Oh)D levels among women reporting pnv use in the third trimester,27BUT this study DID NOT include women of african descent and DID NOT have the power to address POTENTIAL INTERACTION by bmi.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 232), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 333), ('PROBLEM_COMPLICATION', 431), ('INCOMPLETE_EVIDENCE', 446), ('INCOMPLETE_EVIDENCE', 491), ('INCOMPLETE_EVIDENCE', 525), ('SUPERFICIAL_RELATIONSHIP', 535)]	10	[('UBERON_0007023', 'adult organism', 32, 'adults'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 279, 'pregnant'), ('GO_0007565', 'female pregnancy', 318, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 361, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 361, '25(OH)D')]
S62-PMC4380518	PMC4380518	9/2014	S62-PMC4380518	['we also LACKED DATA on Vitamin D binding protein which MAY DIFFER by race/ethnicity and COULD AFFECT the ASSOCIATION between pnv use and 25(Oh)D measured in the Plasma.']	[('FULL_UNKNOWN', 8), ('INCOMPLETE_EVIDENCE', 55), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 59), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 94), ('SUPERFICIAL_RELATIONSHIP', 105)]	6	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 137, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 161, 'plasma')]
S65-PMC4380518	PMC4380518	9/2014	S65-PMC4380518	['IN CONTRAST, our data SUPPORT INVESTIGATION into higher doses of Vitamin D in subgroups at high RISK IF BENEFITS are demonstrated by ONGOING TRIALS in Pregnancy of achieving higher 25(Oh)D levels.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 22), ('FUTURE_WORK', 30), ('IMPORTANT_CONSIDERATION', 96), ('FUTURE_PREDICTION', 101), ('IMPORTANT_CONSIDERATION', 104), ('INCOMPLETE_EVIDENCE', 133)]	7	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 181, '25(OH)D')]
S68-PMC4380518	PMC4380518	9/2014	S68-PMC4380518	['IN LIGHT OF two RECENT meta-analyses/systematic reviews CONCLUDING that low 25(Oh)D levels during Pregnancy are ASSOCIATED with SEVERAL morbidities in Pregnancy15,16, optimizing Vitamin D status during Pregnancy MAY BE IMPORTANT.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 16), ('PROBABLE_UNDERSTANDING', 56), ('SUPERFICIAL_RELATIONSHIP', 112), ('INCOMPLETE_EVIDENCE', 128), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 219)]	7	[('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 76, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy15'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]
S30-PMC4396835	PMC4396835	1/2015	S30-PMC4396835	['season of Birth findings constitute another LINK between autism and Vitamin D. in europe a MAJOR proportion of the population have CONSIDERABLY lower 25(Oh)D in winter and spring compared TO summer and autumn [36,41].']	[('SUPERFICIAL_RELATIONSHIP', 44), ('IMPORTANT_CONSIDERATION', 91), ('ANOMALY_CURIOUS_FINDING', 131), ('QUESTION_ANSWERED_BY_THIS_WORK', 188)]	4	[('GO_0007567', 'parturition', 10, 'birth'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D')]
S110-PMC4396835	PMC4396835	1/2015	S110-PMC4396835	['25-Hydroxyvitamin D in children with asd RELATED to iq\nthere was no relation between iq and Vitamin D level, that is, the group with intellectual disability did not display lower 25(Oh)D levels compared to those without.']	[('SUPERFICIAL_RELATIONSHIP', 41)]	1	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 0, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 179, '25(OH)D')]
S130-PMC4396835	PMC4396835	1/2015	S130-PMC4396835	['HOWEVER, the LACK OF effect of season of sampling (= season of Birth in OUR STUDY) on 25(Oh)D levels in our african/middle east group, all having low Vitamin D status throughout the year, HAS also BEEN REPORTED in women with african/middle east origin living in norway [59].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 72), ('INCOMPLETE_EVIDENCE', 188), ('INCOMPLETE_EVIDENCE', 202)]	5	[('GO_0007567', 'parturition', 63, 'birth'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
S169-PMC4396835	PMC4396835	1/2015	S169-PMC4396835	['three DIFFERENT independent findings POINT towards a ROLE for Vitamin D in the development of asd: (1) increased risk for asd in offspring of migrants, especially from countries with a dark-skinned population and from cultures where women use covered clothing; (2) low 25(Oh)D levels in groups of newborn children, who later have developed asd, and in groups of children and Adults with asd; and (3) an ASSOCIATION between season of Birth and asd, in OUR STUDY not extending to the high-risk groups of migrants, SUGGESTING that these groups are exposed to suboptimal Vitamin D levels the whole year.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 6), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 53), ('SUPERFICIAL_RELATIONSHIP', 403), ('QUESTION_ANSWERED_BY_THIS_WORK', 451), ('INCOMPLETE_EVIDENCE', 512)]	6	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 269, '25(OH)D'), ('UBERON_0007023', 'adult organism', 375, 'adults'), ('GO_0007567', 'parturition', 433, 'birth'), ('CHEBI_27300', 'vitamin D', 567, 'vitamin D')]
S170-PMC4396835	PMC4396835	1/2015	S170-PMC4396835	['ALTHOUGH low levels of Vitamin D COULD have a Genetic origin and as SUCH be ASSOCIATED with asd, OUR STUDY is the FIRST TO RULE OUT asd-related lifestyle mechanisms AS EXPLANATION for low 25(Oh)D levels, SINCE the samples were taken in the Newborn Period.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 33), ('PROBABLE_UNDERSTANDING', 68), ('SUPERFICIAL_RELATIONSHIP', 76), ('QUESTION_ANSWERED_BY_THIS_WORK', 97), ('INCOMPLETE_EVIDENCE', 114), ('INCOMPLETE_EVIDENCE', 123), ('PROBABLE_UNDERSTANDING', 165), ('PROBABLE_UNDERSTANDING', 168), ('PROBABLE_UNDERSTANDING', 204)]	10	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('SO_0000704', 'gene', 46, 'genetic'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 194, 'D'), ('UBERON_0007221', 'neonate stage', 240, 'newborn period')]
S29-PMC4427001	PMC4427001	4/2015	S29-PMC4427001	"[""circulating Plasma concentration of 25(Oh)D IS CONSIDERED the MOST RELIABLE INDICATOR of Individual's Vitamin D status.""]"	[('INCOMPLETE_EVIDENCE', 44), ('PROBABLE_UNDERSTANDING', 62), ('IMPORTANT_CONSIDERATION', 67), ('SUPERFICIAL_RELATIONSHIP', 76)]	4	[('UBERON_0001969', 'blood plasma', 12, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 36, '25(OH)D'), ('NCBITaxon_1', 'root', 89, 'individual'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]
S38-PMC4427001	PMC4427001	4/2015	S38-PMC4427001	['currently, LITTLE IS KNOWN about Postpartum Vitamin D status in women with history of gdm and POSSIBLE RELATIONSHIP between 25(Oh)D Plasma levels measured at the time of gdm diagnosis and the degree of Glucose (in)tolerance Postpartum.']	[('FULL_UNKNOWN', 11), ('INCOMPLETE_EVIDENCE', 94), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('GO_0007565', 'female pregnancy', 33, 'postpartum'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 132, 'plasma'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('GO_0007565', 'female pregnancy', 224, 'postpartum')]
S40-PMC4427001	PMC4427001	4/2015	S40-PMC4427001	['THEREFORE, the AIMS of the PRESENT STUDY were (1) TO DETERMINE Midgestational and early Postpartum Vitamin D status by measuring 25(Oh)D Plasma levels in Pregnant women with and without gdm to CONFIRM the hypothetical deficiency in gdm in central european population and (2) to describe the RELATIONSHIP between Midgestational and Postpartum Vitamin D status and parallel changes of parameters characterising Glucose tolerance.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('QUESTION_ANSWERED_BY_THIS_WORK', 50), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 291)]	6	[('GO_0007507', 'heart development', 63, 'midgestational'), ('GO_0007565', 'female pregnancy', 88, 'postpartum'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 132, 'OH ... D'), ('UBERON_0001969', 'blood plasma', 137, 'plasma'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('GO_0007507', 'heart development', 312, 'midgestational'), ('GO_0007565', 'female pregnancy', 331, 'postpartum'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('CHEBI_17234', 'glucose', 409, 'glucose')]
S83-PMC4427001	PMC4427001	4/2015	S83-PMC4427001	"[""in OUR STUDY, we have FOUND that Midgestational Vitamin D deficiency (i.e., 25(Oh)D levels < 50\u2009nmol/l) was present in majority of the study sample, that is, 45 of 47 (95.7%) women with gdm and 27 of 29 (93.1%) healthy Pregnant women ( p = ns, fisher's exact test).""]"	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 22)]	2	[('GO_0007507', 'heart development', 33, 'midgestational'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('GO_0007565', 'female pregnancy', 219, 'pregnant')]
S118-PMC4427001	PMC4427001	4/2015	S118-PMC4427001	['[26] FOUND an inverse ASSOCIATION between second trimester 25(Oh)D levels < 25\u2009nmol/l and 1\u2009hr after load Glucose (50\u2009g) levels; HOWEVER, ONLY 5% of studied women developed gdm and as mentioned above THRESHOLD for Vitamin D deficiency DIFFERED from our study.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 129), ('INCOMPLETE_EVIDENCE', 138), ('PROBABLE_UNDERSTANDING', 200), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235)]	6	[('CHEBI_71657', 'versiconol acetate', 59, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 59, '25(OH ... D'), ('CHEBI_17234', 'glucose', 106, 'glucose'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D')]
S153-PMC4427001	PMC4427001	4/2015	S153-PMC4427001	['POTENTIALLY beneficial EFFECT of Vitamin D supplementation and the PLAUSIBLE pathogenic ROLE of 25(Oh)D deficiency in the subsequent development of diabetes mellitus type 2 in women with gdm history HAS to be FURTHER explored considering the ROLE of Vitamin D in Modulating Insulin sensitivity and Glucose Metabolism.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 67), ('SUPERFICIAL_RELATIONSHIP', 88), ('IMPORTANT_CONSIDERATION', 199), ('FUTURE_WORK', 209), ('SUPERFICIAL_RELATIONSHIP', 242)]	7	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('GO_0065007', 'biological regulation', 263, 'modulating'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('CHEBI_17234', 'glucose', 298, 'glucose'), ('GO_0006006', 'glucose metabolic process', 298, 'glucose metabolism')]
S1518-PMC4448820	PMC4448820	5/2015	S1518-PMC4448820	['caption (boxed-text): text box 52\u2003\nCURRENTLY available Vitamin D BIOMARKERS/indicators\n\n● 25(Oh)D:\n○ GENERALLY RECOGNIZED AS the best currently available biomarker\n○ reflects Intake\n○ functional relevance not clearly established\n● functional biomarkers:\n○ Parathyroid hormone\n○ calcium absorption\n○ Bone Resorption\n○ bone Mineral density\n\nINFLUENCE of inflammation on Vitamin D assessment.']	[('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 65), ('PROBABLE_UNDERSTANDING', 101), ('INCOMPLETE_EVIDENCE', 111), ('PROBABLE_UNDERSTANDING', 111), ('PROBABLE_UNDERSTANDING', 122), ('SUPERFICIAL_RELATIONSHIP', 339)]	7	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 90, '25(OH ... D'), ('GO_0007631', 'feeding behavior', 175, 'intake'), ('GO_0007567', 'parturition', 182, '○'), ('UBERON_0001132', 'parathyroid gland', 256, 'parathyroid'), ('GO_0008218', 'bioluminescence', 299, 'bone resorption ○'), ('CHEBI_46662', 'mineral', 322, 'mineral'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin D')]
S1535-PMC4448820	PMC4448820	5/2015	S1535-PMC4448820	['caption (table-wrap): table 12\n\nsummary of key Nutrient biomarkers1nutrientcommonly used biomarker/indicatorsmagnitude and direction of inflammation effectsettings where usednotesironferritin+++clinical, research, populationstfr+research, populationstfr assays are not yet standardized and compare poorlyhemoglobinclinicalbody Iron+research, populationratio of tfr:ferritin+researchtfr index+research, clinicalzpp+clinical, populationhepcidin0researchvitamin Aretinol−clinical, research, populationrbp−research, populationbreast-milk Retinolresearchretinol dose response testresearchzincserum/Plasma zinc−clinical, populationnot reliable in clinical settings if patient inflamedfolateerythrocyte Folate+clinical, populationplasma or Serum Folate−clinical, populationvitamin B-12serum/Plasma total cobalamin0clinical, populationserum holotranscobalaminresearchsuperior diagnostic performance of holotranscobalamin is controversialplasma/Urine mma0clinical, populationmma assay is more expensiveplasma total Homocysteine+clinicalelevated in both Folate and Vitamin B-12 deficiencyiodineurinary Iodine0Populationno known ASSOCIATION with inflammationvitamin D25(Oh)D−clinical, populationvitamin B-6plasma Pyridoxal 5-Phosphate−research, populationvitamin cserum Ascorbic Acid−research, populationfreshly prepared Serum NEEDS to be promptly Acidified with Meta-Phosphoric Acid and frozen to stabilize Ascorbic Acid\nMma, Methylmalonic Acid; Rbp, Retinol Binding Protein; Stfr, soluble Transferrin Receptor; tfr, Transferrin Receptor; zpp, Zinc Protoporphyrin; 0, no change; 25(Oh)D, 25-Hydroxyvitamin D; −, decrease; +, increase; +++, major increase.']	[('SUPERFICIAL_RELATIONSHIP', 1118), ('FUTURE_WORK', 1316)]	2	"[('CHEBI_33284', 'nutrient', 47, 'nutrient'), ('CHEBI_24870', 'ion', 327, 'iron'), ('CHEBI_80843', 'Leonurine', 459, 'ARetinol'), ('CHEBI_67264', 'geranic acid', 534, 'retinolResearchRetinol'), ('UBERON_0001969', 'blood plasma', 593, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 696, 'folate'), ('UBERON_0001977', 'blood serum', 733, 'serum'), ('CHEBI_30863', '5-azaorotic acid', 739, 'folate'), ('PR_000000037', 'BMP receptor type-2', 774, 'B'), ('UBERON_0001969', 'blood plasma', 784, 'plasma'), ('UBERON_0001088', 'urine', 936, 'urine'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 1006, 'homocysteine'), ('CHEBI_30863', '5-azaorotic acid', 1044, 'folate'), ('CHEBI_27300', 'vitamin D', 1055, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 1055, 'vitamin B-12'), ('CHEBI_30593', 'disilanyl', 1092, 'iodine0PopulationNo'), ('PR_000001177', 'D(2) dopamine receptor', 1155, 'D25'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1159, 'OH)D'), ('PR_000000037', 'BMP receptor type-2', 1192, 'B'), ('CHEBI_18335', ""pyridoxamine 5'-phosphate"", 1202, 'pyridoxal 5-phosphate'), ('CHEBI_22652', 'ascorbic acid', 1259, 'ascorbic acid'), ('UBERON_0001977', 'blood serum', 1310, 'serum'), ('CHEBI_34520', 'acephate', 1337, 'acidified'), ('CHEBI_25286', 'methylbutanoyl-CoA', 1352, 'meta-phosphoric acid'), ('CHEBI_22652', 'ascorbic acid', 1397, 'ascorbic acid'), ('CHEBI_34840', 'methyl methacrylate', 1411, 'MMA'), ('CHEBI_30860', 'methylmalonic acid', 1416, 'methylmalonic acid'), ('PR_000013830', 'calcipressin-2', 1436, 'RBP'), ('CHEBI_26536', 'retinoic acid', 1441, 'retinol'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 1441, 'retinol binding protein'), ('PR_000015619', 'sorcin', 1466, 'sTfR'), ('PR_000001679', 'trace amine-associated receptor 5', 1480, 'transferrin receptor'), ('PR_000001679', 'trace amine-associated receptor 5', 1507, 'transferrin receptor'), ('CHEBI_28783', 'zinc protoporphyrin', 1534, 'zinc protoporphyrin'), ('CHEBI_71657', 'versiconol acetate', 1569, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1578, '25-hydroxyvitamin D')]"
S24-PMC4499946	PMC4499946	7/2015	S24-PMC4499946	['in south asia, there is a high prevalence of biochemical Vitamin D deficiency among women and young infants [15]; in dhaka, we FOUND that 34 % of Pregnant women at 26–29 weeks Gestation ( n = 160) had Serum 25-Hydroxyvitamin D (25(Oh)D) concentrations less than 30 nmol/l, and that 64 % had 25(Oh)D levels less than 50 nmol/l [16], a threshold for sufficiency adopted by the institute of medicine (iom) [17].']	[('INCOMPLETE_EVIDENCE', 127)]	1	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnant'), ('GO_0007565', 'female pregnancy', 176, 'gestation'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 207, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 291, '25(OH)D')]
S97-PMC4499946	PMC4499946	7/2015	S97-PMC4499946	['Pharmacological principles and EMPIRICAL data INDICATE that weekly doses of Vitamin D achieve 25(Oh)D levels SIMILAR TO equivalent daily doses [39]; THUS, the equivalent daily doses in increasing order are 600 iu/day, 2400 iu/day, and 4000 iu/day.']	[('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 109), ('PROBABLE_UNDERSTANDING', 149)]	4	[('CHEBI_52217', 'pharmaceutical', 0, 'Pharmacological'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 94, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 100, 'D')]
S48-PMC4598849	PMC4598849	10/2015	S48-PMC4598849	['compared with north american and european countries (the mean 25(Oh)D levels of Pregnant women in us and uk is APPROXIMATELY 50\u2009nmol/l), asian countries MAYBE have more Pregnant women with Vitamin D deficiency1326272829.']	[('INCOMPLETE_EVIDENCE', 111), ('INCOMPLETE_EVIDENCE', 153)]	2	[('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 62, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('GO_0007565', 'female pregnancy', 169, 'pregnant'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D')]
S54-PMC4598849	PMC4598849	10/2015	S54-PMC4598849	['another case-control study SUGGESTED that infants Born before 32 wks’ Gestation had an increased RISK of Vitamin D deficiency compared with mature infant, HOWEVER, there was no statistically significant difference in mean Cord Blood 25(Oh)D levels between sga and non-sga infants29.']	[('INCOMPLETE_EVIDENCE', 27), ('IMPORTANT_CONSIDERATION', 97), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155), ('ANOMALY_CURIOUS_FINDING', 155)]	4	[('GO_0007567', 'parturition', 50, 'born'), ('GO_0007565', 'female pregnancy', 70, 'gestation'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 222, 'cord'), ('UBERON_0000178', 'blood', 227, 'blood'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 233, '25(OH ... D')]
S56-PMC4598849	PMC4598849	10/2015	S56-PMC4598849	['in THIS STUDY with a large sample, adjustment for more confounders and using non-linear models, we FOUND that there was an inverted u-shaped RELATIONSHIP between Cord Blood 25(Oh)D and Birth weight, SUGGESTING that the newborn with low or high levels of fetal Vitamin D are both in INCREASED risk of growth restriction and higher levels of fetal Vitamin D HAVE not been shown to confer greater BENEFITS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 99), ('SUPERFICIAL_RELATIONSHIP', 141), ('INCOMPLETE_EVIDENCE', 199), ('IMPORTANT_CONSIDERATION', 282), ('IMPORTANT_CONSIDERATION', 356), ('IMPORTANT_CONSIDERATION', 394)]	7	[('UBERON_0002240', 'spinal cord', 162, 'cord'), ('UBERON_0000178', 'blood', 167, 'blood'), ('CHEBI_71657', 'versiconol acetate', 173, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 173, '25(OH)D'), ('GO_0007567', 'parturition', 185, 'birth'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D')]
S60-PMC4598849	PMC4598849	10/2015	S60-PMC4598849	['ALTHOUGH the neonatal 25(Oh)D levels at Birth cannot fully represent the Vitamin D status during CRITICAL times of Gestation DUE TO a half-life of several weeks of 25(Oh)D34, IT was quite POSSIBLE that the neonates with lower or higher Cord Blood 25(Oh)D levels MAY also have lower or higher average levels of 25(Oh)D during the whole Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 97), ('PROBLEM_COMPLICATION', 125), ('ANOMALY_CURIOUS_FINDING', 175), ('INCOMPLETE_EVIDENCE', 188), ('INCOMPLETE_EVIDENCE', 262)]	7	[('CHEBI_71657', 'versiconol acetate', 22, '25(OH)D'), ('GO_0007567', 'parturition', 40, 'birth'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'gestation'), ('CHEBI_79189', 'D-ribofuranose-2,5-bisphosphate', 164, '25(OH)D34'), ('PR_000001177', 'D(2) dopamine receptor', 170, 'D34'), ('UBERON_0002240', 'spinal cord', 236, 'cord'), ('UBERON_0000178', 'blood', 241, 'blood'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 253, 'D'), ('CHEBI_71657', 'versiconol acetate', 310, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 316, 'D'), ('GO_0007565', 'female pregnancy', 335, 'pregnancy')]
S72-PMC4598849	PMC4598849	10/2015	S72-PMC4598849	['first, we ONLY measured 25(Oh)D concentrations, which is one member of the Vitamin D family.']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('CHEBI_71657', 'versiconol acetate', 24, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S73-PMC4598849	PMC4598849	10/2015	S73-PMC4598849	['at Birth, there are POTENTIAL changes to levels of Vitamin D binding protein, 1,25(Oh)2D, the Cyp27 enzyme and Expression of Vitamin D receptors40, which MAY INFLUENCE the ASSOCIATION between 25(Oh)D and fetal growth41.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 154), ('SUPERFICIAL_RELATIONSHIP', 158), ('SUPERFICIAL_RELATIONSHIP', 172)]	4	"[('GO_0007567', 'parturition', 3, 'birth'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 80, '25(OH)2D'), ('PR_000006100', 'aromatase', 94, 'CYP27'), ('GO_0010467', 'gene expression', 111, 'expression'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 133, 'D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D')]"
S72-PMC4632418	PMC4632418	10/2015	S72-PMC4632418	['prevalence of Vitamin D deficiency varied CONSIDERABLY from 3.1% to 94.70%, and 25(Oh)D level of gdm ranged from 16.50 to 97.00 nmol/l with a median of 49.30 nmol/l.']	[('ANOMALY_CURIOUS_FINDING', 42)]	1	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D')]
S74-PMC4632418	PMC4632418	10/2015	S74-PMC4632418	['main analysis\namong the 20 studies, ONLY six SHOWED a significant ASSOCIATION between Vitamin D deficiency (25(Oh)D levels below 50 nmol/l) and risk of gdm.']	[('INCOMPLETE_EVIDENCE', 36), ('INCOMPLETE_EVIDENCE', 45), ('SUPERFICIAL_RELATIONSHIP', 66)]	3	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 108, '25(OH)D')]
S84-PMC4632418	PMC4632418	10/2015	S84-PMC4632418	['this result SHOWED Serum 25(Oh)D level was significant lower in participants with gdm than the control and also DEMONSTRATED that Vitamin D deficiency is significantly ASSOCIATED with an INCREASED RISK of gmd.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 112), ('SUPERFICIAL_RELATIONSHIP', 168), ('IMPORTANT_CONSIDERATION', 187)]	4	[('UBERON_0001977', 'blood serum', 19, 'serum'), ('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S88-PMC4632418	PMC4632418	10/2015	S88-PMC4632418	['exclusion of two studies [15,36] in which Pregnant women were Vitamin D sufficient (with 25(Oh)D level greater than 75 nmol/l) yielded SIMILAR results (wmd = −5.04; 95% ci, −6.43 to −3.64), and LITTLE evidence of heterogeneity was OBSERVED among the remaining studies ( i2= 37.50%, p = 0.077).']	[('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 194), ('INCOMPLETE_EVIDENCE', 231)]	3	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D')]
S109-PMC4632418	PMC4632418	10/2015	S109-PMC4632418	['UNDOUBTEDLY, the 25(Oh)D level in two studies was high, WHEREAS the prevalence of Vitamin D deficiency was low.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56)]	3	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S119-PMC4632418	PMC4632418	10/2015	S119-PMC4632418	['besides, EARLIER STUDIES have IDENTIFIED a NUMBER OF FACTORS that INFLUENCE Serum levels of 25(Oh)D, including obesity, fat malabsorption syndrome which is UNABLE TO absorb the fat-soluble Vitamin D, medications enhancing the Catabolism of 25(Oh)D and 1,25(Oh)2D3, and so on [5].']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 53), ('SUPERFICIAL_RELATIONSHIP', 66), ('DIFFICULT_TASK', 156)]	6	[('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D'), ('GO_0009056', 'catabolic process', 226, 'catabolism'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('CHEBI_73394', 'Ala-Ser', 254, '25(OH)2D3')]
S72-PMC4632423	PMC4632423	10/2015	S72-PMC4632423	['analysis of Serum levels of Micronutrients in the random subset of 25 very severely obese compared with 25 lean women CONFIRMED the significantly lower circulating levels of iron, vitamin b12, Folate, Vitamin A, copper, zinc and selenium with TRENDS for lower Vitamin E/Cholesterol and 25(Oh)D in very severely obese in early Pregnancy (table 3).']	[('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 243), ('SUPERFICIAL_RELATIONSHIP', 243)]	3	[('UBERON_0001977', 'blood serum', 12, 'serum'), ('CHEBI_33839', 'macromolecule', 28, 'micronutrients'), ('CHEBI_30863', '5-azaorotic acid', 193, 'folate'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin A'), ('CHEBI_28384', 'vitamin K', 260, 'Vitamin E'), ('CHEBI_16113', 'cholesterol', 270, 'cholesterol'), ('CHEBI_71657', 'versiconol acetate', 286, '25(OH)D'), ('GO_0007565', 'female pregnancy', 326, 'pregnancy')]
S64-PMC4684854	PMC4684854	12/2015	S64-PMC4684854	['many FACTORS MAY AFFECT the resultant status of Vitamin D in the body (AS reflected by measurement of 25(Oh)D levels) after Ingested supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 17), ('PROBABLE_UNDERSTANDING', 71)]	4	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 108, 'D'), ('GO_0007631', 'feeding behavior', 124, 'ingested')]
S137-PMC4684854	PMC4684854	12/2015	S137-PMC4684854	"[""as discussed, individual Vitamin D indices CAN be INFLUENCED by various DETERMINANTS DESPITE specific levels of supplementation; it is THUS the author's RECOMMENDATION that a personalized medical approach be taken via individual screening for 25(Oh)D as a routine part of Preconception and Prenatal care.""]"	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 50), ('SUPERFICIAL_RELATIONSHIP', 72), ('ANOMALY_CURIOUS_FINDING', 85), ('PROBABLE_UNDERSTANDING', 135), ('FUTURE_WORK', 153)]	6	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 243, '25(OH)D'), ('GO_0007565', 'female pregnancy', 272, 'preconception'), ('GO_0007565', 'female pregnancy', 290, 'prenatal')]
S91-PMC4689556	PMC4689556	12/2015	S91-PMC4689556	['secondary analysis included bolus and daily Vitamin D groups combined (combined Vitamin D) compared with the control group and the RELATIONSHIP between 25(Oh)D levels measured in Cord Blood at Delivery and in the child at age three years.']	[('SUPERFICIAL_RELATIONSHIP', 131)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 152, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 179, 'cord'), ('UBERON_0000178', 'blood', 184, 'blood'), ('GO_0007567', 'parturition', 193, 'delivery')]
S12-PMC4690051	PMC4690051	12/2015	S12-PMC4690051	['WHILE THRESHOLDS for Vitamin D sufficiency HAVE BEEN DEBATED RECENTLY [10,11], low circulating levels of 25(Oh)D HAVE BEEN ASSOCIATED with increased mortality in black and white older adults dwelling in north america [12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 6), ('INCOMPLETE_EVIDENCE', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 53), ('INCOMPLETE_EVIDENCE', 61), ('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 123)]	7	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D')]
S15-PMC4690051	PMC4690051	12/2015	S15-PMC4690051	['biologically, higher Melanin Pigment in Dermis of Individuals with african ancestry CONTRIBUTES to lower production of 25(Oh)D, YET higher bioavailable 1,25(Oh)2-D circulates due to lower levels of Vitamin D Binding Protein (Vdbp) [10].']	[('SUPERFICIAL_RELATIONSHIP', 84), ('ANOMALY_CURIOUS_FINDING', 128)]	2	[('CHEBI_25179', 'melanins', 21, 'melanin'), ('CHEBI_26130', 'biological pigment', 29, 'pigment'), ('UBERON_0002067', 'dermis', 40, 'dermis'), ('NCBITaxon_1', 'root', 50, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('CHEBI_34890', '2-nitrofuran', 157, 'OH)2-D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 198, 'vitamin D binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 225, 'VDBP')]
S74-PMC4690051	PMC4690051	12/2015	S74-PMC4690051	['BASED ON supplemental studies of Vitamin D during Pregnancy, a 10 ng/ml increase in 25(Oh)D has resulted in a PROTECTIVE odds ratio for healthy Pregnancy outcomes [37]; THUS, we ASSESSED such EFFECTS on Cognitive and language scaled scores.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 110), ('PROBABLE_UNDERSTANDING', 169), ('QUESTION_ANSWERED_BY_THIS_WORK', 178), ('SUPERFICIAL_RELATIONSHIP', 192)]	5	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 84, '25(OH)D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0050890', 'cognition', 203, 'cognitive')]
S76-PMC4690051	PMC4690051	12/2015	S76-PMC4690051	['using stepwise selection (0.20 for entry, 0.05 to stay) to remove the insignificant variables, we retained 25(Oh)D status in the model while assessing the following POSSIBLE CONFOUNDERS: race (aa or ea), maternal iq, use of tobacco products or Alcohol during Pregnancy, maternal dietary Intake of Vitamin D, age, pre-Pregnancy bmi, total number of completed Pregnancies, Gestational hypertension or Gestational diabetes, insurance status, level of maternal education, marital status, child’s age at cv2, and Gestational age at Birth.']	[('INCOMPLETE_EVIDENCE', 165), ('PROBLEM_COMPLICATION', 174)]	2	[('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 107, '25(OH)D'), ('CHEBI_30879', 'alcohol', 244, 'alcohol'), ('GO_0007565', 'female pregnancy', 259, 'pregnancy'), ('GO_0007631', 'feeding behavior', 287, 'intake'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D'), ('GO_0007565', 'female pregnancy', 317, 'pregnancy'), ('GO_0007565', 'female pregnancy', 358, 'pregnancies'), ('GO_0007565', 'female pregnancy', 371, 'gestational'), ('GO_0007565', 'female pregnancy', 399, 'gestational'), ('GO_0007565', 'female pregnancy', 508, 'gestational'), ('GO_0007567', 'parturition', 527, 'birth')]
S170-PMC4690051	PMC4690051	12/2015	S170-PMC4690051	['DUE TO phlebotomy limits in infants and THE BURDEN of other candle procedures, this candle sub-study lacks repeated measures of 25(Oh)D status for participants and lacks individual assessments of Parathyroid hormone status or Vitamin D receptor ( vdr ) genotype.']	[('PROBLEM_COMPLICATION', 0), ('IMPORTANT_CONSIDERATION', 40)]	2	[('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 128, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 196, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S106-PMC4691762	PMC4691762	12/2015	S106-PMC4691762	['we will not be monitoring Serum 25(Oh)D for safety reasons nor considering the association between 25(Oh)D and outcome frequency given that 400\u2005Iu HAS BEEN SHOWN to be SAFE in term babies,1926preterm infants27and is the current RECOMMENDED dose in the usa, canada, the uk and europe.18\n\ndiscussion\nthe results of the vitality trial will determine WHETHER Vitamin D supplementation has a ROLE in optimising infant Immune health in the first year of Life, reducing the risk of allergic disease and Respiratory diseases.']	[('INCOMPLETE_EVIDENCE', 147), ('IMPORTANT_CONSIDERATION', 168), ('FUTURE_WORK', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 347), ('SUPERFICIAL_RELATIONSHIP', 387)]	5	[('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 99, '25(OH)D'), ('CHEBI_17883', 'hydrogen chloride', 144, 'IU'), ('CHEBI_27300', 'vitamin D', 355, 'vitamin D'), ('UBERON_0002405', 'immune system', 413, 'immune'), ('UBERON_0000104', 'life cycle', 448, 'life'), ('UBERON_0001004', 'respiratory system', 496, 'respiratory')]
S7-PMC4719746	PMC4719746	1/2016	S7-PMC4719746	['ethnicity, education, season and intake of Vitamin D were independently ASSOCIATED with 25(Oh)D. at gw 28, the mean 25(Oh)d had increased from 23 (sd:7.8) to 47 (27) nmol/l ( p \u2009<\u20090.01) in women who were RECOMMENDED Vitamin D supplementation, with small or no change in women with sufficient Vitamin D levels at baseline.']	[('SUPERFICIAL_RELATIONSHIP', 72), ('FUTURE_WORK', 204)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('CHEBI_51686', 'haematoxylin', 118, '(OH'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 292, 'vitamin D')]
S9-PMC4719746	PMC4719746	1/2016	S9-PMC4719746	['the Serum levels of 25(Oh)D increased significantly from gw 15 to 28 in Vitamin D deficient women who received a RECOMMENDATION for supplementation.']	[('FUTURE_WORK', 113)]	1	[('UBERON_0001977', 'blood serum', 4, 'serum'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 22, '('), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
S38-PMC4719746	PMC4719746	1/2016	S38-PMC4719746	['in THIS PAPER, Vitamin D deficiency was DEFINED AS 25(Oh) D <50\xa0nmol/l, and severe Vitamin D deficiency was DEFINED as 25(Oh) D <25\xa0nmol/l, IN ACCORDANCE WITH RELEVANT LITERATURE [20].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('PROBABLE_UNDERSTANDING', 40), ('PROBABLE_UNDERSTANDING', 48), ('PROBABLE_UNDERSTANDING', 108), ('INCOMPLETE_EVIDENCE', 140), ('IMPORTANT_CONSIDERATION', 159), ('INCOMPLETE_EVIDENCE', 168)]	7	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 51, '25(OH) D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 121, '(OH) D')]
S50-PMC4719746	PMC4719746	1/2016	S50-PMC4719746	['the RECOMMENDATION of Vitamin D supplementation\npre-planned, and ACCORDING TO the protocol, women with 25(Oh)D less than the laboratory’s lower reference range (<37\xa0nmol/l) at Gestational week 15 were provided with written information describing their 25(Oh)D D concentration, and they were RECOMMENDED to consult their general practitioner (gp) for treatment.']	[('FUTURE_WORK', 4), ('INCOMPLETE_EVIDENCE', 65), ('FUTURE_WORK', 291)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 176, 'gestational'), ('CHEBI_29156', 'Gly-tRNA(Gly)', 252, '25(OH)D D'), ('PR_000007367', 'fibrosin-1-like protein', 252, '25(OH)D D')]
S63-PMC4719746	PMC4719746	1/2016	S63-PMC4719746	['explanatory linear regression models were performed TO ASSESS the relationship between ethnicity and the concentration of 25(Oh)D, both at inclusion and in Gestational week 28, accounting for the following POTENTIAL CONFOUNDING FACTORS: Gestational week, age, parity, season, education, Vitamin D supplements and pre-Pregnancy bmi.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('INCOMPLETE_EVIDENCE', 206), ('PROBLEM_COMPLICATION', 216)]	3	[('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 128, 'D'), ('GO_0007565', 'female pregnancy', 156, 'gestational'), ('GO_0007565', 'female pregnancy', 237, 'gestational'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin D'), ('GO_0007565', 'female pregnancy', 317, 'pregnancy')]
S87-PMC4719746	PMC4719746	1/2016	S87-PMC4719746	['crude mean (sd) Vitamin D [25(Oh)D in nmol/l] levels according to POTENTIAL explanatory factorsat inclusionat Gestational week 28 n \u2009=\u2009748 n \u2009=\u2009748mean(sd)mean(sd)overall mean 25(Oh)d50(27)59(29)age at inclusion\u2009\u2009\u2009≤30\xa0years47(25)55(27)\u2009\u2009\u2009>30\xa0years54(28)62(30)parity (para 0 ref)53(26)61(29)\u2009\u2009\u2009para 152(28)59(27)\u2009\u2009\u2009para ≥242(25)52(30)western europe (ref)69(24)72(28)\u2009\u2009\u2009south asia32(19)46(23)\u2009\u2009\u2009middle east34(20)51(29)\u2009\u2009\u2009sub-saharan africa38(18)45(25)\u2009\u2009\u2009east asia51(17)53(19)\u2009\u2009\u2009other56(21)63(26)season of Blood sample\u2009\u2009\u2009summer56(29)60(29)\u2009\u2009\u2009winter46(24)57(27)education level (>12\xa0years ref)60(27)67(27)\u2009\u2009\u200910-12 years46(25)56(29)\u2009\u2009\u2009<10\xa0years37(20)44(23)Vitamin D supplements\u2009\u2009\u2009≥10\xa0μga57(26)61(28)\u2009\u2009\u2009no or <10\xa0μg42(26)53(29)pre-Pregnancy bmi; kg/m2(normal weight (<25) ref)51(27)59(29)\u2009\u2009\u2009overweight (≥25/<30)51(27)61(31)\u2009\u2009\u2009obesity (≥30)48(24)54(24)\naintake of ≥10\xa0μg Vitamin D daily past two weeks\n\ncaption (fig): fig.']	[('INCOMPLETE_EVIDENCE', 66)]	1	[('CHEBI_28384', 'vitamin K', 16, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 16, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 27, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 110, 'gestational'), ('CHEBI_30778', 'gallic acid', 176, '25(OH)'), ('UBERON_0000178', 'blood', 503, 'blood'), ('CHEBI_28384', 'vitamin K', 650, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 724, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 863, 'vitamin D')]
S90-PMC4719746	PMC4719746	1/2016	S90-PMC4719746	['in addition, education, Intake of Vitamin D supplements and season were INDEPENDENTLY ASSOCIATED with 25(Oh)D concentrations at inclusion.']	[('SUPERFICIAL_RELATIONSHIP', 72), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	[('GO_0007631', 'feeding behavior', 24, 'intake'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D')]
S95-PMC4719746	PMC4719746	1/2016	S95-PMC4719746	"['=\u20090.24independent variabler2adj.b95\xa0% cib95\xa0% cir2adj.b95\xa0% cib95\xa0% cilowerupperlowerupperlowerupperloweruppergestational week at inclusion (<15 ref)−0.0010.01ᅟ≥15−0.56−4.43.3 −6.4−10−2.3**−4.6−8.3−0.92* age at inclusion0.03 0.940.551.3** 0.14−0.210.490.03 1.10.641.5**0.700.261.1** parity (para 0 ref)0.020.01ᅟpara1−1.2−5.43.10.24−3.13.6−2.8−7.41.8 −4.4−8.7−0.22* ᅟpara ≥2 −11−17−6.3** −3.2−7.61.3 −9.3−15−3.8** −5.4−110.25geographic region (western europe ref)0.380.16ᅟsouth asia −37−40−33**−28−33−23**−26−31−21**−17−23−11** ᅟmiddle east −34−39−30**−24−29−18**−21−26−15**−9.5−16−2.9** ᅟsub-saharan africa −31−37−25**−20−27−13**−26−34−19**−12−20−3.1** ᅟeast asia −17−24−10**−11−18−3.9**−19−28−11**−11−20−1.6* ᅟother −13−19−6.4**−7.6−14−0.90*−9.0−17−1.3* −1.4−9.66.9season (summer ref)0.030.01ᅟwinter −9.9−14−6.1**−5.2−8.9−1.4**−5.7−9.8−1.6** −1.3−6.13.4geographic region*seasona−11−16−4.8**−15−22−7.4** education level (>12 y ref)0.110.08ᅟ10-12 year −14−18−10**−3.7−7.1−0.30*−11−15−6.8** −1.8−6.12.5ᅟ<10\xa0year −23−28−17**−5.2−10−0.31*−23−29−17**−8.6−15−2.5** Vitamin D supplements (≥10μgbref)0.080.02ᅟno or <10\xa0μg −15−19−11**−11−14−7.7**−8.2−13−3.8**−9.8−14−5.8** pre-Pregnancy bmi (<25\xa0kg/m2ref)−0.001−0.001ᅟ≥25\xa0kg/m2−0.76−4.73.2−0.11−4.44.2\nathe EFFECT of season on 25(Oh)d differed by ethnicity: the interaction term is ""1"" for records with both non-western and winter and ""0"" for western and summer (ref)\nbintake of ≥10\xa0μg Vitamin D daily past two weeks\nbold numbers indicate p \u2009<\u20090.05 (* p \u2009<\u20090.05, ** p \u2009<\u20090.01)\n\nVitamin D status at Gestational week 28\nat the beginning of the third trimester, the prevalence of 25(Oh)D <50\xa0nmol/l among the largest ethnic minority groups was lower than at study inclusion: south asia: 62\xa0%, the middle east: 58\xa0% and sub-saharan africa: 63\xa0%.']"	[('SUPERFICIAL_RELATIONSHIP', 1248)]	1	[('CHEBI_28384', 'vitamin K', 1059, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1168, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 1268, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1268, '25(OH'), ('CHEBI_27300', 'vitamin D', 1427, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 1435, 'D'), ('CHEBI_28384', 'vitamin K', 1519, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1618, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 1618, '25 ... OH ... D')]
S99-PMC4719746	PMC4719746	1/2016	S99-PMC4719746	['in addition, age, parity, education, intake of Vitamin D supplementation and Gestational week at inclusion were independently ASSOCIATED with 25(Oh)D concentrations.']	[('SUPERFICIAL_RELATIONSHIP', 126)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 148, 'D')]
S133-PMC4719746	PMC4719746	1/2016	S133-PMC4719746	['HOWEVER, direct comparison of 25(Oh)D values between studies are hampered by DIFFERENT methodologies such as INCONSISTENT definitions of Vitamin D deficiency, laboratory measurements and degree of adjustment for POSSIBLE CONFOUNDERS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 109), ('INCOMPLETE_EVIDENCE', 212), ('PROBLEM_COMPLICATION', 221)]	5	[('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S147-PMC4719746	PMC4719746	1/2016	S147-PMC4719746	['SEVERAL STUDIES among Pregnant women have SHOWED a marked increase in 25(Oh)D with daily supplements of Vitamin D [11,24,43,44].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 42)]	2	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S149-PMC4719746	PMC4719746	1/2016	S149-PMC4719746	['HOWEVER, SOME EVIDENCE SUGGESTS Vitamin D binding protein MAY increase and the free fraction of 25(Oh)D MAY decrease [46,47].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 104)]	5	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D')]
S152-PMC4719746	PMC4719746	1/2016	S152-PMC4719746	['the SMALL increase of 25(Oh)D OBSERVED among women with a slight deficiency at baseline who did not receive the recommendation, MAY BE RELATED to usual practices in norway of routinely RECOMMENDING a daily intake of 10\xa0μg Vitamin D as part of Antenatal Care [21].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 135), ('FUTURE_WORK', 185)]	5	[('CHEBI_71657', 'versiconol acetate', 22, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 22, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 243, 'antenatal care')]
S154-PMC4719746	PMC4719746	1/2016	S154-PMC4719746	['compared with no change or a small increase in 25(Oh)D concentrations in women with adequate levels or mild Vitamin D deficiency, this DIFFERENTIAL change may INDICATE a beneficial EFFECT of the RECOMMENDATIONS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('INCOMPLETE_EVIDENCE', 159), ('SUPERFICIAL_RELATIONSHIP', 181), ('FUTURE_WORK', 195)]	4	[('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
S157-PMC4719746	PMC4719746	1/2016	S157-PMC4719746	['supplementation with a higher dose of Vitamin D than 20\xa0μg or 30\xa0μg would LIKELY be sufficient to achieve acceptable 25(Oh)D concentration in Pregnancy.']	[('PROBABLE_UNDERSTANDING', 74)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 117, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]
S160-PMC4719746	PMC4719746	1/2016	S160-PMC4719746	['after identifying participants with low 25(Oh)D values at study inclusion, and RECOMMENDING treatment with daily moderate doses of Vitamin D, the daily intake of Supplements significantly increased and the prevalence of severe Vitamin D deficiency was substantially reduced.']	[('FUTURE_WORK', 79)]	1	[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 162, 'supplements'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]
S7-PMC4764019	PMC4764019	1/2016	S7-PMC4764019	['the barker HYPOTHESIS HAS BEEN ELABORATED and evaluated in several reviews,2–4BUT TO THE BEST OF MY KNOWLEDGE, there HAS BEEN NO ATTEMPT to evaluate the HYPOTHESIS specifically for Vitamin D. THUS, what i PROPOSE TO explore in THIS very brief REVIEW is the EVIDENCE RELATING UNRECOGNIZED, Perinatal Vitamin D inadequacy to increased risk of certain chronic diseases later in Life, that is, to ascertain WHETHER any such EFFECTS MIGHT be an instance of the “barker HYPOTHESIS.”\ni deliberately avoid use of labels such as “deficient” or “insufficient” in characterizing Vitamin D status, AS these terms are OFTEN LINKED to specific values for serum 25-Hydroxyvitamin D [25(Oh)D], about which there is considerable CONTROVERSY.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 31), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 77), ('PROBABLE_UNDERSTANDING', 82), ('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 126), ('INCOMPLETE_EVIDENCE', 153), ('PROBABLE_UNDERSTANDING', 192), ('INCOMPLETE_EVIDENCE', 205), ('QUESTION_ANSWERED_BY_THIS_WORK', 205), ('QUESTION_ANSWERED_BY_THIS_WORK', 213), ('QUESTION_ANSWERED_BY_THIS_WORK', 227), ('QUESTION_ANSWERED_BY_THIS_WORK', 243), ('INCOMPLETE_EVIDENCE', 257), ('SUPERFICIAL_RELATIONSHIP', 266), ('INCOMPLETE_EVIDENCE', 275), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 403), ('SUPERFICIAL_RELATIONSHIP', 420), ('INCOMPLETE_EVIDENCE', 428), ('INCOMPLETE_EVIDENCE', 464), ('PROBABLE_UNDERSTANDING', 586), ('PROBABLE_UNDERSTANDING', 605), ('SUPERFICIAL_RELATIONSHIP', 611), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 712)]	25	[('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('GO_0036268', 'swimming', 289, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 289, 'perinatal'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D'), ('UBERON_0000104', 'life cycle', 375, 'life'), ('CHEBI_27300', 'vitamin D', 568, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 647, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 668, '25(OH)D')]
S44-PMC4764019	PMC4764019	1/2016	S44-PMC4764019	['briefly, at age 5 years, 13% of children Born of mothers in the lowest quartile of Vitamin D status [25(Oh)D <18 ng/ml] exhibited Learning disability, as contrasted with ONLY 4% of children Born of mothers in the highest 25(Oh)D quartile (>29 ng/ml), that is, a better than 3-fold increase in risk of the lowest quartile.']	[('ANOMALY_CURIOUS_FINDING', 170)]	1	[('GO_0007567', 'parturition', 41, 'born'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 101, '25 ... OH ... D'), ('GO_0007612', 'learning', 130, 'learning'), ('GO_0007567', 'parturition', 190, 'born'), ('CHEBI_71657', 'versiconol acetate', 221, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 221, '25(OH)D')]
S3-PMC4785305	PMC4785305	3/2016	S3-PMC4785305	['our HYPOTHESIS is that in middle eastern Pregnant women, a Vitamin D dose of 3000\u2005iu/day is REQUIRED to reach a DESIRABLE maternal 25-Hydroxyvitamin D [25(Oh)D] level, and to positively IMPACT infant bone Mineral content (bmc).']	[('INCOMPLETE_EVIDENCE', 4), ('IMPORTANT_CONSIDERATION', 92), ('IMPORTANT_CONSIDERATION', 112), ('SUPERFICIAL_RELATIONSHIP', 186)]	4	[('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 131, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 152, '25(OH)D'), ('CHEBI_46662', 'mineral', 205, 'mineral')]
S22-PMC4785305	PMC4785305	3/2016	S22-PMC4785305	['WHILE the total Calcitriol levels double in the first trimester, free Calcitriol levels do not increase until the third trimester and remain so until Lactation.24conversely, Parathyroid hormone (pth) levels decrease early on and increase back to mid-normal range by term.2the total calcium level decreases during Pregnancy, due to haemodilution, WHILE the ionised calcium level remains stable.2vitamin D binding proteins also increase during Pregnancy secondary to high Oestrogen levels,45but the 25-Hydroxyvitamin D (25(Oh)D) level, the single best nutritional INDICATOR of Vitamin D status,6remains stable.7the changes in Calcitriol levels led to the description of Pregnancy as a state of ‘absorptive hypercalciuria’.12the above Adaptive physiology is KEY to SAFETY CONSIDERATIONS when using Vitamin D supplementation during Pregnancy, as well as to determining key biochemical and hormonal parameters to be monitored.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 346), ('SUPERFICIAL_RELATIONSHIP', 562), ('IMPORTANT_CONSIDERATION', 755), ('IMPORTANT_CONSIDERATION', 762), ('IMPORTANT_CONSIDERATION', 769)]	6	[('CHEBI_17823', 'calcitriol', 16, 'calcitriol'), ('CHEBI_17823', 'calcitriol', 70, 'calcitriol'), ('GO_0007595', 'lactation', 150, 'lactation'), ('UBERON_0001132', 'parathyroid gland', 174, 'parathyroid'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy'), ('PR_000006444', 'diacylglycerol kinase delta', 402, 'D'), ('GO_0007565', 'female pregnancy', 442, 'pregnancy'), ('CHEBI_50114', 'estrogen', 470, 'oestrogen'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 497, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 518, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 575, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 624, 'calcitriol'), ('GO_0007565', 'female pregnancy', 668, 'pregnancy'), ('GO_0018888', '3-chloroacrylic acid metabolic process', 732, 'adaptive'), ('CHEBI_27300', 'vitamin D', 795, 'vitamin D'), ('GO_0007565', 'female pregnancy', 828, 'pregnancy')]
S23-PMC4785305	PMC4785305	3/2016	S23-PMC4785305	['maternal Vitamin D status during Pregnancy\nvitamin D deficiency during Pregnancy is PREVALENT worldwide, ESPECIALLY in developing countries.8in a systematic review of 18 studies conducted in western countries during the first Trimester, white caucasian Pregnant women were found to have a mean 25(Oh)D level between 29 and 73\u2005nmol/l.9mean 25(Oh)D levels were lower in non-caucasian Pregnant women, ranging between 15.2 and 43\u2005nmol/l.9in addition to ethnicity, higher latitude was a significant predisposing FACTOR for hypovitaminosis d.9similarly, in non-western countries, more than half of the Pregnant women who were beyond their first trimester had 25(Oh)D levels below 75\u2005nmol/l; these include countries such as india,10kuwait,11pakistan12and turkey.13even lower levels (<25\u2005nmol/l) HAVE BEEN REPORTED at Delivery in saudi arabia, iran and the united arab emirates.14furthermore, immigrant women were at PARTICULAR RISK.1516an OBSERVATIONAL study from the netherlands SHOWED significantly lower 25(Oh)D levels during the first Trimester in immigrant Pregnant women (turkish, moroccan and others), compared to western participants.17\n\nASSOCIATION between maternal Vitamin D status and maternal adverse outcomes\nVitamin D insufficiency during Pregnancy is ASSOCIATED with adverse maternal outcomes such as increased risk of Gestational diabetes mellitus (gdm), preeclampsia, caesarean-section Delivery and bacterial vaginosis.18in a recent meta-analysis of observational studies, the risk of gdm was FOUND TO BE increased by 40–84% in Pregnant women with low 25(Oh)D levels, defined as <50\u2005nmol/l or <75\u2005nmol/l, DEPENDING ON the studies.19–21while Preeclampsia risk was significantly increased in Vitamin D insufficient women,22c-section rates were INCONSISTENTLY AFFECTED by Vitamin D status.23HOWEVER, THESE FINDINGS REMAIN LIMITED by the inherent BIASES of OBSERVATIONAL studies, INCONSISTENT adjustment for CONFOUNDERS, in addition to the wide HETEROGENEITY in Vitamin D assays and Vitamin D cut-offs definition.']	[('IMPORTANT_CONSIDERATION', 84), ('IMPORTANT_CONSIDERATION', 105), ('SUPERFICIAL_RELATIONSHIP', 507), ('INCOMPLETE_EVIDENCE', 788), ('IMPORTANT_CONSIDERATION', 909), ('INCOMPLETE_EVIDENCE', 932), ('INCOMPLETE_EVIDENCE', 973), ('SUPERFICIAL_RELATIONSHIP', 1139), ('SUPERFICIAL_RELATIONSHIP', 1259), ('ANOMALY_CURIOUS_FINDING', 1503), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1752), ('SUPERFICIAL_RELATIONSHIP', 1767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1796), ('INCOMPLETE_EVIDENCE', 1807), ('INCOMPLETE_EVIDENCE', 1822), ('INCOMPLETE_EVIDENCE', 1829), ('PROBLEM_COMPLICATION', 1853), ('INCOMPLETE_EVIDENCE', 1863), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1886), ('PROBLEM_COMPLICATION', 1914), ('DIFFICULT_TASK', 1951)]	22	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 51, 'D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 226, 'trimester'), ('GO_0007565', 'female pregnancy', 253, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 294, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 294, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 345, 'D'), ('GO_0007565', 'female pregnancy', 382, 'pregnant'), ('GO_0007565', 'female pregnancy', 596, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 653, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 653, '25(OH)D'), ('GO_0007567', 'parturition', 810, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 1000, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1000, '25(OH)D'), ('GO_0009294', 'DNA mediated transformation', 1032, 'trimester'), ('GO_0007565', 'female pregnancy', 1055, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1168, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1215, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1246, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1327, 'gestational'), ('GO_0007567', 'parturition', 1396, 'delivery'), ('GO_0007565', 'female pregnancy', 1538, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 1562, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 1651, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 1700, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1779, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1968, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D')]
S24-PMC4785305	PMC4785305	3/2016	S24-PMC4785305	"[""ASSOCIATION between maternal Vitamin D level and neonatal adverse outcomes\nlow maternal 25(Oh)D levels were RECENTLY LINKED to fetal programming, and were found TO be ASSOCIATED with adverse events in neonates, resulting in small for Gestational age (sga) at Birth,1923and also later on during childhood, leading to reduced muscle and bone mass in offspring at 4 and 9\u2005years.2425this MAY BE EXPLAINED by the fact that maternal Vitamin D is ESSENTIAL for fetal Musculoskeletal integrity, as it Regulates neonatal bone accrual, POSSIBLY through specific proteins that are responsible for Placental Calcium Transport.26RECENTLY, data from the southampton women's survey (sws) SHOWED that maternal 25(Oh)D level is significantly CORRELATED with Placental Amino Acid transporters Expression, that mediate the Transport Of various Nutrients to the fetus.27furthermore, maternal Vitamin D MAY INFLUENCE the fetal muscle motor Unit size, and CONSEQUENTLY muscle mass and strength after Birth.25it is NOTEWORTHY that fetal bone development is one of the PREDICTORS of peak bone mass, Adult bone Mineral content and Hip geometry, THUS CORRELATING with fracture risk later in Life.2628\n\nVitamin d replacement guidelines during Pregnancy\nthe guidelines regarding Vitamin D replacement or supplementation during Pregnancy VARY substantially.""]"	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 108), ('SUPERFICIAL_RELATIONSHIP', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 161), ('SUPERFICIAL_RELATIONSHIP', 167), ('INCOMPLETE_EVIDENCE', 384), ('ANOMALY_CURIOUS_FINDING', 388), ('PROBABLE_UNDERSTANDING', 391), ('IMPORTANT_CONSIDERATION', 440), ('INCOMPLETE_EVIDENCE', 526), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 614), ('INCOMPLETE_EVIDENCE', 673), ('SUPERFICIAL_RELATIONSHIP', 725), ('INCOMPLETE_EVIDENCE', 882), ('SUPERFICIAL_RELATIONSHIP', 886), ('PROBABLE_UNDERSTANDING', 934), ('ANOMALY_CURIOUS_FINDING', 992), ('SUPERFICIAL_RELATIONSHIP', 1045), ('PROBABLE_UNDERSTANDING', 1120), ('SUPERFICIAL_RELATIONSHIP', 1125), ('DIFFICULT_TASK', 1309)]	21	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('GO_0007565', 'female pregnancy', 234, 'gestational'), ('GO_0007567', 'parturition', 259, 'birth'), ('CHEBI_27300', 'vitamin D', 427, 'vitamin D'), ('UBERON_0002204', 'musculoskeletal system', 460, 'musculoskeletal'), ('GO_0065007', 'biological regulation', 493, 'regulates'), ('UBERON_0001987', 'placenta', 586, 'placental'), ('GO_0006816', 'calcium ion transport', 596, 'calcium transport'), ('CHEBI_71657', 'versiconol acetate', 694, '25(OH)D'), ('UBERON_0001987', 'placenta', 741, 'placental'), ('CHEBI_82880', 'N-acyltetradecaphytosphingosine', 751, 'amino acid'), ('GO_0010467', 'gene expression', 775, 'expression'), ('GO_0006415', 'translational termination', 804, 'transport of ... nutrients'), ('CHEBI_33284', 'nutrient', 825, 'nutrients'), ('CHEBI_27300', 'vitamin D', 872, 'vitamin D'), ('UBERON_0002105', 'vestibulo-auditory system', 919, 'unit'), ('GO_0007567', 'parturition', 978, 'birth'), ('UBERON_0007023', 'adult organism', 1075, 'adult'), ('CHEBI_46662', 'mineral', 1086, 'mineral'), ('UBERON_0001464', 'hip', 1106, 'hip'), ('UBERON_0000104', 'life cycle', 1165, 'life'), ('CHEBI_33229', 'vitamin (role)', 1176, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1216, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1251, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1299, 'pregnancy')]
S25-PMC4785305	PMC4785305	3/2016	S25-PMC4785305	['the 2010 institute of medicine (iom) report on dietary reference intakes for Calcium and Vitamin D RECOMMENDED 600\u2005iu to Pregnant women as the recommended daily allowance (rda), the rda being the dose that is projected to allow at least 97.5% of the Pregnant women population to reach the DESIRABLE target 25(Oh)D level ≥50\u2005nmol/l.29this RECOMMENDATION was BASED ON OBSERVATIONAL studies, NONE of which were conducted in the middle east.29CONVERSELY, the Endocrine society 2011 GUIDELINES RECOMMENDED that 1500–2000\u2005iu daily of Vitamin D is NEEDED to reach a target 25(Oh)D level ≥75\u2005nmol/l (a RECOMMENDATION that was graded as weak with moderate quality of evidence).30the american college of obstetricians and gynecologists (acog) does not RECOMMEND screening for Vitamin D level in Pregnancy, and abides by the iom RECOMMENDATIONS.31moreover, the who 2012 guidelines on Vitamin D replacement during Pregnancy DID NOT RECOMMEND vitamin D supplementation as part of Prenatal care.32this was based ON a meta-analysis of Vitamin D trials during Pregnancy, which IDENTIFIED a LIMITED NUMBER of high-quality studies DEMONSTRATING a beneficial EFFECT of supplementation on maternal and neonatal outcomes, and CONCLUDED that FURTHER randomised controlled trials (rcts) ARE NEEDED.33in the uk, HOWEVER, Pregnant women are CONSIDERED AT RISK of Vitamin D deficiency, and supplementation with 400\u2005iu daily is REQUIRED.34\nit is NOT CLEAR WHETHER any of the above RECOMMENDED doses are applicable to non-western populations, with lower baseline Vitamin D levels, such as in lebanon and other middle eastern countries.']	[('FUTURE_WORK', 99), ('IMPORTANT_CONSIDERATION', 289), ('FUTURE_WORK', 338), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 366), ('INCOMPLETE_EVIDENCE', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 437), ('PROBABLE_UNDERSTANDING', 478), ('FUTURE_WORK', 489), ('FUTURE_WORK', 541), ('IMPORTANT_CONSIDERATION', 541), ('FUTURE_WORK', 594), ('FUTURE_WORK', 742), ('FUTURE_WORK', 818), ('INCOMPLETE_EVIDENCE', 912), ('FUTURE_WORK', 920), ('ANOMALY_CURIOUS_FINDING', 998), ('ANOMALY_CURIOUS_FINDING', 998), ('INCOMPLETE_EVIDENCE', 1061), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1113), ('SUPERFICIAL_RELATIONSHIP', 1140), ('INCOMPLETE_EVIDENCE', 1205), ('FUTURE_WORK', 1220), ('FUTURE_WORK', 1264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1288), ('IMPORTANT_CONSIDERATION', 1316), ('INCOMPLETE_EVIDENCE', 1316), ('IMPORTANT_CONSIDERATION', 1327), ('IMPORTANT_CONSIDERATION', 1401), ('FULL_UNKNOWN', 1419), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1429), ('FUTURE_WORK', 1454)]	33	[('CHEBI_31341', 'calcium dihydroxide', 77, 'Calcium'), ('CHEBI_28384', 'vitamin K', 89, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 89, 'Vitamin'), ('GO_0007565', 'female pregnancy', 121, 'pregnant'), ('GO_0007565', 'female pregnancy', 250, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 309, 'OH)D'), ('PR_000013502', 'parvalbumin alpha', 311, ')D'), ('UBERON_0005063', 'left ventricular compact myocardium', 455, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 528, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 566, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 566, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 766, 'vitamin D'), ('GO_0007565', 'female pregnancy', 785, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('GO_0007565', 'female pregnancy', 902, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 938, 'D'), ('GO_0007565', 'female pregnancy', 967, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1020, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1044, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1297, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1338, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin D')]
S28-PMC4785305	PMC4785305	3/2016	S28-PMC4785305	['rcts of Vitamin D supplementation during Pregnancy\ntwo landmark rcts HAVE BEEN conducted in the usa35and the uk.36hollis et al 35SHOWED that in Pregnant women in the usa, with a baseline 25(Oh)D level around 60\u2005nmol/l, a Vitamin dose of 4000\u2005iu daily allowed 82% of participants to reach a 25(Oh)D level of 80\u2005nmol/l, WHILE ONLY 70% and 50% reached this TARGET in the intermediate (2000\u2005iu daily) and low (400\u2005iu daily) doses, respectively.']	[('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 127), ('ANOMALY_CURIOUS_FINDING', 318), ('ANOMALY_CURIOUS_FINDING', 324), ('FUTURE_WORK', 354)]	5	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('GO_0007565', 'female pregnancy', 144, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 221, 'vitamin'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D')]
S30-PMC4785305	PMC4785305	3/2016	S30-PMC4785305	['ONE STUDY from india, comparing non-intervention to Vitamin D supplementation groups, with the dose being DEPENDENT on 25(Oh)D levels at 20\u2005weeks Gestation, SHOWED that Vitamin D supplementation resulted in a significant difference in the achieved 25(Oh)D level at Delivery (43.1 (81.3) nmol/l in the former group versus 56.8 (47.5) nmol/l in the latter group).37hollis et al 36and sablok et al 37SHOWED that Vitamin D supplementation decreased the RISK of Preterm labour, Gestational diabetes and hypertensive complications (all combined).']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 106), ('INCOMPLETE_EVIDENCE', 157), ('INCOMPLETE_EVIDENCE', 395), ('IMPORTANT_CONSIDERATION', 449)]	5	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 125, 'D'), ('GO_0007565', 'female pregnancy', 146, 'gestation'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 248, '25(OH)D'), ('GO_0007567', 'parturition', 265, 'delivery'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin D'), ('GO_0007565', 'female pregnancy', 457, 'preterm'), ('GO_0007565', 'female pregnancy', 473, 'gestational')]
S31-PMC4785305	PMC4785305	3/2016	S31-PMC4785305	['in the middle east and north africa region, there are FEW RECENT rcts that attempted to determine the OPTIMAL regimen of Vitamin D replacement in healthy Pregnant women.38–41WITH the exception of soheilykhah et al 40who ASSESSED the EFFECT of Vitamin D supplementation on Insulin resistance, the primary outcomes in THESE studies were MOSTLY maternal and neonatal 25(Oh)D levels (seeonline supplementary appendix1).']	[('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 58), ('IMPORTANT_CONSIDERATION', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 172), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 233), ('INCOMPLETE_EVIDENCE', 316), ('PROBABLE_UNDERSTANDING', 335)]	8	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('PR_000045358', 'insulin family protein', 272, 'insulin'), ('CHEBI_71657', 'versiconol acetate', 364, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 364, '25 ... OH ... D')]
S38-PMC4785305	PMC4785305	3/2016	S38-PMC4785305	['they ASSESSED the EFFECT of various doses of Vitamin D on the 25(Oh)D level, Immune function and Periodontal disease.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 5), ('SUPERFICIAL_RELATIONSHIP', 18)]	2	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('UBERON_0002405', 'immune system', 77, 'immune'), ('UBERON_0001758', 'periodontium', 97, 'periodontal')]
S40-PMC4785305	PMC4785305	3/2016	S40-PMC4785305	['objectives\nthe two primary OBJECTIVES of this trial, comparing the effect of high-dose versus low-dose Vitamin D, are as follows:\nthe proportion of women who will reach the iom defined desirable 25(Oh)D level ≥50\u2005nmol/l at Delivery.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 27)]	1	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 195, '25(OH)D'), ('GO_0007567', 'parturition', 223, 'delivery')]
S42-PMC4785305	PMC4785305	3/2016	S42-PMC4785305	['the secondary OBJECTIVES are to compare the EFFECT of high-dose versus low-dose Vitamin D on:\nmaternal outcomes:\nmean maternal 25(Oh)D level at Delivery.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 44)]	2	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000011594', 'inositol polyphosphate 5-phosphatase OCRL', 130, 'OH ...'), ('GO_0007567', 'parturition', 144, 'delivery')]
S86-PMC4785305	PMC4785305	3/2016	S86-PMC4785305	['Vitamin D supplementation ≤200\u2005iu daily.ii\nexclusion criteria:\n25(Oh)D level <25\u2005nmol/l, AS it would be UNETHICAL to randomise Pregnant women to the low dose of Vitamin D, and 25(Oh)D level >75\u2005nmol/l (30\u2005ng/ml), as Vitamin D supplementation with routine Prenatal multivitamins would be sufficient.']	[('PROBABLE_UNDERSTANDING', 89), ('DIFFICULT_TASK', 104)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 63, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 182, 'D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'prenatal')]
S125-PMC4785305	PMC4785305	3/2016	S125-PMC4785305	['this meta-analysis SHOWED that, in Pregnant women from the mena region, a Vitamin D dose of 800–2000\u2005iu daily results in an increase in the 25(Oh)D level by 2.5\u2005nmol/l, and a high dose of >2000\u2005iu daily results in an increase in the 25(Oh)D level by 1.67\u2005nmol/l.']	[('INCOMPLETE_EVIDENCE', 19)]	1	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 140, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 146, 'D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D')]
S156-PMC4785305	PMC4785305	3/2016	S156-PMC4785305	['in addition, women with a 25(Oh)D level >75\u2005nmol/l will be excluded in order to prevent reaching supranormal levels of 25(Oh)D SHOULD they be allocated to the high-Vitamin D dose.']	[('FUTURE_WORK', 127)]	1	[('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 26, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 122, 'OH)D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S40-PMC4800340	PMC4800340	5/2016	S40-PMC4800340	['in the boston Birth cohort study, Cord Blood Vitamin D deficiency [25(Oh)D concentration <11 ng/ml] was not FOUND TO be ASSOCIATED with Food sensitization to eight common Food Allergen in children.67HOWEVER, when individual Genetic variant of 4 CANDIDATE Genes INVOLVED in Ige synthesis and Vitamin D Metabolism were jointly considered, there is a statistically strong Gene-Vitamin D INTERACTION (pinteraction=9×10-6) on Food sensitization.']	[('ANOMALY_CURIOUS_FINDING', 108), ('SUPERFICIAL_RELATIONSHIP', 120), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 261), ('SUPERFICIAL_RELATIONSHIP', 384)]	6	[('GO_0007567', 'parturition', 14, 'birth'), ('UBERON_0002240', 'spinal cord', 34, 'cord'), ('UBERON_0000178', 'blood', 39, 'blood'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D'), ('CHEBI_33290', 'food', 136, 'food'), ('CHEBI_33290', 'food', 171, 'food'), ('CHEBI_50904', 'allergen', 176, 'allergen'), ('SO_0000704', 'gene', 224, 'genetic'), ('SO_0000704', 'gene', 255, 'genes'), ('GO_0007630', 'jump response', 273, 'IgE'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 273, 'IgE'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 299, 'D metabolism'), ('SO_0000704', 'gene', 369, 'gene'), ('CHEBI_27300', 'vitamin D', 374, 'vitamin D'), ('CHEBI_33290', 'food', 421, 'food')]
S20-PMC4811107	PMC4811107	3/2016	S20-PMC4811107	['these analyses COULD identify Pregnant women who NEED a Prenatal Vitamin D intervention tailored to them BASED ON the various characteristics, as well as identifying children who MAY have a lower level of 25(Oh)D at Birth and MAY BE prioritized for Vitamin D screening.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 49), ('SUPERFICIAL_RELATIONSHIP', 105), ('INCOMPLETE_EVIDENCE', 179), ('INCOMPLETE_EVIDENCE', 226)]	5	[('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('GO_0007565', 'female pregnancy', 56, 'prenatal'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('GO_0007567', 'parturition', 216, 'birth'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]
S109-PMC4811107	PMC4811107	3/2016	S109-PMC4811107	"[""NOT ONLY do these studies INDICATE that use of the Prenatal level of 25(Oh)D to represent the child's early Life Vitamin D level is not specific, but also the data SUGGEST that a maternal THRESHOLD exists below which the mother LIMITS her CONTRIBUTION of 25(Oh)D to the fetus.""]"	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 164), ('PROBABLE_UNDERSTANDING', 188), ('SUPERFICIAL_RELATIONSHIP', 228), ('SUPERFICIAL_RELATIONSHIP', 239)]	6	[('GO_0007565', 'female pregnancy', 51, 'prenatal'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 75, 'D'), ('UBERON_0000104', 'life cycle', 108, 'life'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 255, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 257, '(OH)D')]
S111-PMC4811107	PMC4811107	3/2016	S111-PMC4811107	['furthermore, children who are black and not firstborn and those Born to women with very low 25(Oh)D MAY identify a PRIORITY group for Vitamin D deficiency screening.']	[('INCOMPLETE_EVIDENCE', 100), ('IMPORTANT_CONSIDERATION', 115)]	2	[('GO_0007567', 'parturition', 64, 'born'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
S113-PMC4811107	PMC4811107	3/2016	S113-PMC4811107	"[""conclusions\nthe degree to which a newborn's Vitamin D [25(Oh)D] level is ASSOCIATED with their mother's Prenatal level varies by several INTERRELATED FACTORS including maternal race, Birth order, and the actual maternal level.""]"	[('SUPERFICIAL_RELATIONSHIP', 73), ('SUPERFICIAL_RELATIONSHIP', 137), ('SUPERFICIAL_RELATIONSHIP', 150)]	3	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('GO_0007565', 'female pregnancy', 104, 'prenatal'), ('GO_0007567', 'parturition', 183, 'birth')]
S116-PMC4811107	PMC4811107	3/2016	S116-PMC4811107	['children who are not firstborn, those who are black, and those Born to women with very low 25(Oh)D MAY identify a PRIORITY group for Vitamin D deficiency screening.']	[('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 114)]	2	[('GO_0007567', 'parturition', 63, 'born'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
S12-PMC4811441	PMC4811441	3/2016	S12-PMC4811441	['in conclusion, an increase in 25(Oh)D concentration during Pregnancy of at LEAST 30 nmol/l, REGARDLESS OF Vitamin D status in t1, was ASSOCIATED with a lower odds ratio for Preeclampsia.']	[('PROBABLE_UNDERSTANDING', 75), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 173, 'preeclampsia')]
S29-PMC4811441	PMC4811441	3/2016	S29-PMC4811441	['poorer Vitamin D status (measured as 25-Hydroxyvitamin D (25(Oh)D) during Pregnancy HAS BEEN ASSOCIATED with INCREASED RISKS of pe and Gestational hypertension in SOME [11,12] BUT NOT ALL observational studies [13,14].']	[('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 93), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 163), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176), ('ANOMALY_CURIOUS_FINDING', 180)]	6	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 37, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 135, 'gestational')]
S87-PMC4811441	PMC4811441	3/2016	S87-PMC4811441	['Vitamin D status was used as time-varying in model 1, where the mean of the 25(Oh)D concentration in t1 and t3 was used as a PROXY for Vitamin D status at Gestational week 25 and the concentration at week 32 (t3) was duplicated for week 37.']	[('SUPERFICIAL_RELATIONSHIP', 125)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'gestational')]
S136-PMC4811441	PMC4811441	3/2016	S136-PMC4811441	['also, an increase in 25(Oh)D ≥30 nmol/l was not associated with Pregnancy-induced hypertension.10.1371/journal.pone.0152198.t004\n\ncaption (table-wrap): table 4\nbivariable and multivariable logistic regression analysis of the DETERMINANTS of Pregnancy-induced hypertension.bivariablemultivariableabor95% cipbor95% ciplowerupperlowerupper25(Oh)D t10.0081.0081.0011.0140.0240.0021.0020.9931.0100.709obesity t10.3661.4430.8972.3210.131-0.1690.8440.4641.5380.844nulliparity0.3611.4351.0391.9830.0290.2051.2280.8541.7650.269excessive gwg0.4731.6041.1462.2460.0060.3631.4380.9952.0780.054preexisting medical condition t10.6321.8810.8764.0400.1050.0891.0930.4542.6290.842assisted reproduction0.1821.2000.7881.8280.3950.0841.0880.6561.8030.745tobacco use t1-0.6330.5310.2161.3080.169-0.4470.6400.2621.5630.327height0.0541.0551.0291.083<0.0010.0351.0351.0051.0660.021age ≥40 years t1-0.1410.8680.3732.0240.744-0.1920.8250.3122.1840.699dbp t10.0871.0911.0691.114<0.0010.0881.0921.0671.117<0.001\n25(Oh)d = 25-Hydroxyvitamin D, t1 = first trimester, gwg = Gestational weight gain, dbp = diastolic Blood pressure,\ndichotomous: age ≥40 years, obesity, nulliparity, excessive gwg, preexisting medical condition and assisted reproduction\na.adjusted for multifetal Pregnancy, baseline employment status, Gestational age at t1, month of Conception and northern european country of Birth\n\ndiscussion\nthese results are the primary outcome of the gravid study–TO OUR KNOWLEDGE the FIRST STUDY reporting on the RELATIONSHIP between longitudinal Vitamin D status and its RELATION to pe and Gestational bp trajectory.']	[('SUPERFICIAL_RELATIONSHIP', 225), ('PROBABLE_UNDERSTANDING', 1438), ('INCOMPLETE_EVIDENCE', 1459), ('SUPERFICIAL_RELATIONSHIP', 1488), ('SUPERFICIAL_RELATIONSHIP', 1547)]	5	[('CHEBI_71657', 'versiconol acetate', 21, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 21, '25(OH)D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy'), ('CHEBI_33010', 'chromide(1-)', 338, '(OH)D'), ('CHEBI_63056', 'zinc cation', 984, '25(OH'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 994, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 1043, 'gestational'), ('UBERON_0000178', 'blood', 1084, 'blood'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1286, 'gestational'), ('GO_0007620', 'copulation', 1318, 'conception'), ('GO_0007567', 'parturition', 1362, 'birth'), ('CHEBI_27300', 'vitamin D', 1522, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1566, 'gestational')]
S137-PMC4811441	PMC4811441	3/2016	S137-PMC4811441	['our results SUGGEST that an increase of AT LEAST 30 nmol/l in 25(Oh)D concentration during Pregnancy is RELATED to lower odds of pe, REGARDLESS OF Vitamin D status in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 12), ('PROBABLE_UNDERSTANDING', 40), ('SUPERFICIAL_RELATIONSHIP', 104), ('INCOMPLETE_EVIDENCE', 133)]	4	[('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy')]
S169-PMC4811441	PMC4811441	3/2016	S169-PMC4811441	['our results SHOW that an increment in 25(Oh)D concentration during Pregnancy is ASSOCIATED with lower odds of pe, REGARDLESS OF early Pregnancy Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 114)]	3	[('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S171-PMC4811441	PMC4811441	3/2016	S171-PMC4811441	['in conclusion, an increase in 25(Oh)D concentration during Pregnancy of at LEAST 30 nmol/l, REGARDLESS OF Vitamin D status at t1, was ASSOCIATED with a lower odds ratio for pe.']	[('PROBABLE_UNDERSTANDING', 75), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
S12-PMC4829940	PMC4829940	5/2016	S12-PMC4829940	['the MAJOR circulating form and indicator of Vitamin D status, 25-Hydroxyvitamin D (25(Oh)D), is supplied by 25-hydroxylation of Vitamin D produced in the skin upon uvb radiation or Vitamin D from the diet[1].']	[('IMPORTANT_CONSIDERATION', 4)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 62, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 128, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S14-PMC4829940	PMC4829940	5/2016	S14-PMC4829940	['low 25(Oh)D levels HAVE BEEN ASSOCIATED with a range of adverse conditions, from Pregnancy outcomes to childhood illnesses and chronic disease including osteoporosis, cancer and Cardiovascular disease in Adulthood[3], ALTHOUGH randomized controlled trials of Vitamin D supplements do NOT SUPPORT causality for Extra-Skeletal outcomes[4],[5].']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 29), ('ANOMALY_CURIOUS_FINDING', 218), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 284)]	4	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 4, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy'), ('UBERON_0004535', 'cardiovascular system', 178, 'cardiovascular'), ('UBERON_0000113', 'post-juvenile adult stage', 204, 'adulthood'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 310, 'extra-skeletal')]
S28-PMC4829940	PMC4829940	5/2016	S28-PMC4829940	['another STUDY explored epigenetic Regulation of Vitamin D converting enzymes[18], WHILE a third FOUND a RELATIONSHIP between methylation of the Genes Cyp24R1 and Cyp27A1 and variations in circulating 25(Oh)D levels[19].']	[('INCOMPLETE_EVIDENCE', 8), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 104)]	4	[('GO_0065007', 'biological regulation', 34, 'regulation'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('SO_0000704', 'gene', 144, 'genes'), ('PR_000006101', 'cytochrome P450 1A1', 150, 'CYP24R1'), ('PR_000006101', 'cytochrome P450 1A1', 162, 'CYP27A1'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 200, '25(OH ... D')]
S127-PMC4829940	PMC4829940	5/2016	S127-PMC4829940	['HOWEVER, a FEW other STUDIES have explored RELATIONSHIPS between Vitamin D supplementation or circulating 25(Oh)D and methylation at a few Cpg Sites in two to four candidate Genes in Adults[18],[46], and one Genome-wide Dna Methylation study explored ASSOCIATION with Vitamin D deficiency in african children[17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 251)]	4	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 106, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 106, '25(OH)D'), ('SO_0000036', 'matrix_attachment_site', 139, 'CpG sites'), ('SO_0000704', 'gene', 174, 'genes'), ('UBERON_0007023', 'adult organism', 183, 'adults'), ('SO_0001026', 'genome', 208, 'genome'), ('GO_0006306', 'DNA methylation', 220, 'DNA methylation'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D')]
S19-PMC4832516	PMC4832516	10/2015	S19-PMC4832516	['marked seasonal changes HAVE BEEN REPORTED in maternal circulating 25-Hydroxyvitamin D levels (25(Oh)D)[11], which reflect sunshine exposure and directly INFLUENCE fetal Vitamin D exposure.']	[('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 154)]	2	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 67, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 95, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S10-PMC4859539	PMC4859539	5/2016	S10-PMC4859539	['the LACK OF association between Vitamin D status and Cathelicidin in THIS STUDY MAY BE DUE TO the NARROW RANGE in OBSERVED 25(Oh)D values and WARRANTS ADDITIONAL STUDIES for further observation.']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 69), ('INCOMPLETE_EVIDENCE', 80), ('PROBLEM_COMPLICATION', 87), ('PROBLEM_COMPLICATION', 98), ('INCOMPLETE_EVIDENCE', 114), ('FUTURE_WORK', 142), ('FUTURE_WORK', 151)]	8	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('PR_000006009', 'alpha-catulin', 53, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D')]
S47-PMC4859539	PMC4859539	5/2016	S47-PMC4859539	['four multivariable regressions were performed TO ASSESS WHETHER any significant ASSOCIATIONS existed between the natural logarithm of each subject’s cathelicidin concentration and each of the following Vitamin D measurements: (1) child’s current 25(Oh)D at time of follow-up, (2) child’s 25(Oh)d at Birth, (3) maternal 25(Oh)D throughout Pregnancy (visits 3 to 7 as area under the curve), and (4) maternal 25(Oh)D one month before Delivery; all analyses controlled for race/ethnicity, age, gender, and percent fat.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 80)]	3	[('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 246, '25(OH)D'), ('CHEBI_37972', 'phosphorus-32 atom', 288, '25'), ('CHEBI_17792', 'organohalogen compound', 291, 'OH'), ('GO_0007567', 'parturition', 299, 'birth'), ('CHEBI_71657', 'versiconol acetate', 319, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 319, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 338, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0007567', 'parturition', 431, 'delivery')]
S56-PMC4859539	PMC4859539	5/2016	S56-PMC4859539	['of the children in the cohort, 20.3% were FOUND TO BE Vitamin D deficient, as defined by a 25(Oh)D concentration <20 ng/ml.10.1371/journal.pone.0152711.t001\n\ncaption (table-wrap): table 1\nchild sociodemographics and clinical characteristics.characteristicvalue\xa0n = 133race/ethnicity [n (%)]\xa0\xa0\xa0\xa0\xa0black41 (30.8)\xa0\xa0\xa0\xa0white38 (28.6)\xa0\xa0\xa0\xa0hispanic54 (40.6)gender [n (%)]\xa0\xa0\xa0\xa0\xa0female62 (46.6)\xa0\xa0\xa0\xa0male71 (53.4)age1(years)4.7 ± 1.2 (2–7)bmi116.1 ± 2.5 (12.1–28.8)% fat125.5 ± 6.1 (14.6–42.9)no.']	[('ANOMALY_CURIOUS_FINDING', 42)]	1	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D')]
S97-PMC4859539	PMC4859539	5/2016	S97-PMC4859539	"[""in MODELS 1 and 4, there was also a TREND NOTED with the child’s percent fat being positively ASSOCIATED with Cathelicidin (beta = 0.028, p = 0.052 and beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\n\ncaption (table-wrap): table 3\nmultivariable linear regression models assessing factors associated with natural logarithm for Cathelicidin.model 1 \xa0\xa0independent variablesbetase1p valuerace/ethnicity\xa0\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child's current 25(Oh)D-0.0050.010.598 model 2 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child's 25(Oh)D at Birth-0.0030.010.748 model 3 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicity\xa0\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.0120.010.359maternal 25(Oh)D throughout Pregnancy<-0.000100.999 model 4 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicity\xa0\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(Oh)D 1-month before Delivery0.0030.010.606\n1se represents standard error\n\ndiscussion\nin THIS STUDY of healthy children whose mothers had participated in a Vitamin D supplementation trial during Pregnancy, DESPITE DIFFERENCES in both maternal and childhood Vitamin D status, there were no significant differences in Cathelicidin concentration between the three racial/ethnic groups studied.""]"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 42), ('SUPERFICIAL_RELATIONSHIP', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 1391), ('ANOMALY_CURIOUS_FINDING', 1508), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1516)]	7	[('CHEBI_3364', 'Canthiumine', 110, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 110, 'cathelicidin'), ('CHEBI_3461', 'Casuarictin', 337, 'Cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 572, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 572, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 801, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 807, 'D'), ('GO_0007567', 'parturition', 812, 'birth'), ('CHEBI_71657', 'versiconol acetate', 1042, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1048, 'D'), ('GO_0007565', 'female pregnancy', 1061, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 1300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1300, '25(OH)D'), ('GO_0007567', 'parturition', 1323, 'delivery0'), ('CHEBI_27300', 'vitamin D', 1458, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1497, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1559, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 1618, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 1618, 'cathelicidin')]
S76-PMC4889866	PMC4889866	5/2016	S76-PMC4889866	['association of maternal and Cord Vitamin D level with Tlr-Stimulated cytokine Response\nBECAUSE the distribution of most cytokine levels and Vitamin D concentrations was highly skewed (data not shown), we used natural log-transformed 25(Oh)D and cytokine levels for correlation analysis.']	[('PROBABLE_UNDERSTANDING', 87)]	1	[('UBERON_0000948', 'heart', 28, 'Cord'), ('CHEBI_28384', 'vitamin K', 33, 'Vitamin D'), ('GO_0036462', 'TRAIL-activated apoptotic signaling pathway', 54, 'TLR-Stimulated'), ('GO_0060033', 'anatomical structure regression', 78, 'Response'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 233, '25(OH ... D')]
S121-PMC4889866	PMC4889866	5/2016	S121-PMC4889866	['first, the predominantly low Serum level of 25(Oh)D in THIS STUDY has LIMITED our ability TO DETERMINE WHETHER there is an ASSOCIATION between higher concentration of Vitamin D and infection.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 55), ('INCOMPLETE_EVIDENCE', 70), ('QUESTION_ANSWERED_BY_THIS_WORK', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('SUPERFICIAL_RELATIONSHIP', 123)]	5	[('UBERON_0001977', 'blood serum', 29, 'serum'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S7049-PMC4896250	PMC4896250	4/2016	S7049-PMC4896250	['a496 the EFFECT of Cord Serum 25-Hydroxyvitamin D (25(Oh)D) on the development of atopic dermatitis in first 3 years of Life : cocoa study\n\nhyun-ju cho1, youn ho shin2, eun lee3, young-ho kim3, darae lee3, mi-jin kang4, song-i yang5, kangmo ahn6, kyung won kim7, yoon hee kim7, hye-sung won3, soo hyun kim2, suk-joo choi6, young han kim7, jong kwan jun8, eun-jin kim9, jeom gyu lee9, so-yeon lee5, soo-jong hong1, dongin suh10\n\n1department of pediatrics, childhood asthma atopy center, environmental health center, asan medical center, university of ulsan college of medicine, south korea;2cha medical center;3asan medical center;4asan institute for Life science, asan medical center;5hallym university sacred Heart hospital;6samsung medical center;7yonsei university college of medicine;8seoul national university college of medicine;9korea national institute of health;10seoul national university hospital\n\ncorrespondence: hyun-ju cho – department of pediatrics, childhood asthma atopy center, environmental health center, asan medical center, university of ulsan college of medicine, south korea\nbackground: the ASSOCIATION between Serum Vitamin D deficiency at Birth and atopic dermatitis (ad) is UNCERTAIN.']	[('SUPERFICIAL_RELATIONSHIP', 9), ('SUPERFICIAL_RELATIONSHIP', 1115), ('FULL_UNKNOWN', 1201)]	3	"[('UBERON_0000948', 'heart', 19, 'Cord'), ('UBERON_0001977', 'blood serum', 24, 'Serum'), ('CHEBI_27844', ""2',3'-cyclic AMP"", 30, '25-Hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 51, '25(OH)D'), ('UBERON_0000104', 'life cycle', 120, 'Life'), ('UBERON_0000104', 'life cycle', 650, 'Life'), ('UBERON_0000948', 'heart', 710, 'Heart'), ('UBERON_0001977', 'blood serum', 1135, 'serum'), ('CHEBI_27300', 'vitamin D', 1141, 'vitamin D'), ('GO_0007567', 'parturition', 1165, 'birth')]"
S87-PMC4903143	PMC4903143	5/2016	S87-PMC4903143	['Vitamin D\nthere is general CONSENSUS in the medical literature that the Vitamin D status of many Individuals and population groups throughout much of the world (as reflected by population measurements of Serum 25(Oh)D levels) is INSUFFICIENT for OPTIMAL health [74].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('PROBABLE_UNDERSTANDING', 27), ('PROBLEM_COMPLICATION', 229), ('IMPORTANT_CONSIDERATION', 246)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('NCBITaxon_1', 'root', 97, 'individuals'), ('UBERON_0001977', 'blood serum', 204, 'serum'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 210, '25(OH ... D')]
S100-PMC4929134	PMC4929134	8/2016	S100-PMC4929134	['DEFICIENCIES in Vitamin A (Retinol\xa0<\xa00.7\xa0μmol/l), Vitamin D (25(Oh)D\xa0<\xa050\xa0nmol/l), Folate (Folic Acid\xa0<\xa013.6\xa0nmol/l), Vitamin B12 (cobalamin\xa0<\xa0150\xa0pmol/l), and iron (Transferrin Receptor to ferritin ratio\xa0>\xa0500\xa0μg/μg) were present in 8.4, 18.5, 6.4, 20.1, and 11.6% of children using conventional cut-offs (schulze et al.']	[('IMPORTANT_CONSIDERATION', 0)]	1	[('CHEBI_27300', 'vitamin D', 16, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 27, 'retinol'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 61, '25(OH)D'), ('CHEBI_30863', '5-azaorotic acid', 83, 'folate'), ('CHEBI_30751', 'formic acid', 91, 'folic acid'), ('CHEBI_33279', 'vitamin D5', 118, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 118, 'vitamin B12'), ('PR_000001679', 'trace amine-associated receptor 5', 166, 'transferrin receptor')]
S7-PMC4930210	PMC4930210	7/2016	S7-PMC4930210	['there was a significant RELATIONSHIP between maternal reported dietary Vitamin D intake (diet and supplement) and 25(Oh)D and 3-Epi-25(Oh)D3Concentrations in an adjusted linear regression model.']	[('SUPERFICIAL_RELATIONSHIP', 24)]	1	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('CHEBI_34304', 'fenobucarb', 126, '3-epi-25'), ('CHEBI_73735', 'gadoterate', 135, 'OH)D3concentrations')]
S14-PMC4930210	PMC4930210	7/2016	S14-PMC4930210	['the iom has RECOMMENDED a 25(Oh)D cut point of >50 nmol/l to define Vitamin D sufficiency, AS this level is ASSOCIATED with PREVENTION of the bone manifestations of Vitamin D deficiency (rickets and osteomalacia) for 97.5% of canadians and americans.']	[('FUTURE_WORK', 12), ('PROBABLE_UNDERSTANDING', 91), ('SUPERFICIAL_RELATIONSHIP', 108), ('SUPERFICIAL_RELATIONSHIP', 124)]	4	[('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 32, 'D'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
S18-PMC4930210	PMC4930210	7/2016	S18-PMC4930210	['HOWEVER, the daily use of Vitamin D supplements CONTRIBUTED to a better 25-Hydroxycholecalciferol (25(Oh)D) status [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 48)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_50545', 'trans-isoeugenol', 72, '25-hydroxycholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D')]
S23-PMC4930210	PMC4930210	7/2016	S23-PMC4930210	['the BEST clinical laboratory INDICATOR of Vitamin D status is the Blood concentration of 25(Oh)D [4].']	[('IMPORTANT_CONSIDERATION', 4), ('SUPERFICIAL_RELATIONSHIP', 29)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0000178', 'blood', 66, 'blood'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 95, 'D')]
S68-PMC4930210	PMC4930210	7/2016	S68-PMC4930210	['Plasma concentrations of 25(Oh)D at <25 nmol/l [3,4], <50 nmol/l [3,4], and <75 nmol/l [5,6] were used to REFLECT several laboratory definitions of Vitamin D status CURRENTLY used.']	[('PROBABLE_UNDERSTANDING', 106), ('INCOMPLETE_EVIDENCE', 165)]	2	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 31, 'D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S73-PMC4930210	PMC4930210	7/2016	S73-PMC4930210	['a multiple linear regression analysis was used to examine the ASSOCIATION between women’s Plasma 25(Oh)D (D2+ D3) concentration and their reported dietary Vitamin D intake in supplements and diet adjusted for the potential covariates of maternal age, maternal bmi at second trimester, season (summer from may 01-oct 31 and winter from nov 01-apr 30), and race (caucasian vs .']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('UBERON_0001969', 'blood plasma', 90, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 97, '25(OH ... D'), ('CHEBI_29108', 'calcium(2+)', 106, 'D2+'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 106, 'D2'), ('PR_000001177', 'D(2) dopamine receptor', 110, 'D3'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S106-PMC4930210	PMC4930210	7/2016	S106-PMC4930210	['three-epi-25(Oh)D3Comprised 5.0% of total 25(Oh)D. when 3-epi-25(oh)D3Was EXCLUDED from the Vitamin D estimations, 19% of women were considered to have levels <75 nmol/l; HOWEVER, with 3-Epi-25(Oh)D3Included, the percentage of women with Vitamin D concentration of <75 nmol/l decreased to 12%.']	[('INCOMPLETE_EVIDENCE', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 171)]	2	[('CHEBI_37194', 'nonaplumbide(4-)', 10, '25(OH)D3comprised'), ('CHEBI_71657', 'versiconol acetate', 42, '25(OH)D'), ('PR_000012979', 'DNA-directed DNA/RNA polymerase mu', 68, 'D3was'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_62409', 'trans,trans-deca-2,4-dienoyl-CoA', 185, '3-epi'), ('CHEBI_75897', 'iron(2+) sulfides', 191, '25(OH)D3included'), ('PR_000027695', 'nuclear receptor coactivator 3 isoform 1 phosphorylated 3', 191, '25(OH)D3included'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D')]
S109-PMC4930210	PMC4930210	7/2016	S109-PMC4930210	['ASSOCIATION between women’s Plasma 25(Oh)D and 3-Epi-25(Oh)D3Concentration and maternal reported Vitamin D intake .']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('UBERON_0001969', 'blood plasma', 28, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 35, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 41, 'D'), ('CHEBI_58090', 'L-cysteate(1-)', 47, '3-epi-25(OH)D3concentration'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
S111-PMC4930210	PMC4930210	7/2016	S111-PMC4930210	['there was a significant ASSOCIATION between maternal Plasma 25(Oh)D and total reported Vitamin D intake during the second Trimester of Pregnancy (β: 0.09, 95% ci: 0.06 to 0.13) in an adjusted linear regression model.']	[('SUPERFICIAL_RELATIONSHIP', 24)]	1	[('UBERON_0001969', 'blood plasma', 53, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 60, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 122, 'trimester'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy')]
S112-PMC4930210	PMC4930210	7/2016	S112-PMC4930210	['season of sampling and race were also significantly ASSOCIATED with 25(Oh)D concentration (table 4).10.1371/journal.pone.0157262.g002\n\ncaption (fig): fig 2\nabsolute concentrations of (a) Plasma 25(Oh)D, and (b) Plasma 3-Epi-25(Oh)D3Versus maternal Vitamin D intake (iu/day) in a longitudinal cohort of Pregnant women and their infants in alberta, canada.']	[('SUPERFICIAL_RELATIONSHIP', 52)]	1	[('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 68, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 187, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 211, 'plasma'), ('CHEBI_34304', 'fenobucarb', 218, '3-epi-25'), ('CHEBI_51048', '(R,R)-diepoxybutane', 226, '(OH)D3versus'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 302, 'pregnant')]
S137-PMC4930210	PMC4930210	7/2016	S137-PMC4930210	['another RECENT american longitudinal STUDY of 193 Pregnant women from mid-Pregnancy to Birth SHOWED Consuming a Prenatal Vitamin D supplement (334 iu/day) did not PREVENT precipitous drops in maternal Plasma 25(Oh)D concentration [28].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 163)]	4	[('GO_0007565', 'female pregnancy', 50, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 87, 'birth'), ('GO_0007631', 'feeding behavior', 100, 'consuming'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 201, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 208, '25(OH)D')]
S139-PMC4930210	PMC4930210	7/2016	S139-PMC4930210	['one STRENGTH of THE CURRENT STUDY is its use of a quantification method capable of ACCURATELY measuring 25(Oh)D (separating epimer) and adding the potential CONTRIBUTION of dietary Vitamin D to the total intake ESTIMATE.']	[('IMPORTANT_CONSIDERATION', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('SUPERFICIAL_RELATIONSHIP', 83), ('SUPERFICIAL_RELATIONSHIP', 157), ('INCOMPLETE_EVIDENCE', 211)]	5	[('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 104, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S143-PMC4930210	PMC4930210	7/2016	S143-PMC4930210	['the fact that season significantly AFFECTED 25(Oh)D concentration BUT NOT 3-epi-25(oh)d3suggests that Vitamin D supplements COULD BE a source for 3-Epi-25(Oh)D3As SHOWN in a PREVIOUS STUDY [30].']	[('SUPERFICIAL_RELATIONSHIP', 35), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 66), ('INCOMPLETE_EVIDENCE', 124), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 174)]	5	"[('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 50, 'D'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_63219', ""alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer"", 146, '3-epi-25(OH)D3as'), ('PR_000006270', 'triokinase/FMN cyclase', 158, 'D3as')]"
S164-PMC4930210	PMC4930210	7/2016	S164-PMC4930210	['THUS, it APPEARS that ALTHOUGH winter uvr exposure MAY BE insufficient, VARIATIONS in summer sun exposure will alter fall 25(Oh)D concentration and THUS indirectly INFLUENCE winter Vitamin D levels.']	[('PROBABLE_UNDERSTANDING', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('ANOMALY_CURIOUS_FINDING', 22), ('INCOMPLETE_EVIDENCE', 51), ('DIFFICULT_TASK', 72), ('PROBABLE_UNDERSTANDING', 148), ('SUPERFICIAL_RELATIONSHIP', 164)]	7	[('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 122, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S168-PMC4930210	PMC4930210	7/2016	S168-PMC4930210	['WHILE the current canadian cancer society RECOMMENDATIONS [38] are to avoid sun exposure or failing that, use of sunscreen at all times when out in the sun, our participants undoubtedly were getting sunlight exposure AS SEEN by a seasonal variation in 25(Oh)D.\nin CONCLUSION, we FOUND a 20% rate of Vitamin D insufficiency (<75 nmol/l) in a large, well-nourished cohort of Pregnant women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 42), ('INCOMPLETE_EVIDENCE', 217), ('INCOMPLETE_EVIDENCE', 220), ('INCOMPLETE_EVIDENCE', 264), ('INCOMPLETE_EVIDENCE', 279)]	6	[('CHEBI_71657', 'versiconol acetate', 252, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 252, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D'), ('GO_0007565', 'female pregnancy', 373, 'pregnant')]
S32-PMC4934634	PMC4934634	11/2015	S32-PMC4934634	['BASED ON lower circulating 25(Oh)D concentrations at a given Vitamin D supplement level in obese and overweight subjects compared to normal weight subjects, ekwaru and coworkers RECENTLY RECOMMENDED that “Vitamin D supplementation be 2–3 times higher for obese subjects and 1.5 times higher for overweight subjects relative to normal weight subjects” [10].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 178), ('FUTURE_WORK', 187)]	3	[('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 27, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
S66-PMC4934634	PMC4934634	11/2015	S66-PMC4934634	[', REPORTED that 47.4% of women with recurrent Pregnancy losses (rpl), defined as three or more consecutive spontaneous Abortions before 20 weeks Gestation, had low Serum 25(Oh)D levels e.g., below 30 ng/ml, the Endocrine society cut-off for Vitamin D sufficiency status (table 1) [25].']	[('INCOMPLETE_EVIDENCE', 2)]	1	[('GO_0007565', 'female pregnancy', 46, 'pregnancy'), ('GO_0006915', 'apoptotic process', 119, 'abortions'), ('GO_0007565', 'female pregnancy', 145, 'gestation'), ('UBERON_0001977', 'blood serum', 164, 'serum'), ('CHEBI_71657', 'versiconol acetate', 170, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 170, '25(OH ... D'), ('UBERON_0005063', 'left ventricular compact myocardium', 211, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D')]
S70-PMC4934634	PMC4934634	11/2015	S70-PMC4934634	[', REPORTED that danish women (odense child cohort) with 25(Oh)D levels < 50 nmol/l (iom cut-off for Vitamin D sufficiency and endocrine society cut-off for deficiency,table 1) had a greater than 2-fold increased adjusted hazards ratio for First-Trimester Miscarriage [27].']	[('INCOMPLETE_EVIDENCE', 2)]	1	[('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 56, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007631', 'feeding behavior', 239, 'first'), ('GO_0009294', 'DNA mediated transformation', 245, 'trimester'), ('GO_0046660', 'female sex differentiation', 255, 'miscarriage')]
S97-PMC4934634	PMC4934634	11/2015	S97-PMC4934634	['IN CONTRAST TO iom RECOMMENDATIONS, the endocrine society RECOMMENDS a Vitamin D intake of AT LEAST 600 iu/day, BUT states that 1500–2000 iu/day MAY BE needed for Pregnant or Lactating females to maintain a 25(Oh)D level ≥ 30 ng/ml.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 19), ('FUTURE_WORK', 58), ('PROBABLE_UNDERSTANDING', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 145)]	6	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnant'), ('GO_0007594', 'puparial adhesion', 175, 'lactating'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D')]
S98-PMC4934634	PMC4934634	11/2015	S98-PMC4934634	['WHILE 25(Oh)D remains constant, the concentrations of total 1,25(Oh)2D and Vitamin D binding protein increase in the first to second Trimester and remain elevated until 3 months Postpartum [36].']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	"[('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 62, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 133, 'trimester'), ('GO_0007565', 'female pregnancy', 178, 'postpartum')]"
S112-PMC4934634	PMC4934634	11/2015	S112-PMC4934634	['first Trimester 25(Oh)D levels were found to be lower in women diagnosed with Gestational diabetes COMPARED TO controls, translating to a 2.6-fold increased risk of developing Gestational diabetes when Serum Vitamin D levels were ≤20 ng/ml, the iom cut-off for Vitamin D sufficiency [42].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 99)]	1	[('GO_0009294', 'DNA mediated transformation', 6, 'trimester'), ('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 22, 'D'), ('GO_0007565', 'female pregnancy', 78, 'gestational'), ('GO_0007565', 'female pregnancy', 176, 'gestational'), ('UBERON_0001977', 'blood serum', 202, 'serum'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D')]
S142-PMC4934634	PMC4934634	11/2015	S142-PMC4934634	['it SHOULD BE NOTED that OTHER STUDIES have FAILED TO CONFIRM OBSERVATIONS that lower 25(Oh)D status is ASSOCIATED with the occurrence of Preeclampsia, and it is STILL UNCLEAR WHETHER suboptimal Vitamin D status is a cause, OR an EFFECT, of preeclampsia [55,56].']	[('IMPORTANT_CONSIDERATION', 3), ('ANOMALY_CURIOUS_FINDING', 10), ('ANOMALY_CURIOUS_FINDING', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('INCOMPLETE_EVIDENCE', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 43), ('ANOMALY_CURIOUS_FINDING', 43), ('DIFFICULT_TASK', 43), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 61), ('SUPERFICIAL_RELATIONSHIP', 103), ('FULL_UNKNOWN', 161), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 175), ('SUPERFICIAL_RELATIONSHIP', 229)]	14	[('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 137, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
S160-PMC4934634	PMC4934634	11/2015	S160-PMC4934634	['combining the main comorbidities, for every 10 ng/ml increase in 25(Oh)D at Delivery, the odds ratio was reduced to 0.84 ( p = 0.006) INDICATING fewer adverse Pregnancy outcomes as maternal Vitamin D levels increased.']	[('INCOMPLETE_EVIDENCE', 134)]	1	[('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 65, '25(OH)D'), ('GO_0007567', 'parturition', 76, 'delivery'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S163-PMC4934634	PMC4934634	11/2015	S163-PMC4934634	['WHILE Serum Vitamin D levels improved in the intervention group, ONLY 15% of the women obtained levels of ≥30 ng/ml (Endocrine society cut-off for Vitamin D sufficiency) DUE to severely low baseline 25(Oh)D levels in this population (3–9 ng/ml).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 65), ('IMPORTANT_CONSIDERATION', 170), ('IMPORTANT_CONSIDERATION', 170)]	4	[('UBERON_0001977', 'blood serum', 6, 'serum'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 117, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 199, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 199, '25(OH ... D')]
S164-PMC4934634	PMC4934634	11/2015	S164-PMC4934634	['THUS, it is NOT SURPRISING that this study FOUND no effect of the Vitamin D supplementation on incidences of Preterm Birth, Preeclampsia, or small for Gestation age SINCE 23% of participants had persistent Serum 25(Oh)D below 10 ng/ml which IS CONSIDERED Vitamin D deficiency status by both the iom and endocrine society (table 1).']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 165), ('INCOMPLETE_EVIDENCE', 241)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'preterm birth'), ('GO_0007128', 'meiotic prophase I', 124, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'gestation'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S166-PMC4934634	PMC4934634	11/2015	S166-PMC4934634	[', provided Vitamin D supplement doses DEPENDING ON baseline level of Serum 25(Oh)D levels or placebo [62].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0001977', 'blood serum', 69, 'serum'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 75, '25(OH)D')]
S184-PMC4934634	PMC4934634	11/2015	S184-PMC4934634	['using dietary Intake data ALONE CAN be PROBLEMATIC SINCE uvb-induced skin Formation of Vitamin D CAN significantly alter Serum 25(Oh)D, THUS, dietary Intakes MIGHT not be a reliable INDICATOR of overall Vitamin D status.']	[('ANOMALY_CURIOUS_FINDING', 26), ('INCOMPLETE_EVIDENCE', 32), ('PROBLEM_COMPLICATION', 39), ('PROBABLE_UNDERSTANDING', 51), ('PROBLEM_COMPLICATION', 51), ('INCOMPLETE_EVIDENCE', 97), ('PROBABLE_UNDERSTANDING', 136), ('INCOMPLETE_EVIDENCE', 158), ('SUPERFICIAL_RELATIONSHIP', 182)]	9	[('GO_0007631', 'feeding behavior', 14, 'intake'), ('GO_0009057', 'macromolecule catabolic process', 74, 'formation'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('GO_0007631', 'feeding behavior', 150, 'intakes'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D')]
S199-PMC4934634	PMC4934634	11/2015	S199-PMC4934634	['ALTHOUGH Cord Blood 25(Oh)D levels were significantly higher in the supplemented children compared TO the control group, ONLY a small percentage of offspring receiving daily Vitamin D (13%) or bolus Vitamin D (3%) had Cord Blood Vitamin D levels ≥ 50 nmol/l.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 99), ('ANOMALY_CURIOUS_FINDING', 121)]	3	[('UBERON_0009472', 'axilla', 9, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 20, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 218, 'cord'), ('UBERON_0000178', 'blood', 223, 'blood'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S226-PMC4934634	PMC4934634	11/2015	S226-PMC4934634	['the long half-life and Storage Of 25(Oh)D in fat MAY pose PROBLEMS with regard to Vitamin D toxicity.']	[('INCOMPLETE_EVIDENCE', 49), ('PROBLEM_COMPLICATION', 58)]	2	[('GO_1990170', 'stress response to cadmium ion', 23, 'storage of 25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S239-PMC4934634	PMC4934634	11/2015	S239-PMC4934634	['loss of function of 24-hydroxlase (Cyp24A1), the enzyme responsible for the breakdown of 1,25(Oh)2D and 25(Oh)D, CAN increase the risk of Vitamin D toxicity due to a reduced ability to inactivate these Vitamin D Compounds in the body [86].']	[('INCOMPLETE_EVIDENCE', 113)]	1	[('PR_000006101', 'cytochrome P450 1A1', 35, 'CYP24A1'), ('CHEBI_82784', 'PVP38-Ag NP', 89, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_36357', 'polyatomic entity', 212, 'compounds')]
S253-PMC4934634	PMC4934634	11/2015	S253-PMC4934634	['also, studies powered TO DETERMINE the EFFECT of separate ethnic groups’ varying baseline Vitamin D levels on 25(Oh)D levels after different Vitamin D supplementation doses will provide more concrete INFORMATION for individualized RECOMMENDATIONS during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 39), ('INCOMPLETE_EVIDENCE', 200), ('FUTURE_WORK', 231)]	4	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 112, '(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]
S262-PMC4934634	PMC4934634	11/2015	S262-PMC4934634	['a one-time, Oral bolus of Vitamin D is an EFFECTIVE way to treat Vitamin D deficiency AS 25(Oh)D levels quickly rise following supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('PROBABLE_UNDERSTANDING', 86)]	2	[('UBERON_0000165', 'mouth', 12, 'oral'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D')]
S265-PMC4934634	PMC4934634	11/2015	S265-PMC4934634	['it is not COMPLETELY known HOW large, acute increases in circulating 25(Oh)D levels immediately following supplementation CAN AFFECT a fetus/infant, who are VULNERABLE to Vitamin D toxicity at this time in development.']	[('PROBABLE_UNDERSTANDING', 10), ('EXPLICIT_QUESTION', 27), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 126), ('IMPORTANT_CONSIDERATION', 157)]	5	[('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 69, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
S269-PMC4934634	PMC4934634	11/2015	S269-PMC4934634	[', designed a study TO DETERMINE an oral dosage of Vitamin D that would achieve a 25(Oh)D level of 75 nmol/l or greater in 97.5% of newborn, Breastfed infants by three months of age [93].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 19)]	1	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('GO_0007567', 'parturition', 140, 'breastfed')]
S280-PMC4934634	PMC4934634	11/2015	S280-PMC4934634	['a RECENT case report on an exclusively Breastfed four-month old infant receiving over the counter liquid Vitamin D supplementation SHOWED 25(Oh)D levels of 294 ng/ml, severe hypercalcemia, hypercalciuria, and nephrocalcinosis [95].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 131)]	2	[('GO_0007567', 'parturition', 39, 'breastfed'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 138, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 144, 'D')]
S306-PMC4934634	PMC4934634	11/2015	S306-PMC4934634	['WHILE the ESSENTIALITY of adequate Vitamin D during Pregnancy is not DISPUTED, CONTROVERSY exists over the RECOMMENDED dietary intake levels, the mathematical approaches to calculating that level, and the endpoints used to determine REQUIREMENTS; the concentrations of circulating 25(Oh)D that denote deficiency, insufficiency and adequacy status; and WHETHER race, body weight or OTHER factors SHOULD BE TAKEN into account when making dietary RECOMMENDATIONS, similarly, it is NOT CLEAR WHAT Vitamin D supplementation regimens are most EFFECTIVE during Pregnancy; WHETHER mother, child OR both SHOULD BE supplemented; and WHETHER there are long-term CONSEQUENCES of supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 79), ('FUTURE_WORK', 107), ('IMPORTANT_CONSIDERATION', 233), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 352), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 381), ('FUTURE_WORK', 395), ('IMPORTANT_CONSIDERATION', 405), ('FUTURE_WORK', 444), ('FULL_UNKNOWN', 478), ('EXPLICIT_QUESTION', 488), ('SUPERFICIAL_RELATIONSHIP', 537), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 565), ('FUTURE_WORK', 595), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 623), ('PROBLEM_COMPLICATION', 651)]	18	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 281, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 281, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 493, 'vitamin D'), ('GO_0007565', 'female pregnancy', 554, 'pregnancy')]
S10-PMC4944244	PMC4944244	7/2016	S10-PMC4944244	['FURTHER STUDIES NEED TO BE conducted among health care workers to determine their level of knowledge RELATED to Vitamin D, AS they are front liner in detecting the hypovitaminosis d.\n\nbackground\nmalaysia is rich with sunshine, a MAJOR source of Vitamin D. HOWEVER, a study by moy [1] among a cohort of malays SHOWED that 67.9\xa0% had insufficient Vitamin D especially in women, with Serum mean concentration of 25(Oh)D of 36.2\u2009±\u200913.4\xa0nmol/l in women and 56.2\u2009±\u200918.9\xa0nmol/l in men.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 16), ('SUPERFICIAL_RELATIONSHIP', 101), ('PROBABLE_UNDERSTANDING', 123), ('IMPORTANT_CONSIDERATION', 229), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 256), ('INCOMPLETE_EVIDENCE', 309)]	7	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 345, 'vitamin D'), ('UBERON_0001977', 'blood serum', 381, 'serum'), ('CHEBI_71657', 'versiconol acetate', 409, '25(OH)D')]
S14-PMC4944244	PMC4944244	7/2016	S14-PMC4944244	['[3] among primary school children in malaysia had SHOWN lack of Vitamin D with 70.4\xa0% having Serum 25 (Oh) D <50\xa0nmol/l.']	[('INCOMPLETE_EVIDENCE', 50)]	1	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0001977', 'blood serum', 93, 'serum'), ('CHEBI_71657', 'versiconol acetate', 99, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 99, '25 (OH) D')]
S49-PMC4944244	PMC4944244	7/2016	S49-PMC4944244	['they also underwent skin color measurement using the fitzpatrick skin type chart measurement (fstcm) and mexameter (mx) 18; weight and height measurements and Blood test for Vitamin D. hypovitaminosis D was DEFINED as Serum 25(Oh)D\u2009<\u200950\xa0nmol/l.']	[('PROBABLE_UNDERSTANDING', 207)]	1	[('UBERON_0000178', 'blood', 159, 'blood'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 201, 'D'), ('UBERON_0001977', 'blood serum', 218, 'serum'), ('CHEBI_71657', 'versiconol acetate', 224, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 224, '25(OH)D')]
S75-PMC4944244	PMC4944244	7/2016	S75-PMC4944244	['caption (table-wrap): table 1\n\nsocio-demographic, Antenatal, skin characteristics and Vitamin D intake of first trimester Pregnant women ( n \u2009=\u2009396)independent variablesnpercentmean\u2009±\u2009sd /\xa0median (iqr 25\xa0%, 75\xa0%)a) socio-demographic factors\u2003age (year)28.06\u2009±\u20094.09 (min\u2009=\u200918, max\u2009=\u200940)\u2003ethnic groups\u2003\u2003malay30777.5\u2003\u2003chinese4411.2\u2003\u2003indian358.8\u2003\u2003others102.5\u2003educational status\u2003\u2003primary school164.0\u2003\u2003secondary school14937.6\u2003\u2003tertiary school23158.4\u2003working status\u2003\u2003working30176.0\u2003\u2003not working9524.0\u2003household members3 (2,4) (min\u2009=\u20092, max\u2009=\u200912)\u2003household income per monthrm3500 (2800,5000) (min\u2009=\u2009rm900, max\u2009=\u2009rm20 000)b) factors related to Antenatal\u2003Week Of Pregnancy10 (8,12) (min\u2009=\u20094, max\u2009=\u200912)\u2003gravidity2 (1,3) (min\u2009=\u20091, max\u2009=\u20099)\u2003parity0 (0,1) (min\u2009=\u20090, max\u2009=\u20096)\u2003smoking status\u2003\u2003yes30.8\u2003\u2003no39399.2\u2003last child Birth\u2003\u2003≤ 2\xa0years12461.1\u2003\u2003>2\xa0years7938.9\u2003\u2003not applicable (first Pregnancy)193\u2003still breastfeeding\u2003\u2003yes4122.9\u2003\u2003no13879.1\u2003\u2003not applicable (no child)217\u2003body mass index (bmi) before Pregnancy(kg/m2)22.69 (19.95, 26.36) (min\u2009=\u200914.29, max\u2009=\u200953.90)\u2003weight at first Antenatal visit (kg)57.70 (49.60,68.00) (min\u2009=\u200933.00, max\u2009=\u2009148.70)c) factors related to skin\u2003fitzpatrick skin classification\u2003\u2003skin type i -ii10326.0\u2003\u2003skin type iii17343.7\u2003\u2003skin type iv-vi12030.3\u2003Melanin indices (using mexameter 18) (0-999.000)302.17 (245.00, 302.17) (min\u2009=\u2009133.33, max\u2009=\u2009949.33)\u2003sun protection score (0-8)5 (4,5) (min\u2009=\u20090, max\u2009=\u20097)\u2003the length of time exposed to sunlight (minutes per week)37.50 (0,150) (min\u2009=\u20090, max\u2009=\u20091680)d) factors related to Vitamin D intake\u2003intake of Vitamin D in Food (iu/day)202.16 (124.94, 334.62) (min\u2009=\u200913.50, max\u2009=\u20091523.12)\u2003the number of respondents taking Antenatal Supplements\u2003\u2003taking Supplements containing Vitamin D4411.1\u2003\u2003taking supplements without Vitamin D intake61.5\u2003\u2003not taking supplement34687.4\u2003Calcium and Vitamin D supplement\u2003\u2003no38697.5\u2003\u2003yes102.5\u2003intake of Vitamin D from Food and supplements (iu/day)220.04 (137.88, 376.45) (min\u2009=\u200915.10, max\u2009=\u20091523.12)\u2003the level of Vitamin D taken from Food and supplements (iu/day)\u2003\u2003<200\xa0iu/day17844.90\u2003\u2003≥200\xa0iu/day21855.10\n\ncaption (table-wrap): table 2\n\nSerum Vitamin D (25(Oh)D) concentrations among first Trimester Pregnant women ( n \u2009=\u2009396)Serum Vitamin dnpercentmedian (iqr 25\xa0%, 75\xa0%)Serum concentration of 25 (Oh)D nmol/l27.11 (19.87,36.99) (min\u2009=\u20097.50, max\u2009=\u2009121.43)Serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<25.00\xa0nmol/l17443.9\u200325-49.99\xa0nmol/l18446.5\u200350-74.99\xa0nmol/l338.3\u2003≥75\xa0nmol/l51.3serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<50\xa0nmol/l35890.4\u2003≥50\xa0nmol/l389.6\ntable\xa03shows the association between each independent variable with hypovitaminosis d. age, ethnicity, education level, fitzpatrick classification, Melanin indices, sun protection score and Intake of Vitamin D from Food have ASSOCIATION with hypovitaminosis D ( p \u2009<\u20090.05).']	[('SUPERFICIAL_RELATIONSHIP', 2779)]	1	[('GO_0007567', 'parturition', 50, 'antenatal'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant'), ('GO_0003410', 'anterior rotation of the optic cup', 634, 'antenatal Week of pregnancy10'), ('GO_0007567', 'parturition', 806, 'Birth'), ('GO_0007565', 'female pregnancy', 869, 'pregnancy'), ('GO_0007565', 'female pregnancy', 984, 'pregnancy'), ('GO_0007567', 'parturition', 1064, 'antenatal'), ('CHEBI_25179', 'melanins', 1260, 'Melanin'), ('CHEBI_27300', 'vitamin D', 1528, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1555, 'vitamin D'), ('CHEBI_33290', 'food', 1568, 'food'), ('GO_0007567', 'parturition', 1667, 'antenatal'), ('CHEBI_33341', 'titanium atom', 1677, 'supplements'), ('CHEBI_33341', 'titanium atom', 1697, 'supplements'), ('CHEBI_72741', '2-arachidonyl-sn-glycero-3-phosphoethanolamine', 1720, 'vitamin D4411'), ('CHEBI_27300', 'vitamin D', 1764, 'vitamin D'), ('CHEBI_31341', 'calcium dihydroxide', 1815, 'Calcium'), ('CHEBI_27300', 'vitamin D', 1827, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1879, 'vitamin D'), ('CHEBI_33290', 'food', 1894, 'food'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D'), ('CHEBI_33290', 'food', 2010, 'food'), ('UBERON_0001977', 'blood serum', 2114, 'Serum'), ('CHEBI_27300', 'vitamin D', 2120, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 2131, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 2131, '25 ... OH ... D'), ('GO_0009294', 'DNA mediated transformation', 2167, 'trimester'), ('GO_0007565', 'female pregnancy', 2177, 'pregnant'), ('UBERON_0001977', 'blood serum', 2203, 'Serum'), ('CHEBI_33229', 'vitamin (role)', 2209, 'vitamin'), ('UBERON_0001977', 'blood serum', 2249, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2272, '25 (OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 2272, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 2279, 'D'), ('UBERON_0001977', 'blood serum', 2333, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2356, '25 (OH) D'), ('CHEBI_71657', 'versiconol acetate', 2489, '25 (OH) D'), ('CHEBI_25179', 'melanins', 2702, 'melanin'), ('GO_0007631', 'feeding behavior', 2744, 'intake'), ('CHEBI_27300', 'vitamin D', 2754, 'vitamin D'), ('CHEBI_33290', 'food', 2769, 'food'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2812, 'D')]
S100-PMC4944244	PMC4944244	7/2016	S100-PMC4944244	['this is IN LINE WITH OUR STUDY, where the PREVALENCE of hypovitaminosis D (25 (Oh) D Serum <50\xa0nmol/l) in the first trimester was high (90.4\xa0%) and only 11.1\xa0% took supplements containing Vitamin D. moreover, most of them had just started the Supplements and the results MAY not have AFFECTED their Vitamin D status yet.']	[('INCOMPLETE_EVIDENCE', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('IMPORTANT_CONSIDERATION', 42), ('INCOMPLETE_EVIDENCE', 271), ('SUPERFICIAL_RELATIONSHIP', 284)]	5	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 72, 'D'), ('CHEBI_71657', 'versiconol acetate', 75, '25 (OH) D'), ('PR_000003010', 'moesin isoform 1', 78, '(OH ... D'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 243, 'supplements'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D')]
S104-PMC4944244	PMC4944244	7/2016	S104-PMC4944244	['in comparison, our results SHOWED a much lower prevalence of Vitamin D deficiency with 43.9\xa0% having Serum 25(Oh)D <25\xa0nmol/l (table\xa02).']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 101, 'serum'), ('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 107, '25(OH)D')]
S131-PMC4944244	PMC4944244	7/2016	S131-PMC4944244	['in order to standardize the level of Vitamin D, cut off point for Serum 25(Oh) D of <50\xa0nmol/l was used for comparison between VARIOUS STUDIES.']	[('INCOMPLETE_EVIDENCE', 127)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH) D')]
S171-PMC4944244	PMC4944244	7/2016	S171-PMC4944244	['HOWEVER, this ASSUMPTION would not be EFFECTIVE for countries with less exposure to the sun, where low education was ASSOCIATED with lower Serum 25(Oh)D, PERHAPS AS a result of less dietary intake of Vitamin D and less opportunity for sunbathing leisure and vacation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 117), ('INCOMPLETE_EVIDENCE', 154), ('PROBABLE_UNDERSTANDING', 162)]	6	[('UBERON_0001977', 'blood serum', 139, 'serum'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 145, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
S203-PMC4944244	PMC4944244	7/2016	S203-PMC4944244	['OUR STUDY SHOWED SIMILAR results where fair skin such as chinese had a higher level of Serum 25(Oh) D. initially, by using simple logistic regression analysis, the skin color type, Melanin index measurement and sun protection score SHOWED CORRELATION with Vitamin D status ( p \u2009<\u20090.05).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 232), ('SUPERFICIAL_RELATIONSHIP', 239)]	5	[('UBERON_0001977', 'blood serum', 87, 'serum'), ('CHEBI_71657', 'versiconol acetate', 93, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 93, '25(OH) D'), ('CHEBI_25179', 'melanins', 181, 'melanin'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]
S213-PMC4944244	PMC4944244	7/2016	S213-PMC4944244	['ALTHOUGH over half of respondents had met the rni for Vitamin D (≥200\xa0iu/day), many respondents STILL had Serum 25(Oh)D\u2009<\u200950\xa0nmol/l.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 96), ('IMPORTANT_CONSIDERATION', 96)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 112, '25(OH ... D')]
S217-PMC4944244	PMC4944244	7/2016	S217-PMC4944244	['[22] also CLAIMED that there was a significant difference in Serum 25(Oh)D between Pregnant women who took 400\xa0iu or more Vitamin D as Supplements during the Antenatal period and Pregnant women who took\u2009<\u2009400\xa0iu/day or none (or 0.19; 95\xa0% ci: 0.06 to 0.56, p <0.01).']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('UBERON_0001977', 'blood serum', 61, 'serum'), ('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 67, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 135, 'supplements'), ('GO_0007567', 'parturition', 158, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 158, 'antenatal'), ('GO_0007565', 'female pregnancy', 179, 'pregnant')]
S10-PMC4973215	PMC4973215	8/2016	S10-PMC4973215	['THUS, levels of neonates at Birth depend entirely on that of the mother and, ACCORDINGLY, SEVERAL STUDIES have CONSISTENTLY CORRELATED Cord Blood 25(Oh)D levels to those of their mothers.1,2,3,4,5,6in addition, maternal Vitamin D deficiency HAS BEEN LINKED to decreased fetal growth and Birth size in OBSERVATIONAL studies.7,8,9\nmaternal Vitamin D deficiency is PREVALENT, the extent of which CAN be INFLUENCED by many variables including skin pigmentation, sun exposure, season, age, Vitamin supplementation and obesity.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 77), ('INCOMPLETE_EVIDENCE', 90), ('PROBABLE_UNDERSTANDING', 111), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 250), ('INCOMPLETE_EVIDENCE', 301), ('IMPORTANT_CONSIDERATION', 362), ('INCOMPLETE_EVIDENCE', 393), ('SUPERFICIAL_RELATIONSHIP', 400)]	11	[('GO_0007567', 'parturition', 28, 'birth'), ('UBERON_0002240', 'spinal cord', 135, 'cord'), ('UBERON_0000178', 'blood', 140, 'blood'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('GO_0007567', 'parturition', 287, 'birth'), ('CHEBI_27300', 'vitamin D', 338, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 485, 'vitamin')]
S38-PMC4973215	PMC4973215	8/2016	S38-PMC4973215	['differences in the distributions of Cord Blood 25(Oh)D concentrations by race were evident (figure 1), with a higher proportion of Vitamin D-deficient samples FOUND in the black population.']	[('INCOMPLETE_EVIDENCE', 159)]	1	[('UBERON_0009472', 'axilla', 36, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 47, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S43-PMC4973215	PMC4973215	8/2016	S43-PMC4973215	['race, medicaid status, higher bmi at Delivery and lack of Prenatal vitamin use were all ASSOCIATED with Vitamin D deficiency (25(Oh)D <50\u2009nmol\u2009l−1; p<0.01).']	[('SUPERFICIAL_RELATIONSHIP', 88)]	1	[('GO_0007567', 'parturition', 37, 'delivery'), ('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D')]
S70-PMC4973215	PMC4973215	8/2016	S70-PMC4973215	"[""for white mothers, measurement of maternal Serum 25(Oh)D at <22 weeks' Gestation SHOWED a u-shaped RELATIONSHIP between Vitamin D status and risk of sga, where the highest risk for sga was SEEN with both low and high Vitamin D levels.""]"	[('INCOMPLETE_EVIDENCE', 81), ('SUPERFICIAL_RELATIONSHIP', 99), ('INCOMPLETE_EVIDENCE', 189)]	3	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 71, 'gestation'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D')]
S72-PMC4973215	PMC4973215	8/2016	S72-PMC4973215	['in a larger study, burris et al.14EXAMINED the RELATIONSHIP between second-Trimester Serum 25(Oh)D levels and sga in blacks and whites and FOUND a higher risk of sga in both Vitamin D-deficient black and white infants.']	[('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 139)]	3	[('GO_0009294', 'DNA mediated transformation', 75, 'trimester'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 91, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
S80-PMC4973215	PMC4973215	8/2016	S80-PMC4973215	['ALTHOUGH Cord Blood 25(Oh)D levels do CORRELATE to maternal levels, FACTORS that AFFECT fetal growth MAY not be uniform throughout Pregnancy and this DIFFERENCE in timing COULD AFFECT study FINDINGS.1,3,4,5,6in addition, maternal characteristics such as obesity or pre-eclampsia COULD also AFFECT results that MAY NOT HAVE BEEN SEEN IF Vitamin D samples were obtained during early Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 68), ('SUPERFICIAL_RELATIONSHIP', 81), ('INCOMPLETE_EVIDENCE', 101), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 150), ('INCOMPLETE_EVIDENCE', 171), ('SUPERFICIAL_RELATIONSHIP', 177), ('INCOMPLETE_EVIDENCE', 190), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 290), ('INCOMPLETE_EVIDENCE', 310), ('INCOMPLETE_EVIDENCE', 314), ('INCOMPLETE_EVIDENCE', 318), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 333)]	15	[('UBERON_0002240', 'spinal cord', 9, 'cord'), ('UBERON_0000178', 'blood', 14, 'blood'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 22, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D'), ('GO_0007565', 'female pregnancy', 381, 'pregnancy')]
S35-PMC4979151	PMC4979151	8/2016	S35-PMC4979151	['there is NO standard classification of Vitamin D status based on 25(Oh)D3Concentrations in Cord Blood; THUS, for the PURPOSE of the PRESENT STUDY we stratified the participants into four groups based on Serum 25(Oh)D concentrations as done earlier [20] :(1) ≥76\xa0nmol/l (high); (2) 50–75\xa0nmol/l (moderate); (3) 30–49\xa0nmol/l (low); (4) <30\xa0nmol/l (very low).']	[('FULL_UNKNOWN', 9), ('PROBABLE_UNDERSTANDING', 103), ('QUESTION_ANSWERED_BY_THIS_WORK', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 132)]	4	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_73735', 'gadoterate', 65, '25(OH)D3concentrations'), ('PR_000029608', 'DISP complex protein LRCH3', 65, '25 ... OH ... D3concentrations'), ('UBERON_0002240', 'spinal cord', 91, 'cord'), ('UBERON_0000178', 'blood', 96, 'blood'), ('UBERON_0001977', 'blood serum', 203, 'serum'), ('CHEBI_71657', 'versiconol acetate', 209, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 209, '25(OH)D')]
S177-PMC4992225	PMC4992225	8/2016	S177-PMC4992225	['caption (table-wrap): table 4\n\n25(Oh)D concentrations and depression scores in nulliparous and multiparous subgroupsvariables mean (sd)nulliparousmultiparousvitamin D groupcontrol groupn p -valuevitamin D groupcontrol groupn p -value*25(Oh)D at baseline (ng/ml)13.13(6.91)13.25 (6.55)41/510.9312.49 (9.08)9.31 (5.34)34/270.1525(Oh)D at Delivery (ng/ml)18.40 (11.38)12.49 (6.29)33/430.0116.58 (8.54)11.36 (5.47)28/250.02depression score at baseline8.41(3.52)8.73 (3.57)41/510.678.47 (4.35)8.48 (4.30)34/270.99depression score at 38-40w Gestation6.47(3.43)7.98 (3.74)38/460.065.80 (3.62)7.44 (4.28)30/270.12depression score at Postpartum (4w)4.59(3.24)7.27 (4.04)34/450.0024.60 (3.40)7.52 (4.70)30/270.01depression score at Postpartum (8w)4.18(3.79)7.24 (3.79)34/450.0014.20 (3.79)7.07 (4.37)30/270.01\n*mann–whitney u test\nwe EXAMINED the CORRELATION between change in Vitamin D concentrations and change in depression scores at 38–40 weeks of Gestation, 4 and 8 weeks Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 824), ('SUPERFICIAL_RELATIONSHIP', 837)]	2	[('CHEBI_71657', 'versiconol acetate', 31, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 31, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 203, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 203, 'D'), ('CHEBI_71657', 'versiconol acetate', 234, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 240, 'D'), ('CHEBI_33010', 'chromide(1-)', 327, '(OH)D'), ('GO_0007567', 'parturition', 336, 'delivery'), ('GO_0007565', 'female pregnancy', 535, 'gestation6'), ('GO_0007565', 'female pregnancy', 625, 'postpartum'), ('GO_0007565', 'female pregnancy', 722, 'postpartum'), ('CHEBI_27300', 'vitamin D', 867, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'gestation'), ('GO_0007565', 'female pregnancy', 967, 'postpartum')]
S156-PMC5024513	PMC5024513	9/2016	S156-PMC5024513	['the pooled mean for Vitamin D status as reflected in Blood 25 (Oh)D in THIS REVIEW was significantly below recommended levels across all trimesters.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 71)]	1	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('UBERON_0000178', 'blood', 53, 'blood'), ('CHEBI_71657', 'versiconol acetate', 59, '25 (OH)D'), ('PR_000008838', 'serine protease HTRA1', 59, '25 (OH ... D')]
S69-PMC5045784	PMC5045784	10/2016	S69-PMC5045784	['a variety of host FACTORS MAY confer altered susceptibility to bpd in preterm infants and SOME of these MAY BE Genetic and RELATED to Vitamin D bioavailability that is not REFLECTED in 25(Oh)D levels.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 90), ('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 123), ('INCOMPLETE_EVIDENCE', 172), ('SUPERFICIAL_RELATIONSHIP', 172)]	7	[('SO_0000704', 'gene', 111, 'genetic'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 185, '25(OH)D')]
S70-PMC5045784	PMC5045784	10/2016	S70-PMC5045784	['for example, common Vitamin D-related polymorphisms, in Vitamin D-binding protein or vdr LIKELY alter the bioavailable levels of 25(Oh)D.24A STUDY by koroglu et al.25EXAMINED the ROLE of the vdr variant Fok 1 in bpd risk among 109 preterm neonates but DID NOT FIND a significant change in the odds ratio.']	[('PROBABLE_UNDERSTANDING', 89), ('INCOMPLETE_EVIDENCE', 137), ('INCOMPLETE_EVIDENCE', 164), ('SUPERFICIAL_RELATIONSHIP', 179), ('INCOMPLETE_EVIDENCE', 252)]	5	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 129, '25(OH ... D'), ('PR_000007593', 'glutamate carboxypeptidase 2', 203, 'Fok 1')]
S74-PMC5045784	PMC5045784	10/2016	S74-PMC5045784	['fetal and newborn concentrations of 25(Oh)D DEPEND ON and CORRELATE with maternal Serum levels AS the fetus has no endogenous production of 25(Oh)d and DEPENDS on transplacental transfer.28THIS occurs MAINLY in the third trimester and THEREFORE, as we and others PREVIOUSLY REPORTED, preterm infants are at INCREASED RISK of Vitamin D deficiency.10,29our PRIOR STUDY DEMONSTRATED that Birth before 32 completed weeks of Gestation is an INDEPENDENT RISK FACTOR for low 25(Oh)d levels at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 58), ('PROBABLE_UNDERSTANDING', 95), ('SUPERFICIAL_RELATIONSHIP', 152), ('PROBABLE_UNDERSTANDING', 187), ('PROBABLE_UNDERSTANDING', 201), ('PROBABLE_UNDERSTANDING', 235), ('INCOMPLETE_EVIDENCE', 263), ('IMPORTANT_CONSIDERATION', 307), ('INCOMPLETE_EVIDENCE', 355), ('INCOMPLETE_EVIDENCE', 367), ('SUPERFICIAL_RELATIONSHIP', 436), ('SUPERFICIAL_RELATIONSHIP', 448)]	13	[('CHEBI_71657', 'versiconol acetate', 36, '25(OH)D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_63056', 'zinc cation', 140, '25(OH'), ('CHEBI_27300', 'vitamin D', 325, 'vitamin D'), ('GO_0007567', 'parturition', 385, 'birth'), ('GO_0007565', 'female pregnancy', 420, 'gestation'), ('CHEBI_30778', 'gallic acid', 468, '25(OH)'), ('GO_0007567', 'parturition', 486, 'birth')]
S86-PMC5045784	PMC5045784	10/2016	S86-PMC5045784	['mccarthy et al.29REPORTED that in a cohort of 274 preterm infants (<32 weeks) in ireland, levels of 25(Oh)D REMAINED under 20\u2009ng\u2009ml−1in 78% of subjects DESPITE 18 days on average of enteral Feeding and Vitamin D supplementation.29a RECENT intervention TRIAL by fort et al.17DEMONSTRATED that biochemical Vitamin D deficiency among EXTREMELY preterm infants CAN be reduced by additional supplementation with 200 units of Vitamin D daily, and PREVENTED by additional supplementation with 800 units of Vitamin D daily17and these two regimens were FOUND TO BE SAFE.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 108), ('ANOMALY_CURIOUS_FINDING', 152), ('INCOMPLETE_EVIDENCE', 232), ('PROBABLE_UNDERSTANDING', 272), ('PROBABLE_UNDERSTANDING', 272), ('IMPORTANT_CONSIDERATION', 331), ('INCOMPLETE_EVIDENCE', 357), ('SUPERFICIAL_RELATIONSHIP', 441), ('ANOMALY_CURIOUS_FINDING', 544), ('IMPORTANT_CONSIDERATION', 556)]	11	[('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 106, 'D'), ('GO_0007631', 'feeding behavior', 190, 'feeding'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 304, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D')]
S91-PMC5045784	PMC5045784	10/2016	S91-PMC5045784	['in CONCLUSION, we FOUND that low 25(Oh)D levels (<30\u2009ng\u2009ml−1) are frequent and MODIFIABLE among preterm infants at Birth, HOWEVER, in our study samples we did not detect any association between Vitamin D status and Pulmonary or other morbidities of prematurity.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 18), ('IMPORTANT_CONSIDERATION', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 122)]	4	[('CHEBI_71657', 'versiconol acetate', 33, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 39, 'D'), ('GO_0007567', 'parturition', 115, 'birth'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('UBERON_0002048', 'lung', 215, 'pulmonary')]
S92-PMC5045784	PMC5045784	10/2016	S92-PMC5045784	"[""the CURRENT PRACTICE of TARGETING nutritional Intake of 400\u2009iu per day Vitamin D is sufficient to achieve Serum 25(Oh)D levels >30\u2009ng\u2009ml−1at 36 weeks' corrected age.""]"	[('INCOMPLETE_EVIDENCE', 4), ('FUTURE_WORK', 24)]	2	[('GO_0007631', 'feeding behavior', 46, 'intake'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 112, '25(OH)D')]
S71-PMC5062906	PMC5062906	10/2016	S71-PMC5062906	['results\n\ndietary depletion of circulating Plasma 25(Oh)D is DEPENDENT on Genetic background\nTO DETERMINE the extent of Vitamin D depletion in g0dams Fed diet lacking Vitamin d (lvd) compared with dams on control diet (con) (fig.']	[('SUPERFICIAL_RELATIONSHIP', 60), ('QUESTION_ANSWERED_BY_THIS_WORK', 92)]	2	[('UBERON_0001969', 'blood plasma', 42, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('SO_0000704', 'gene', 73, 'genetic'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0007631', 'feeding behavior', 149, 'fed'), ('CHEBI_33229', 'vitamin (role)', 166, 'vitamin')]
S251-PMC5062906	PMC5062906	10/2016	S251-PMC5062906	['our data HIGHLIGHT two mechanisms that CONTRIBUTE to interindividual DIFFERENCES in response to Vitamin D deficiency: the Genetic INFLUENCE on maternal Plasma depletion of 25(Oh)D and the INFLUENCE of parent and grandparent of origin in the extent of Vitamin D-DEPENDENT developmental and epigenetic outcomes.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 39), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 69), ('SUPERFICIAL_RELATIONSHIP', 130), ('SUPERFICIAL_RELATIONSHIP', 188), ('SUPERFICIAL_RELATIONSHIP', 261)]	6	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('SO_0000704', 'gene', 122, 'genetic'), ('UBERON_0001969', 'blood plasma', 152, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 172, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
S30-PMC5064894	PMC5064894	10/2016	S30-PMC5064894	['similarly, a decrease in parent-reported ari was NOTED in children in mongolia given Vitamin D-fortified Milk (300\xa0iu of Vitamin D3) [23], in a setting in which children had very low baseline Serum 25 (Oh) D levels.']	[('ANOMALY_CURIOUS_FINDING', 49)]	1	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('UBERON_0001913', 'milk', 105, 'milk'), ('CHEBI_33279', 'vitamin D5', 121, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 121, 'vitamin D3'), ('UBERON_0001977', 'blood serum', 192, 'serum'), ('CHEBI_71657', 'versiconol acetate', 198, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 198, '25 (OH) D')]
S35-PMC5064894	PMC5064894	10/2016	S35-PMC5064894	['HOWEVER, the researchers identified multiple LIMITATIONS in their study including lack OF blinding of participants and subjective outcomes, SMALL sample size and LIMITED statistical power, and dosages of Vitamin D that lead to ONLY 13\xa0% of the daily group and 3\xa0% of the bolus group having Cord Serum 25 (Oh) D levels considered to be in a sufficient range.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 45), ('ANOMALY_CURIOUS_FINDING', 87), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 162), ('ANOMALY_CURIOUS_FINDING', 227)]	6	[('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 290, 'cord'), ('UBERON_0001977', 'blood serum', 295, 'serum'), ('CHEBI_71657', 'versiconol acetate', 301, '25 (OH) D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 305, 'OH ... D')]
S10-PMC5084041	PMC5084041	10/2016	S10-PMC5084041	['the DETERMINANTS of season-corrected change in 25(Oh)D were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake, Vitamin D supplementation and recent travel <35° n. in CONCLUSION, season-corrected 25(Oh)D concentration increased during Pregnancy and DEPENDED PARTLY on lifestyle FACTORS.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 188), ('SUPERFICIAL_RELATIONSHIP', 270), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 299)]	5	[('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('GO_0007601', 'visual perception', 72, 'seeking'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 133, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 141, 'D'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 256, 'pregnancy')]
S22-PMC5084041	PMC5084041	10/2016	S22-PMC5084041	['SINCE data on Gestational Vitamin D status in populations living at latitudes without seasonality in cutaneous Vitamin D Synthesis are SCARCE, a season-corrected analysis is a way of investigating changes in 25(Oh)D during Pregnancy per se.']	[('PROBLEM_COMPLICATION', 0), ('INCOMPLETE_EVIDENCE', 135)]	2	[('GO_0007565', 'female pregnancy', 14, 'gestational'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 111, 'vitamin D synthesis'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('GO_0007565', 'female pregnancy', 223, 'pregnancy')]
S23-PMC5084041	PMC5084041	10/2016	S23-PMC5084041	['such analyses of 25(Oh)D concentrations during Pregnancy SHOW that Vitamin D status between early and late Pregnancy tracks moderately and that change DEPENDS ON supplement use, Gestational weight gain and physical activity [12].']	[('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 151)]	2	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH)D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('GO_0007565', 'female pregnancy', 178, 'gestational')]
S96-PMC5084041	PMC5084041	10/2016	S96-PMC5084041	['in a multivariable logistic regression analysis, DETERMINANTS relating to odds of 25(Oh)D concentrations <30 nmol/l at t1 were of non-north european origin, sampling in spring, never exposing skin when sunny, no Vitamin D supplementation, lower dietary Vitamin D intake and lower age (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 49)]	1	[('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D')]
S97-PMC5084041	PMC5084041	10/2016	S97-PMC5084041	['among the subgroup ( n = 316) of women Born in africa and asia, DETERMINANTS of 25(Oh)D concentrations <30 nmol/l were not taking Vitamin D supplements, never exposing skin when sunny and lower age (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('GO_0007567', 'parturition', 39, 'born'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S106-PMC5084041	PMC5084041	10/2016	S106-PMC5084041	['a season-corrected analysis of change in 25(Oh)D SHOWED that the DETERMINANTS of change in 25(Oh)D during Pregnancy were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake at t3, Vitamin D supplementation at t3 and having travelled to <35° n in the past six months (adjusted r2= 0.186) (table 3).']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 65)]	2	[('CHEBI_71657', 'versiconol acetate', 41, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 47, 'D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0007601', 'visual perception', 133, 'seeking'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
S107-PMC5084041	PMC5084041	10/2016	S107-PMC5084041	['Gestational weight gain, bmi and age were not significantly associated with change in 25(Oh)D. in the subgroup of women Born in africa and asia, only Vitamin D supplementation at t3 was a DETERMINANT of season-corrected change in Vitamin D status during Pregnancy (adjusted r2= 0.115) (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 188)]	1	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007567', 'parturition', 120, 'born'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]
S116-PMC5084041	PMC5084041	10/2016	S116-PMC5084041	['RISK FACTORS for Vitamin D deficiency (25(Oh)D <30 nmol/l) in early Pregnancy were IN LINE WITH PREVIOUS FINDINGS [13,17,27].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 83), ('INCOMPLETE_EVIDENCE', 96)]	3	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 39, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy')]
S124-PMC5084041	PMC5084041	10/2016	S124-PMC5084041	['in OUR STUDY, the proportion of women using Vitamin D supplements was SIMILAR at t1 and t3, but IT IS POSSIBLE that supplement use CONTRIBUTED to the increase in 25(Oh)D if supplementation was initiated shortly before t1.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 70), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 131)]	4	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 162, '25(OH)D')]
S138-PMC5084041	PMC5084041	10/2016	S138-PMC5084041	['moon et al SHOWED that Vitamin D supplementation is RELATED to changes in 25(Oh)D between the first and the third trimester, which SUPPORTS OUR FINDINGS [12].']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 52), ('INCOMPLETE_EVIDENCE', 131), ('QUESTION_ANSWERED_BY_THIS_WORK', 140)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D')]
S18-PMC5085625	PMC5085625	9/2016	S18-PMC5085625	['HERE, it is hydroxylated to 25(Oh)D, a major form of Vitamin D found in the Blood.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('UBERON_0000178', 'blood', 76, 'blood')]
S19-PMC5085625	PMC5085625	9/2016	S19-PMC5085625	['Blood concentration of 25(Oh)D REFLECTS actual content of Vitamin D in the Human body [7].']	[('SUPERFICIAL_RELATIONSHIP', 31)]	1	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 75, 'human')]
S22-PMC5085625	PMC5085625	9/2016	S22-PMC5085625	['according TO the Endocrine society, insufficiency and deficiency of Vitamin D are DEFINED as concentrations of 25(Oh)D equal to 20–30 ng/ml and <20 ng/ml, respectively.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('PROBABLE_UNDERSTANDING', 82)]	2	[('UBERON_0005063', 'left ventricular compact myocardium', 17, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 111, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 117, 'D')]
S44-PMC5085625	PMC5085625	9/2016	S44-PMC5085625	['HOWEVER, deficiency of Vitamin D (concentration 25(Oh)D <20 ng/ml) was RECOGNIZED in as many as 45.6% patients participating in the study.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 71)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 51, 'OH ... D')]
S68-PMC5085625	PMC5085625	9/2016	S68-PMC5085625	['taking into account INCONCLUSIVE results of cross-sectional and cohort studies analyzing the ASSOCIATION between Vitamin D status and occurrence of Pregnancy pathologies [28,29], the AIM of OUR STUDY was to asses 25(Oh)D status in women with Gestational hypertension (gh).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('SUPERFICIAL_RELATIONSHIP', 93), ('QUESTION_ANSWERED_BY_THIS_WORK', 183), ('QUESTION_ANSWERED_BY_THIS_WORK', 190)]	4	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('GO_0007565', 'female pregnancy', 242, 'gestational')]
S90-PMC5085625	PMC5085625	9/2016	S90-PMC5085625	['ACCORDING to barebring et al., AT LEAST a 30 nmol/l increase in Serum 25(Oh)D concentration is ASSOCIATED with lower odds of pe, REGARDLESS OF Vitamin D status in early Pregnancy [13].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('PROBABLE_UNDERSTANDING', 31), ('SUPERFICIAL_RELATIONSHIP', 95), ('INCOMPLETE_EVIDENCE', 129)]	4	[('UBERON_0001977', 'blood serum', 64, 'serum'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy')]
S110-PMC5085625	PMC5085625	9/2016	S110-PMC5085625	['owing the POTENTIAL CONTRIBUTION of an altered Vitamin D Metabolism to diabetes mellitus, we compared Serum concentrations of 25(Oh)D in patients with type 1 and 2 gdm (gdm g1 and gdm g2) and healthy controls.']	[('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 20)]	2	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 47, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 102, 'serum'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D')]
S86-PMC5095257	PMC5095257	11/2016	S86-PMC5095257	['verifying Vitamin D deficiency and aad risk by ascertaining 25 (Oh)D status in infancy, HOWEVER, will be difficult given the RARITY of the condition and the fact that diagnosis is USUALLY made in Individuals in their third to fifth decade.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 88), ('DIFFICULT_TASK', 125), ('INCOMPLETE_EVIDENCE', 180)]	3	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25 (OH)D'), ('NCBITaxon_1', 'root', 196, 'individuals')]
S4-PMC5129897	PMC5129897	10/2016	S4-PMC5129897	['we used 25(Oh)D concentration–health outcome RELATIONS for Breast cancer and Cardiovascular disease and results of clinical trials with Vitamin D for Respiratory infections and Musculoskeletal disorders to ESTIMATE the reductions in disease BURDEN for increased 25(Oh)D concentrations.']	[('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 206), ('IMPORTANT_CONSIDERATION', 241)]	3	[('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 14, 'D'), ('UBERON_0000310', 'breast', 59, 'breast'), ('UBERON_0004535', 'cardiovascular system', 77, 'cardiovascular'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 150, 'respiratory'), ('UBERON_0002204', 'musculoskeletal system', 177, 'musculoskeletal'), ('CHEBI_71657', 'versiconol acetate', 262, '25(OH)D')]
S8-PMC5129897	PMC5129897	10/2016	S8-PMC5129897	['introduction\nduring the past 15\xa0years, CONSIDERABLE INTEREST in the health BENEFITS of Vitamin D has emerged BECAUSE People with higher ultraviolet-b (uvb) exposure and/or 25-Hydroxyvitamin D [25(Oh)D] concentrations have lower RISK of many diseases and conditions.1our analysis is LIMITED to the diseases with the greatest economic EFFECT and the STRONGEST evidence of PROTECTIVE ROLES of Vitamin D—namely, cancer, Cardiovascular disease (cvd), dementia, diabetes mellitus (dm), falls and fractures, multiple sclerosis (ms), and Respiratory Tract infections.']	[('ANOMALY_CURIOUS_FINDING', 39), ('IMPORTANT_CONSIDERATION', 52), ('INCOMPLETE_EVIDENCE', 52), ('IMPORTANT_CONSIDERATION', 75), ('PROBABLE_UNDERSTANDING', 109), ('IMPORTANT_CONSIDERATION', 228), ('INCOMPLETE_EVIDENCE', 282), ('SUPERFICIAL_RELATIONSHIP', 333), ('INCOMPLETE_EVIDENCE', 348), ('SUPERFICIAL_RELATIONSHIP', 370), ('SUPERFICIAL_RELATIONSHIP', 381)]	11	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 117, 'people'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 172, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 390, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 416, 'cardiovascular'), ('UBERON_0000065', 'respiratory tract', 530, 'respiratory tract')]
S16-PMC5129897	PMC5129897	10/2016	S16-PMC5129897	['NEITHER ASSUMPTION holds for Vitamin D. robert heaney OUTLINED the GUIDELINES for Nutrient studies including Vitamin D. the most RELEVANT features are that one SHOULD start with an understanding of the 25(Oh)D concentration–health outcome RELATION, 25(Oh)D concentrations SHOULD BE measured in prospective participants, ONLY those with low concentrations SHOULD BE enrolled, sufficient Vitamin D SHOULD BE given to raise 25(Oh)D concentrations to where a significant beneficial EFFECT is expected, and achieved 25(Oh)D concentrations SHOULD BE measured.2until those steps are followed routinely, FEW Vitamin D clinical TRIALS will report beneficial EFFECTS.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 8), ('INCOMPLETE_EVIDENCE', 54), ('IMPORTANT_CONSIDERATION', 67), ('PROBABLE_UNDERSTANDING', 67), ('IMPORTANT_CONSIDERATION', 129), ('FUTURE_WORK', 160), ('SUPERFICIAL_RELATIONSHIP', 239), ('FUTURE_WORK', 272), ('INCOMPLETE_EVIDENCE', 320), ('FUTURE_WORK', 355), ('FUTURE_WORK', 396), ('SUPERFICIAL_RELATIONSHIP', 478), ('FUTURE_WORK', 534), ('INCOMPLETE_EVIDENCE', 596), ('FUTURE_WORK', 619), ('SUPERFICIAL_RELATIONSHIP', 649)]	17	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_33284', 'nutrient', 82, 'nutrient'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 202, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 249, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 386, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 421, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 427, 'D'), ('CHEBI_71657', 'versiconol acetate', 511, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 517, 'D'), ('CHEBI_27300', 'vitamin D', 600, 'vitamin D')]
S23-PMC5129897	PMC5129897	10/2016	S23-PMC5129897	['the PURPOSE of THIS NEW STUDY is to revisit Vitamin D concentrations of canadians and to ESTIMATE the economic BENEFIT of increasing 25(Oh)D concentrations, with the knowledge that overall 25(Oh)D concentrations have gone down since our PREVIOUS STUDY.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('FULL_UNKNOWN', 20), ('INCOMPLETE_EVIDENCE', 89), ('IMPORTANT_CONSIDERATION', 111), ('INCOMPLETE_EVIDENCE', 237)]	6	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 139, 'D'), ('CHEBI_71657', 'versiconol acetate', 189, '25(OH)D')]
S27-PMC5129897	PMC5129897	10/2016	S27-PMC5129897	['materials and methods\npublications on the RELATIONS between 25(Oh)D concentrations and health outcomes were obtained LARGELY by searchingpubmed.govandscholar.google.comfor terms such as Vitamin D, 25-Hydroxyvitamin D, meta-analysis, Back and Spine disorders, cancer, Cardiovascular disease, Immune System, osteoporosis, Respiratory infection, economic BURDEN, canada, cost, season, mortality, incidence , and risk .']	[('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 117), ('IMPORTANT_CONSIDERATION', 352)]	3	[('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 60, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 197, '25-hydroxyvitamin D'), ('UBERON_0001137', 'dorsum', 233, 'back'), ('UBERON_0001013', 'adipose tissue', 242, 'spine'), ('UBERON_0004535', 'cardiovascular system', 267, 'cardiovascular'), ('UBERON_0002405', 'immune system', 291, 'immune system'), ('UBERON_0001004', 'respiratory system', 320, 'respiratory')]
S70-PMC5129897	PMC5129897	10/2016	S70-PMC5129897	['a meta-analysis of Lung cancer incidence versus 25(Oh)D concentration at the time of enrollment FOUND that relative risk decreased from 1.0 at 20\xa0nmol/l to 0.86 at 40\xa0nmol/l and 0.84 at 50\xa0nmol/l, after which the 95% confidence intervals became very large.47most of the 13 studies were prospective studies with long follow-up times, and ONE STUDY involved smokers who had taken large doses of Vitamin A, which MAY have AFFECTED cancer risk since it competes with Vitamin D.50thus, doubling the calculated change in relative risk to 0.72 at 40\xa0nmol/l and 0.68 at 50\xa0nmol/l and higher SEEMS REASONABLE.']	[('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 337), ('INCOMPLETE_EVIDENCE', 410), ('SUPERFICIAL_RELATIONSHIP', 419), ('ANOMALY_CURIOUS_FINDING', 583), ('PROBABLE_UNDERSTANDING', 583), ('PROBABLE_UNDERSTANDING', 589)]	7	[('UBERON_0002048', 'lung', 19, 'lung'), ('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 48, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 54, 'D'), ('CHEBI_27300', 'vitamin D', 393, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 463, 'vitamin D')]
S78-PMC5129897	PMC5129897	10/2016	S78-PMC5129897	['a clinical trial involving 8- to 12-year-old schoolchildren in japan receiving 1200 iu/d of Vitamin D3Found a significant reduction in incidence of type a influenza for those who had not been taking Vitamin D supplements (relative risk = 0.36 [95% ci, 0.17–0.79]).33a study in mongolia involving children near 10\xa0y of age with a baseline 25(Oh)D concentration of 18\xa0nmol/l (95% ci, 13–25\xa0nmol/l) FOUND that giving them a loading dose of Vitamin D3Followed by 300 iu/d of Vitamin D, which raised the 25(Oh)D concentration to 47\xa0nmol/l (95% ci, 39–57\xa0nmol/l), resulted in a 3-month adjusted relative risk of acute Respiratory Tract infections (aris) of 0.50 (95% ci, 0.28–0.88).34that study SHOWS that People with low 25(Oh)D concentrations have significant reductions in aris with modest increases in 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 396), ('INCOMPLETE_EVIDENCE', 689)]	2	[('CHEBI_59712', 'squarate', 92, 'vitamin D3found'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 92, 'vitamin D3found'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 338, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 338, '25(OH)D'), ('CHEBI_83261', 'pyribencarb', 437, 'vitamin D3followed'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 499, '25(OH)D'), ('UBERON_0000065', 'respiratory tract', 612, 'respiratory tract'), ('NCBITaxon_10088', 'Mus <genus>', 700, 'people'), ('CHEBI_71657', 'versiconol acetate', 716, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 800, '25(OH)D')]
S82-PMC5129897	PMC5129897	10/2016	S82-PMC5129897	['a comparison during september–october FOUND a relative risk of clinical Upper Respiratory Tract infection of 0.79 (95% ci, 0.61–1.03; p = 0.09) for 258 students taking 10,000 iu/wk of Vitamin D3, compared with 234 students taking a placebo.58ALTHOUGH that study DID NOT measure 25(Oh)D concentrations, it INDICATES that young canadians taking the equivalent of 1400 iu/d of Vitamin D had a marginally nonsignificantly reduced risk of Upper Respiratory Tract infections.']	[('INCOMPLETE_EVIDENCE', 38), ('ANOMALY_CURIOUS_FINDING', 240), ('INCOMPLETE_EVIDENCE', 262), ('INCOMPLETE_EVIDENCE', 305)]	4	[('UBERON_0001557', 'upper respiratory tract', 72, 'upper respiratory tract'), ('CHEBI_33279', 'vitamin D5', 184, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 184, 'vitamin D3'), ('CHEBI_71657', 'versiconol acetate', 278, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 284, 'D'), ('CHEBI_27300', 'vitamin D', 374, 'vitamin D'), ('UBERON_0001557', 'upper respiratory tract', 434, 'upper respiratory tract')]
S112-PMC5129897	PMC5129897	10/2016	S112-PMC5129897	['a prospective study in korea FOUND that incidence of depressive symptoms was increased for those Individuals with 25(Oh)D concentrations <50\xa0nmol/l compared with those with >50\xa0nmol/l if they had Serum Total Cholesterol levels of < 240\xa0mg/dl (odds ratio [or] = 1.60 [95% ci, 1.23–2.08]) but NOT for those with Serum Total Cholesterol >240\xa0ng/dl (or = 0.97 [95% ci, 0.52–1.81]) after adjustment for confounding variables.75a study in italy conducted a clinical trial with Vitamin D for outpatients of mean age 74 ± 6\xa0years with mdd being treated with antidepressant therapy.76at the start of the 4-week trial, mean hamilton depression rating scale scores were 21.1 for the treated cases and 21.5 for the comparison subjects.']	[('INCOMPLETE_EVIDENCE', 29), ('ANOMALY_CURIOUS_FINDING', 291)]	2	[('NCBITaxon_1', 'root', 97, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 114, '25(OH)D'), ('UBERON_0001977', 'blood serum', 196, 'serum'), ('CHEBI_15891', 'taurine', 202, 'total'), ('CHEBI_16113', 'cholesterol', 208, 'cholesterol'), ('UBERON_0001977', 'blood serum', 310, 'serum'), ('CHEBI_66254', 'topopyrone C', 316, 'total cholesterol'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D')]
S117-PMC5129897	PMC5129897	10/2016	S117-PMC5129897	"[""the annual economic BURDEN of crohn's disease in canada is $1.7\xa0billion, WHEREAS that of ulcerative colitis is $1.2\xa0billion.78several papers HAVE REPORTED inverse CORRELATIONS between Vitamin D status and incidence, prevalence, and/or severity of Inflammatory Bowel disease.79,80\nEVIDENCE is mounting that higher 25(Oh)D concentrations are ASSOCIATED with BETTER Pregnancy and Birth outcomes.""]"	[('IMPORTANT_CONSIDERATION', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('INCOMPLETE_EVIDENCE', 141), ('SUPERFICIAL_RELATIONSHIP', 163), ('INCOMPLETE_EVIDENCE', 280), ('SUPERFICIAL_RELATIONSHIP', 340), ('IMPORTANT_CONSIDERATION', 356)]	7	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001782', 'pigmented layer of retina', 247, 'inflammatory bowel'), ('CHEBI_71657', 'versiconol acetate', 313, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 319, 'D'), ('GO_0007565', 'female pregnancy', 363, 'pregnancy'), ('GO_0007567', 'parturition', 377, 'birth')]
S118-PMC5129897	PMC5129897	10/2016	S118-PMC5129897	"[""“the CURRENTLY AVAILABLE results INDICATE that Vitamin D supplementation during Pregnancy reduces the RISK of Preterm Birth, low Birth weight, Dental caries of infancy, and neonatal infectious diseases such as Respiratory infections and sepsis.”81furthermore, with UNFOLDING RESEARCH into fetal origins of pediatric and Adult disease, EVIDENCE increasingly INDICATES that Gestational Vitamin D indices MAY determine health in later Life.82for example, an INTERESTING cohort study CORRELATING maternal Vitamin D levels at 18\xa0weeks' Pregnancy and health outcomes of progeny FOUND that Gestational Vitamin D deficiency was ASSOCIATED with a higher risk of impaired Lung Development in 6-year-old offspring, Neurocognitive difficulties at age 10\xa0years, increased risk of Eating disorders in Adolescence, and lower peak bone mass at 20\xa0y.83\na RECENT STUDY CONCLUDED that Vitamin D is reduces exacerbations of asthma.84\n\nall-cause mortality rate\ngarland and colleagues85presented a meta-analysis of 32 prospective observational studies that investigated all-cause mortality rate with respect to 25(Oh)D concentration at time of enrollment.""]"	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 33), ('IMPORTANT_CONSIDERATION', 102), ('INCOMPLETE_EVIDENCE', 265), ('INCOMPLETE_EVIDENCE', 335), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 402), ('ANOMALY_CURIOUS_FINDING', 455), ('SUPERFICIAL_RELATIONSHIP', 480), ('INCOMPLETE_EVIDENCE', 572), ('SUPERFICIAL_RELATIONSHIP', 620), ('INCOMPLETE_EVIDENCE', 838), ('INCOMPLETE_EVIDENCE', 851)]	13	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0007565', 'female pregnancy', 110, 'preterm'), ('GO_0007567', 'parturition', 118, 'birth'), ('GO_0007567', 'parturition', 129, 'birth'), ('UBERON_0001091', 'calcareous tooth', 143, 'dental'), ('UBERON_0001004', 'respiratory system', 210, 'respiratory'), ('UBERON_0007023', 'adult organism', 320, 'adult'), ('GO_0007565', 'female pregnancy', 372, 'gestational'), ('CHEBI_27300', 'vitamin D', 384, 'vitamin D'), ('UBERON_0000104', 'life cycle', 432, 'life'), ('CHEBI_27300', 'vitamin D', 501, 'vitamin D'), ('GO_0007565', 'female pregnancy', 531, 'pregnancy'), ('GO_0007565', 'female pregnancy', 583, 'gestational'), ('CHEBI_27300', 'vitamin D', 595, 'vitamin D'), ('GO_0030324', 'lung development', 662, 'lung development'), ('UBERON_0002048', 'lung', 662, 'lung'), ('GO_0050905', 'neuromuscular process', 704, 'neurocognitive'), ('GO_0051318', 'G1 phase', 767, 'eating'), ('GO_0048848', 'neurohypophysis morphogenesis', 787, 'adolescence'), ('CHEBI_27300', 'vitamin D', 866, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1089, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1089, '25(OH ... D')]
S150-PMC5129897	PMC5129897	10/2016	S150-PMC5129897	['estimate of reduction in economic BURDEN in canada if all inhabitants had 25(Oh)D concentrations >100\xa0nmol/l after several years.outcometotal economic burden in 2016 ($b)reduction due to improving Vitamin D status (%)reduction in economic BURDEN due to improving Vitamin D status ($b)deaths in canada in 201139reduction in deaths, using deaths for 2011cancer7.3151.172,47610,870cvd24.6143.460,9108530dementia16.271.110,000700dm15.7182.871941290ms3.7401.5500 ref.92200osteoporosis (Hip fractures)5.0221.1\xa0\xa0respiratory infections6.1251.557671440total78.615.912.5156,84723,030\nnote: total deaths in canada in 2011 were 242,07488\n$b, billions of dollars; cvd, cardiovascular disease; dm, diabetes mellitus; ms, multiple sclerosis.']	[('IMPORTANT_CONSIDERATION', 34), ('IMPORTANT_CONSIDERATION', 239)]	2	[('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 74, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 263, 'vitamin D'), ('UBERON_0001464', 'hip', 481, 'hip')]
S151-PMC5129897	PMC5129897	10/2016	S151-PMC5129897	['as with all ESTIMATES, these have uncertainties, including the 25(Oh)D concentration–health outcome RELATIONS used; the ESTIMATES of economic BURDENS; whether reducing risk of specific diseases would translate into the same fraction of economic BURDEN; the extent to which changing risk-modifying risk factors such as smoking, alcohol Consumption, diet, and obesity modify the relative reduction due to higher 25(Oh)D concentration; and that the analysis omitted several Vitamin D–sensitive diseases and conditions BECAUSE of LIMITED UNDERSTANDING of the EFFECTS.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 100), ('INCOMPLETE_EVIDENCE', 120), ('IMPORTANT_CONSIDERATION', 142), ('IMPORTANT_CONSIDERATION', 245), ('PROBLEM_COMPLICATION', 515), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 555)]	8	[('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 63, '25(OH)D'), ('GO_0007631', 'feeding behavior', 335, 'consumption'), ('CHEBI_71657', 'versiconol acetate', 410, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D')]
S158-PMC5129897	PMC5129897	10/2016	S158-PMC5129897	['the ESTIMATES intable\xa09SHOW a POTENTIAL large BENEFIT of improving Vitamin D status in terms of reduction in economic BURDEN ($12.5billion) and premature deaths (23,000/yr) ON THE BASIS OF the types of disease for which EVIDENCE IS STRONG that higher 25(Oh)D concentrations have beneficial EFFECTS.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 30), ('IMPORTANT_CONSIDERATION', 46), ('IMPORTANT_CONSIDERATION', 118), ('INCOMPLETE_EVIDENCE', 173), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 290)]	8	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 251, '25(OH)D')]
S161-PMC5129897	PMC5129897	10/2016	S161-PMC5129897	['those ESTIMATES are SIMILAR TO those in the PREVIOUS PAPER on THIS topic, which ESTIMATED that if the 25(Oh)D concentration of all canadians were raised from a mean value of 67\xa0nmol/l to 105\xa0nmol/l, the death rate could fall by 37,000 (22,300–52,300 deaths), REPRESENTING 16.1% (9.7%–22.7%) of annual deaths, and the economic BURDEN could fall by 6.9% (3.8%–10.0%), or $14.4\xa0billion ($8.0\xa0billion–$20.1\xa0billion).89that paper CONSIDERED HOW Vitamin D AFFECTS cancer, cvd, dm, falls and fractures, Heart disease, influenza and pneumonia, ms, and septicemia as well as Pregnancy and Birth outcomes.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 53), ('QUESTION_ANSWERED_BY_THIS_WORK', 62), ('INCOMPLETE_EVIDENCE', 80), ('PROBABLE_UNDERSTANDING', 259), ('IMPORTANT_CONSIDERATION', 326), ('INCOMPLETE_EVIDENCE', 425), ('EXPLICIT_QUESTION', 436), ('SUPERFICIAL_RELATIONSHIP', 450)]	11	[('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 440, 'vitamin D'), ('UBERON_0000948', 'heart', 496, 'heart'), ('GO_0007565', 'female pregnancy', 566, 'pregnancy'), ('GO_0007567', 'parturition', 580, 'birth')]
S168-PMC5129897	PMC5129897	10/2016	S168-PMC5129897	['for some intermediate situations, such as cancer, survival rates are better with higher 25(Oh)D concentrations.12,93thus, EVEN IF all canadians achieved concentrations of > 100\xa0nmol/l immediately, the beneficial EFFECTS would accrue slowly, PERHAPS over 10–20\xa0y because for many health outcomes, the beneficial EFFECTS of Vitamin D are much stronger for PREVENTION than for treatment.']	[('ANOMALY_CURIOUS_FINDING', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('SUPERFICIAL_RELATIONSHIP', 212), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 311), ('SUPERFICIAL_RELATIONSHIP', 354)]	6	[('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 94, 'D'), ('CHEBI_27300', 'vitamin D', 322, 'vitamin D')]
S176-PMC5129897	PMC5129897	10/2016	S176-PMC5129897	['the results of observational studies are GENERALLY not well-SUPPORTED by clinical trials of Vitamin D supplementation.94the primary REASON for that lack OF support SEEMS TO be that the trials were NOT WELL DESIGNED, being based LARGELY on the guidelines for Pharmaceutical Drugs RATHER than for Nutrients.2another WORRISOME POINT is that clinical trials have BEEN much more successful when baseline 25(Oh)D concentrations were low.']	[('PROBABLE_UNDERSTANDING', 41), ('INCOMPLETE_EVIDENCE', 60), ('PROBABLE_UNDERSTANDING', 132), ('ANOMALY_CURIOUS_FINDING', 153), ('ANOMALY_CURIOUS_FINDING', 164), ('INCOMPLETE_EVIDENCE', 197), ('INCOMPLETE_EVIDENCE', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 279), ('IMPORTANT_CONSIDERATION', 314), ('IMPORTANT_CONSIDERATION', 324), ('ANOMALY_CURIOUS_FINDING', 359)]	11	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_52217', 'pharmaceutical', 258, 'pharmaceutical'), ('CHEBI_23888', 'drug', 273, 'drugs'), ('CHEBI_33284', 'nutrient', 295, 'nutrients'), ('CHEBI_71657', 'versiconol acetate', 399, '25(OH)D')]
S177-PMC5129897	PMC5129897	10/2016	S177-PMC5129897	['for example, 50% of the clinical trials with baseline 25(Oh)D concentration <50\xa0nmol/l FOUND beneficial EFFECTS of Vitamin D on BIOMARKERS of inflammation, WHEREAS ONLY 26% of those with higher baseline 25(Oh)D concentrations did.3the DIFFERENT results with respect to baseline 25(Oh)D concentration MAY BE DUE TO the LIMITED accuracy of clinical trials but COULD also be DUE TO CONSIDERABLY less BENEFIT for those with 25(Oh)D concentrations above 50\xa0nmol/l.']	[('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 128), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156), ('ANOMALY_CURIOUS_FINDING', 156), ('ANOMALY_CURIOUS_FINDING', 164), ('INCOMPLETE_EVIDENCE', 164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('INCOMPLETE_EVIDENCE', 300), ('PROBLEM_COMPLICATION', 307), ('INCOMPLETE_EVIDENCE', 318), ('INCOMPLETE_EVIDENCE', 358), ('PROBLEM_COMPLICATION', 372), ('ANOMALY_CURIOUS_FINDING', 379), ('IMPORTANT_CONSIDERATION', 397)]	15	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 203, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 203, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 278, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 284, 'D'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D')]
S192-PMC5129897	PMC5129897	10/2016	S192-PMC5129897	['one was a meta-analysis of observational studies.104the OTHER was a study of cancer incidence by occupation in nordic countries.49\n\nconclusions\nmany People living in canada do not have OPTIMAL 25(Oh)D concentrations AS a result of limited solar uvb exposure and/or not obtaining enough Vitamin D from Food or supplements.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('IMPORTANT_CONSIDERATION', 185), ('PROBABLE_UNDERSTANDING', 216)]	3	[('NCBITaxon_10088', 'Mus <genus>', 149, 'people'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 193, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 294, 'D'), ('CHEBI_33290', 'food', 301, 'food')]
S41-PMC5146866	PMC5146866	12/2016	S41-PMC5146866	['THEREFORE, the total level of cb Vitamin D measured in THIS STUDY is equal to [25(Oh)D3] levels, which is the main contributor to the [25(Oh)D] pool.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 55)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_62946', 'ammonium sulfate', 79, '25(OH)D3'), ('CHEBI_71657', 'versiconol acetate', 135, '25(OH)D')]
S42-PMC5146866	PMC5146866	12/2016	S42-PMC5146866	['data presentation and statistical analyses\nthe results of [25(Oh) D] were analyzed as a continuous variable and were also stratified with respect to the aap’s definition of Vitamin D status [8,9] AS severe (<5\xa0ng/ml) or mild/moderate deficient (5–15\xa0ng/ml), insufficient (16–20\xa0ng/ml), and sufficient (21–100\xa0ng/ml).']	[('PROBABLE_UNDERSTANDING', 196)]	1	[('CHEBI_71657', 'versiconol acetate', 59, '25(OH) D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]
S0-PMC5155676	PMC5155676	12/2016	S0-PMC5155676	['DETERMINANTS of the maternal 25-Hydroxyvitamin D response to Vitamin D supplementation during Pregnancy\n\nabstract\n\ncontext:\ncurrent approaches to Antenatal Vitamin D supplementation do NOT ACCOUNT for interindividual differences in 25-Hydroxyvitamin D (25(Oh)D) response.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 185)]	2	"[('CHEBI_27844', ""2',3'-cyclic AMP"", 29, '25-Hydroxyvitamin D'), ('CHEBI_28384', 'vitamin K', 61, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 61, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'Pregnancy'), ('GO_0007567', 'parturition', 146, 'antenatal'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 232, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 253, '25(OH)D')]"
S17-PMC5155676	PMC5155676	12/2016	S17-PMC5155676	['NONETHELESS, the institute of medicine (iom) has SUGGESTED that risk of Vitamin D insufficiency, DEFINED as a 25(Oh)D less than 50 nmol/l, SHOULD BE avoided during Pregnancy (5), and this is SUPPORTED by the RECENT global consensus on the prevention of rickets (6).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 49), ('PROBABLE_UNDERSTANDING', 97), ('FUTURE_WORK', 139), ('INCOMPLETE_EVIDENCE', 191), ('INCOMPLETE_EVIDENCE', 208)]	6	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('GO_0007565', 'female pregnancy', 164, 'pregnancy')]
S20-PMC5155676	PMC5155676	12/2016	S20-PMC5155676	['ALTHOUGH Vitamin D supplementation CAN improve maternal 25(Oh)D status (10), LITTLE IS KNOWN about HOW maternal characteristics MIGHT INFLUENCE the 25(Oh)d achieved after supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 35), ('FULL_UNKNOWN', 77), ('EXPLICIT_QUESTION', 99), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 134)]	6	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 148, '25(OH)')]
S21-PMC5155676	PMC5155676	12/2016	S21-PMC5155676	['in nonpregnant Adults, baseline 25(Oh)D concentration, body weight/adiposity and age are IMPORTANT DETERMINANTS of the incremental rise in 25(Oh)D after Vitamin D supplementation (13,14).']	[('IMPORTANT_CONSIDERATION', 89), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('UBERON_0007023', 'adult organism', 15, 'adults'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 38, 'D'), ('CHEBI_30778', 'gallic acid', 139, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 145, 'D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S24-PMC5155676	PMC5155676	12/2016	S24-PMC5155676	['we THEREFORE undertook THIS STUDY TO DETERMINE maternal characteristics ASSOCIATED with achieved 25(Oh)D after Antenatal Vitamin D supplementation in the context of a double-blind, randomized, placebo-controlled trial.']	[('PROBABLE_UNDERSTANDING', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 34), ('SUPERFICIAL_RELATIONSHIP', 72)]	4	[('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 103, 'D'), ('GO_0007567', 'parturition', 111, 'antenatal'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S75-PMC5155676	PMC5155676	12/2016	S75-PMC5155676	['percentage of women achieving Vitamin D replete status (>50 nmol/l) according to randomization group and season of Deliveryseason of Deliveryplacebo1000 iu/d Cholecalciferol p comparing randomization groupswinter (december–may)13.975.0<.001summer (june–november)54.290.1<.001 p comparing seasons<.001<.001\n\ndeterminants of maternal 25(Oh)D at 34 weeks of Gestation\nin univariate analysis, maternal age, baseline 25(Oh)D, season of Delivery and compliance with study Medication were significantly ASSOCIATED with 34 week 25(Oh)D in both the Placebo and Vitamin D supplementation groups (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 496)]	1	[('CHEBI_28384', 'vitamin K', 30, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 30, 'Vitamin D'), ('GO_0006260', 'DNA replication', 115, 'DeliverySeason'), ('GO_0006260', 'DNA replication', 133, 'DeliveryPlacebo1000'), ('CHEBI_16113', 'cholesterol', 158, 'Cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 332, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 355, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 412, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 415, 'OH ... D'), ('GO_0007567', 'parturition', 431, 'delivery'), ('CHEBI_60211', 'compound Z', 466, 'medication'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 520, '25(OH)D'), ('CHEBI_26130', 'biological pigment', 540, 'placebo'), ('CHEBI_27300', 'vitamin D', 552, 'vitamin D')]
S82-PMC5155676	PMC5155676	12/2016	S82-PMC5155676	['in multiple linear regression analysis, maternal factors significantly ASSOCIATED with greater 25(Oh)D at 34 weeks of Gestation in the Vitamin D supplementation group were lower Pregnancy weight gain (kg) (β = −0.81; 95% confidence interval [ci] −1.39, −0.22; p = .007), higher compliance (%) (β = 0.28; 95%ci 0.072, 0.48; p = .008), higher early Pregnancy 25(Oh)D (nmol/l) (β = 0.28; 95%ci 0.16, 0.40; p< .001), and summer Delivery (summer vs winter) (β = 10.51; 95%ci 6.40, 14.63; p< .001) (figure 2a).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_71657', 'versiconol acetate', 95, '25(OH)D'), ('GO_0007565', 'female pregnancy', 118, 'gestation'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('GO_0007565', 'female pregnancy', 347, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 357, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 357, '25(OH)D'), ('GO_0007567', 'parturition', 424, 'delivery')]
S84-PMC5155676	PMC5155676	12/2016	S84-PMC5155676	['when achievement of Vitamin D replete status at 34 weeks of Gestation was considered INSTEAD of absolute 25(Oh)D concentration, in multivariate analyses, Delivery in summer (relative risk [rr] = 1.20; 95%ci 1.09, 1.33; p< .001), white ethnicity (rr = 1.27; 95%ci 1.17, 1.37; p< .001), greater compliance with Medication (%) (rr = 1.01; 95%ci 1.00, 1.02; p = .03), and greater early Pregnancy 25(Oh)D concentration (nmol/l) (rr = 1.003; 95%ci 1.001, 1.006; p = .007) were significantly ASSOCIATED with achieving 25(Oh)D >50 nmol/l in the women randomized to Cholecalciferol.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('SUPERFICIAL_RELATIONSHIP', 485)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 111, 'D'), ('GO_0007567', 'parturition', 154, 'delivery'), ('CHEBI_60211', 'compound Z', 309, 'medication'), ('GO_0007565', 'female pregnancy', 382, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 392, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 511, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 511, '25(OH)D'), ('CHEBI_52550', 'theopalauamide', 557, 'cholecalciferol')]
S95-PMC5155676	PMC5155676	12/2016	S95-PMC5155676	['the maternal characteristics ASSOCIATED with 25(Oh)D at 34 weeks of Gestation and achieving Vitamin D replete status were SIMILAR TO those observed in the whole cohort.']	[('SUPERFICIAL_RELATIONSHIP', 29), ('INCOMPLETE_EVIDENCE', 122)]	2	[('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 51, 'D'), ('GO_0007565', 'female pregnancy', 68, 'gestation'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S97-PMC5155676	PMC5155676	12/2016	S97-PMC5155676	['this dose achieved Vitamin D repletion in over 80% of women, without leading to 25(Oh)D levels POTENTIALLY ASSOCIATED with Vitamin D toxicity (at least within the included baseline of 25–100 nmol/l 25(Oh)D).']	[('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 107)]	2	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 198, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 198, '25(OH ... D')]
S98-PMC5155676	PMC5155676	12/2016	S98-PMC5155676	['however, gaining less weight during Pregnancy, having a higher 25(Oh)D in early Pregnancy, Delivering in summer and having higher compliance with supplementation were INDEPENDENTLY ASSOCIATED with achieving a greater 25(Oh)D concentration in late Pregnancy among women randomized to Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 167), ('SUPERFICIAL_RELATIONSHIP', 181)]	2	[('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 63, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0006900', 'vesicle budding from membrane', 91, 'delivering'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 247, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
S99-PMC5155676	PMC5155676	12/2016	S99-PMC5155676	['THUS, those women who are AT RISK of Vitamin D insufficiency in early Pregnancy, gain greater weight, and Deliver in winter MIGHT NEED supplementation with a higher dose of Cholecalciferol to achieve SIMILAR 25(Oh)D concentrations.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 26), ('INCOMPLETE_EVIDENCE', 124), ('IMPORTANT_CONSIDERATION', 130), ('SUPERFICIAL_RELATIONSHIP', 200)]	5	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007567', 'parturition', 106, 'deliver'), ('CHEBI_52550', 'theopalauamide', 173, 'cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 214, 'D')]
S105-PMC5155676	PMC5155676	12/2016	S105-PMC5155676	['metaanalysis of Vitamin D supplementation STUDIES has SUGGESTED that over 50% of the variance in 25(Oh)D increment in response to supplementation is explained by body weight (13).']	[('INCOMPLETE_EVIDENCE', 42), ('INCOMPLETE_EVIDENCE', 54)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 103, 'D')]
S109-PMC5155676	PMC5155676	12/2016	S109-PMC5155676	['HOWEVER, IMPORTANTLY, when using a 25(Oh)D more than 50 nmol/l as a cut-point for repletion, Pregnancy weight gain was not an independent predictor of achieving Vitamin D repletion.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9)]	3	[('CHEBI_71657', 'versiconol acetate', 35, '25(OH)D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S112-PMC5155676	PMC5155676	12/2016	S112-PMC5155676	['HOWEVER, it is NOTABLE that there were marked DIFFERENCES in baseline 25(Oh)D concentrations between these investigations, and we OBSERVED that initial 25(Oh)D status was positively ASSOCIATED with both the LIKELIHOOD of achieving Vitamin D replete status and absolute 25(Oh)D status at 34 weeks of Gestation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 46), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 182), ('PROBABLE_UNDERSTANDING', 207)]	7	[('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 76, 'D'), ('CHEBI_63056', 'zinc cation', 152, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('GO_0007565', 'female pregnancy', 299, 'gestation')]
S113-PMC5155676	PMC5155676	12/2016	S113-PMC5155676	['IMPORTANTLY, the difference between the 25(Oh)D achieved at 34 weeks of Gestation in women randomized to Placebo compared with Cholecalciferol decreased with increasing baseline 25(Oh)D. this is CONSISTENT with PREVIOUS STUDIES in Adults, which HAVE SHOWN that the incremental response to Vitamin D supplementation is higher in Vitamin D insufficient than replete subjects (13,14) and that the increase in 25(Oh)D relative to supplementation dose is negatively ASSOCIATED with dose of vitamin D supplement (26).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 195), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 461)]	5	[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('GO_0007565', 'female pregnancy', 72, 'gestation'), ('CHEBI_26130', 'biological pigment', 105, 'placebo'), ('CHEBI_52550', 'theopalauamide', 127, 'cholecalciferol'), ('CHEBI_33010', 'chromide(1-)', 180, '(OH)D'), ('UBERON_0007023', 'adult organism', 231, 'adults'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 493, 'D')]
S115-PMC5155676	PMC5155676	12/2016	S115-PMC5155676	['this mechanism MIGHT be IMPORTANT in preventing hypervitaminosis D. HOWEVER, studies comparing the effectiveness of DIFFERING doses of Vitamin D in Pregnancy HAVE SHOWN that 4000 iu/d CAN achieve a higher 25(Oh)D than 400 iu/d (10,28), BUT WHETHER these higher doses are of clinical benefit is YET to be DEMONSTRATED (4,29) and at the general population level, lower doses would be compatible with keeping 25(Oh)D below a concentration which MIGHT be concerning.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 240), ('ANOMALY_CURIOUS_FINDING', 294), ('INCOMPLETE_EVIDENCE', 304), ('INCOMPLETE_EVIDENCE', 442)]	11	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 65, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 205, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 211, 'D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D')]
S118-PMC5155676	PMC5155676	12/2016	S118-PMC5155676	['hollis et al SIMILARLY FOUND that EVEN with 4000 iu/d Vitamin D during Pregnancy, african-american women had lower 25(Oh)D in late Pregnancy than caucasian or hispanic women (10).']	[('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 23), ('ANOMALY_CURIOUS_FINDING', 34)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 121, 'D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]
S120-PMC5155676	PMC5155676	12/2016	S120-PMC5155676	['maternal age was also positively ASSOCIATED in univariate analyses with 25(Oh)D achieved at 34 weeks of Gestation in women who received Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 33)]	1	[('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('GO_0007565', 'female pregnancy', 104, 'gestation'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S123-PMC5155676	PMC5155676	12/2016	S123-PMC5155676	['data from healthy and hospitalized Adults have SIMILARLY SHOWN that older Individuals achieve a higher 25(Oh)D after Vitamin D supplementation (13,32).']	[('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 47)]	2	[('UBERON_0007023', 'adult organism', 35, 'adults'), ('NCBITaxon_1', 'root', 74, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 105, '('), ('PR_000006444', 'diacylglycerol kinase delta', 109, 'D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S127-PMC5155676	PMC5155676	12/2016	S127-PMC5155676	['as baseline 25(Oh)D was ASSOCIATED with the LIKELIHOOD of achieving Vitamin D replete status, it is LIKELY that women with very low levels of 25(Oh)D at baseline will require a higher supplementation dose to achieve Vitamin D repletion.']	[('SUPERFICIAL_RELATIONSHIP', 24), ('PROBABLE_UNDERSTANDING', 44), ('PROBABLE_UNDERSTANDING', 100)]	3	[('CHEBI_71657', 'versiconol acetate', 12, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 144, '(OH)D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]
S132-PMC5155676	PMC5155676	12/2016	S132-PMC5155676	['it HAS BEEN demonstrated PREVIOUSLY that the incremental rise in 25(Oh)D after supplementation DIFFERS by Single Nucleotide Polymorphisms in Vitamin D Binding Protein (33,34) and 25-hydroxylase Genes (33).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 25), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95)]	3	[('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 65, '25(OH ... D'), ('SO_0000694', 'SNP', 106, 'single nucleotide polymorphisms'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 141, 'vitamin D binding protein'), ('SO_0000704', 'gene', 194, 'genes')]
S136-PMC5155676	PMC5155676	12/2016	S136-PMC5155676	['FUTURE STUDIES SHOULD AIM to determine appropriate doses to enable consistent repletion of 25(Oh)D during Pregnancy, and OUR FINDINGS SUPPORT the NOTION that clinical approaches to Vitamin D repletion MAY BE informed by individual characteristics.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 121), ('INCOMPLETE_EVIDENCE', 134), ('INCOMPLETE_EVIDENCE', 146), ('INCOMPLETE_EVIDENCE', 201)]	6	[('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 93, '(OH ... D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S44-PMC5310660	PMC5310660	1/2017	S44-PMC5310660	['in ireland, a higher prevalence of Vitamin D deficiency (25(Oh)D <27.5 nmol/l) was OBSERVED in Pregnant than in nonpregnant women, both in spring (44% vs. 18%) and in winter (35% vs 29%) [15].']	[('INCOMPLETE_EVIDENCE', 83)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('GO_0007565', 'female pregnancy', 95, 'pregnant')]
S46-PMC5310660	PMC5310660	1/2017	S46-PMC5310660	['in the usa, in winter and spring, a Vitamin D deficiency (25(Oh)D <37 nmol/l) was FOUND in 5% of new mothers and in 9.7% of their newborns [16].']	[('INCOMPLETE_EVIDENCE', 82)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D')]
S47-PMC5310660	PMC5310660	1/2017	S47-PMC5310660	['in italy, low Vitamin D levels (25(Oh)D<25 nmol/l) were FOUND in 18% of new mothers and in 38% of their newborns [17].']	[('INCOMPLETE_EVIDENCE', 56)]	1	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D')]
S16-PMC5340372	PMC5340372	3/2017	S16-PMC5340372	['measurements of Vitamin D Serum level 25-Hydroxyvitamin D [25(Oh)D] have yielded CONFLICTING results regarding the RELATIONSHIP between maternal- or Cord-Blood levels and subsequent Asthma Development [6–15].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 81), ('SUPERFICIAL_RELATIONSHIP', 115)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 38, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 59, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 149, 'cord'), ('UBERON_0000178', 'blood', 154, 'blood'), ('GO_0035801', 'adrenal cortex development', 182, 'asthma development')]
S93-PMC5340372	PMC5340372	3/2017	S93-PMC5340372	['ALTHOUGH a circulating level of 25(Oh)D less than 20 ng/ml is DEFINED AS Vitamin D deficiency [27,28], the mean levels MAY VARY among DIFFERENT populations [29].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 62), ('PROBABLE_UNDERSTANDING', 70), ('INCOMPLETE_EVIDENCE', 119), ('DIFFICULT_TASK', 123), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 134)]	6	[('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 38, 'D'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S117-PMC5340372	PMC5340372	3/2017	S117-PMC5340372	['in THIS STUDY, infants with low 25(Oh)D had higher rrs BUT SIMILAR vmaxfrc, which IMPLIES that low Perinatal Vitamin D levels MIGHT be ASSOCIATED with a higher resistance of the Extrathoracic Airway.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('ANOMALY_CURIOUS_FINDING', 55), ('SUPERFICIAL_RELATIONSHIP', 59), ('PROBABLE_UNDERSTANDING', 82), ('INCOMPLETE_EVIDENCE', 126), ('SUPERFICIAL_RELATIONSHIP', 135)]	6	[('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('GO_0036268', 'swimming', 99, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 99, 'perinatal'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('UBERON_0001601', 'extra-ocular muscle', 178, 'extrathoracic airway')]
S70-PMC5371920	PMC5371920	3/2017	S70-PMC5371920	['for example, maternal 25(oh)-Vitamin D [25(Oh)D] status INFLUENCES offspring bone mass at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 56)]	1	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('GO_0007567', 'parturition', 90, 'birth')]
S135-PMC5371920	PMC5371920	3/2017	S135-PMC5371920	['IN CONTRAST, 25(Oh)D concentrations in mothers allocated to Vitamin D supplementation rose REGARDLESS OF season of Delivery.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 91)]	2	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 19, 'D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007567', 'parturition', 115, 'delivery')]
S17-PMC5405075	PMC5405075	4/2017	S17-PMC5405075	['ALTHOUGH 25(Oh)D circulating levels do not substantially differentiate or MAY BE reduced compared to non-Pregnant women, Serum concentrations of Vitamin D active Metabolite, 1,25(Oh)2D, are significantly elevated from early Pregnancy (13,14).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 74)]	2	"[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 162, 'metabolite'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 176, '25(OH)2D'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy')]"
S19-PMC5405075	PMC5405075	4/2017	S19-PMC5405075	['it SHOULD BE NOTICED that high Maternal Intake of 25(Oh)D or exceeding Vitamin D Serum levels during Pregnancy is not COMPLICATED from either hypercalcemia or hypercalciuria (16).']	[('IMPORTANT_CONSIDERATION', 3), ('ANOMALY_CURIOUS_FINDING', 13), ('DIFFICULT_TASK', 118)]	3	[('GO_0007618', 'mating', 31, 'maternal'), ('GO_0007631', 'feeding behavior', 40, 'intake'), ('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0001977', 'blood serum', 81, 'serum'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]
S34-PMC5405075	PMC5405075	4/2017	S34-PMC5405075	['maternal Vitamin D status and ASSOCIATIONS with asthma in early Life\nthe PUTATIVE EFFECT of Prenatal exposure to Vitamin D on asthmatic phenotypes in early Life has been initially investigated via observational studies based on either maternal dietary Intake of Vitamin D or 25(Oh)D levels in Venous maternal and/or Cord Blood [reviewed in ref.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('PROBABLE_UNDERSTANDING', 73), ('SUPERFICIAL_RELATIONSHIP', 82)]	3	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0000104', 'life cycle', 64, 'Life'), ('GO_0007565', 'female pregnancy', 92, 'prenatal'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('UBERON_0000104', 'life cycle', 156, 'life'), ('GO_0007631', 'feeding behavior', 252, 'intake'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 275, '25(OH)D'), ('UBERON_0001638', 'vein', 293, 'venous'), ('UBERON_0002240', 'spinal cord', 316, 'cord'), ('UBERON_0000178', 'blood', 321, 'blood')]
S38-PMC5405075	PMC5405075	4/2017	S38-PMC5405075	['CONSEQUENTLY, longitudinal studies measuring 25(Oh)D levels, a POSSIBLE more objective INDICATOR of Vitamin D status, were DESIGNED TO explore the POSSIBLE IMPACT of Vitamin D on asthma-like symptoms or asthma.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 87), ('QUESTION_ANSWERED_BY_THIS_WORK', 123), ('QUESTION_ANSWERED_BY_THIS_WORK', 132), ('INCOMPLETE_EVIDENCE', 147), ('SUPERFICIAL_RELATIONSHIP', 156)]	7	[('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 47, '('), ('PR_000006444', 'diacylglycerol kinase delta', 51, 'D'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D')]
S52-PMC5405075	PMC5405075	4/2017	S52-PMC5405075	['DESPITE that there was no difference preserved in the offspring’s 25(Oh)D level at the age of 18months, a statistically significant lower proportion of children, belonged to Vitamins D groups, were sensitized to Mite Antigens, as indicated by specific Ige measurements.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 66, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamins D'), ('CHEBI_46662', 'mineral', 212, 'mite'), ('NCBITaxon_10088', 'Mus <genus>', 212, 'mite'), ('CHEBI_59132', 'antigen', 217, 'antigens'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 252, 'IgE')]
S5-PMC5418719	PMC5418719	5/2017	S5-PMC5418719	['Vitamin D intake of 800\xa0iu/day SAFELY achieved an 88% PROBABILITY of Vitamin D sufficiency at 36\xa0weeks Postmenstrual age in vlbw infants with Cord-blood levels of 25(Oh)D\u2009≥\u200910\xa0ng/ml, and 65% PROBABILITY of Vitamin D sufficiency was OBSERVED in infants with 25 Ohd concentrations\u2009<\u200910\xa0ng/ml at Birth.']	[('IMPORTANT_CONSIDERATION', 31), ('PROBABLE_UNDERSTANDING', 54), ('PROBABLE_UNDERSTANDING', 191), ('INCOMPLETE_EVIDENCE', 232)]	4	"[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0008283', 'cell proliferation', 103, 'postmenstrual'), ('UBERON_0002240', 'spinal cord', 142, 'cord'), ('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 163, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 257, '25 OHD'), ('GO_0007567', 'parturition', 293, 'birth')]"
S14-PMC5418719	PMC5418719	5/2017	S14-PMC5418719	['ALTHOUGH the incidence of Vitamin D insufficiency in preterm infants varies according TO DIFFERENT geographical locations, mean Serum 25(Oh)D levels during 1–3 days after Birth in preterm infants ranges from 9.5 to 25\xa0ng/ml in both europe and western world [4–7].']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 86), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 89)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0001977', 'blood serum', 128, 'serum'), ('CHEBI_71657', 'versiconol acetate', 134, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 134, '25(OH ... D'), ('GO_0007567', 'parturition', 171, 'birth')]
S16-PMC5418719	PMC5418719	5/2017	S16-PMC5418719	['WHILE Breast Milk Feeding is currently RECOMMENDED as a source of early nutrition in full and preterm infants, an infant diet with Breast Milk alone does not contain enough Vitamin D. the definition of Vitamin D sufficiency in preterm infants is STILL CONTROVERSIAL; optimal Vitamin D status is BASED ON the Vitamin D concentrations for multiple health outcomes in Adults with a target value for 25(Oh)D levels >30\xa0ng/ml [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 39), ('IMPORTANT_CONSIDERATION', 246), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 252), ('QUESTION_ANSWERED_BY_THIS_WORK', 295), ('SUPERFICIAL_RELATIONSHIP', 295)]	6	[('UBERON_0001348', 'brown adipose tissue', 6, 'breast milk'), ('GO_0007614', 'short-term memory', 13, 'milk'), ('GO_0007631', 'feeding behavior', 18, 'feeding'), ('UBERON_0001348', 'brown adipose tissue', 131, 'breast milk'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 275, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D'), ('UBERON_0007023', 'adult organism', 365, 'adults'), ('CHEBI_71657', 'versiconol acetate', 396, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 396, '25(OH ... D')]
S19-PMC5418719	PMC5418719	5/2017	S19-PMC5418719	['the AIM of THIS STUDY was TO DETERMINE WHETHER daily Vitamin D supplementation with a high dose of 800\xa0iu is SAFE and EFFECTIVE to increase the proportion of vlbw infants with 25(Oh)D\u2009>\u200930\xa0ng/ml, from 2\xa0weeks of age until hospital discharge.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 39), ('IMPORTANT_CONSIDERATION', 109), ('SUPERFICIAL_RELATIONSHIP', 118)]	6	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 176, '25(OH)D')]
S33-PMC5418719	PMC5418719	5/2017	S33-PMC5418719	['we determined the efficacy and SAFETY of early supplementation with 800\xa0iu Vitamin D.\n\noutcome measures\nthe primary outcome measured the proportion of Vitamin D sufficiency (>30\xa0ng/ml) at 32 and 36\xa0weeks pma and was analyzed by Cord Blood 25(Oh)D levels (<10\xa0ng/ml versus\u2009≥\u200910\xa0ng/ml) at Birth.']	[('IMPORTANT_CONSIDERATION', 31)]	1	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('UBERON_0009472', 'axilla', 228, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 239, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 239, '25(OH)D'), ('GO_0007567', 'parturition', 287, 'birth')]
S35-PMC5418719	PMC5418719	5/2017	S35-PMC5418719	['the 25(Oh)D cutoff of 30\xa0ng/ml was chosen based on the earlier STUDY, in which this level was considered to be Vitamin D sufficiency [9].']	[('INCOMPLETE_EVIDENCE', 63)]	1	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 10, 'D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
S70-PMC5418719	PMC5418719	5/2017	S70-PMC5418719	['HOWEVER, neonates Born during the Vitamin D Synthesis period, from april to october (20 neonates, 69%), had higher 25(Oh)D concentrations in Cord Blood samples than those not Born during the Vitamin D Synthesis period (7 neonates, 35%; p \u2009=\u20090.023; table\xa01).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0)]	2	[('GO_0007567', 'parturition', 18, 'born'), ('CHEBI_28384', 'vitamin K', 34, 'Vitamin D'), ('GO_0042358', 'thiamine diphosphate catabolic process', 34, 'Vitamin D synthesis'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 121, 'D'), ('UBERON_0002240', 'spinal cord', 141, 'cord'), ('UBERON_0000178', 'blood', 146, 'blood'), ('GO_0007567', 'parturition', 175, 'born'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 191, 'vitamin D synthesis')]
S77-PMC5418719	PMC5418719	5/2017	S77-PMC5418719	['caption (table-wrap): table 2\n\nVitamin D statusvariablecord 25(Oh)D concentrations <10\xa0ng/mlcord 25(Oh)D concentrations ≥10\xa0ng/ml p at Birth\u2003n2029\u2003Serum 25(Oh)D levels8.3\u2009±\u20091.921.4\u2009±\u20098.5<0.001\u2003Vitamin D sufficiency (>30\xa0ng/ml)0 (0%)5 (17%)0.0732\u2009±\u20091\xa0weeks Postmenstrual age\u2003n1318\u2003Serum 25(Oh)d levels15.3\u2009±\u200910.124.1\u2009±\u20099.30.05\u2003Vitamin D sufficiency (>30\xa0ng/ml)3 (23%)4 (22%)1.0036\u2009±\u20091\xa0weeks Postmenstrual age\u2003n1726\u2003Serum 25(Oh)D levels43.1\u2009±\u200920.357.7\u2009±\u200921.90.03\u2003Vitamin D sufficiency (>30\xa0ng/ml)11 (65%)23 (88%)0.12\ndata are presented as n (%), median (range), or mean\u2009±\u2009sd\ntable\xa03presents the levels of Serum calcium, Phosphorous, alkaline phosphatase level at Birth, 32\u2009±\u20091\xa0weeks pma, and 36\u2009±\u20091\xa0weeks pma as MARKERS of Vitamin D status.']	[('SUPERFICIAL_RELATIONSHIP', 710)]	1	[('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('GO_0007567', 'parturition', 135, 'birth'), ('UBERON_0001977', 'blood serum', 147, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 153, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 153, '25(OH)D'), ('CHEBI_28384', 'vitamin K', 193, 'Vitamin D'), ('GO_0008283', 'cell proliferation', 256, 'postmenstrual'), ('UBERON_0001977', 'blood serum', 280, 'Serum'), ('CHEBI_63056', 'zinc cation', 286, '25(OH'), ('CHEBI_28384', 'vitamin K', 326, 'Vitamin D'), ('GO_0008283', 'cell proliferation', 390, 'postmenstrual'), ('UBERON_0001977', 'blood serum', 414, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 420, '25(OH)D'), ('CHEBI_28384', 'vitamin K', 461, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 603, 'serum'), ('CHEBI_30207', 'phosphorus(.)', 618, 'phosphorous'), ('GO_0007567', 'parturition', 661, 'birth'), ('CHEBI_27300', 'vitamin D', 721, 'vitamin D')]
S90-PMC5418719	PMC5418719	5/2017	S90-PMC5418719	['among vlbw infants with 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml at Birth, none had an excess level of 25(Oh)D >80\xa0ng/ml after 800\xa0iu Vitamin D supplementation, ALTHOUGH 35% of infants with Vitamin D deficiency from Birth were still Vitamin D insufficient at 36\xa0weeks pma.']	[('ANOMALY_CURIOUS_FINDING', 154)]	1	[('CHEBI_71657', 'versiconol acetate', 24, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 30, 'D'), ('GO_0007567', 'parturition', 61, 'birth'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 102, 'D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('GO_0007567', 'parturition', 209, 'birth'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S92-PMC5418719	PMC5418719	5/2017	S92-PMC5418719	['WHILE the use of 800\xa0iu/d of Vitamin D achieved Serum 25(Oh)D concentrations to the ADEQUATE range of 30–80\xa0ng/ml without toxicity at 36\xa0weeks pma, this dose MAY STILL be too low to restore Vitamin D stores for the MAJORITY of infants with 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml at Birth.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 84), ('INCOMPLETE_EVIDENCE', 158), ('IMPORTANT_CONSIDERATION', 162), ('PROBABLE_UNDERSTANDING', 215)]	5	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('UBERON_0001977', 'blood serum', 48, 'serum'), ('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('GO_0007567', 'parturition', 277, 'birth')]
S97-PMC5418719	PMC5418719	5/2017	S97-PMC5418719	['serial measurements of Serum 25(Oh)D to evaluate Vitamin D status during hospitalization MAY HELP to identify preterm infants AT RISK of Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 89), ('FUTURE_WORK', 93), ('IMPORTANT_CONSIDERATION', 126)]	3	[('UBERON_0001977', 'blood serum', 23, 'serum'), ('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 29, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S101-PMC5418719	PMC5418719	5/2017	S101-PMC5418719	['preterm infants with radiologic evidence of rickets or high alkaline phosphatase (>800\xa0iu/l) are GENERALLY given the upper intake total of 800\xa0iu/day of Vitamin D. DESPITE Vitamin D supplementation, it is DIFFICULT to maintain the RECOMMENDED daily Vitamin D intake from dietary in preterm infants, and there are FEW EVIDENCE-based data to support Vitamin D supplementation to meet a desired Serum 25(Oh)D ACCORDING to Vitamin D status at Birth in preterm infants.']	[('PROBABLE_UNDERSTANDING', 97), ('ANOMALY_CURIOUS_FINDING', 164), ('DIFFICULT_TASK', 205), ('FUTURE_WORK', 231), ('INCOMPLETE_EVIDENCE', 313), ('SUPERFICIAL_RELATIONSHIP', 406)]	6	[('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin D'), ('UBERON_0001977', 'blood serum', 392, 'serum'), ('CHEBI_71657', 'versiconol acetate', 398, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 401, 'OH ... D'), ('CHEBI_27300', 'vitamin D', 419, 'vitamin D'), ('GO_0007567', 'parturition', 439, 'birth')]
S103-PMC5418719	PMC5418719	5/2017	S103-PMC5418719	['CONSISTENT with PREVIOUS reports about a dose-response EFFECT of Vitamin D supplementation [2,23], we OBSERVED that early supplementation with 800\xa0iu Vitamin D safely achieved an 88% PROBABILITY of Vitamin D sufficiency at 36 pma in the MAJORITY of infants with Cord-Blood levels of 25(Oh)D\u2009≥\u200910\xa0ng/ml.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 102), ('PROBABLE_UNDERSTANDING', 183), ('PROBABLE_UNDERSTANDING', 237)]	6	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 262, 'cord'), ('UBERON_0000178', 'blood', 267, 'blood'), ('CHEBI_71657', 'versiconol acetate', 283, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 283, '25(OH ... D')]
S107-PMC5418719	PMC5418719	5/2017	S107-PMC5418719	['HOWEVER, RECOMMENDED oral Vitamin D supplementation to attain adequate Serum 25(Oh)D concentrations has not been recognized in vlbw infants with underlying level of Vitamin D deficiency from Birth.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 9)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0001977', 'blood serum', 71, 'serum'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 83, 'D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007567', 'parturition', 191, 'birth')]
S110-PMC5418719	PMC5418719	5/2017	S110-PMC5418719	['a randomized controlled trial in 100 infants with Gestational age between 23 and 27\xa0weeks DEMONSTRATED that the 800\xa0iu/d dose of Vitamin D supplementation PREVENTED Vitamin D deficiency, without toxicity, with concentrations above the desired 25(Oh)D range of 20–60\xa0ng/ml in the majority of infants on day 28 [2].']	[('INCOMPLETE_EVIDENCE', 90), ('SUPERFICIAL_RELATIONSHIP', 155)]	2	[('GO_0007565', 'female pregnancy', 50, 'gestational'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D')]
S112-PMC5418719	PMC5418719	5/2017	S112-PMC5418719	['[9] established the 800\xa0iu/d dosage of Vitamin D met the 25(Oh)D\u2009>\u200930\xa0ng/ml in 81% of study infants at the age of 3\xa0months, WHILE the 400\xa0iu/d dosage of Vitamin D sustained those concentration in 55% of study infants.']	[('ANOMALY_CURIOUS_FINDING', 124)]	1	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S117-PMC5418719	PMC5418719	5/2017	S117-PMC5418719	['in addition, circulating 25(Oh)D levels are INFLUENCED by ethnicity, Genetic factors and maternal FACTORS such as Prenatal Vitamin D intake and Gestational diabetes mellitus [27,28].']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 98)]	2	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 31, 'D'), ('SO_0000704', 'gene', 69, 'genetic'), ('GO_0007565', 'female pregnancy', 114, 'prenatal'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007565', 'female pregnancy', 144, 'gestational')]
S119-PMC5426325	PMC5426325	4/2017	S119-PMC5426325	['THUS, we CANNOT RULE OUT WHETHER the Birth cohort results REFLECT a TRUE adverse EFFECT of Vitamin D on bone; one PREVIOUS STUDY did indeed report borderline significant inverse ASSOCIATIONS between maternal late Pregnancy 25(Oh)D concentrations and offspring Forearm fractures(12).']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('SUPERFICIAL_RELATIONSHIP', 58), ('PROBABLE_UNDERSTANDING', 68), ('SUPERFICIAL_RELATIONSHIP', 81), ('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 178)]	8	[('GO_0007567', 'parturition', 37, 'birth'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 223, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 223, '25(OH)D'), ('UBERON_0002386', 'forelimb zeugopod', 260, 'forearm')]
S152-PMC5426325	PMC5426325	4/2017	S152-PMC5426325	['UNFORTUNATELY, we LACK INFORMATION on Vitamin D status among danish women in the Reproductive age during the fortification period, BUT for comparision, a study SHOWED that among 850 Pregnant women recruited from the second-largest city in denmark in 1988–1989 (the period without fortification), only 6·3 of the Pregnant women had a Serum 25(Oh)D concentration ≤25 nmol/l(12); the median concentrations of 76·2 (95 % ci 23·0, 152·1) nmol/l were also above the ‘OPTIMAL level’ as STATED by the us Endocrine society(62,63).']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 461), ('INCOMPLETE_EVIDENCE', 479)]	7	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0000003', 'reproduction', 81, 'reproductive'), ('GO_0007565', 'female pregnancy', 182, 'pregnant'), ('GO_0007565', 'female pregnancy', 312, 'pregnant'), ('UBERON_0001977', 'blood serum', 333, 'serum'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 339, '25(OH)D'), ('UBERON_0005063', 'left ventricular compact myocardium', 496, 'Endocrine')]
S36-PMC5489519	PMC5489519	6/2017	S36-PMC5489519	['Serum 25(Oh)D levels were measured to evaluate the active form of Vitamin D [1,25(Oh)2D] status in maternal blood as classified by the Endocrine society clinical practice GUIDELINE25.']	[('PROBABLE_UNDERSTANDING', 171)]	1	"[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_37958', 'dye', 77, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 79, '25(OH)2D'), ('UBERON_0005063', 'left ventricular compact myocardium', 135, 'Endocrine')]"
S37-PMC5489519	PMC5489519	6/2017	S37-PMC5489519	['measurement of total circulating 25(Oh)D concentrations IDENTIFIED seven samples with normal range (>30\u2009ng/ml) and THEREFORE considered Vitamin D-sufficient group.']	[('INCOMPLETE_EVIDENCE', 56), ('PROBABLE_UNDERSTANDING', 115)]	2	[('CHEBI_71657', 'versiconol acetate', 33, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 33, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S46-PMC5513133	PMC5513133	7/2017	S46-PMC5513133	['during the course of Pregnancy, EVIDENCE from observational studies SHOWS DIVERGENT data on the concentration of Serum 25(Oh)D levels in different Trimesters of Pregnancy, with EITHER decline [41], increase [42], or absence of change in Vitamin D levels with progression [43,44].']	[('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 177)]	4	[('GO_0007565', 'female pregnancy', 21, 'pregnancy'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 119, '25(OH)D'), ('GO_0043033', 'isoamylase complex', 147, 'trimesters'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]
S121-PMC5513133	PMC5513133	7/2017	S121-PMC5513133	['another prospective cohort study of nulliparous women with singleton Pregnancies FOUND no significant association between Vitamin D deficiency in the 1st Trimester and risk for pe; HOWEVER, at 24–26\xa0weeks of Gestation mean maternal 25(Oh)D was significantly lower in women who developed pe COMPARED WITH those who did not ( p \xa0=\xa00.03) [60].']	[('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('ANOMALY_CURIOUS_FINDING', 181), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 290)]	4	[('GO_0007565', 'female pregnancy', 69, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 154, 'trimester'), ('GO_0007565', 'female pregnancy', 208, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 232, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 232, '25(OH ... D')]
S129-PMC5513133	PMC5513133	7/2017	S129-PMC5513133	['germany, 2–14 [85]case control20 – women with peat Delivery43 – healthy Pregnant controls\u2003mohaghegh et al., iran, 2015 [89]case control41 -- women with pe 50 – healthy Pregnant controlstime of labor\u2003powe, usa, 2010 [86]nested case control39 -- developed pe 131 – healthy Pregnant controls1st Trimester\u2003robinson et al., usa, 2010 [25]case control50 -- women with eospe29\xa0weeks Gestation100 – healthy Pregnant controls\u2003schneuer et al., australia, 2014 [114]nested case control5109 Pregnant women (223 with pe and 29/223 with eospe)10–14\xa0weeks Gestation\u2003singla et al., india, 2015 [87]case control74 -- nulliparous women with pe>30\xa0weeks Gestation100 -- healthy nulliparous controls\u2003ullah et al., bangladesh, 2013 [82]case control33 -- women with pe>20\xa0weeks Gestation79 – normal Pregnancy controls\u2003wetta et al., uk, 2013 [96]case control100 -women with pe15–21\xa0weeks Gestation200 – healthy Pregnant controls\u2003woodham et al., usa, 2011 [15]nested case control41 – women with severe pe2nd trimester121 – uncomplicated birth controls\u2003xu et al., usa, 2014 [53]case control100 – women with pe≤ 24\xa0weeks Gestation100 – uncomplicated Birth controls\u2003yu et al., uk, 2012 [115]case control60 –late pe11–13\xa0weeks Gestation30 –early pe1000 – healthy controlsretrospective cohort study\u2003alvarez-fernandez et al., spain, 2014 [90]retrospective cohort257 -- women attending obstetric triage with suspicion of pe1st trimester and 20\xa0weeks of Gestation\u2003scholl et al., usa, 2013 [78]retrospective cohort1141 -- low income and minority Pregnant womenentry to care (mean 13.7\xa0±\xa05.7\xa0weeks)prospective cohort studies\u2003burris et al., usa, 2014 [94]prospective cohort1591 -- Pregnant women16.4–36.9\xa0weeks Gestation\u2003haugen et al., norway, 2000 [77]prospective cohort23,423 -- Pregnant womenvitamin D intake at weeks 15, 22, and 30 Gestation\u2003shand et al., canada, 2010 [37]prospective cohort221 -- women at risk for pe10–20\xa0weeks Gestation\u2003wei et al., canda 2012 [60]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe12–18\xa0weeks Gestation, 24-26 weeks Gestation\u2003wei, canada, 2013 [14]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe24–26\xa0weeks Gestation\u2003zhou, china, 2014 [116]prospective cohort74 – women with pe16–20 weeks\xa0Gestation\n\ncaption (table-wrap): table 3\n\nASSOCIATION between Vitamin D and pre-eclampsia (pe) in observational studiesauthor, location, yearkey findingsresultsaugust et al., usa, 1992 [88]↓ 1,25Oh2D in women with pe vs chronic htn and normal women1,25 Oh2D levels:pe: 37.8 +/− 15\xa0pg/ml chronic htn: 75 +/− 15\xa0pg/ml ( p \xa0<\xa00.05); normal women: 65 +/− 10\xa0pg/ml ( p \xa0<\xa00.05)fernandez- alonzo et al., spain, 2012 [97]↔ Pe and 25(Oh)D levels25(Oh)D: <49.9\xa0nmol/l: 28.6% (2/7 women); 49.9–74.9\xa0nmol/l: 42.9% (3/7 women); ≥ 74.9\xa0nmol/l: 28.6% (2/7 women) ( p \xa0=\xa00.91)pena hr, et al.']	[('SUPERFICIAL_RELATIONSHIP', 2026), ('SUPERFICIAL_RELATIONSHIP', 2199), ('SUPERFICIAL_RELATIONSHIP', 2350)]	3	[('GO_0007567', 'parturition', 51, 'delivery43'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('GO_0007565', 'female pregnancy', 168, 'pregnant'), ('GO_0007565', 'female pregnancy', 271, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 292, 'trimester'), ('GO_0007565', 'female pregnancy', 376, 'gestation100'), ('GO_0007565', 'female pregnancy', 399, 'pregnant'), ('GO_0007565', 'female pregnancy', 479, 'pregnant'), ('GO_0007565', 'female pregnancy', 541, 'gestation'), ('GO_0007565', 'female pregnancy', 635, 'gestation100'), ('GO_0007565', 'female pregnancy', 756, 'gestation79'), ('GO_0007565', 'female pregnancy', 777, 'pregnancy'), ('GO_0007565', 'female pregnancy', 865, 'gestation200'), ('GO_0007565', 'female pregnancy', 888, 'pregnant'), ('GO_0007565', 'female pregnancy', 1095, 'gestation100'), ('GO_0007567', 'parturition', 1124, 'birth'), ('GO_0007565', 'female pregnancy', 1199, 'gestation30'), ('GO_0007565', 'female pregnancy', 1422, 'gestation'), ('GO_0007565', 'female pregnancy', 1513, 'pregnant'), ('GO_0007565', 'female pregnancy', 1646, 'pregnant'), ('GO_0007565', 'female pregnancy', 1676, 'gestation'), ('GO_0007565', 'female pregnancy', 1746, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1768, 'D'), ('GO_0007565', 'female pregnancy', 1801, 'gestation'), ('GO_0007565', 'female pregnancy', 1899, 'gestation'), ('GO_0007565', 'female pregnancy', 1961, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1986, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2054, 'gestation'), ('GO_0007565', 'female pregnancy', 2077, 'gestation'), ('GO_0007565', 'female pregnancy', 2134, 'pregnant'), ('CHEBI_27300', 'vitamin D', 2159, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2227, 'gestation'), ('GO_0007565', 'female pregnancy', 2308, 'gestation'), ('CHEBI_27300', 'vitamin D', 2370, 'vitamin D'), ('CHEBI_72639', '13-HODE', 2501, '25OH2D'), ('CHEBI_72639', '13-HODE', 2558, '25 OH2D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2724, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2731, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2747, '(OH)D')]
S130-PMC5513133	PMC5513133	7/2017	S130-PMC5513133	['brazil 2015 [83]↑ frequency of 25(Oh)D deficiency <20\xa0ng/ml in pe compared to healthy non obese controlspe: 52.1% (25 women)non obese controls: 14.9%(7 women)( p \xa0=\xa00.0006)abedi et al., iran, 2014 [84]↑ Vitamin D deficiency (<25.0\xa0nmol/l) in pe casesor\xa0=\xa024.0495% ci: 2.14–285.4achkar et al., canada, 2015 [81]↑ pe in women with 25(Oh)D\xa0<\xa030\xa0nmol/l vs women with at least 50\xa0nmol/ladjusted or: 2.2395% ci: 1.29–3.83anderson et al., usa, 2015 [111]↔ proportion of women with inadequate <30\xa0ng/ml 25(Oh)D levels in htn group vs control group73% (htn/pe group) vs 69% (control group)( p \xa0=\xa00.22)baker et al., 2010 [80]↑ severe pe in women with 25(Oh)D\xa0<\xa050\xa0nmol/l compared to levels of at least 75\xa0nmol/ladjusted or: 5.4195% ci: 2.02–14.52( p \xa0=\xa00.001)bodnar et al., usa, 2007 [18]↑ pe in women with 25(Oh)D\xa0<\xa037.5\xa0nmol/l compared to levels of >37.5\xa0nmol/ladjusted or: 5.095% ci: 1.7–14.1bodnar et al., usa, 2014 [79]↓ severe pe in women with 25(Oh)D\xa0≥\xa050\xa0nmol/l COMPARED to levels <50\xa0nmol/ladjusted rr: 0.6595% ci: 0.43–0.98gidlof s, et al.']	[('ANOMALY_CURIOUS_FINDING', 960)]	1	[('CHEBI_71657', 'versiconol acetate', 31, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 31, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 329, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 329, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 495, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 495, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 641, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 641, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 797, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 797, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 940, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 940, '25(OH)D')]
S132-PMC5513133	PMC5513133	7/2017	S132-PMC5513133	['germany, 2–14 [85]↓ 25(Oh)D levels in pe in summer compared to controls, 1,25(Oh)2D ↓ only in winter25(Oh)D: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, ( p \xa0<\xa00.001); 1,25(Oh)2D: 291\xa0±\xa0217 vs 612.3\xa0±\xa0455\xa0pmol/ml ( p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ mean 25(Oh)D in pe compared to Pregnant controls without pe25(Oh)D:Pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women with pe and controls with 25(Oh)D\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 to 4.50robinson et al., usa, 2010 [25]↑ eospe in women with maternal 25(Oh)D levels <=19.6\xa0nmol/l compared to levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe or eospe and low 25(Oh)D (< 25\xa0nmol/l)adjusted or- all pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 to 9.89singla et al., india, 2015 [87]↓ mean Serum Vitamin D in women with pe vs controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe per 25\xa0nmol/l decrease in 25(Oh)D leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ between pe and 25-Oh D\xa0<\xa030\xa0ng/ml and <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ severe pe in women with 10\xa0nmol/l increase in maternal 25(Oh)D leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe in women with Vitamin D deficiency (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ Serum Vitamin D raw values in pe and controls25(Oh)D levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) ( p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe in women with 25(Oh)D levels <50\xa0nmol/l compared TO levels >50\xa0nmol/l after 20\xa0weeks of Gestationor: 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe in women with 25(Oh)D\xa0<\xa049.9\xa0nmol/l and hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ Pe and 25(Oh)D levels compared at each 25\xa0nmol/l increase in 25 (Oh)Dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe in women taking 10–15 mcg/d as compared with no supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe and 25(Oh)D levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ Pe and 25(Oh)D\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe and women with ↓ pigf levels and maternal 25(Oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe and 25(Oh)D levels25(Oh)D levelsgroup a ( n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; group b ( n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; group c ( n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; ( p \xa0=\xa00.900)\na case-cohort study of women from 12 different united states (us) sites whose vitamin D levels were measured at ≤26\xa0weeks of Gestation SHOWED that 25(Oh)D levels greater than 50\xa0nmol/l were ASSOCIATED with a 40% reduction in risk for severe pe (0.65 [95% ci 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of pe when 25(Oh)D levels were greater than 50\xa0nmol/l [79].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1791), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2293), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2609), ('INCOMPLETE_EVIDENCE', 2914), ('SUPERFICIAL_RELATIONSHIP', 2969)]	5	"[('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 75, '25(OH)2D ↓'), ('CHEBI_33010', 'chromide(1-)', 102, '(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 168, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 265, '25'), ('PR_000011614', 'opioid growth factor receptor', 268, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 271, 'D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 322, 'OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 327, 'PE'), ('CHEBI_71657', 'versiconol acetate', 444, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 444, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 725, 'OH)D'), ('UBERON_0001977', 'blood serum', 867, 'serum'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1043, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1043, '25(OH ... D'), ('CHEBI_72765', 'verruculogen', 1134, '25-OH D'), ('CHEBI_71657', 'versiconol acetate', 1343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1434, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1519, 'serum'), ('CHEBI_27300', 'vitamin D', 1525, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 1566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1759, 'OH)D'), ('GO_0007565', 'female pregnancy', 1830, 'gestationOR'), ('CHEBI_71657', 'versiconol acetate', 1920, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2030, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2037, '25(OH)D'), ('CHEBI_982', '2-Aceto-2-hydroxybutanoate', 2091, '25 (OH)DAdjusted'), ('CHEBI_71657', 'versiconol acetate', 2303, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2303, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2393, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2400, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 2534, '25(OH'), ('CHEBI_71657', 'versiconol acetate', 2619, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2635, '(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2865, 'D'), ('GO_0007565', 'female pregnancy', 2904, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 2926, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 3159, '25(OH)D')]"
S186-PMC5513133	PMC5513133	7/2017	S186-PMC5513133	['SUGGESTED that EARLIER STUDIES have measured total 25(Oh)D AS a Vitamin D/Vitamin D binding protein (vdp) Complex, and not the free vitamin.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('PROBABLE_UNDERSTANDING', 59), ('DIFFICULT_TASK', 106)]	4	[('CHEBI_71657', 'versiconol acetate', 51, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 74, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 74, 'Vitamin D'), ('GO_0032991', 'protein-containing complex', 106, 'complex')]
S0-PMC5524288	PMC5524288	7/2017	S0-PMC5524288	['maternal 25(Oh)D concentrations ≥40 ng/ml ASSOCIATED with 60% lower Preterm Birth RISK among general obstetrical patients at an urban medical center\n\nabstract\n\nbackground\nGIVEN the HIGH RATE of Preterm Birth (ptb) nationwide and data from rcts DEMONSTRATING risk reduction with Vitamin D supplementation, the medical university of south carolina (musc) implemented a NEW standard of care for Pregnant women to receive Vitamin D testing and supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 82), ('INCOMPLETE_EVIDENCE', 171), ('IMPORTANT_CONSIDERATION', 181), ('INCOMPLETE_EVIDENCE', 244), ('FULL_UNKNOWN', 367)]	6	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 68, 'preterm birth'), ('GO_0007565', 'female pregnancy', 194, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('GO_0007565', 'female pregnancy', 392, 'pregnant'), ('CHEBI_27300', 'vitamin D', 418, 'vitamin D')]
S17-PMC5524288	PMC5524288	7/2017	S17-PMC5524288	['multiple epidemiologic STUDIES have FOUND an ASSOCIATION between higher maternal Serum 25-Hydroxyvitamin D [25(Oh)D] concentration, the physiological measure of Vitamin D status, and lower ptb RISK [4–10].']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 45), ('IMPORTANT_CONSIDERATION', 193)]	4	[('UBERON_0001977', 'blood serum', 81, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 87, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 108, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S18-PMC5524288	PMC5524288	7/2017	S18-PMC5524288	['Serum 25(Oh)D concentration captures the EFFECT of multiple Vitamin D input sources (Supplement, sun, and Food) and makes provision for inter-individual VARIABILITY in dose response [11].']	[('SUPERFICIAL_RELATIONSHIP', 41), ('DIFFICULT_TASK', 153)]	2	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 6, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 85, 'supplement'), ('CHEBI_33290', 'food', 106, 'food')]
S118-PMC5524288	PMC5524288	7/2017	S118-PMC5524288	['among women with initial 25(Oh)D concentrations <40 ng/ml, the significantly lower ptb rate (60%) for those who achieved ≥40 ng/ml COMPARED TO those who did not reach the target concentration on a follow-up test SUGGESTS that maternal Vitamin D status is a MODIFIABLE RISK FACTOR that CAN be addressed during the Prenatal period.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 257), ('SUPERFICIAL_RELATIONSHIP', 268), ('INCOMPLETE_EVIDENCE', 285)]	5	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 25, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('GO_0007565', 'female pregnancy', 313, 'prenatal')]
S126-PMC5524288	PMC5524288	7/2017	S126-PMC5524288	['additionally, using Serum 25(Oh)D concentration is a BETTER INDICATOR of Vitamin D status and statistically more powerful than using reported Intake BECAUSE it ACCOUNTS FOR all Vitamin D input sources (sun exposure, Food, and Supplements) and makes provision for inter-Individual VARIABILITY in Vitamin D dose response.']	[('PROBABLE_UNDERSTANDING', 53), ('SUPERFICIAL_RELATIONSHIP', 60), ('PROBABLE_UNDERSTANDING', 149), ('INCOMPLETE_EVIDENCE', 160), ('DIFFICULT_TASK', 280)]	5	[('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 28, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 32, 'D'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007631', 'feeding behavior', 142, 'intake'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D'), ('CHEBI_33290', 'food', 216, 'food'), ('CHEBI_33341', 'titanium atom', 226, 'supplements'), ('NCBITaxon_1', 'root', 269, 'individual'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D')]
S127-PMC5524288	PMC5524288	7/2017	S127-PMC5524288	['a LIMITATION of THIS STUDY was that nearly two-thirds of the women (63%) had ONLY one 25(Oh)D test during Pregnancy, which PROHIBITED assessment by Trimester and a more thorough analysis of Vitamin D BENEFIT among those with low initial levels.']	[('INCOMPLETE_EVIDENCE', 2), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 77), ('DIFFICULT_TASK', 123), ('IMPORTANT_CONSIDERATION', 200)]	5	[('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 148, 'trimester'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S1-PMC5537904	PMC5537904	7/2017	S1-PMC5537904	['we EXAMINED ASSOCIATIONS between Prenatal Vitamin D intake, 25-Hydroxyvitamin D (25(Oh)D) in Cord Blood, and offspring size and body composition at Birth and 5 months.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 12)]	2	[('GO_0007565', 'female pregnancy', 33, 'prenatal'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 60, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 93, 'cord'), ('UBERON_0000178', 'blood', 98, 'blood'), ('GO_0007567', 'parturition', 148, 'birth')]
S5-PMC5537904	PMC5537904	7/2017	S5-PMC5537904	['non-hispanic white race, lower Pre-Pregnancy bmi, higher Prenatal Vitamin D intake, and summer Births were ASSOCIATED with higher Cord Blood 25(Oh)D. higher 25(Oh)D was ASSOCIATED with lower Birthweight ( β = –6.22, p = 0.02), but as maternal bmi increased, this ASSOCIATION became increasingly positive in direction and magnitude ( β = 1.05, p = 0.04).']	[('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 169), ('SUPERFICIAL_RELATIONSHIP', 263)]	3	[('GO_0007568', 'aging', 31, 'pre'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007565', 'female pregnancy', 57, 'prenatal'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007567', 'parturition', 95, 'births'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('UBERON_0000178', 'blood', 135, 'blood'), ('CHEBI_63056', 'zinc cation', 141, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 147, 'D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 157, '25(OH ... D'), ('GO_0007596', 'blood coagulation', 191, 'birthweight')]
S17-PMC5537904	PMC5537904	7/2017	S17-PMC5537904	['WHILE NUMEROUS STUDIES HAVE REPORTED that higher maternal Vitamin D intake (from Food and/or dietary supplements) is ASSOCIATED with increased Prenatal and/or cord Blood 25(Oh)D levels [14,15,16,17], it is NOT CLEAR WHETHER this TRANSLATES TO an EFFECT on neonatal adiposity.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 117), ('FULL_UNKNOWN', 206), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 216), ('SUPERFICIAL_RELATIONSHIP', 229), ('SUPERFICIAL_RELATIONSHIP', 246)]	8	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_33290', 'food', 81, 'food'), ('GO_0007565', 'female pregnancy', 143, 'prenatal'), ('UBERON_0000178', 'blood', 164, 'blood'), ('CHEBI_71657', 'versiconol acetate', 170, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 176, 'D')]
S21-PMC5537904	PMC5537904	7/2017	S21-PMC5537904	['PRIOR STUDIES VARY strongly in methodology, PARTICULARLY in regard to assessment of Prenatal Vitamin D intake, timing and source of 25(Oh)D measurements, a method for assessing neonatal adiposity, and CONSIDERATION of OTHER contributing factors such as maternal obesity.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('IMPORTANT_CONSIDERATION', 44), ('FUTURE_WORK', 201), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 218)]	5	[('GO_0007565', 'female pregnancy', 84, 'prenatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 138, 'D')]
S102-PMC5537904	PMC5537904	7/2017	S102-PMC5537904	['the FIRST analysis evaluated the ASSOCIATION of maternal oral Intake of Vitamin D during Pregnancy with Cord Blood 25(Oh)D. this model was adjusted for season of Birth, maternal age, pre-Pregnancy bmi, race/ethnicity, household income, gwg, and Gestational age at Birth and considered the following interaction terms: Vitamin D intake × bmi, Vitamin D intake × gwg, Vitamin D intake × race/ethnicity, season × bmi, season × gwg, and season × race/ethnicity.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 33)]	2	[('GO_0007631', 'feeding behavior', 62, 'intake'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 104, 'cord'), ('UBERON_0000178', 'blood', 109, 'blood'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 115, '25(OH ... D'), ('GO_0007567', 'parturition', 162, 'birth'), ('GO_0007565', 'female pregnancy', 187, 'pregnancy'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('GO_0007567', 'parturition', 264, 'birth'), ('CHEBI_27300', 'vitamin D', 318, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 366, 'vitamin D')]
S143-PMC5537904	PMC5537904	7/2017	S143-PMC5537904	['AS EXPECTED, 25(Oh)D at Birth was PREDICTED by both modifiable (maternal bmi, Prenatal Vitamin D intake) and non-modifiable (race/ethnicity, season of Birth) FACTORS.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 34), ('SUPERFICIAL_RELATIONSHIP', 158)]	3	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 19, 'D'), ('GO_0007567', 'parturition', 24, 'birth'), ('GO_0007565', 'female pregnancy', 78, 'prenatal'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007567', 'parturition', 151, 'birth')]
S144-PMC5537904	PMC5537904	7/2017	S144-PMC5537904	['randomized clinical trials HAVE SHOWN that Prenatal Vitamin D supplementation increases both maternal 25(Oh)D and offspring birthweight [8].']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 105, 'OH ... D')]
S150-PMC5537904	PMC5537904	7/2017	S150-PMC5537904	['IT IS POSSIBLE that the differential ASSOCIATIONS between 25(Oh)D and Birthweight according to maternal bmi we OBSERVED are DUE TO VARIATIONS in overall energy intake or OTHER nutritional factors that are concomitant with increased Vitamin D intake and THUS increased 25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 111), ('PROBLEM_COMPLICATION', 124), ('DIFFICULT_TASK', 131), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('PROBABLE_UNDERSTANDING', 253)]	7	[('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH)D'), ('GO_0007596', 'blood coagulation', 70, 'birthweight'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D')]
S151-PMC5537904	PMC5537904	7/2017	S151-PMC5537904	['OUR finding that the ASSOCIATION between Cord Blood 25(Oh)D and Birthweight varies according to maternal bmi MUST BE REPLICATED in OTHER studies, including intervention trials, TO DETERMINE IF Vitamin D supplementation RECOMMENDATIONS to modify Birthweight SHOULD BE bmi-specific.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 21), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 117), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 190), ('FUTURE_WORK', 219), ('FUTURE_WORK', 257)]	9	[('UBERON_0009472', 'axilla', 41, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 52, '25(OH)D'), ('GO_0007596', 'blood coagulation', 64, 'birthweight'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007596', 'blood coagulation', 245, 'birthweight')]
S166-PMC5537904	PMC5537904	7/2017	S166-PMC5537904	['these data are IN AGREEMENT with results of Prenatal Vitamin D supplementation trials, which REPORTED that EVEN with supplementation, women with non-white race/ethnicity, higher pre-Pregnancy bmis, and winter Deliveries had lower 25(Oh)D levels in Pregnancy [15,61].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 93), ('ANOMALY_CURIOUS_FINDING', 107)]	3	[('GO_0007565', 'female pregnancy', 44, 'prenatal'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007567', 'parturition', 209, 'deliveries'), ('CHEBI_71657', 'versiconol acetate', 230, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 230, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy')]
S173-PMC5537904	PMC5537904	7/2017	S173-PMC5537904	['continued RESEARCH into the IMPLICATIONS of Cord Blood 25(Oh)D status IS NEEDED to guide RECOMMENDATIONS for Prenatal Vitamin D intake.']	[('FUTURE_WORK', 10), ('IMPORTANT_CONSIDERATION', 28), ('FUTURE_WORK', 70), ('FUTURE_WORK', 89)]	4	[('UBERON_0002240', 'spinal cord', 44, 'cord'), ('UBERON_0000178', 'blood', 49, 'blood'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
S179-PMC5537904	PMC5537904	7/2017	S179-PMC5537904	['we were ONLY able to use crude ESTIMATES of offspring Intake of Vitamin D Postnatally from formula or infant supplements, which MAY have prevented us from detecting ASSOCIATIONS between 25(Oh)D at Birth and 5-month body composition that varied by Postnatal Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 165)]	4	[('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'postnatally'), ('CHEBI_71657', 'versiconol acetate', 186, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 192, 'D'), ('GO_0007567', 'parturition', 197, 'birth'), ('GO_0007567', 'parturition', 247, 'postnatal'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D')]
S181-PMC5537904	PMC5537904	7/2017	S181-PMC5537904	['the ethnically-diverse cohort, validated measures of 25(Oh)D and body composition, and detailed data on maternal Vitamin D intake during Pregnancy are all STRENGTHS of our study.']	[('IMPORTANT_CONSIDERATION', 155)]	1	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 53, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy')]
S0-PMC5546866	PMC5546866	8/2017	S0-PMC5546866	['response to antenatal Cholecalciferol supplementation is ASSOCIATED with common Vitamin D–related Genetic variants\n\nabstract\n\ncontext:\nSingle-Nucleotide Polymorphisms (Snps) in Genes RELATED to Vitamin D Metabolism HAVE BEEN ASSOCIATED with Serum 25-Hydroxyvitamin D [25(Oh)D] concentration, BUT these RELATIONSHIPS have NOT BEEN EXAMINED following Antenatal Cholecalciferol supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 57), ('SUPERFICIAL_RELATIONSHIP', 183), ('INCOMPLETE_EVIDENCE', 215), ('SUPERFICIAL_RELATIONSHIP', 225), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 292), ('SUPERFICIAL_RELATIONSHIP', 302), ('FULL_UNKNOWN', 321)]	7	[('CHEBI_16113', 'cholesterol', 22, 'Cholecalciferol'), ('CHEBI_28384', 'vitamin K', 80, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 80, 'Vitamin D'), ('SO_0000704', 'gene', 98, 'Genetic'), ('SO_0000694', 'SNP', 135, 'Single-nucleotide polymorphisms'), ('SO_0000694', 'SNP', 168, 'SNPs'), ('SO_0000704', 'gene', 177, 'genes'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 202, 'D metabolism'), ('UBERON_0001977', 'blood serum', 241, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 247, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D'), ('GO_0007567', 'parturition', 349, 'antenatal'), ('CHEBI_52550', 'theopalauamide', 359, 'cholecalciferol')]
S11-PMC5546866	PMC5546866	8/2017	S11-PMC5546866	['conclusions:\nGenetic variation in Dhcr7 , which encodes 7-Dehyrocholesterol reductase in the Epidermal Vitamin D Biosynthesis pathway, APPEARS to modify baseline 25(Oh)D. IN CONTRAST, the response to Antenatal Cholecalciferol supplementation was ASSOCIATED with Snps in Cyp2R1 , which MAY alter 25-hydroxylase activity, and gc , which MAY AFFECT Vitamin D binding Protein Synthesis or Metabolite affinity.']	[('ANOMALY_CURIOUS_FINDING', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 171), ('SUPERFICIAL_RELATIONSHIP', 246), ('INCOMPLETE_EVIDENCE', 285), ('INCOMPLETE_EVIDENCE', 335), ('SUPERFICIAL_RELATIONSHIP', 339)]	6	[('SO_0000704', 'gene', 13, 'Genetic'), ('PR_000006474', 'ATP-dependent RNA helicase A', 34, 'DHCR7'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 56, '7-dehyrocholesterol'), ('UBERON_0007376', 'outer epithelium', 93, 'epidermal'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 103, 'vitamin D biosynthesis'), ('PR_000006444', 'diacylglycerol kinase delta', 111, 'D'), ('CHEBI_71657', 'versiconol acetate', 162, '25(OH)D'), ('GO_0007567', 'parturition', 200, 'antenatal'), ('CHEBI_52550', 'theopalauamide', 210, 'cholecalciferol'), ('SO_0000694', 'SNP', 262, 'SNPs'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 270, 'CYP2R1'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D'), ('GO_0006412', 'translation', 364, 'protein synthesis'), ('CHEBI_39382', 'flufenoxuron', 385, 'metabolite')]
S12-PMC5546866	PMC5546866	8/2017	S12-PMC5546866	['abstract:teaser\nASSOCIATIONS between Snps in the Vitamin D Metabolism pathway and 25(Oh)D were ASSESSED before and after Antenatal Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 95)]	2	[('SO_0000694', 'SNP', 37, 'SNPs'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 49, 'vitamin D metabolism'), ('PR_000006444', 'diacylglycerol kinase delta', 57, 'D'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('GO_0007567', 'parturition', 121, 'antenatal'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S19-PMC5546866	PMC5546866	8/2017	S19-PMC5546866	['in a PREVIOUS Genome-wide association study (gwas), we DEMONSTRATED that a NUMBER OF Single-Nucleotide Polymorphisms (Snps) in or near to Genes encoding KEY components of the Vitamin D Metabolism pathway are ASSOCIATED with Serum 25(Oh)D level (8).']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 55), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 153), ('SUPERFICIAL_RELATIONSHIP', 208)]	5	[('SO_0001026', 'genome', 14, 'genome'), ('SO_0000694', 'SNP', 85, 'single-nucleotide polymorphisms'), ('SO_0000694', 'SNP', 118, 'SNPs'), ('SO_0000704', 'gene', 138, 'genes'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 175, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 224, 'serum'), ('CHEBI_71657', 'versiconol acetate', 230, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 233, 'OH ... D')]
S21-PMC5546866	PMC5546866	8/2017	S21-PMC5546866	['several of these Snps have been ASSOCIATED with the Serum 25(Oh)D increase in response to Vitamin D supplementation in SMALL STUDIES (9–11).']	[('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 119)]	2	[('SO_0000694', 'SNP', 17, 'SNPs'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S129-PMC5546866	PMC5546866	8/2017	S129-PMC5546866	['the Dhcr7 Gene encodes 7-Dhc reductase, which converts 7-Dhc back to Cholesterol, thereby reducing the availability of 7-Dhc for conversion to previtamin d. the ASSOCIATION of this Snp with only baseline 25(Oh)D is biologically CONSISTENT with the NOTION that the relative proportion of 25(Oh)D obtained from Vitamin D Biosynthesis in the skin AS OPPOSED TO dietary intake is lower following supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 161), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 248), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 344)]	4	[('PR_000006474', 'ATP-dependent RNA helicase A', 4, 'DHCR7'), ('SO_0000704', 'gene', 10, 'gene'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 23, '7-DHC'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 55, '7-DHC'), ('CHEBI_16113', 'cholesterol', 69, 'cholesterol'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 119, '7-DHC'), ('SO_0000694', 'SNP', 181, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 204, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 287, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 293, 'D'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 309, 'vitamin D biosynthesis')]
S130-PMC5546866	PMC5546866	8/2017	S130-PMC5546866	['Cyp2R1 encodes a 25-hydroxylase, a KEY enzyme INVOLVED in the conversion of Vitamin D to 25(Oh)D (23).']	[('IMPORTANT_CONSIDERATION', 35), ('SUPERFICIAL_RELATIONSHIP', 46)]	2	[('PR_000006110', 'cytochrome P450 27, mitochondrial', 0, 'CYP2R1'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D')]
S132-PMC5546866	PMC5546866	8/2017	S132-PMC5546866	['we FOUND that the rs10741657 Snp was not associated with baseline 25(Oh)D BUT was ASSOCIATED with the response to Gestational Vitamin D supplementation, THEREFORE SUGGESTING that this Snp ONLY modifies 25(Oh)D status when the substrate is more readily available and that at the baseline measurement, saturation of the enzyme had not been reached.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 74), ('SUPERFICIAL_RELATIONSHIP', 82), ('PROBABLE_UNDERSTANDING', 153), ('INCOMPLETE_EVIDENCE', 163), ('ANOMALY_CURIOUS_FINDING', 188)]	6	[('SO_0000694', 'SNP', 29, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 66, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('SO_0000694', 'SNP', 184, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 202, '25(OH)D')]
S134-PMC5546866	PMC5546866	8/2017	S134-PMC5546866	['BECAUSE the g Allele at rs10741657, which was more frequent in our population, was ASSOCIATED with lower 25(Oh)D following supplementation, it COULD BE POSTULATED that this Allele previously conferred an evolutionary advantage to prevent Vitamin D toxicity.']	[('PROBLEM_COMPLICATION', 0), ('SUPERFICIAL_RELATIONSHIP', 83), ('INCOMPLETE_EVIDENCE', 143), ('INCOMPLETE_EVIDENCE', 152)]	4	[('SO_0001023', 'allele', 14, 'allele'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('SO_0001023', 'allele', 173, 'allele'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D')]
S137-PMC5546866	PMC5546866	8/2017	S137-PMC5546866	['we SIMILARLY FOUND that the c Allele was ASSOCIATED with lower achieved 25(Oh)D following Antenatal Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 3), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 41)]	3	[('SO_0001023', 'allele', 30, 'allele'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 75, 'OH ... D'), ('GO_0007567', 'parturition', 90, 'antenatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
S19-PMC5634602	PMC5634602	10/2017	S19-PMC5634602	['the authors of THIS PAPER HOWEVER, CONCLUDE that doses of supplementation of Vitamin D SHOULD ensure 25(Oh)D levels of 75 nmol/l to maintain Skeletal health.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 26), ('INCOMPLETE_EVIDENCE', 35), ('FUTURE_WORK', 87)]	4	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 107, 'D'), ('UBERON_0004288', 'skeleton', 141, 'skeletal')]
S30-PMC5634602	PMC5634602	10/2017	S30-PMC5634602	['as the ROLE of Vitamin D in Immune function, Respiratory health, allergy and atopic disease, and many other Tissue and Organ functions becomes apparent, adjustments have BEEN SUGGESTED in OPTIMAL Serum level of 25(Oh)D [12–14].']	[('SUPERFICIAL_RELATIONSHIP', 7), ('INCOMPLETE_EVIDENCE', 170), ('IMPORTANT_CONSIDERATION', 188)]	3	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0002405', 'immune system', 28, 'immune'), ('UBERON_0001004', 'respiratory system', 45, 'respiratory'), ('UBERON_0000479', 'tissue', 108, 'tissue'), ('UBERON_0000062', 'organ', 119, 'organ'), ('UBERON_0001977', 'blood serum', 196, 'serum'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 217, 'D')]
S36-PMC5634602	PMC5634602	10/2017	S36-PMC5634602	['IMPORTANTLY, SEVERAL STUDIES have DOCUMENTED an ASSOCIATION with decreasing 25(Oh)D levels and lower Gestational age at Delivery allowing for a situation where preterm infants are a highly vulnerable population at Birth with regards to their Vitamin D status [15,28,30].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 48)]	4	[('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 82, 'D'), ('GO_0007565', 'female pregnancy', 101, 'gestational'), ('GO_0007567', 'parturition', 120, 'delivery'), ('GO_0007567', 'parturition', 214, 'birth'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D')]
S96-PMC5634602	PMC5634602	10/2017	S96-PMC5634602	['INITIAL STUDIES of and RECOMMENDATIONS for Vitamin D intake were designed to PREVENT rickets in term infants targeting a Serum 25(Oh)D level of >50 nmol/l [36,37].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 77)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D')]
S4-PMC5638722	PMC5638722	8/2017	S4-PMC5638722	['in the PRESENT STUDY, severe Vitamin D deficiency (group 1) was DEFINED AS a 25-Hydroxyvitamin D (25(Oh)D) concentration <5 ng/ml; Vitamin D insufficiency (group 2), 25(Oh)D concentration ≥5 ng/ml and <15 ng/ml; and Vitamin D sufficiency (group 3), 25(Oh)D concentration ≥15 ng/ml.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7), ('PROBABLE_UNDERSTANDING', 64), ('PROBABLE_UNDERSTANDING', 72)]	3	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 77, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 166, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 172, 'D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 249, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 255, 'D')]
S2-PMC5659607	PMC5659607	10/2017	S2-PMC5659607	['objective\nTO perform a combined analysis of the two trials AND INVESTIGATE whether maternal 25-Hydroxy-Vitamin D (25(Oh)D) level at trial entry modified the intervention effect.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 59)]	2	[('CHEBI_70487', '(-)-sanguinolignan C', 92, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D')]
S13-PMC5659607	PMC5659607	10/2017	S13-PMC5659607	['conclusions\nthis combined analysis SHOWS that Vitamin D supplementation during Pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, ESPECIALLY among women with 25(Oh)D level ≥ 30 ng/ml at randomization, where the risk was almost halved.']	[('INCOMPLETE_EVIDENCE', 35), ('ANOMALY_CURIOUS_FINDING', 172)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 200, '25(OH)D')]
S21-PMC5659607	PMC5659607	10/2017	S21-PMC5659607	['a recent meta-analysis SUGGESTED that INSUFFICIENT power DUE TO an OVERESTIMATION of the treatment effect MAY HAVE BEEN one of the ISSUES for the non-significance of the FINDINGS[11], BUT we HYPOTHESIZED that maternal 25(Oh)D level at trial entry MAY also have INFLUENCED the EFFECT of the Vitamin D supplementation[12].']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 38), ('PROBLEM_COMPLICATION', 38), ('PROBLEM_COMPLICATION', 57), ('PROBLEM_COMPLICATION', 67), ('INCOMPLETE_EVIDENCE', 106), ('INCOMPLETE_EVIDENCE', 110), ('PROBLEM_COMPLICATION', 131), ('INCOMPLETE_EVIDENCE', 170), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 184), ('INCOMPLETE_EVIDENCE', 191), ('INCOMPLETE_EVIDENCE', 247), ('SUPERFICIAL_RELATIONSHIP', 261), ('SUPERFICIAL_RELATIONSHIP', 276)]	14	[('CHEBI_71657', 'versiconol acetate', 218, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 224, 'D'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D')]
S22-PMC5659607	PMC5659607	10/2017	S22-PMC5659607	['we THEREFORE conducted a combined analysis of the two trials including the primary end-point asthma/recurrent wheeze by age 3 years as well as the secondary end-points specific Ige, total Ige, eczema and Lower Respiratory Tract infections (lrti) and did 25(Oh)D level-based analyses to determine WHETHER nutritional status at entry to the trials INFLUENCED the EFFECT of Vitamin D.\n\nmethods\nvdaart: monitored by nhlbi and copsac: approved by the ethics committee for copenhagen.']	[('PROBABLE_UNDERSTANDING', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 296), ('SUPERFICIAL_RELATIONSHIP', 346), ('SUPERFICIAL_RELATIONSHIP', 361)]	4	[('GO_0071743', 'IgE immunoglobulin complex, circulating', 177, 'IgE'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 188, 'IgE'), ('UBERON_0004905', 'articulation', 204, 'lower respiratory tract'), ('CHEBI_71657', 'versiconol acetate', 254, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 254, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 371, 'vitamin D')]
S72-PMC5659607	PMC5659607	10/2017	S72-PMC5659607	['the Vitamin D intervention resulted in a significant increase in the mothers post-interventional 25(Oh)D levels in both trials (table 1): in vdaart an increase from 23ng/ml to 39ng/ml and in copsac2010an increase from 31ng/ml to 43ng/ml, respectively.10.1371/journal.pone.0186657.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the two trials.trialno.interventionduration of interventionfollow-upinclusion/ exclusion criteria25(Oh)D levels:control group (pre- to post-intervention)25(Oh)D levels: treatment group (pre- to post-intervention)asthma/ wheeze ESTIMATES (95% ci) vdaart, double blinded, multicenter rct, usa (2009) 806active: 4,000 + 400 iu/dplacebo:400 iu/dfrom 10–18 weeks of Gestation until Birth3 years of follow-up by quarterly phone calls andannual visits to the clinicinclusion: parental asthma, allergy or eczemaexclusion: maternal chronic disease23 ng/ml to 27 ng/ml23 ng/ml to 39 ng/mlhr: 0.8 (0.6–1.00)or: 0.72 (0.52–1.00) copsac2010, double blinded, single center rct, denmark (2008) 581active: 2,400 + 400 iu/dplacebo: 400 iu/dfrom 22–26 weeks of Gestation until 1 week Postpartum3 years of follow-up with visits to the clinic at age 1\xa0week, 1, 3, 6, 12, 18, 24, 30, 36 months and at acute Airway symptoms, plus a daily diaryinclusion: no criteriaexclusion: maternal chronic disease31 ng/ml to 29 ng/ml31 ng/ml to 43 ng/mlhr: 0.76 (0.52–1.12)or: 0.77 (0.5–1.18)\nin vdaart, 625 women (78%) had an initial 25(Oh)D level <30 ng/ml (307 received Vitamin d and 318 placebo) and 176 women (22%) had a level ≥30 ng/ml at trial entry (95 received Vitamin D and 81 placebo).']	[('INCOMPLETE_EVIDENCE', 562)]	1	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 97, '25(OH ... D'), ('CHEBI_33010', 'chromide(1-)', 434, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 488, '25(OH)D'), ('GO_0007565', 'female pregnancy', 696, 'gestation'), ('GO_0007567', 'parturition', 712, 'birth3'), ('GO_0007565', 'female pregnancy', 1078, 'gestation'), ('GO_0007565', 'female pregnancy', 1101, 'postpartum3'), ('UBERON_0001005', 'respiratory airway', 1221, 'airway'), ('CHEBI_71657', 'versiconol acetate', 1435, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1435, '25(OH ... D'), ('CHEBI_33229', 'vitamin (role)', 1473, 'vitamin'), ('CHEBI_27300', 'vitamin D', 1570, 'vitamin D')]
S73-PMC5659607	PMC5659607	10/2017	S73-PMC5659607	['CORRESPONDINGLY, in copsac, 276 women (48%) had an initial level <30 ng/ml (139 received Vitamin D and 137 placebo) and 301 women (52%) had an initial level of 25(Oh)D ≥30 ng/ml (153 received Vitamin D and 148 placebo).']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 160, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 160, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]
S94-PMC5659607	PMC5659607	10/2017	S94-PMC5659607	['an analysis of initial 25(Oh)D level and randomization group, SHOWED a lower risk of asthma/recurrent wheeze in women with 25(Oh)D level ≥ 30ng/ml and randomized to Vitamin D (women with initial 25(Oh)D <30 ng/ml and randomized to Placebo as reference), or = 0.58 (0.37–0.91), p = 0.02, i2= 0%, p = 0.35.']	[('INCOMPLETE_EVIDENCE', 62)]	1	[('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 25, '('), ('PR_000006444', 'diacylglycerol kinase delta', 29, 'D'), ('CHEBI_30778', 'gallic acid', 123, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 129, 'D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 195, '25(OH ... D'), ('CHEBI_26130', 'biological pigment', 231, 'placebo')]
S120-PMC5659607	PMC5659607	10/2017	S120-PMC5659607	['DESPITE these DIFFERENCES, the trials SIMILARLY SHOWED that the Vitamin D supplementation resulted in significantly increased post-interventional 25(Oh)D levels in the mothers.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('SUPERFICIAL_RELATIONSHIP', 38), ('INCOMPLETE_EVIDENCE', 48)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 146, '25(OH ... D')]
S121-PMC5659607	PMC5659607	10/2017	S121-PMC5659607	['furthermore, taking advantage of these DIFFERENCES in the combined analysis by utilizing the measured 25(Oh)D levels at study entry, unmasked the most pronounced protective EFFECT of the Vitamin D intervention in women with 25(Oh)D level ≥ 30 ng/ml.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 39), ('SUPERFICIAL_RELATIONSHIP', 173)]	2	[('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 108, 'D'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 224, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 230, 'D')]
S135-PMC5659607	PMC5659607	10/2017	S135-PMC5659607	['to explore that ISSUE, we performed the combined analyses stratified for the women’s 25(Oh)D level at trial entry, which SHOWED that the Vitamin D supplement resulted in a significantly reduced RISK of asthma/recurrent wheeze in the offspring of women with 25(Oh)D ≥ 30 ng/ml, BUT a much SMALLER and statistically non-significant EFFECT among women with 25(Oh)D < 30 ng/ml.']	[('PROBLEM_COMPLICATION', 16), ('INCOMPLETE_EVIDENCE', 121), ('IMPORTANT_CONSIDERATION', 194), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 277), ('INCOMPLETE_EVIDENCE', 288), ('SUPERFICIAL_RELATIONSHIP', 330)]	6	[('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 257, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 257, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 354, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 354, '25(OH)D')]
S144-PMC5659607	PMC5659607	10/2017	S144-PMC5659607	['we OBSERVED that the Vitamin D supplement resulted in a significant increase in post-interventional maternal 25(Oh)D level in both trials, BUT levels ≥ 30 ng/ml were ONLY achieved in 75% of the supplemented mothers in vdaart and 82% in copsac2010underscoring that too low a dose MAY have attenuated the trial results in both trials but to a greater extent in vdaart POSSIBLY because of the increased african american enrollment.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 139), ('INCOMPLETE_EVIDENCE', 166), ('INCOMPLETE_EVIDENCE', 279), ('INCOMPLETE_EVIDENCE', 366)]	5	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 109, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 109, '25(OH ... D')]
S145-PMC5659607	PMC5659607	10/2017	S145-PMC5659607	['the LACK OF effect of the Vitamin D supplement among women with low 25(Oh)D levels at trial entry also SUGGESTS that the dose MIGHT have been too low to reverse developmental changes caused by insufficient Vitamin D exposure before the supplementation was initiated.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 126)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 74, 'D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D')]
S153-PMC5659607	PMC5659607	10/2017	S153-PMC5659607	['conclusion\nthis combined analysis SHOWS a significant and clinically IMPORTANT 26% PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy on the RISK of asthma/recurrent wheeze in the offspring, with a more pronounced risk reduction of 46% in women with 25(Oh)D level ≥ 30 ng/ml at trial entry.']	[('INCOMPLETE_EVIDENCE', 34), ('IMPORTANT_CONSIDERATION', 69), ('SUPERFICIAL_RELATIONSHIP', 83), ('SUPERFICIAL_RELATIONSHIP', 94), ('IMPORTANT_CONSIDERATION', 154)]	5	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 263, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 263, '25(OH)D')]
S13-PMC5664622	PMC5664622	9/2017	S13-PMC5664622	['IN LIGHT OF the ONGOING DEBATE on the OPTIMAL Vitamin D concentration in Pregnant women, MOST EXPERTS are of the OPINION that the 25(Oh)D concentration in maternal Blood SHOULD exceed 30 ng/ml [2,8,9].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('IMPORTANT_CONSIDERATION', 38), ('PROBABLE_UNDERSTANDING', 89), ('PROBABLE_UNDERSTANDING', 94), ('INCOMPLETE_EVIDENCE', 113), ('FUTURE_WORK', 170), ('IMPORTANT_CONSIDERATION', 170)]	9	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('UBERON_0000178', 'blood', 164, 'blood')]
S26-PMC5679631	PMC5679631	11/2017	S26-PMC5679631	['GIVEN that Vitamin D status is a MODIFIABLE FACTOR which MAY INFLUENCE Intestinal Microbiotic Homeostasis, which in turn is INDICATED to be IMPORTANT in the prevention of Immune mediated diseases, we INVESTIGATED WHETHER maternal use of multivitamin supplements containing Vitamin D, maternal Vitamin D status (25 Hydroxyvitamin D (25(Oh)D), OR administration of Vitamin D supplement to the baby INFLUENCES the presence and abundance of several key bacterial taxa of the infant Gut microbiota.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 33), ('SUPERFICIAL_RELATIONSHIP', 44), ('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 61), ('INCOMPLETE_EVIDENCE', 124), ('IMPORTANT_CONSIDERATION', 140), ('QUESTION_ANSWERED_BY_THIS_WORK', 200), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 213), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 342), ('SUPERFICIAL_RELATIONSHIP', 396)]	11	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0000160', 'intestine', 71, 'intestinal'), ('CHEBI_75293', 'methyltrioctylammonium', 82, 'microbiotic'), ('GO_0055074', 'calcium ion homeostasis', 82, 'microbiotic homeostasis'), ('UBERON_0002405', 'immune system', 171, 'immune'), ('CHEBI_27300', 'vitamin D', 273, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D'), ('CHEBI_67828', 'rel-(3aR,4S,6aS,7R,9aR,10aS)-10a-Hydroxy-7-isopropyl-1,4,9a-trimethyl-4,5,6,6a,7,8,9,9a,10,10a-decahydro-3aH-dicyclopenta[a,d]cycloocten-3-one', 311, '25 hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin D'), ('UBERON_0001555', 'digestive tract', 478, 'gut')]
S42-PMC5679631	PMC5679631	11/2017	S42-PMC5679631	['diet and sunlight exposure were NOT CONSIDERED AS 25(Oh)D concentrations were measured in mothers providing an estimation of exposure based on all sources and only “yellow fat spreads” were fortified with Vitamin D in the netherlands at the time of the study.']	[('INCOMPLETE_EVIDENCE', 32), ('PROBABLE_UNDERSTANDING', 47)]	2	[('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
S88-PMC5679631	PMC5679631	11/2017	S88-PMC5679631	['during seasons of both high and low cutaneous Production Of Vitamin D, the mean maternal Plasma 25(Oh)D concentrations were significantly greater in mothers who used Vitamin D containing supplements COMPARED TO those who did not.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 199)]	1	[('GO_0018240', 'protein S-linked glycosylation via cysteine', 46, 'production of vitamin D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 89, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 96, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D')]
S89-PMC5679631	PMC5679631	11/2017	S89-PMC5679631	['use of multivitamin supplements containing Vitamin D and maternal obesity were ASSOCIATED with maternal 25(Oh)D level during both low and high seasons, WHILE recruitment group was significantly ASSOCIATED with 25(Oh)D concentration ONLY during the high season.10.1371/journal.pone.0188011.t002\n\ncaption (table-wrap): table 2\nmean maternal 25(Oh)D concentration according to season of Blood sampling and use of multivitamin supplements containing Vitamin D.Blood sampling in high season of cutaneous Vitamin D productionblood sampling in low season of cutaneous Vitamin D production maternal use of multivitamin supplement containing Vitamin Dmaternal Plasma 25(Oh)d nmol/lmaternal Plasma 25(Oh)D nmol/l no (mean (sd))45.2 (17.0)30.1 (13.5)yes (mean (sd))53.3 (17.8)40.9 (16.1)p value&p = 0.000p = 0.000model # beta (95% ci)beta (95% ci) constant52.7 (47.7, 57.7)34.6 (29.5, 39.7)maternal use of multivitamin supplement containing Vitamin D (yes vs .']	[('SUPERFICIAL_RELATIONSHIP', 79), ('ANOMALY_CURIOUS_FINDING', 152), ('SUPERFICIAL_RELATIONSHIP', 194), ('INCOMPLETE_EVIDENCE', 232)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 104, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 210, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 339, '25 ... OH ... D'), ('UBERON_0000178', 'blood', 384, 'blood'), ('CHEBI_27300', 'vitamin D', 446, 'vitamin D'), ('UBERON_0000178', 'blood', 456, 'Blood'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin D'), ('CHEBI_61716', 'alpha-Kdo-CH2OH-(2->4)-alpha-Kdo', 633, 'vitamin DMaternal'), ('UBERON_0001969', 'blood plasma', 651, 'Plasma'), ('CHEBI_63056', 'zinc cation', 658, '25(OH'), ('UBERON_0001969', 'blood plasma', 681, 'Plasma'), ('CHEBI_71657', 'versiconol acetate', 688, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 930, 'vitamin D')]
S92-PMC5679631	PMC5679631	11/2017	S92-PMC5679631	['conventional recruitment group -4.6 (-7.8, -1.4) -3.1 (-6.4, 0.3)\nhigh season = april–october, low season = november–march; overweight = body mass index > 90thpercentile;\n&unpaired t-test;\n#regression coefficients (beta) from multivariable linear regression analysis INDICATE the difference in maternal Plasma 25(Oh)D in nmol/l between the group of mothers taking multivitamin supplement containing Vitamin D and those who did not while controlling for the other factors in the model\n\nmaternal Vitamin D intake through use of multivitamin supplements containing Vitamin d\nmaternal use of multivitamin supplements containing Vitamin D was not associated with the prevalence of any of the bacteria in both the unadjusted and adjusted analyses (data not shown).']	[('INCOMPLETE_EVIDENCE', 267)]	1	[('UBERON_0001969', 'blood plasma', 303, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 310, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 310, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 399, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 494, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 562, 'vitamin'), ('CHEBI_27300', 'vitamin D', 624, 'vitamin D')]
S130-PMC5679631	PMC5679631	11/2017	S130-PMC5679631	['ALTHOUGH Vitamin D promotes Immune tolerance, adequate Adaptive Immune Response, as measured by Igg Production in response to infection or vaccination, HAS BEEN observed in patients with relatively high Serum 25(Oh)D levels, SUGGESTING that Vitamin D maintains Immune stability by preventing excessive Immune Responses in EITHER direction [26].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 152), ('INCOMPLETE_EVIDENCE', 225), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 322)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('UBERON_0002405', 'immune system', 28, 'immune'), ('GO_0002250', 'adaptive immune response', 55, 'adaptive immune response'), ('UBERON_0002405', 'immune system', 64, 'immune'), ('GO_0032608', 'interferon-beta production', 96, 'IgG production'), ('GO_0071735', 'IgG immunoglobulin complex', 96, 'IgG'), ('UBERON_0001977', 'blood serum', 203, 'serum'), ('CHEBI_71657', 'versiconol acetate', 209, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 209, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('UBERON_0002405', 'immune system', 261, 'immune'), ('GO_0006955', 'immune response', 302, 'immune responses'), ('UBERON_0002405', 'immune system', 302, 'immune')]
S146-PMC5679631	PMC5679631	11/2017	S146-PMC5679631	['in a FUTURE STUDY, it would be PREFERABLE to investigate the IMPACT of Postnatal Vitamin D supplementation in older infants whose 25(Oh)D concentrations have reached a steady state.']	[('FUTURE_WORK', 5), ('PROBABLE_UNDERSTANDING', 31), ('SUPERFICIAL_RELATIONSHIP', 61)]	3	[('GO_0007567', 'parturition', 71, 'postnatal'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D')]
S159-PMC5679631	PMC5679631	11/2017	S159-PMC5679631	['TO OUR KNOWLEDGE, THIS is the FIRST report of a large scale observational study INDICATING that Prenatal Vitamin D exposure, AS measured either by maternal use of multivitamin supplements containing Vitamin D, or 25(Oh)D quintiles, INFLUENCES several IMPORTANT bacterial taxa within the infant Gut.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 80), ('PROBABLE_UNDERSTANDING', 125), ('SUPERFICIAL_RELATIONSHIP', 232), ('IMPORTANT_CONSIDERATION', 251)]	7	[('GO_0007565', 'female pregnancy', 96, 'prenatal'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('UBERON_0001555', 'digestive tract', 294, 'gut')]
S18-PMC5706533	PMC5706533	11/2017	S18-PMC5706533	['beyond its established INFLUENCE on bone growth and Calcium Homeostasis,1vitamin D and its RELATED Metabolites have HYPOTHESISED EFFECTS on the risk of Cardiovascular diseases,2cancer,3respiratory infections,4asthma,5conditions RELATED to Pregnancy (such as pre-eclampsia, Gestational diabetes), and Birth outcomes.6concern that Vitamin D deficiency is a global PUBLIC HEALTH PROBLEM HAS BEEN sparked by numerous REPORTS of the high proportion of Individuals in studies throughout the world who have relatively low Serum/Plasma concentrations of 25-hydroxyvitamin d (25(Oh)D),7the conventional circulating BIOMARKER of Vitamin D status.8there HAS BEEN particular ATTENTION to the high prevalence of vitamin d deficiency in Pregnant women and newborns.7\nin 2010, dietary reference intakes for Vitamin D for canada and the us from the institute of medicine were based solely on bone health—particularly in young children (for instance, rickets) and older Adults (for instance, osteoporosis).1considerable SKEPTICISM was cast onto the LINK between Vitamin D and Extraskeletal health conditions or the POTENTIAL benefits (versus risks) of intakes larger than the recommended dietary allowance (600 iu/day for MOST children and Adults).1THE institute’s report DID NOT RECOMMEND higher intakes during Pregnancy and Lactation.1a 2016 update of the cochrane collaboration systematic review and meta-analysis of trials of Vitamin D in Pregnancy (versus placebo or no Supplement), HOWEVER, TENTATIVELY CONCLUDED that Prenatal Vitamin D supplementation “MAY reduce the risk of pre-eclampsia, low birthweight and Preterm Birth.”6other RECENT systematic reviews that included trials with active control arms (in which participants received Vitamin D) ACKNOWLEDGED the POTENTIAL EFFECT of Vitamin D on fetal growth910but DID NOT FIND evidence of EFFECTS on OTHER maternal, fetal, or infant outcomes.91011citing the 2016 cochrane review,6the world health organization guidelines for Antenatal care ADVISE against routine Vitamin D supplementation in Pregnancy.12dietary and supplementation RECOMMENDATIONS, HOWEVER, vary widely across other professional organisations (appendix 1), and there REMAINS a LACK OF CONSENSUS on target health outcomes, indications for Prenatal supplementation, or EVIDENCE BASED regimens for supplement dose (or fortification STRATEGIES).']	[('SUPERFICIAL_RELATIONSHIP', 23), ('SUPERFICIAL_RELATIONSHIP', 91), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 129), ('SUPERFICIAL_RELATIONSHIP', 228), ('IMPORTANT_CONSIDERATION', 362), ('IMPORTANT_CONSIDERATION', 376), ('PROBLEM_COMPLICATION', 376), ('INCOMPLETE_EVIDENCE', 384), ('INCOMPLETE_EVIDENCE', 413), ('SUPERFICIAL_RELATIONSHIP', 606), ('INCOMPLETE_EVIDENCE', 643), ('IMPORTANT_CONSIDERATION', 663), ('INCOMPLETE_EVIDENCE', 663), ('IMPORTANT_CONSIDERATION', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1098), ('PROBABLE_UNDERSTANDING', 1205), ('INCOMPLETE_EVIDENCE', 1231), ('INCOMPLETE_EVIDENCE', 1255), ('FUTURE_WORK', 1263), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1471), ('INCOMPLETE_EVIDENCE', 1480), ('INCOMPLETE_EVIDENCE', 1492), ('INCOMPLETE_EVIDENCE', 1543), ('INCOMPLETE_EVIDENCE', 1623), ('INCOMPLETE_EVIDENCE', 1738), ('PROBABLE_UNDERSTANDING', 1738), ('INCOMPLETE_EVIDENCE', 1755), ('SUPERFICIAL_RELATIONSHIP', 1765), ('INCOMPLETE_EVIDENCE', 1807), ('SUPERFICIAL_RELATIONSHIP', 1832), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1843), ('FUTURE_WORK', 1983), ('FUTURE_WORK', 2075), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2092), ('ANOMALY_CURIOUS_FINDING', 2092), ('INCOMPLETE_EVIDENCE', 2177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2187), ('INCOMPLETE_EVIDENCE', 2187), ('INCOMPLETE_EVIDENCE', 2277), ('FUTURE_WORK', 2339)]	42	[('GO_0055073', 'cadmium ion homeostasis', 52, 'calcium homeostasis'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 81, 'D'), ('CHEBI_25212', 'metabolite', 99, 'metabolites'), ('UBERON_0004535', 'cardiovascular system', 152, 'cardiovascular'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('GO_0007565', 'female pregnancy', 273, 'gestational'), ('GO_0007567', 'parturition', 300, 'birth'), ('CHEBI_27300', 'vitamin D', 329, 'vitamin D'), ('NCBITaxon_1', 'root', 447, 'individuals'), ('UBERON_0001977', 'blood serum', 515, 'serum'), ('UBERON_0001969', 'blood plasma', 521, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 567, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('GO_0007565', 'female pregnancy', 723, 'pregnant'), ('CHEBI_27300', 'vitamin D', 792, 'vitamin D'), ('UBERON_0007023', 'adult organism', 953, 'adults'), ('CHEBI_27300', 'vitamin D', 1045, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 1059, 'extraskeletal'), ('UBERON_0007023', 'adult organism', 1223, 'adults'), ('GO_0007565', 'female pregnancy', 1295, 'pregnancy'), ('GO_0007595', 'lactation', 1309, 'lactation'), ('CHEBI_27300', 'vitamin D', 1413, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1426, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 1458, 'supplement'), ('GO_0007565', 'female pregnancy', 1507, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1516, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1601, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 1727, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1775, 'vitamin D'), ('GO_0007567', 'parturition', 1968, 'antenatal'), ('CHEBI_27300', 'vitamin D', 2006, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2035, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2248, 'prenatal')]
S46-PMC5706533	PMC5706533	11/2017	S46-PMC5706533	['when multiple comparisons from the same trial were included in the same meta-analysis, we divided the control group sample size corresponding to each comparison by the number of intervention arms to avoid double counting participants.14\nwe conducted subgroup meta-analyses according to a priori defined sources of potential clinical and methodological heterogeneity17: control arm type (Placebo versus Vitamin D containing active control); dosing frequency (regular versus bolus); baseline Vitamin D status categorised as low (mean 25(Oh)D <30 nmol/l) versus sufficient (≥30 nmol/l), based on maternal mean 25(Oh)D in the control group at enrolment (“initial baseline”) or at/near delivery (“modified baseline,” which THEORETICALLY takes into account the effect of active control supplementation); intervention dose (among regular dose trials), defined as low (<2000 iu/day) versus high (≥2000 iu/day).']	[('INCOMPLETE_EVIDENCE', 718)]	1	[('CHEBI_26130', 'biological pigment', 387, 'placebo'), ('CHEBI_27300', 'vitamin D', 402, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 532, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 538, 'D'), ('CHEBI_71657', 'versiconol acetate', 607, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 613, 'D')]
S80-PMC5706533	PMC5706533	11/2017	S80-PMC5706533	['figures are number (percentage) unless stated otherwisecharacteristicall trialsregular dose trials*Bolus dose trials*trials4337†8†intervention arms55469participants enrolled:\u2003total840676871031\u2003median within individual trials (min-max)133 (16-1134)133 (16-1134)118 (50-235)meta-analyses to which each trial contributed:\u2003median maternal outcomes (min-max)2 (0-6)2 (0-6)2 (0-4)\u2003median newborn/infant outcomes (min-max)3 (0-17)3 (0-17)4 (0-7)\u2003trials that DID not contribute data to any meta-analyses2 (4.7)2 (5.4)0 (0.0)geographical region:\u2003europe7 (16.3)7 (18.9)2 (25.0)\u2003south east asia6 (14.0)2 (5.4)4 (50.0)\u2003americas5 (11.6)5 (13.5)0 (0.0)\u2003eastern mediterranean21 (48.8)19 (51.4)2 (25.0)\u2003western pacific4 (9.3)4 (10.8)0 (0.0)health status at enrolment:\u2003generally healthy37 (86.0)33 (89.2)6 (75.0)\u2003Gestational diabetes4 (9.3)2 (5.4)2 (25.0)\u2003hypocalcaemia1 (2.3)1 (2.7)\u2003multiple sclerosis1 (2.3)1 (2.7)0 (0.0)baseline Vitamin D status‡:\u2003mean 25(Oh)D <30 nmol/l10 (23.3)9 (24.3)2 (25.0)\u2003mean 25(Oh)D ≥30 nmol/l23 (53.5)20 (54.1)3 (37.5)\u2003not reported10 (23.3)8 (21.6)3 (37.5)type of Vitamin D§:\u2003d24 (7.3)3 (6.5)1 (11.1)\u2003d348 (87.3)40 (87.0)8 (88.9)\u2003not reported3 (5.5)3 (6.5)0 (0.0)supplementation frequency§:\u2003daily31 (56.4)31 (67.4)—\u2003weekly5 (9.1)5 (10.9)—\u2003every 2 weeks6 (10.9)6 (13.0)—\u2003monthly3 (5.5)3 (6.5)—\u2003 every 2 months1 (1.8)1 (2.2)—\u2003single dose3 (5.5)—3 (33.3)\u2003two doses4 (7.3)—4 (44.4)\u2003other2 (3.6)—2 (22.2)intervention dose§¶:\u2003median (min-max)2000 (200-7543)2000 (200-7543)—\u2003regular dose <2000 iu/day24 (52.2)24 (52.2)—\u2003regular dose ≥2000 iu/day22 (47.8)22 (47.8)—control intervention type:\u2003placebo29 (67.4)23 (62.2)8 (100.0)\u2003active14 (32.6)14 (37.8)0 (0.0)median Vitamin D dose in active control arms (min-max)400 (200-600)400 (200-600)—timing of initiation of supplementation§:\u20031st trimester19 (34.5)18 (39.1)1 (11.1)\u20032nd trimester30 (54.5)24 (52.2)6 (66.7)\u20033rd trimester5 (9.1)3 (6.5)2 (22.2)\u2003not reported1 (1.8)1 (2.2)0 (0.0)\n*regular dosing refers to regimens in which Supplement was administered at least three times at regular frequency throughout Pregnancy (daily, weekly, every 2 weeks, monthly, or every 2 months ); bolus dosing refers to interventions administered either once or twice during intervention period.']	[('ANOMALY_CURIOUS_FINDING', 451)]	1	[('NCBITaxon_10088', 'Mus <genus>', 99, 'Bolus'), ('GO_0007565', 'female pregnancy', 796, 'Gestational'), ('CHEBI_27300', 'vitamin D', 915, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 939, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 988, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1078, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1671, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 1981, 'supplement'), ('GO_0007565', 'female pregnancy', 2062, 'pregnancy')]
S93-PMC5706533	PMC5706533	11/2017	S93-PMC5706533	['estimated mean change in effective Vitamin D dose for every 20 nmol/l increase in baseline mean 25(Oh)D concentration was increase of 208 iu/day (p=0.54)\n\nEFFECTS on maternal and Cord Blood 25-Hydroxyvitamin D concentrations\nwe performed meta-analyses for 11 maternal and 27 neonatal/infant outcomes (tables 2 and 3).']	[('SUPERFICIAL_RELATIONSHIP', 155)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 96, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 179, 'cord'), ('UBERON_0000178', 'blood', 184, 'blood'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 190, '25-hydroxyvitamin D')]
S96-PMC5706533	PMC5706533	11/2017	S96-PMC5706533	['higher regular dose regimens (≥2000 iu/day) LED TO a greater average increment in Maternal Delivery and Cord 25(Oh)D than lower doses (tables s1 and s2 in appendix 10); HOWEVER, the linear dose-response curves for maternal and Cord Blood INDICATED modest EFFECTS of increasing Vitamin D doses on the increment in 25(Oh)D concentrations (fig s2 and s4 in Appendix 10).']	[('SUPERFICIAL_RELATIONSHIP', 44), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169), ('INCOMPLETE_EVIDENCE', 238), ('SUPERFICIAL_RELATIONSHIP', 255)]	4	[('GO_0007618', 'mating', 82, 'maternal'), ('GO_0007567', 'parturition', 91, 'delivery'), ('UBERON_0002240', 'spinal cord', 104, 'cord'), ('CHEBI_71657', 'versiconol acetate', 109, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 109, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 227, 'cord'), ('UBERON_0000178', 'blood', 232, 'blood'), ('CHEBI_27300', 'vitamin D', 277, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 313, '25(OH)D'), ('UBERON_0001154', 'vermiform appendix', 354, 'appendix')]
S114-PMC5706533	PMC5706533	11/2017	S114-PMC5706533	['in a post hoc analysis of the EFFECT on Birth weight that took into account both effective dose and baseline Vitamin D status, there was a significant dose-response effect in trials in which mean baseline 25(Oh)D was 30-50 nmol/l but no association in trials with mean 25(Oh)d <30 nmol/l (fig s29 in appendix 10).']	[('SUPERFICIAL_RELATIONSHIP', 30)]	1	[('GO_0007567', 'parturition', 40, 'birth'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 269, '25(OH')]
S154-PMC5706533	PMC5706533	11/2017	S154-PMC5706533	['two trials INDICATED that Vitamin D COULD enhance Postnatal linear growth, an outcome RELATED to growth plates for which a HYPOTHESISED ROLE of Vitamin D is logical,26and which is the primary focus of our AS YET unpublished trial in bangladesh.27in the FEW STUDIES reporting EFFECTS on infant bone mass, results were MIXED; the largest of these trials—the mavidos study in the uk, which excluded women with 25(Oh)D concentrations <25 nmol/l28—has scheduled follow-up of children at age 4 years.29infant rickets was NOT REPORTED in any trials; THOUGH RARE, this is one of the MOST LIKELY paediatric conditions to be directly caused by poor maternal and early infant Vitamin D status.30adverse events were infrequently REPORTED, resulting in unreliable meta-analyses.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 136), ('INCOMPLETE_EVIDENCE', 205), ('ANOMALY_CURIOUS_FINDING', 208), ('INCOMPLETE_EVIDENCE', 253), ('SUPERFICIAL_RELATIONSHIP', 275), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 317), ('INCOMPLETE_EVIDENCE', 515), ('ANOMALY_CURIOUS_FINDING', 543), ('INCOMPLETE_EVIDENCE', 550), ('PROBABLE_UNDERSTANDING', 575), ('PROBABLE_UNDERSTANDING', 580), ('INCOMPLETE_EVIDENCE', 717)]	16	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 50, 'postnatal'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 407, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 413, 'D'), ('CHEBI_27300', 'vitamin D', 665, 'vitamin D')]
S159-PMC5706533	PMC5706533	11/2017	S159-PMC5706533	['the INTERPRETATION of Micronutrient intervention trials, HOWEVER, is COMPLEX BECAUSE all Individuals have some Vitamin D intake or Endogenous production.35the EFFECT of a given dose depends on the difference between the intervention and control doses (or the difference in mean 25(Oh)D in the intervention versus control group at/near delivery) as well as baseline Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 4), ('PROBABLE_UNDERSTANDING', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 57), ('DIFFICULT_TASK', 69), ('PROBABLE_UNDERSTANDING', 77), ('SUPERFICIAL_RELATIONSHIP', 159)]	6	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 22, 'micronutrient'), ('NCBITaxon_1', 'root', 89, 'individuals'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0009790', 'embryo development', 131, 'endogenous'), ('CHEBI_71657', 'versiconol acetate', 278, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 278, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 365, 'vitamin D')]
S163-PMC5706533	PMC5706533	11/2017	S163-PMC5706533	['MANY of the REPORTED doses, HOWEVER, DID NOT yield EFFECTS on maternal 25(Oh)D that would be expected BASED ON Vitamin D pharmacokinetics.3637the muted dose-25(Oh)D RELATION COULD BE ATTRIBUTED to high baseline 25(Oh)D, low precision of 25(Oh)D assays, low rates of adherence to supplementation regimens, or lower than labeled Vitamin D content of the Supplements.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 51), ('QUESTION_ANSWERED_BY_THIS_WORK', 102), ('ANOMALY_CURIOUS_FINDING', 108), ('SUPERFICIAL_RELATIONSHIP', 165), ('INCOMPLETE_EVIDENCE', 174), ('SUPERFICIAL_RELATIONSHIP', 183)]	10	[('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 73, '(OH ... D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 237, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 352, 'supplements')]
S164-PMC5706533	PMC5706533	11/2017	S164-PMC5706533	['we CONSIDERED the weak ASSOCIATION between dose and 25(Oh)D to reflect the overall low quality of many of the trials, which TEMPERED expectations of finding dose DEPENDENT EFFECTS of Vitamin D on clinical outcomes.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('SUPERFICIAL_RELATIONSHIP', 162), ('SUPERFICIAL_RELATIONSHIP', 172)]	5	[('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 52, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]
S2-PMC5732505	PMC5732505	12/2017	S2-PMC5732505	['our OBJECTIVE was to compare maternal 25-Hydroxy Vitamin D concentrations [25(Oh)D] between mothers with and without gdm, and TO INVESTIGATE IF an ASSOCIATION existed between maternal Vitamin D concentration and infant Birth size.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 126), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('SUPERFICIAL_RELATIONSHIP', 147)]	4	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 38, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007567', 'parturition', 219, 'birth')]
S15-PMC5732505	PMC5732505	12/2017	S15-PMC5732505	['a sufficient maternal Vitamin D status, specified AS 25(Oh)D above 50\xa0nmol/l, MAY BE a threshold above which the physiological REQUIREMENTS of Pregnancy are achieved.']	[('PROBABLE_UNDERSTANDING', 50), ('INCOMPLETE_EVIDENCE', 78), ('IMPORTANT_CONSIDERATION', 127)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 59, 'D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
S48-PMC5732505	PMC5732505	12/2017	S48-PMC5732505	['we employed ucb 25(Oh)D to REFLECT both the maternal Vitamin D status at the end of Pregnancy and the newborn’s Vitamin D status at Birth [1].']	[('PROBABLE_UNDERSTANDING', 27)]	1	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007567', 'parturition', 132, 'birth')]
S49-PMC5732505	PMC5732505	12/2017	S49-PMC5732505	['we DEFINED Vitamin D deficiency AS 25(Oh)D\u2009<\u200950\xa0nmol/l, and Vitamin D sufficiency AS 25(Oh)D\u2009≥\u200950\xa0nmol/l, SINCE a concentration of ≥50\xa0nmol/l IS CONSIDERED sufficient for bone health [17].']	[('PROBABLE_UNDERSTANDING', 3), ('PROBABLE_UNDERSTANDING', 32), ('PROBABLE_UNDERSTANDING', 82), ('PROBABLE_UNDERSTANDING', 106), ('INCOMPLETE_EVIDENCE', 142)]	5	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 35, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D')]
S50-PMC5732505	PMC5732505	12/2017	S50-PMC5732505	['suboptimal Vitamin D status was DEFINED AS 25(Oh)D\u2009<\u200980\xa0nmol/l, and optimal Vitamin D status AS 25(Oh)D\u2009≥\u200980\xa0nmol/l, AS HAS BEEN SUGGESTED BASED ON calcium absorption STUDIES [18].']	[('PROBABLE_UNDERSTANDING', 32), ('PROBABLE_UNDERSTANDING', 40), ('PROBABLE_UNDERSTANDING', 93), ('PROBABLE_UNDERSTANDING', 117), ('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 139), ('INCOMPLETE_EVIDENCE', 167)]	7	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 43, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D')]
S117-PMC5732505	PMC5732505	12/2017	S117-PMC5732505	['the PREVALENCE of Vitamin D deficiency [25(Oh)D\u2009<\u200950\xa0nmol/l] during Pregnancy was SIMILAR between mothers with or without gdm [4.9% (4/81) vs 3.3% (21/642), p \u2009=\u20090.51].']	[('IMPORTANT_CONSIDERATION', 4), ('SUPERFICIAL_RELATIONSHIP', 82)]	2	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 46, 'D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy')]
S132-PMC5732505	PMC5732505	12/2017	S132-PMC5732505	['abbreviations: gwg, Gestational weight gain; gdm, Gestational diabetes mellitus; 25(Oh)D, 25-Hydroxy Vitamin D; suboptimal, ucb, Umbilical Cord Blood; 25(Oh)D\u2009<\u200980\xa0nmol/l; optimal 25(Oh)D\u2009≥\u200980\xa0nmol/l\n\ndiscussion\nthe primary FOCUS of this work was TO DETERMINE WHETHER 25(Oh)D concentration differs between mothers with AND without gdm, and WHETHER Vitamin D status AFFECTS Birth size in normal-Birth-weight infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 224), ('QUESTION_ANSWERED_BY_THIS_WORK', 247), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 260), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 340), ('SUPERFICIAL_RELATIONSHIP', 365)]	5	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('GO_0007565', 'female pregnancy', 50, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 90, '25-hydroxy vitamin D'), ('UBERON_0002331', 'umbilical cord', 129, 'umbilical cord'), ('UBERON_0000178', 'blood', 144, 'blood'), ('CHEBI_71657', 'versiconol acetate', 151, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin D'), ('GO_0007567', 'parturition', 373, 'birth'), ('GO_0007567', 'parturition', 394, 'birth')]
S134-PMC5732505	PMC5732505	12/2017	S134-PMC5732505	['ALMOST ALL mother-child pairs (97%) were Vitamin D sufficient [25(Oh)D\u2009≥\u200950\xa0nmol/l], and ABOUT half of the mother-child pairs had optimal Vitamin D status [25(Oh)D\u2009≥\u200980\xa0nmol/l].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 89)]	2	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 156, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 162, 'D')]
S144-PMC5732505	PMC5732505	12/2017	S144-PMC5732505	['IN ACCORDANCE with OTHER STUDIES, our results IMPLY that in a Vitamin D sufficient population, the ASSOCIATION between 25(Oh)D and gdm MAY NOT exist [8,21,22].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('PROBABLE_UNDERSTANDING', 46), ('SUPERFICIAL_RELATIONSHIP', 99), ('INCOMPLETE_EVIDENCE', 135)]	5	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D')]
S152-PMC5732505	PMC5732505	12/2017	S152-PMC5732505	['maternal Vitamin D status ASSOCIATED with Birth size: Pregnancy 25(Oh)D SHOWED a positive ASSOCIATION towards Birth weight, BUT ucb 25(Oh)D an inverse ASSOCIATION with Head circumference, WHILE ONLY the inverse ASSOCIATION with Head circumference was VERIFIED with linear model.']	[('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 72), ('SUPERFICIAL_RELATIONSHIP', 90), ('ANOMALY_CURIOUS_FINDING', 124), ('SUPERFICIAL_RELATIONSHIP', 151), ('ANOMALY_CURIOUS_FINDING', 188), ('ANOMALY_CURIOUS_FINDING', 194), ('SUPERFICIAL_RELATIONSHIP', 211), ('INCOMPLETE_EVIDENCE', 251)]	9	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 42, 'birth'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('GO_0007567', 'parturition', 110, 'birth'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('UBERON_0000033', 'head', 168, 'head'), ('UBERON_0000033', 'head', 228, 'head')]
S176-PMC5732505	PMC5732505	12/2017	S176-PMC5732505	['sufficient maternal Vitamin D status, specified AS 25(Oh)D above 50\xa0nmol/l, SEEMS a threshold value, above which the physiological REQUIREMENTS of Pregnancy are achieved.']	[('PROBABLE_UNDERSTANDING', 48), ('PROBABLE_UNDERSTANDING', 76), ('IMPORTANT_CONSIDERATION', 131)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 51, '25(OH)D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy')]
S35-PMC5827025	PMC5827025	2/2018	S35-PMC5827025	['influence of demographic characteristics on Gestational Serum 25(Oh)D concentration\nthe demographic characteristics for INFLUENCING Gestational Vitamin D status were analyzed.']	[('SUPERFICIAL_RELATIONSHIP', 120)]	1	[('GO_0007565', 'female pregnancy', 44, 'gestational'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 62, '25(OH)D'), ('GO_0007565', 'female pregnancy', 132, 'gestational'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S101-PMC5827025	PMC5827025	2/2018	S101-PMC5827025	['follow-up, SEVERAL randomized TRIAL of Vitamin D supplementation FOUND that the rate of Preterm Delivery is significant more lower in Pregnant women with Serum 25(Oh)D ≥40\u2009ng/ml COMPARED TO those with Serum 25(Oh)D ≤20\u2009ng/ml, SUGGESTING higher 25(Oh)D concentration was ASSOCIATED with an decreased risk of Preterm Delivery35–38.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 270)]	5	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'preterm'), ('GO_0007567', 'parturition', 96, 'delivery'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('CHEBI_63056', 'zinc cation', 160, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 166, 'D'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 210, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 213, 'D'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('GO_0007565', 'female pregnancy', 307, 'preterm'), ('GO_0008219', 'cell death', 315, 'delivery35')]
S27-PMC5941617	PMC5941617	5/2018	S27-PMC5941617	['Vitamin D deficiency: ranges, analytic methods, and epidemiology\nthe MAJOR circulating form of Vitamin D is 25(Oh)D, having a half-life of 2–3\xa0weeks.']	[('IMPORTANT_CONSIDERATION', 69)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 108, '25(OH)D')]
S29-PMC5941617	PMC5941617	5/2018	S29-PMC5941617	['in literature, several cut-offs HAVE BEEN PROPOSED for Vitamin D deficiency with respect to Serum 25(Oh)D levels measured with a RELIABLE assay.']	[('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 42), ('IMPORTANT_CONSIDERATION', 129)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0001977', 'blood serum', 92, 'serum'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 98, '25(OH)D')]
S45-PMC5941617	PMC5941617	5/2018	S45-PMC5941617	['caption (table-wrap): table 3\n\ncut-off points for the definition of Vitamin D status based on circulating levels of 25(Oh)Dsevere deficiencydeficiencyinsufficiencysufficiency25(Oh)D< 10\xa0ng/ml (< 25\xa0nmol/l)< 20\xa0ng/ml (< 50\xa0nmol/l)20–29\xa0ng/ml (50–74\xa0nmol/l)≥ 30\xa0ng/ml (≥ 75\xa0nmol/l)\nconversion factor: ng/ml\u2009=\u2009nmol/l*0.401; nmol/l\u2009=\u2009ng/ml*2.496\nVitamin D status is DEFINED by the measurement of 25(Oh)D concentrations.']	[('PROBABLE_UNDERSTANDING', 362)]	1	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_77894', 'aci-nitroethane', 116, '25(OH)DSevere'), ('CHEBI_33010', 'chromide(1-)', 176, '(OH)D'), ('CHEBI_28384', 'vitamin K', 342, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 392, '25(OH)D')]
S49-PMC5941617	PMC5941617	5/2018	S49-PMC5941617	['the measurement of 25(Oh)D is DIFFICULT DUE TO its lipophilic nature, the binding to Vitamin D binding protein, the DIFFERENT circulating forms that also include epimers and isobars, and the standardization.']	[('DIFFICULT_TASK', 30), ('PROBLEM_COMPLICATION', 40), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116)]	3	[('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S67-PMC5941617	PMC5941617	5/2018	S67-PMC5941617	['other italian data are present in literature, ALTHOUGH they SHOW SOME LIMITATIONS, regarding SMALL populations, analytic methods for 25(Oh)D, the season of recruitment, the prevalence of overweight/obesity, Vitamin D supplements, sunscreens, ethnicity, and uncovered areas of latitude.']	[('ANOMALY_CURIOUS_FINDING', 46), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 70), ('PROBLEM_COMPLICATION', 70), ('INCOMPLETE_EVIDENCE', 93)]	6	[('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
S71-PMC5941617	PMC5941617	5/2018	S71-PMC5941617	['caption (table-wrap): table 4\n\nprevalence of hypovitaminosis d in healthy children and adolescents living in italystudyperiod of enrolmentnumberm (%)age (range or as specified)city/region (latitude)% overweight% obese% receiving Vitamin D% not caucasian25(Oh)D assaysevere deficiency, % [25(Oh)D\u2009<\u200910\xa0ng/ml]deficiency, % [25(Oh)D\u2009<\u200920\xa0ng/ml]insufficiency, % [25(Oh)D: 20–29.9\xa0ng/ml]hypovitaminosis D, % [25(Oh)D\u2009<\u200930\xa0ng/ml]FACTORS for ASSOCIATED with Serum 25(Oh)D levelslippi g et al.']	[('SUPERFICIAL_RELATIONSHIP', 423), ('SUPERFICIAL_RELATIONSHIP', 435)]	2	[('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 255, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 288, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 322, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 359, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 398, 'D'), ('CHEBI_71657', 'versiconol acetate', 404, '25(OH)D'), ('UBERON_0001977', 'blood serum', 451, 'serum'), ('CHEBI_71657', 'versiconol acetate', 457, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 457, '25 ... OH ... D')]
S103-PMC5941617	PMC5941617	5/2018	S103-PMC5941617	['in 2016 the united kingdom scientific advisory committee on nutrition (sacn) reviewed THE EVIDENCE on Vitamin D and health and RECOMMENDED that Serum 25(Oh)D levels of all children and adolescents in the united kingdom SHOULD NOT fall below 10\xa0ng/ml (a so-CALLED “population PROTECTIVE level”) at any time of the year to protect Musculoskeletal health.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 86), ('INCOMPLETE_EVIDENCE', 90), ('FUTURE_WORK', 127), ('FUTURE_WORK', 219), ('INCOMPLETE_EVIDENCE', 255), ('SUPERFICIAL_RELATIONSHIP', 275)]	6	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('UBERON_0001977', 'blood serum', 144, 'serum'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('UBERON_0002204', 'musculoskeletal system', 329, 'musculoskeletal')]
S105-PMC5941617	PMC5941617	5/2018	S105-PMC5941617	['in 2016 also the european Food safety authority (efsa) revised dietary reference values for Vitamin D. CONSIDERING a Serum 25(Oh)D levels of 20\xa0ng/ml AS a SUITABLE target value, under conditions of minimal cutaneous Vitamin D synthesis efsa RECOMMENDED an adequate intake of 400\xa0iu/day for infants aged 7–11\xa0months and of 600\xa0iu/day for children aged 1–17\xa0years [26].']	[('PROBABLE_UNDERSTANDING', 103), ('PROBABLE_UNDERSTANDING', 150), ('IMPORTANT_CONSIDERATION', 155), ('FUTURE_WORK', 241)]	4	[('CHEBI_33290', 'food', 26, 'Food'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 100, 'D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 123, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]
S113-PMC5941617	PMC5941617	5/2018	S113-PMC5941617	['moreover, newborns from deficient mothers are at INCREASED RISK for Vitamin D deficiency AS Cord Blood and neonatal 25(Oh)D levels highly CORRELATE with maternal Vitamin d status during Gestation [92,93].']	[('IMPORTANT_CONSIDERATION', 49), ('PROBABLE_UNDERSTANDING', 89), ('SUPERFICIAL_RELATIONSHIP', 138)]	3	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 92, 'cord'), ('UBERON_0000178', 'blood', 97, 'blood'), ('CHEBI_71657', 'versiconol acetate', 116, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 162, 'vitamin'), ('GO_0007565', 'female pregnancy', 186, 'gestation')]
S141-PMC5941617	PMC5941617	5/2018	S141-PMC5941617	['in 2013 the aap RECOMMENDED a daily Vitamin D intake of 200–400\xa0iu for vlbw infants, AS their smaller size MAY LEAD TO a lower need for Vitamin D to ensure adequate Serum 25(Oh)D levels.']	[('FUTURE_WORK', 16), ('PROBABLE_UNDERSTANDING', 85), ('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 111)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('UBERON_0001977', 'blood serum', 165, 'serum'), ('CHEBI_71657', 'versiconol acetate', 171, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 177, 'D')]
S143-PMC5941617	PMC5941617	5/2018	S143-PMC5941617	['DIFFERENTLY, CONSIDERING the high prevalence of Vitamin D deficiency during Pregnancy, the espghan RECOMMENDED for preterm infants a Vitamin D intake of 800–1000\xa0iu/day during the first months of Life to rapidly correct fetal low Serum 25(Oh)D levels [125].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 13), ('FUTURE_WORK', 99)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('UBERON_0000104', 'life cycle', 196, 'life'), ('UBERON_0001977', 'blood serum', 230, 'serum'), ('CHEBI_71657', 'versiconol acetate', 236, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 236, '25(OH ... D')]
S152-PMC5941617	PMC5941617	5/2018	S152-PMC5941617	['RECENTLY RECOMMENDED Vitamin D supplementation at 800\xa0iu/day to enhance Vitamin D status during early hospitalization in vlbw infants with Serum 25(Oh)D levels <\u200910\xa0ng/ml at Birth [142].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 9)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('UBERON_0001977', 'blood serum', 139, 'serum'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 145, '25 ... OH ... D'), ('GO_0007567', 'parturition', 174, 'birth')]
S157-PMC5941617	PMC5941617	5/2018	S157-PMC5941617	['SUGGESTED for extremely low Gestational age newborns an initial Vitamin D supplementation at 800\xa0iu/day for 1–2\xa0weeks to restore Serum 25(Oh)D levels followed by a lower dosage (200\xa0iu/day) [143].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('GO_0007565', 'female pregnancy', 28, 'gestational'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0001977', 'blood serum', 129, 'serum'), ('CHEBI_71657', 'versiconol acetate', 135, '25(OH)D')]
S162-PMC5941617	PMC5941617	5/2018	S162-PMC5941617	['supplementation at 400\xa0iu/day for variable length (up to 12\xa0months) was USUALLY INSUFFICIENT in raising Serum 25(Oh)D levels >\u200930\xa0ng/ml [78,147–149,151–153,160–162], particularly in subjects with Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 72), ('PROBLEM_COMPLICATION', 80)]	2	[('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 110, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S163-PMC5941617	PMC5941617	5/2018	S163-PMC5941617	['a RECENT rct performed during winter SHOWED that a Vitamin D intake up to 800\xa0iu/day was REQUIRED by white danish children (4–8\xa0years) to maintain Serum 25(Oh)D\u2009>\u200920\xa0ng/ml.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 37), ('IMPORTANT_CONSIDERATION', 89)]	3	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('UBERON_0001977', 'blood serum', 147, 'serum'), ('CHEBI_71657', 'versiconol acetate', 153, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 153, '25(OH)D')]
S165-PMC5941617	PMC5941617	5/2018	S165-PMC5941617	['another rct DEMONSTRATED that white uk adolescents (14–18\xa0years) REQUIRED higher intake of Vitamin D (up to 1200\xa0iu/day) during winter to achieve 25(Oh)D concentration\u2009>\u200920\xa0ng/ml in 97.5% of cases.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 65)]	2	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 146, '25(OH ... D')]
S181-PMC5941617	PMC5941617	5/2018	S181-PMC5941617	['subsequent italian cross sectional studies enrolling children and adolescents living in the north-western area of tuscany, central italy (latitude between 43°n and 44°n) not receiving Vitamin D supplementation CONFIRMED seasonal variability in Serum 25(Oh)D levels, with lower concentrations during late winter-early spring months (february–april), with negligible amount of Vitamin D obtained from diet [50,79], ACCORDING TO OTHER italian pediatric studies [70,76–78,83].']	[('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 413), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 426)]	3	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001977', 'blood serum', 244, 'serum'), ('CHEBI_71657', 'versiconol acetate', 250, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 250, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 375, 'vitamin D')]
S197-PMC5941617	PMC5941617	5/2018	S197-PMC5941617	['indeed, Serum 25(Oh)D evaluation SHOULD BE reserved to subjects AT RISK for Vitamin D deficiency, BUT INDICATIONS for 25(Oh)D measurement significantly VARY among different societies (table\xa08) [9,11,13,15,20–23,27,30].']	[('FUTURE_WORK', 33), ('IMPORTANT_CONSIDERATION', 64), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 98), ('INCOMPLETE_EVIDENCE', 102), ('DIFFICULT_TASK', 152)]	5	[('UBERON_0001977', 'blood serum', 8, 'serum'), ('CHEBI_71657', 'versiconol acetate', 14, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D')]
S198-PMC5941617	PMC5941617	5/2018	S198-PMC5941617	['we RECOMMEND against routine 25(Oh)D testing in children and adolescents, SUGGESTING to limit Serum 25(Oh)D levels evaluation in children and adolescents with multiple RISK FACTORS for Vitamin D deficiency.']	[('FUTURE_WORK', 3), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 168)]	3	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('UBERON_0001977', 'blood serum', 94, 'serum'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]
S211-PMC5941617	PMC5941617	5/2018	S211-PMC5941617	['a RECENT GLOBAL CONSENSUS RECOMMENDATIONS on prevention and management of nutritional rickets DEFINED Vitamin D deficiency AS Serum 25(Oh)D\u2009<\u2009\xa012\xa0ng/ml, CONSIDERING the increased incidence of rickets with Serum 25(Oh)D levels under this THRESHOLD [28].']	[('INCOMPLETE_EVIDENCE', 2), ('IMPORTANT_CONSIDERATION', 9), ('PROBABLE_UNDERSTANDING', 16), ('FUTURE_WORK', 26), ('INCOMPLETE_EVIDENCE', 94), ('PROBABLE_UNDERSTANDING', 94), ('PROBABLE_UNDERSTANDING', 123), ('IMPORTANT_CONSIDERATION', 153), ('PROBABLE_UNDERSTANDING', 237)]	9	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('UBERON_0001977', 'blood serum', 126, 'serum'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('UBERON_0001977', 'blood serum', 205, 'serum'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 211, '25(OH ... D')]
S256-PMC5941617	PMC5941617	5/2018	S256-PMC5941617	['SEVERAL STUDIES evaluated the ASSOCIATION between Vitamin D status and bone mass in children and adolescents, USUALLY SEARCHING for a CORRELATION between actual Serum 25(Oh)D levels and bone mass.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 30), ('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 134)]	5	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0001977', 'blood serum', 161, 'serum'), ('CHEBI_71657', 'versiconol acetate', 167, '25(OH)D')]
S264-PMC5941617	PMC5941617	5/2018	S264-PMC5941617	['HOWEVER, the EFFECT of supplementation became significant on total body bmc and Lumbar Spine bmd by dividing the sample into two groups, depending on Vitamin D status [25(Oh)D levels <\u200914\xa0ng/ml vs. ≥ 14\xa0ng/ml], SUGGESTING that Vitamin D supplementation MAY result in a clinically significant increase in bone mass in subjects with Vitamin D deficiency.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 253)]	4	[('UBERON_0006074', 'lumbar region of vertebral column', 80, 'lumbar spine'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 168, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin D')]
S269-PMC5941617	PMC5941617	5/2018	S269-PMC5941617	['in 2016, sacn and efsa revised dietary reference values for Vitamin D reporting an INCREASED RISK of adverse Musculoskeletal health outcomes at Serum 25(Oh)D levels in the range of deficiency, BUT with DIFFERENT THRESHOLDS (<\u200910\xa0ng/ml and\u2009<\u2009\xa020\xa0ng/ml, respectively) [25,26].']	[('IMPORTANT_CONSIDERATION', 83), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 202), ('PROBABLE_UNDERSTANDING', 212)]	4	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('UBERON_0002204', 'musculoskeletal system', 109, 'musculoskeletal'), ('UBERON_0001977', 'blood serum', 144, 'serum'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 150, '25 ... OH ... D')]
S283-PMC5941617	PMC5941617	5/2018	S283-PMC5941617	['HOWEVER, the most RECENT STUDY SUGGESTED that Vitamin D status during childhood MIGHT be more RELEVANT for bone health that maternal 25(Oh)D levels during fetal Life [237].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 80), ('IMPORTANT_CONSIDERATION', 94), ('SUPERFICIAL_RELATIONSHIP', 94)]	6	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('UBERON_0000104', 'life cycle', 161, 'life')]
S292-PMC5941617	PMC5941617	5/2018	S292-PMC5941617	['camargo et al., after adjusting for season of Birth, FOUND that newborns with Vitamin D Cord Blood levels <\u200910\xa0ng/ml had a two-fold (odds ratio: 2.16; 95% ci 1.35–3.46) increased risk of Respiratory infections by 3\xa0months of age as COMPARED TO newborns with 25(Oh)D concentrations >\u200930\xa0ng/ml [252].']	[('INCOMPLETE_EVIDENCE', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 232)]	2	[('GO_0007567', 'parturition', 46, 'birth'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 88, 'cord'), ('UBERON_0000178', 'blood', 93, 'blood'), ('UBERON_0001004', 'respiratory system', 187, 'respiratory'), ('CHEBI_71657', 'versiconol acetate', 258, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 258, '25(OH)D')]
S317-PMC5941617	PMC5941617	5/2018	S317-PMC5941617	['in an usa study a SIMILAR ASSOCIATION was OBSERVED between skin or soft Tissue infections by staphylococcus aureus strains and Vitamin D levels [25(Oh)D\u2009<\u200930\xa0ng/ml] in 202 children [276].']	[('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 18), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 42)]	4	[('UBERON_0000479', 'tissue', 72, 'tissue'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D')]
S333-PMC5941617	PMC5941617	5/2018	S333-PMC5941617	['an italian rct was performed TO TEST WHETHER Vitamin D3Supplementation (oral 100000\xa0iu every 3\xa0months for 4 doses) COULD improve Vitamin D status and AFFECT the t-Cell phenotype in hiv-infected patients aged 8 to 26\xa0years with Serum 25(Oh) D\u2009<\u200930\xa0ng/ml.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 37), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 150)]	4	[('CHEBI_52915', 'phosphatediyl group', 45, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CL_0000622', 'acinar cell', 162, '-cell'), ('UBERON_0001977', 'blood serum', 227, 'serum'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH) D')]
S341-PMC5941617	PMC5941617	5/2018	S341-PMC5941617	['significant ASSOCIATION between active tuberculosis and Vitamin D deficiency [25(Oh)D levels <\u200920\xa0ng/ml] HAS BEEN EVIDENCED in an australian study including 91 children with latent or active tuberculosis and 236 controls [296], SIMILARLY TO one uk study [297].']	[('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 105), ('INCOMPLETE_EVIDENCE', 114), ('INCOMPLETE_EVIDENCE', 228)]	4	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 78, '25(OH)D')]
S359-PMC5941617	PMC5941617	5/2018	S359-PMC5941617	['furthermore, PREVIOUS STUDIES focused on the ASSOCIATION between Serum 25(Oh)D levels and the Expression of Genes INVOLVED in the Proliferation and Cells Differentiation, showing an anti-proliferative activity of Vitamin D with CONSEQUENTLY remodeling inhibition [309–312].']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 45), ('SUPERFICIAL_RELATIONSHIP', 114), ('PROBABLE_UNDERSTANDING', 228)]	4	[('UBERON_0001977', 'blood serum', 65, 'serum'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 77, 'D'), ('GO_0010467', 'gene expression', 94, 'expression'), ('SO_0000704', 'gene', 108, 'genes'), ('GO_0007565', 'female pregnancy', 130, 'proliferation ...'), ('GO_0030154', 'cell differentiation', 148, 'cells differentiation'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
S370-PMC5941617	PMC5941617	5/2018	S370-PMC5941617	['in 966 children DEMONSTRATED that Vitamin D deficiency [Serum 25(Oh)D\u2009<\u2009\xa020\xa0ng/ml] was the MAJOR PREDICTIVE factor of asthma RISK [327], and gale et al.']	[('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 91), ('SUPERFICIAL_RELATIONSHIP', 97), ('IMPORTANT_CONSIDERATION', 125)]	4	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 62, '25(OH ... D')]
S386-PMC5941617	PMC5941617	5/2018	S386-PMC5941617	['two STUDIES in vitro SHOWED the IMPORTANCE of Vitamin D supplementation in patients affected by Corticosteroid-resistant asthma [315,343] BUT two other STUDIES DEMONSTRATED in vivo that lower 25(Oh)D levels were ASSOCIATED with an increase in Corticosteroids use and an IMPAIRED Lung function [344,345].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('IMPORTANT_CONSIDERATION', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 138), ('INCOMPLETE_EVIDENCE', 152), ('INCOMPLETE_EVIDENCE', 160), ('SUPERFICIAL_RELATIONSHIP', 212), ('IMPORTANT_CONSIDERATION', 270)]	8	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_36916', 'cation', 96, 'corticosteroid'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('CHEBI_50850', 'etabonate ester', 243, 'corticosteroids'), ('UBERON_0002048', 'lung', 279, 'lung')]
S394-PMC5941617	PMC5941617	5/2018	S394-PMC5941617	['a RECENT large STUDY FOUND NO EVIDENCE that Genetically determined reduction in 25(Oh)D levels conferred an increased risk for ad, SUGGESTING that EFFORTS to increase Vitamin D are UNLIKELY to reduce risks of the atopic disease [349].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 131), ('FUTURE_WORK', 147), ('PROBABLE_UNDERSTANDING', 181)]	6	[('SO_0000704', 'gene', 44, 'genetically'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S400-PMC5941617	PMC5941617	5/2018	S400-PMC5941617	['HOWEVER, it HAS BEEN SUGGESTED that in patients with a more SEVERE ad, unresponsive to common therapy and with low Serum 25(Oh)D levels, a trial of Vitamin D supplementation CAN BE CONSIDERED [352].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 60), ('FUTURE_WORK', 174), ('FUTURE_WORK', 181)]	5	[('UBERON_0001977', 'blood serum', 115, 'serum'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 127, 'D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S403-PMC5941617	PMC5941617	5/2018	S403-PMC5941617	['the SO-called ecological studies SUGGEST the RELATIONSHIP between latitude, the consequent level of sun exposure, Vitamin D Production and subsequent Serum 25(Oh)D levels and the prevalence and severity of allergic diseases.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 45)]	3	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0006272', 'leading strand elongation', 122, 'D production'), ('UBERON_0001977', 'blood serum', 150, 'serum'), ('CHEBI_71657', 'versiconol acetate', 156, '25(OH)D')]
S422-PMC5941617	PMC5941617	5/2018	S422-PMC5941617	['IF data of OBSERVATIONAL studies in general population in infancy are ENCOURAGING, in the daisy study, conducted in subjects at higher RISK, the Vitamin D nutritional intake in the first years of Life as well as the Serum 25(Oh)D levels at 9\xa0months of age were not associated with the development of Autoantibodies or with the progression to t1dm [381].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 11), ('FUTURE_WORK', 70), ('IMPORTANT_CONSIDERATION', 135)]	4	[('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('UBERON_0000104', 'life cycle', 196, 'life'), ('UBERON_0001977', 'blood serum', 216, 'serum'), ('CHEBI_71657', 'versiconol acetate', 222, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 222, '25 ... OH ... D'), ('GO_0044308', 'axonal spine', 300, 'autoantibodies')]
S435-PMC5941617	PMC5941617	5/2018	S435-PMC5941617	['a recent meta-analysis SHOWED that patients with crohn’s disease ( n \u2009=\u2009129808, age 11–48\xa0years) had lower Serum 25(Oh)D concentrations compared with healthy controls, with an overall prevalence of Vitamin D deficiency [25(Oh)D\u2009<\u2009\xa020\xa0ng/ml] of 57.7% and an inverse CORRELATION between Serum 25(Oh)D levels and the severity of disease [399].']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 265)]	2	[('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_63056', 'zinc cation', 113, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 119, 'D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('UBERON_0001977', 'blood serum', 285, 'serum'), ('CHEBI_71657', 'versiconol acetate', 291, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 291, '25(OH ... D')]
S450-PMC5941617	PMC5941617	5/2018	S450-PMC5941617	['finally, a single age DEPENDENT high-dose oral Vitamin D3(the SO-CALLED stoss therapy; <\u20093\xa0years: 200000\xa0iu; 4–12\xa0years 400000\xa0iu; >\u200912\xa0years 800000\xa0iu) was SAFE and efficacious in achieving and maintaining Serum 25(Oh)D levels >\u200920\xa0ng/ml during a 6-month period in ibd children with Vitamin D deficiency [412].']	[('SUPERFICIAL_RELATIONSHIP', 22), ('INCOMPLETE_EVIDENCE', 62), ('IMPORTANT_CONSIDERATION', 157)]	3	[('CHEBI_33279', 'vitamin D5', 47, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 47, 'vitamin D3'), ('UBERON_0001977', 'blood serum', 207, 'serum'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 213, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]
S476-PMC5941617	PMC5941617	5/2018	S476-PMC5941617	['FUTURE RESEARCH will clarify the IDEAL Vitamin D dosing regimen to treat Vitamin D deficiency and to maintain Serum 25(Oh)D levels ≥30\xa0ng/ml in cd children and adolescents [406].']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 33)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('CHEBI_71657', 'versiconol acetate', 116, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 116, '25(OH ... D')]
S482-PMC5941617	PMC5941617	5/2018	S482-PMC5941617	['a RECENT meta-analysis of 4 rcts and 11 non-rcts, ONLY 1 enrolling children [442], SHOWED that weight loss marginally improved Vitamin D in comparison with weight maintenance under similar Vitamin D intake [443], CONFIRMING that increased adiposity causes SUBOPTIMAL Serum 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 50), ('INCOMPLETE_EVIDENCE', 83), ('PROBABLE_UNDERSTANDING', 213), ('IMPORTANT_CONSIDERATION', 256)]	5	[('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D'), ('UBERON_0001977', 'blood serum', 267, 'serum'), ('CHEBI_71657', 'versiconol acetate', 273, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 273, '25(OH ... D')]
S509-PMC5941617	PMC5941617	5/2018	S509-PMC5941617	['regarding Adolescence, the society for adolescent health and medicine RECOMMENDED that obese adolescent without a 25(Oh)D measurement empirically receive Vitamin D supplementation at 1000\xa0iu/day [21].']	[('FUTURE_WORK', 70)]	1	[('GO_0048848', 'neurohypophysis morphogenesis', 10, 'adolescence'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 120, 'D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
S511-PMC5941617	PMC5941617	5/2018	S511-PMC5941617	['DIFFERENTLY, sacn CONFIRMED that obese People are AT RISK of low Serum 25(Oh)D concentrations, but HIGHLIGHTED that CURRENTLY EVIDENCE is INSUFFICIENT to RECOMMEND for obese Individuals different reference Nutrient intake of Vitamin D from that PROPOSED for the general uk population [25].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('IMPORTANT_CONSIDERATION', 50), ('INCOMPLETE_EVIDENCE', 99), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 126), ('INCOMPLETE_EVIDENCE', 138), ('FUTURE_WORK', 154), ('INCOMPLETE_EVIDENCE', 245)]	9	[('NCBITaxon_10088', 'Mus <genus>', 39, 'people'), ('UBERON_0001977', 'blood serum', 65, 'serum'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 71, '25(OH ... D'), ('NCBITaxon_1', 'root', 174, 'individuals'), ('CHEBI_33284', 'nutrient', 206, 'nutrient'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D')]
S521-PMC5941617	PMC5941617	5/2018	S521-PMC5941617	['several OBSERVATIONAL STUDIES have LINKED autism spectrum disorders and low Serum 25(Oh)D levels during Pregnancy because of Vitamin D pleiotropic activity [469–476].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 35)]	2	[('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S523-PMC5941617	PMC5941617	5/2018	S523-PMC5941617	['particularly, a RECENT meta-analysis SHOWED that Serum 25(Oh)D levels in children and adolescents (age 2–16\xa0years) with autism spectrum disorders were significantly lower than controls, SUGGESTING that lower Vitamin D levels MIGHT be a risk factor for autism [480].']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 186), ('INCOMPLETE_EVIDENCE', 225)]	4	[('UBERON_0001977', 'blood serum', 49, 'serum'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D')]
S554-PMC5941617	PMC5941617	5/2018	S554-PMC5941617	['supplementing Pregnant women with Vitamin D in a single or continued dose increases Serum 25(Oh)D at term and MAY reduce the RISK of Preeclampsia, low Birth weight and Preterm Birth.']	[('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 125)]	2	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0001977', 'blood serum', 84, 'serum'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 93, 'OH ... D'), ('GO_0007128', 'meiotic prophase I', 133, 'preeclampsia'), ('GO_0007567', 'parturition', 151, 'birth'), ('GO_0007565', 'female pregnancy', 168, 'preterm'), ('GO_0007567', 'parturition', 176, 'birth')]
S560-PMC5941617	PMC5941617	5/2018	S560-PMC5941617	['SUGGESTED that a Vitamin D intake of AT LEAST 4000\xa0iu/day SHOULD BE CONSIDERED in all Pregnant women to maintain Serum 25(Oh)D levels ≥40\xa0ng/ml [513,514].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 37), ('FUTURE_WORK', 58), ('FUTURE_WORK', 68)]	4	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnant'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 119, '25(OH)D')]
S568-PMC5941617	PMC5941617	5/2018	S568-PMC5941617	['we do not RECOMMEND routine screening of Serum 25(Oh)D levels in all Pregnant and breastfeeding women, BUT we SUGGEST to CONSIDER Vitamin D testing in women with multiple RISK FACTORS for Vitamin D deficiency, PARTICULARLY if not receiving Vitamin D supplementation.']	[('FUTURE_WORK', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('INCOMPLETE_EVIDENCE', 110), ('FUTURE_WORK', 121), ('SUPERFICIAL_RELATIONSHIP', 171), ('ANOMALY_CURIOUS_FINDING', 210), ('IMPORTANT_CONSIDERATION', 210)]	7	[('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 47, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D')]
S572-PMC5941617	PMC5941617	5/2018	S572-PMC5941617	['after completion of treatment, Serum 25(Oh)D concentrations SHOULD BE revaluated, AS it is not unusual for a second course of treatment to be necessary to achieve adequate Vitamin D status [23].']	[('FUTURE_WORK', 60), ('PROBABLE_UNDERSTANDING', 82)]	2	[('UBERON_0001977', 'blood serum', 31, 'serum'), ('CHEBI_71657', 'versiconol acetate', 37, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 37, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]
S577-PMC5941617	PMC5941617	5/2018	S577-PMC5941617	['daily administration of 2000\xa0iu of Vitamin D3For 16\xa0weeks was EFFECTIVE in increasing Serum 25(Oh)D levels >\u200930\xa0ng/ml also in black adolescents (14–18\xa0years) with Vitamin D deficiency [151].']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('CHEBI_27364', 'zinc molecular entity', 35, 'vitamin D3for'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S582-PMC5941617	PMC5941617	5/2018	S582-PMC5941617	['a RECENT 1-year-RCT compared three different regimens for asymptomatic children and adolescents with Vitamin D deficiency and insufficiency (400\xa0iu/day, 45000\xa0iu weekly for 2\xa0months then 400\xa0iu daily, 2000\xa0iu/day for 3\xa0months then 1000\xa0iu/day), SUGGESTING that low loading dose with high maintenance dose is PREFERRED to achieve steady increase in Serum 25(Oh)D levels avoiding hypercalcemic side effects [521].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 245), ('PROBABLE_UNDERSTANDING', 308)]	3	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001977', 'blood serum', 348, 'serum'), ('CHEBI_71657', 'versiconol acetate', 354, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 354, '25(OH)D')]
S591-PMC5941617	PMC5941617	5/2018	S591-PMC5941617	['adolescents with SEVERE Vitamin D deficiency treated with an intramuscular injection of a megadose of Vitamin D3(10000\xa0iu/kg, maximum 600000\xa0iu) had insufficient serum 25(Oh)D after 3\xa0months [522].']	[('IMPORTANT_CONSIDERATION', 17)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 102, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 102, 'vitamin D3'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D')]
S614-PMC5941617	PMC5941617	5/2018	S614-PMC5941617	['summary of RECOMMENDATIONS\n\ndefinition of Vitamin D status\n\nindividual Vitamin D status can be assessed evaluating Serum circulating 25(Oh)D levels.']	[('FUTURE_WORK', 11)]	1	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0001977', 'blood serum', 115, 'serum'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 139, 'D')]
S615-PMC5941617	PMC5941617	5/2018	S615-PMC5941617	['DEPENDING ON 25(Oh)D levels, Vitamin D status can be defined as follows:\nsufficiency ≥30\xa0ng/ml\ninsufficiency 20–29\xa0ng/ml\ndeficiency <\u200920\xa0ng/ml\nsevere deficiency <\u200910\xa0ng/ml\nthe term hypovitaminosis D refers to Serum 25(Oh)D levels <\u200930\xa0ng/ml.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 197, 'D'), ('UBERON_0001977', 'blood serum', 209, 'serum'), ('CHEBI_71657', 'versiconol acetate', 215, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 215, '25(OH)D')]
S616-PMC5941617	PMC5941617	5/2018	S616-PMC5941617	['evaluation of Vitamin D status\n\nthe isotope dilution- lc-ms/ms is CONSIDERED the PREFERRED method for measuring Serum 25(Oh)D levels, especially in the Neonatal Period.']	[('INCOMPLETE_EVIDENCE', 66), ('PROBABLE_UNDERSTANDING', 81)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0001977', 'blood serum', 112, 'serum'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 118, '25(OH ... D'), ('UBERON_0007221', 'neonate stage', 152, 'neonatal period')]
S628-PMC5941617	PMC5941617	5/2018	S628-PMC5941617	['we SUGGEST to measure Serum 25(Oh)D levels in infants with multiple RISK FACTORS for Vitamin D deficiency (table\xa06).']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 68)]	2	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 34, 'D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
S647-PMC5941617	PMC5941617	5/2018	S647-PMC5941617	['we SUGGEST to measure Serum 25(Oh)D levels in presence of multiple RISK FACTORS for Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 67)]	2	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 28, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]
S683-PMC5941617	PMC5941617	5/2018	S683-PMC5941617	['Serum 25(Oh)D evaluation MAY BE CONSIDERED in children with SEVERE ad unresponsive to common therapy and multiple RISK FACTORS for Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 25), ('FUTURE_WORK', 32), ('IMPORTANT_CONSIDERATION', 32), ('IMPORTANT_CONSIDERATION', 60), ('SUPERFICIAL_RELATIONSHIP', 114)]	5	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S700-PMC5941617	PMC5941617	5/2018	S700-PMC5941617	['we SUGGEST against further 25(Oh)D evaluations in case of sufficient 25(Oh)D levels or documented normalization of Vitamin D status and strict adherence to the gluten-free diet.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S711-PMC5941617	PMC5941617	5/2018	S711-PMC5941617	['if an obese Individual does not receive Vitamin D supplementation and has a sedentary indoor lifestyle with consequent reduced sun exposure, Serum 25(Oh)D evaluation MAY BE CONSIDERED to confirm Vitamin D deficiency and start adequate treatment.']	[('INCOMPLETE_EVIDENCE', 166), ('ANOMALY_CURIOUS_FINDING', 170), ('FUTURE_WORK', 173), ('IMPORTANT_CONSIDERATION', 173)]	4	[('NCBITaxon_1', 'root', 12, 'individual'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001977', 'blood serum', 141, 'serum'), ('CHEBI_71657', 'versiconol acetate', 147, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 147, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D')]
S720-PMC5941617	PMC5941617	5/2018	S720-PMC5941617	['we SUGGEST to CONSIDER serum 25(Oh)D testing in women with multiple RISK FACTORS for Vitamin D deficiency, PARTICULARLY if not receiving Vitamin D supplementation, and/or with specific conditions POSSIBLY AFFECTING Pregnancy course (table\xa09).']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 68), ('ANOMALY_CURIOUS_FINDING', 107), ('IMPORTANT_CONSIDERATION', 107), ('INCOMPLETE_EVIDENCE', 196), ('SUPERFICIAL_RELATIONSHIP', 205)]	7	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy')]
S725-PMC5941617	PMC5941617	5/2018	S725-PMC5941617	['management of asymptomatic Vitamin D deficiency and insufficiency\n\nin children and adolescents with asymptomatic Vitamin D deficiency [25(Oh)D\u2009<\u2009\xa020\xa0ng/ml] we RECOMMEND the administration of 2000\xa0iu/day or 50000\xa0iu/week of Vitamin D2Or d3for 6–8\xa0weeks (8\xa0weeks in adolescents) in order to obtain a sufficient Vitamin D status [25(Oh)D\u2009≥\u200930\xa0ng/ml].']	[('FUTURE_WORK', 159)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 135, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 135, '25 ... OH ... D'), ('CHEBI_27329', 'xanthosine phosphate', 223, 'vitamin D2or'), ('PR_000017209', 'utrophin', 223, 'vitamin D2or'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 327, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 333, 'D')]
S727-PMC5941617	PMC5941617	5/2018	S727-PMC5941617	['in presence of adequate Vitamin D status [25(Oh)D\u2009≥\u200930\xa0ng/ml], we RECOMMEND to continue Vitamin D supplementation as RECOMMENDED for age.']	[('FUTURE_WORK', 66), ('FUTURE_WORK', 117)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 42, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 42, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
S730-PMC5941617	PMC5941617	5/2018	S730-PMC5941617	['in case of detection of asymptomatic Vitamin D insufficiency [25(Oh)D between 20 and 29\xa0ng/ml], particularly in subjects AT RISK for vitamin d deficiency, we RECOMMENDED to start Vitamin D supplementation according to the modalities and REQUIREMENTS RECOMMENDED for age.']	[('IMPORTANT_CONSIDERATION', 121), ('FUTURE_WORK', 158), ('IMPORTANT_CONSIDERATION', 237), ('FUTURE_WORK', 250)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]
S21-PMC5956785	PMC5956785	5/2018	S21-PMC5956785	['CONSEQUENTLY, low Vitamin D concentrations are ASSOCIATED with an increase in pro-Inflammatory Mediators and more active disease [6,10] CONSISTENT, for example, with the OBSERVATION that low Serum 25(Oh)D is ASSOCIATED with increased disease activity in rheumatoid arthritis [11].']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 136), ('ANOMALY_CURIOUS_FINDING', 170), ('SUPERFICIAL_RELATIONSHIP', 208)]	5	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_64664', '(2-nitrophenyl)azo group', 81, '-inflammatory mediators'), ('UBERON_0001977', 'blood serum', 191, 'serum'), ('CHEBI_71657', 'versiconol acetate', 197, '25(OH)D')]
S62-PMC5956785	PMC5956785	5/2018	S62-PMC5956785	['defining Vitamin D status\nvitamin D deficiency is DEFINED AS a Serum 25(Oh)D concentration less than 30\xa0nmol/l, a 25(Oh)D concentration between 30 and 50\xa0nmol/l IS CONSIDERED insufficient, greater than 50\xa0nmol/l IS CONSIDERED sufficient and a 25(Oh)D status greater than 125\xa0nmol/l IS CONSIDERED AT RISK of adverse EFFECTS [19].']	[('PROBABLE_UNDERSTANDING', 50), ('PROBABLE_UNDERSTANDING', 58), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 212), ('INCOMPLETE_EVIDENCE', 282), ('IMPORTANT_CONSIDERATION', 296), ('SUPERFICIAL_RELATIONSHIP', 315)]	7	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 34, 'D'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 114, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D')]
S105-PMC5956785	PMC5956785	5/2018	S105-PMC5956785	['1994 39°n [50]jcan\u2009=\u200935 (14)8.8\u2009±\u20094.139.8\u2009±\u200920.5disease activity of jca appears to be ASSOCIATED with lower Vitamin D.mean disease duration 3.4\xa0years control n \u2009=\u200915 25(Oh)D 68.1\u2009±\u200915.5\xa0nmol/l control group taking Corticosteroids n\u2009=\u20094 25(Oh)D 51.4\u2009±\u200924.5\xa0nmol/l.missouri, usa hillman et al.']	[('SUPERFICIAL_RELATIONSHIP', 86)]	1	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 166, '25(OH)D'), ('CHEBI_50850', 'etabonate ester', 214, 'corticosteroids'), ('CHEBI_71657', 'versiconol acetate', 236, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 242, 'D')]
S106-PMC5956785	PMC5956785	5/2018	S106-PMC5956785	['(1994) 37°n [47]jra n \u2009=\u200944 (28)11.8\u2009±\u20093.866.6\u2009±\u200926.7lower bone Mineral content and bone BIOMARKERS in jra patients that controls BUT higher Vitamin D in jra.n\u2009=\u200937 controls 25(Oh)D 53.2\u2009±\u200918.7\xa0nmol/l.milano, italy bianchi et al.']	[('SUPERFICIAL_RELATIONSHIP', 89), ('ANOMALY_CURIOUS_FINDING', 130)]	2	[('CHEBI_46662', 'mineral', 64, 'mineral'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 174, '25(OH ... D')]
S108-PMC5956785	PMC5956785	5/2018	S108-PMC5956785	['reviewsuggests severe jra has an INFLUENCE on bone mass POSSIBLY MEDIATED by a decrease in active Vitamin D Metabolites.study duration one year, controls ONLY measured at baseline 25(Oh)D 92\u2009±\u200917.5\xa0nmol/l n \u2009=\u200920huddinge, sweden johansson et al.']	[('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 65), ('INCOMPLETE_EVIDENCE', 154)]	4	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_25212', 'metabolite', 108, 'metabolites'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D')]
S123-PMC5956785	PMC5956785	5/2018	S123-PMC5956785	['age, ethnicity, season, bmi ASSOCIATED with 25(Oh)D BUT NOT Vitamin D deficiency.no association with whole sample; SMALL negative ASSOCIATION for new onset jia; mean time since onset 28\xa0months.helinski, finland markula-patjas et al.']	[('SUPERFICIAL_RELATIONSHIP', 28), ('ANOMALY_CURIOUS_FINDING', 52), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 130)]	4	[('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 46, '(OH ... D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
S125-PMC5956785	PMC5956785	5/2018	S125-PMC5956785	['2009 52°n [59]pediatric arthralgia n \u2009=\u2009730 25(Oh)D n \u2009=\u200973<\u20091859.9significantly more reported fall and winter as season of onset – more referrals from northern sk 40%\u2009<\u200950\xa0nmol/l 42% 50–75\xa0nmol/l ASSOCIATION between psychological stress, school absenteeism Vitamin D insufficiency and arthralgia.helinski, finland valta et al.']	[('SUPERFICIAL_RELATIONSHIP', 197)]	1	[('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 44, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S140-PMC5956785	PMC5956785	5/2018	S140-PMC5956785	['the 2013, systematic literature review of 19 childhood arthritis STUDIES REPORTED Vitamin D status (14 reporting 25(Oh)D and 11 reporting 1,25(Oh)D) SUGGESTED that at that time there was NO CLEAR LINK between Vitamin D status and children with chronic arthritis [12].']	[('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 73), ('INCOMPLETE_EVIDENCE', 149), ('FULL_UNKNOWN', 187), ('SUPERFICIAL_RELATIONSHIP', 196)]	5	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 113, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 116, 'OH ... D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 143, 'OH)D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S189-PMC5956785	PMC5956785	5/2018	S189-PMC5956785	['the authors QUESTIONED WHETHER jia patients with more SEVERE disease REQUIRE higher supplementation of Vitamin D to maintain normal 25(Oh) D concentrations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 23), ('IMPORTANT_CONSIDERATION', 54), ('IMPORTANT_CONSIDERATION', 69)]	5	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH) D')]
S199-PMC5956785	PMC5956785	5/2018	S199-PMC5956785	['two studies REPORTED Intake of Vitamin D supplements by study participants but neither had a mean 25(Oh)D that reached the OPTIMAL concentration [38,44].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 123)]	2	[('GO_0007631', 'feeding behavior', 21, 'intake'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 104, 'D')]
S205-PMC5956785	PMC5956785	5/2018	S205-PMC5956785	['REPORTED SIMILAR intake of Vitamin D and higher 25(Oh)D in controls, and in the study REPORTED by dey et al.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 9), ('INCOMPLETE_EVIDENCE', 86)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D')]
S219-PMC5956785	PMC5956785	5/2018	S219-PMC5956785	['Corticosteroids promote the breakdown of both 25(Oh)D and 1,25(Oh)D and also counteract EFFECTS of Vitamin D on bone formation [74,75].']	[('SUPERFICIAL_RELATIONSHIP', 88)]	1	[('CHEBI_36961', 'chalcocarbonic acid', 0, 'Corticosteroids'), ('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('CHEBI_17996', 'chloride', 59, ','), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S226-PMC5956785	PMC5956785	5/2018	S226-PMC5956785	['the authors HYPOTHESIZED that the REASON their patients’ 25(Oh)D concentrations were so high was that their PREVIOUS RESEARCH had FOUND low concentrations of 25(Oh)D and they were encouraging their patients to consume Vitamin D fortified Foods and to spend time in the sun [53].']	[('INCOMPLETE_EVIDENCE', 12), ('PROBABLE_UNDERSTANDING', 34), ('INCOMPLETE_EVIDENCE', 108), ('INCOMPLETE_EVIDENCE', 130)]	4	[('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 57, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 60, 'OH ... D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 161, 'OH)D'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D'), ('CHEBI_33290', 'food', 238, 'foods')]
S232-PMC5956785	PMC5956785	5/2018	S232-PMC5956785	['the ROLE and an appropriate amount of Vitamin D intake or 25(Oh)D target for inflammation or disease activity have yet to be established.']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D')]
S279-PMC5956785	PMC5956785	5/2018	S279-PMC5956785	['thus far, we KNOW that there is a ROLE for Vitamin D in the inflammatory pathways, a high prevalence of 25(Oh)D insufficiency among children with jia, and an established LINK of Vitamin D with other Autoimmune diseases.']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 34), ('SUPERFICIAL_RELATIONSHIP', 170)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 199, 'autoimmune')]
S17-PMC6011374	PMC6011374	6/2018	S17-PMC6011374	['in australia and new zealand, the deficiency cut-offs are based on the ROLE of Vitamin D in bone health where Serum 25(Oh)D\u2009≥\u200950\xa0nmol/l at the end of winter is required for optimal Musculoskeletal health [1].']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('CHEBI_71657', 'versiconol acetate', 116, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 116, '25(OH ... D'), ('UBERON_0002204', 'musculoskeletal system', 181, 'musculoskeletal')]
S24-PMC6011374	PMC6011374	6/2018	S24-PMC6011374	['PREVIOUS STUDIES on Pregnant australian and new zealand women have reported that WHILE circulating 25(Oh)D was significantly lower in women with pe, Sptb, gdm and those who Delivered a small-for Gestational age (sga) infant, no association between Vitamin D deficiency and these Pregnancy complications was found after adjusting for covariates [18–20].']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81)]	2	[('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000015390', 'sterol O-acyltransferase 2', 149, 'sPTB'), ('GO_0007567', 'parturition', 173, 'delivered'), ('GO_0007565', 'female pregnancy', 195, 'gestational'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 279, 'pregnancy')]
S29-PMC6011374	PMC6011374	6/2018	S29-PMC6011374	['using a robust, validated chemiluminescent-based assay to measure Serum 25(Oh)D [27], we AIMED TO INVESTIGATE the DIFFERENCES between Vitamin D status in early Pregnancy in two distinct populations of Nulliparous women from australia and new zealand.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 89), ('QUESTION_ANSWERED_BY_THIS_WORK', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114)]	3	[('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('GO_0046662', 'regulation of oviposition', 201, 'nulliparous')]
S30-PMC6011374	PMC6011374	6/2018	S30-PMC6011374	['we also AIMED TO EXAMINE the RELATIONSHIP between Serum 25(Oh)D at 15\u2009±\u20091\xa0weeks’ Gestation and the risk of an adverse Pregnancy outcome and included determining the EFFECT modification of fetal sex on the ASSOCIATION between maternal Vitamin D status and Pregnancy outcome.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 29), ('SUPERFICIAL_RELATIONSHIP', 165), ('SUPERFICIAL_RELATIONSHIP', 205)]	5	[('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 56, '25(OH)D'), ('GO_0007565', 'female pregnancy', 81, 'gestation'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy')]
S45-PMC6011374	PMC6011374	6/2018	S45-PMC6011374	['UNLIKE the PREVIOUSLY published data on Vitamin D in the auckland cohort [20], Serum 25(Oh)D was measured using the ids-isys chemiluminescent-based assay (abacus, als) as per the manufacturer’s instructions.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 11)]	2	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001977', 'blood serum', 79, 'serum'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 85, '25(OH ... D')]
S50-PMC6011374	PMC6011374	6/2018	S50-PMC6011374	['given that the month in which the Serum was sampled heavily INFLUENCES Vitamin D status, “standardised” Serum 25(Oh)D concentrations were calculated as previously described [34] in order to normalise against seasonal VARIATION.']	[('SUPERFICIAL_RELATIONSHIP', 60), ('DIFFICULT_TASK', 217)]	2	[('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 110, '25(OH ... D')]
S62-PMC6011374	PMC6011374	6/2018	S62-PMC6011374	['given that all these factors significantly INFLUENCED Serum 25(Oh)D in the linear regression model, it was unsurprising that Vitamin D status of the women was significantly different between the two recruitment sites.']	[('SUPERFICIAL_RELATIONSHIP', 43)]	1	[('UBERON_0001977', 'blood serum', 54, 'serum'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 60, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S63-PMC6011374	PMC6011374	6/2018	S63-PMC6011374	['HOWEVER, after adjusting for maternal age, bmi, sei, smoking status and Alcohol consumption at 15\u2009±\u20091\xa0weeks’ Gestation, ethnicity, recreational walking and season, the women recruited in adelaide STILL had significantly lower Serum 25(Oh)D when compared with those in auckland (adelaide: 58.4\u2009±\u200950.3 vs. auckland: 70.2\u2009±\u200954.5\xa0nmol/l, p\u2009<\u20090.001) INDICATING the INFLUENCE of OTHER CONFOUNDERS not measured as part of the study on Vitamin D status.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 196), ('INCOMPLETE_EVIDENCE', 345), ('SUPERFICIAL_RELATIONSHIP', 360), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 373), ('PROBLEM_COMPLICATION', 379)]	6	[('CHEBI_30879', 'alcohol', 72, 'alcohol'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('UBERON_0001977', 'blood serum', 226, 'serum'), ('CHEBI_71657', 'versiconol acetate', 232, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 232, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]
S64-PMC6011374	PMC6011374	6/2018	S64-PMC6011374	['caption (table-wrap): table 1\n\nparticipant characteristics and comparison of characteristics between women recruited at the adelaide and auckland scope centresall women (n = 2800)adelaide (n = 1156)auckland (n = 1644) p value*age yrs , mean (sd)28 (6)23.73 (5.11)30.44 (4.82)<0.0001bmi kg/m2, mean (sd)25.8 (5.44)27.04 (6.56)24.88 (4.26)<0.0001ethnicity<0.0001\u2003caucasian2449 (87)1060 (92)1389 (84)\u2003non caucasian351 (13)96 (8)255 (16)smoking status, n (%)<0.0001\u2003no2152 (77)704 (61)1448 (88)\u2003quit during Pregnancy306 (11)175 (15)131 (8)\u2003smoking342 (12)277 (24)65 (4)Alcohol consumption, n (%)<0.0001\u2003no1480 (53)708 (61)772 (47)\u2003stopped during pregnancy1185 (42)397 (34)788 (48)\u2003consuming Alcohol135 (5)51 (4)84 (5)fruit intake, n (%)<0.0001\u2003≥1x per day2032 (73)586 (51)1446 (88)\u20033-6x per week405 (14)272 (24)133 (8)\u20031-2x per week223 (8)181 (16)42 (3)\u20031-3x per month or less140 (5)117 (10)23 (1)recreational walking<0.0001\u2003never428 (15)265 (23)163 (10)\u20031-3 times/week1773 (63)668 (58)1105 (68)\u2003≥4 times/week590 (22)221 (19)369 (23)time watching tv<0.0001\u2003<5 hours per day2404 (86)901 (78)1503 (92)\u2003≥5 hours per day387 (14)253 (22)134 (8)season Serum was sampled0.3213\u2003summer636 (23)278 (24)358 (22)\u2003autumn705 (25)273 (24)432 (26)\u2003winter727 (26)300 (26)427 (26)\u2003spring732 (26)305 (26)427 (26)Serum 25(Oh)D nmol/l , mean (sd)68.09 (27.14)60.06 (23.68)73.74 (27.99)<0.0001vitamin D status<0.0001\u2003<25 nmol/l99 (4)48 (4)51 (3)\u200325-50 nmol/l673 (24)375 (32)298 (18)\u200350-75 nmol/l928 (33)422 (37)506 (31)\u2003>75 nmol/l1098 (39)311 (27)787 (48)\n* p values for continuous variables were determined using a welch’s t-test and categorical variables a fisher’s exact test comparing adelaide and auckland women\n\nstandardising Serum 25(Oh)D based on seasonal variation\nAS EXPECTED, there was a seasonal INFLUENCE on Serum 25(Oh)D and THUS, “standardised” Vitamin D concentrations were calculated to account for the month of Serum collection.']	[('INCOMPLETE_EVIDENCE', 1748), ('SUPERFICIAL_RELATIONSHIP', 1782), ('PROBABLE_UNDERSTANDING', 1813)]	3	[('GO_0007602', 'phototransduction', 503, 'pregnancy306'), ('CHEBI_30879', 'alcohol', 565, 'Alcohol'), ('CHEBI_78635', 'fatty alcohol 16:1', 687, 'alcohol135'), ('UBERON_0001977', 'blood serum', 1142, 'serum'), ('UBERON_0001977', 'blood serum', 1289, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1295, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1375, 'D'), ('UBERON_0001977', 'blood serum', 1706, 'serum'), ('CHEBI_71657', 'versiconol acetate', 1712, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1712, '25(OH)D'), ('UBERON_0001977', 'blood serum', 1795, 'serum'), ('CHEBI_71657', 'versiconol acetate', 1801, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1801, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1834, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1903, 'serum')]
S80-PMC6011374	PMC6011374	6/2018	S80-PMC6011374	['caption (table-wrap): table 2\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaneous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status categorised based on standardised quartiles and clinical definitions of Vitamin D statuspregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci)standardised quartiles**\u2003low711 (25)328 (46)0.95 (0.85, 1.07)46 (6)1.02 (0.66, 1.57))57 (8)0.97 (0.67, 1.42)28 (4)0.79 (0.47, 1.30)36 (5)0.83 (0.54, 1.29)84 (12)1.02 (0.75, 1.39)\u2003low-moderate755 (27)318 (42)1.00 (0.90, 1.12)42 (6)1.07 (0.69, 1.64)65 (9)1.06 (0.74, 1.52)25 (3)0.67 (0.39, 1.16)33 (4)0.87 (0.56, 1.3572 (10)0.98 (0.73, 1.32)\u2003moderate-high702 (25)309 (44)1.0†37 (5)1.0†50 (7)1.0†28 (4)1.0†39 (6)1.0†81 (12)1.0†\u2003high630 (23)258 (41)0.93 (0.82, 1.06)†35 (6)1.24 (0.78, 1.96)40 (6)0.87 (0.58, 1.30)10 (2) 0.47(0.23, 0.96) 30 (5)0.77 (0.48, 1.25)60 (10)0.80 (0.57, 1.11)Vitamin d status\u2003<25 nmol/l99 (4)51 (52)1.10 (0.89, 1.36)8 (8)1.44 (0.68, 3.03))6 (6)0.70 (0.32, 1.52)5 (5)0.98 (0.38, 2.52)7 (7)1.44 (0.68, 3.04)13 (13)1.15 (0.66, 2.01)\u200325-50 nmol/l673 (24)301 (45)0.93 (0.83, 1.03)45 (7)1.18 (0.80, 1.75)59 (9)0.97 (0.71, 1.34)26 (4)0.89 (0.54, 1.47)29 (4)0.75 (0.48, 1.16)74 (11)0.93 (0.69, 1.24)\u2003>50-75 nmol/l928 (33)428 (46)1.0†48 (5)1.0†80 (9)1.0†35 (4)1.0†52 (6)1.0†107 (12)1.0†\u2003>75 nmol/l1098 (39)435 (40)0.95 (0.86, 1.04)60 (5)1.28 (0.87, 1.87)67 (6)0.82 (0.59, 1.12)†26 (2)0.78 (0.48, 1.28)51 (5)0.86 (0.59, 1.26)104 (9)0.86 (0.67, 1.12)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that Serum was sampled based as previously described [34]\n†reference category\n\nSerum 25(Oh)D, Pregnancy outcome and fetal sex\nas THERE IS EVIDENCE to SUGGEST that Vitamin D Metabolism within the Placenta MAY DIFFER with respect to fetal sex [35] THUS, we ASSESSED the EFFECT of “standardised” Vitamin D status on Pregnancy outcome stratified by fetal sex (table\xa03).']	[('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2251), ('INCOMPLETE_EVIDENCE', 2305), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2309), ('PROBABLE_UNDERSTANDING', 2347), ('QUESTION_ANSWERED_BY_THIS_WORK', 2356), ('SUPERFICIAL_RELATIONSHIP', 2369)]	7	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 210, 'preterm birth'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 1141, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1882, 'gestation'), ('CHEBI_30879', 'alcohol', 1906, 'alcohol'), ('UBERON_0001977', 'blood serum', 2060, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2066, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2066, '25(OH)D'), ('UBERON_0001977', 'blood serum', 2106, 'serum'), ('UBERON_0001977', 'blood serum', 2180, 'Serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 2189, 'OH)D'), ('GO_0007565', 'female pregnancy', 2195, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2264, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 2264, 'vitamin D metabolism'), ('UBERON_0001987', 'placenta', 2296, 'placenta'), ('CHEBI_27300', 'vitamin D', 2394, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2414, 'pregnancy')]
S86-PMC6011374	PMC6011374	6/2018	S86-PMC6011374	['caption (table-wrap): table 3\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaeous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status and stratified by fetal sexpregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci)standardised quartiles**males\u2003low367 (26)173 (47)1.00 (0.85, 1.18)24 (7)1.24 (0.65, 2.34)31 (8)1.11 (0.64, 1.94)18 (5)1.25 (0.58, 2.68)22 (6)1.09 (0.60, 1.98)43 (12)1.14 (0.73, 1.79)\u2003low-moderate364 (26)163 (45)1.01 (0.86, 1.19))20 (5)1.11 (0.58, 2.12)32 (9)1.25 (0.73, 2.13)13 (4)1.06 (0.48, 2.38)18 (5)0.93 (0.49, 1.76)45 (12)1.23 (0.80, 1.88)\u2003moderate-high359 (25)152 (42)1.0†16 (4)1.0†23 (6)1.0†11 (3)1.0†18 (5)1.0†35 (10)1.0†\u2003high325 (23)111 (34)0.86 (0.71, 1.04)15 (5)1.18 (0.59, 2.36)17 (5)0.90 (0.50, 1.62)4 (1)0.45 (0.15, 1.38)15 (5)0.97 (0.50, 1.88)26 (8)0.77 (0.47, 1.26)females\u2003low380 (28)169 (44)0.91 (0.77, 1.06)23 (6)0.85 (0.47, 1.55)30 (8)0.87 (0.52, 1.45)13 (3)0.51 (0.25, 1.04)14 (4)0.61 (0.31, 1.18)45 (12)0.88 (0.58, 1.35)\u2003low-moderate353 (26)168 (48)0.99 (0.85, 1.15)24 (7)1.03 (0.57, 1.85)31 (9)0.92 (0.57, 1.50)9 (3) 0.44(0.20, 0.97) 18 (5)0.79 (0.43, 1.45)33 (9)0.74 (0.48, 1.13)\u2003moderate-high334 (24)149 (45)1.0†19 (6)1.0†28 (8)1.0†17 (5)1.0†21 (6)1.0†31 (9)1.0†\u2003high314 (23)128 (41)1.00 (0.84, 1.19)19 (6)1.29 (0.70, 2.35)20 (6)0.85 (0.49, 1.46)6 (2)0.48 (0.19, 1.23)12 (4)0.60 (0.30, 1.21)29 (9)0.82 (0.53, 1.28)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that serum was sampled based as previously described [34]\n†reference category\n\ndiscussion\nthis study ADDS TO THE current body of LITERATURE on Vitamin D status in a population of Pregnant australian and new zealand women and provides INSIGHT into normal circulating levels of 25(Oh)D in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 2125), ('INCOMPLETE_EVIDENCE', 2258)]	2	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 209, 'preterm birth'), ('GO_0007565', 'female pregnancy', 244, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1805, 'gestation'), ('CHEBI_30879', 'alcohol', 1829, 'alcohol'), ('UBERON_0001977', 'blood serum', 1983, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1989, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1989, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2203, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 2300, '25(OH)D'), ('GO_0007565', 'female pregnancy', 2317, 'pregnancy')]
S97-PMC6011374	PMC6011374	6/2018	S97-PMC6011374	['HOWEVER, after adjusting for factors shown to be ASSOCIATED with Vitamin D status including bmi and recreational walking, serum 25(Oh)D remained significantly lower in the women recruited in adelaide SUGGESTING the INFLUENCE of OTHER factors not measured as part of scope for example, hours spent outside in the sun.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 200), ('SUPERFICIAL_RELATIONSHIP', 215), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 228)]	5	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 130, '(OH ... D')]
S98-PMC6011374	PMC6011374	6/2018	S98-PMC6011374	['as INDICATED by the seasonal variation in Serum 25(Oh)D, amongst women recruited in adelaide, Vitamin D status declined significantly from february to april WHILST in the women recruited in auckland, Serum 25(Oh)D in march and april remained elevated before declining.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 157)]	2	[('UBERON_0001977', 'blood serum', 42, 'serum'), ('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 48, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 206, '25(OH)D')]
S101-PMC6011374	PMC6011374	6/2018	S101-PMC6011374	['THEREFORE, the protective ROLE of high 25(Oh)D 15\u2009±\u20091\xa0weeks’ Gestation against gdm, as seen with a decreased risk of gdm in women within the ‘high’ quartile of standardised Vitamin D compared to moderate-high, is CONSISTENT with knowledge about Vitamin D and diabetes.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 213)]	3	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('GO_0007565', 'female pregnancy', 61, 'gestation'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]
S111-PMC6011374	PMC6011374	6/2018	S111-PMC6011374	['lack of statistically significant associations with other Pregnancy complications MAY reflect the fact that this was a largely Vitamin D-replete population (>\u200972% with Serum 25(Oh)D\u2009>\u200950\xa0nmol/l) LIKELY DUE TO their residence latitude as low Serum 25(Oh)D was found in the scope ireland cohort [52].']	[('INCOMPLETE_EVIDENCE', 82), ('PROBABLE_UNDERSTANDING', 195), ('PROBLEM_COMPLICATION', 202)]	3	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('UBERON_0001977', 'blood serum', 168, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 177, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 180, 'D'), ('UBERON_0001977', 'blood serum', 241, 'serum'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 247, '25(OH)D')]
S135-PMC5487839	PMC5487839	3/2016	S135-PMC5487839	['the Ergocalciferol (Vitamin D2) Metabolite, 25(Oh) D, crosses the Placenta; maternal Serum concentrations CORRELATE with foetal concentrations at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 106)]	1	[('CHEBI_4910', 'etomidate', 4, 'ergocalciferol'), ('CHEBI_28934', 'vitamin D2', 20, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 20, 'vitamin D2'), ('CHEBI_39382', 'flufenoxuron', 32, 'metabolite'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 51, 'D'), ('UBERON_0001987', 'placenta', 66, 'placenta'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('GO_0007567', 'parturition', 146, 'birth')]
S445-PMC5941617	PMC5941617	5/2018	S445-PMC5941617	['in ibd pediatric patients, 2000\xa0iu/day of Vitamin D3For 6\xa0months was more EFFECTIVE in raising Serum 25(Oh)D concentrations >\u200930\xa0ng/ml than 400 ui/day or doses up to 2000\xa0iu of Vitamin D2[407,408].']	[('SUPERFICIAL_RELATIONSHIP', 74)]	1	[('CHEBI_27364', 'zinc molecular entity', 42, 'vitamin D3for'), ('UBERON_0001977', 'blood serum', 95, 'serum'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 101, '25(OH ... D'), ('CHEBI_28934', 'vitamin D2', 177, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 177, 'vitamin D2')]
